# EDGAR Filing Document

**Accession Number:** 0002096363
**File Stem:** 0001683168-26-001860
**Filing Date:** 2026-3
**Character Count:** 821829
**Document Hash:** ff0f95a0cbe06cc960b0c6449dbb00e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-001860.hdr.sgml**: 20260316

**ACCESSION NUMBER**: 0001683168-26-001860

**CONFORMED SUBMISSION TYPE**: 1-A/A

**PUBLIC DOCUMENT COUNT**: 64

**FILED AS OF DATE**: 20260316

**DATE AS OF CHANGE**: 20260316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tranquil Healthcare Fund I, LLC
- **CENTRAL INDEX KEY:** 0002096363
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 395126583
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 1-A/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12686
- **FILM NUMBER:** 26757982

**BUSINESS ADDRESS:**
- **STREET 1:** 18200 VON KARMAN AVE.
- **STREET 2:** SUITE 850
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92612
- **BUSINESS PHONE:** 929-288-9573

**MAIL ADDRESS:**
- **STREET 1:** 18200 VON KARMAN AVE.
- **STREET 2:** SUITE 850
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92612

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tranquil Healthcare, Inc.
- **DATE OF NAME CHANGE:** 20251112

## Part

**PART II — INFORMATION REQUIRED IN OFFERING CIRCULAR**

**Preliminary Offering Circular dated March 16, 2026**

**An Offering Statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the Offering Statement filed with the Commission is qualified. This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular or the Offering Statement in which such Final Offering Circular was filed may be obtained.**

 **Tranquil Healthcare Fund I, LLC**

 **BEST EFFORTS OFFERING** 

 **OF** 

 **UP TO 5,500,000 SHARES OF CLASS A PREFERRED SHARES (INCLUDING UP TO 500,000 INCENTIVE SHARES)**

 **$10.00 PER SHARE FOR EACH CLASS A PREFERRED SHARE**

Tranquil Healthcare Fund I, LLC, a Delaware limited liability company (the "***Company***", "***we***", "***us***" or "***our***") are offering up to 5,000,000 shares of our Class A Preferred Shares, which represents a Class A Preferred limited liability interest, at an offering price of $10.00 per share (the "***Offered Shares***"). The minimum purchase requirement is two hundred fifty (250) Offered Shares ($2,500). Additionally, any investor that purchases at least $100,000 of the Offered Shares (the "***Incentive Threshold***"), will receive such number of incentive shares (the "Incentive Shares") equal to their aggregate subscription amount multiplied by ten percent (10%). Accordingly, we may issue up to 500,000 Incentive Shares, assuming all Investors meet the Incentive Threshold.

The Class A Preferred Share being offered are non-voting, except with regard to certain matters, and are entitled to distributions from the Company in preference to the holders of our common shares ("***Common Shares***"). See the section of this Offering Circular entitled "***Description of Securities***" for more information. We do not currently intend to list the Class A Preferred Shares for trading on a national securities exchange and we have not applied for any listing.

We are managed by Tranquil Healthcare Holdings, Inc. ("***Manager***") who owns 100% of the issued and outstanding Common Shares of the Company. The Manager will have substantial control with respect to the Company, including its operations, strategic direction, and determining if and when to issue distributions of cash to the holders of the Class A Preferred Shares and Common Shares (collectively, the "***Shares***", and each person or entity holding Shares, a "***Member***"). See [Risk Factors](#a_010) beginning on page 9 for further discussions and risks associated therewith.

This offering is being conducted by the Company as a direct public offering (i.e., without the benefit of the services of an underwriter or SEC-registered broker-dealer) on a "best efforts" basis in a "Tier 2" Regulation A offering. No sales of Class A Preferred Shares will be made prior to the qualification of the Offering Statement by the United States Securities and Exchange Commission ("***SEC***"). All Class A Preferred Shares will be offered in all jurisdictions at the same price that is set forth in this offering circular. This offering will terminate on the earlier of (a) twelve (12) months from the date this Offering Circular is qualified for sale by the SEC (which date may be extended for an additional 90 days in our sole discretion); (b) the date when all Offered Shares have been sold; or (c) the date on which this offering is earlier terminated by us, in our sole discretion. Subscriptions will be accepted on a rolling basis and, once received, are irrevocable by investors but can be rejected by us prior to acceptance. There is no minimum offering amount and, the Company may immediately deposit the proceeds from accepted subscription agreements into the Company's bank account and may use such proceeds in accordance with the "[Use of Proceeds](#a_011)". The Company has not engaged commissioned sales agents or underwriters. Upon purchasing Class A Preferred Shares, you will be become a Member of the Company and subject to the terms of the Company's operating agreement ("***Operating Agreement***"), adopted March 3, 2026. The Operating Agreement sets forth the rights, preferences, and privileges with respect to the Class A Preferred Shares and Common Shares.

The use of projections or forecasts in this offering is prohibited. No one is permitted to make any oral or written predictions about the cash benefits or tax consequences you will receive from your investment in our Class A Preferred Shares.

This Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the laws of any such state.

 **Investing in our Class A Preferred Shares involves a high degree of risk. See "[Risk Factors](#a_010)" beginning on page 9 for a discussion of certain risks that you should consider in connection with an investment in our Class A Preferred Shares.**

---

| | | |
|:---|:---|:---|
|  | **Price to <br> Public** | **Proceeds to <br> Issuer** |
| Public Offering Price per Offered Share (1)(2) | $10.00 | $50000000 |
| Underwriting Discounts and Commissions (3) | $– | $– |
| Proceeds to Company (Excluding Offering Expenses) | $10.00 | $50000000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) We are offering shares
 on a continuous basis. We are offering up to 5,000,000 Class A Preferred Shares, plus up to 500,000 additional Class A Preferred
 Shares as Incentive Shares for Investors purchasing at least $100,000 in this offering.

(2) This is a "best-efforts"
 offering. We will place 8.00% of the gross proceeds received from this offering into a reserve account "Reserve Account"
 which will be maintained as a contingency reserve to make distributions to the Members in accordance with the Operating Agreement
 (see section of this Offering Circular entitled "Description of Securities").

(3) We are offering these
 securities without an underwriter.

No sale may be made to you in this Offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov. We retain complete discretion to determine that subscribers are qualified purchasers (as defined in Regulation A under the Securities Act) in reliance on the information and representations provided to us regarding their financial situation.

An investment in the Class A Preferred Shares is subject to certain risks and should be made only by persons or entities able to bear the risk of and to withstand the total loss of their investment. Prospective investors should carefully consider and review the information under the heading "[Risk Factors](#a_010)" beginning on page 9.

The SEC does not pass upon the merits of or give its approval to any securities offered or the terms of the Offering, nor does it pass upon the accuracy or completeness of any offering circular or other solicitation materials. These securities are offered pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "***Securities Act***"); however, the SEC has not made an independent determination that the securities offered are exempt from registration.

We expect that our operations will not cause us to meet the definition of an investment company under the Investment Company Act of 1940, as amended (the 1940 Act), because (1) at all times our sole assets will consist only of cash and commercial loans, neither of which is deemed to be a security for purposes of the 1940 Act, and (2) at all times we will not be engaged primarily in owning, holding, investing or trading in securities (as such term is used for purposes of the 1940 Act).

This offering circular is part of an offering statement that we filed with the SEC, using a continuous offering process pursuant to Rule 251(d)(3) of Regulation A, meaning that while the offering of securities is continuous, active sales of securities may happen sporadically over the term of the offering. Further, the acceptance of subscriptions may be briefly paused at times to allow us to effectively and accurately process and settle subscriptions that have been received. Periodically, we will provide an offering circular supplement that may add, update or change information contained in this offering circular. Any statement that we make in this offering circular will be modified or superseded by any inconsistent statement made by us in a subsequent offering circular supplement. The offering statement we filed with the SEC includes exhibits that provide more detailed descriptions of the matters discussed in this offering circular. You should read this offering circular and the related exhibits filed with the SEC and any offering circular supplement, together with additional information contained in our annual reports, semi-annual reports and other reports and information statements that we will file periodically with the SEC. See the section entitled "*[Where You Can Find More Information](#a_00025)*" below for more details.

Our principal offices are located at 18200 Von Karman Ave. Suite 850, Irvine CA 92612, Phone: 646-902-4953, Email: invest@tranquil.healthcare. We maintain a website at http://www.tranquil.healthcare.com We do not incorporate the information on or accessible through our website into this Offering Circular, and you should not consider any information on, or that can be accessed through, our website as a part of this Offering Circular.

This offering circular is following the offering circular format described in Part II of Form 1-A.

**<u>NON-ACCREDITED INVESTOR LIMITATIONS</u>**

**No sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or your net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov.**

**<u>NOTICE TO FOREIGN INVESTORS</u>**

**IF THE INVESTOR LIVES OUTSIDE OF THE UNITED STATES, IT IS THE INVESTOR'S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF ANY RELEVANT TERRITORY OR JURISDICTION OUTSIDE THE UNITED STATES IN CONNECTION WITH ANY PURCHASE OF THE SECURITIES, INCLUDING OBTAINING REQUIRED GOVERNMENTAL OR OTHER CONSENTS OR OBSERVING ANY OTHER REQUIRED LEGAL OR OTHER FORMALITIES. THE COMPANY RESERVES THE RIGHT TO DENY THE PURCHASE OF THE SECURITIES BY ANY FOREIGN INVESTOR.**

**THE U.S. SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES OFFERED ARE EXEMPT FROM REGISTRATION.**

 **The date of this Offering Circular is March 6, 2026.**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
| [IMPORTANT INFORMATION ABOUT THIS OFFERING CIRCULAR](#a_002) | 1 |
| [MARKET AND INDUSTRY DATA](#a_003) | 1 |
| [STATE LAW EXEMPTION AND PURCHASE RESTRICTIONS](#a_004) | 2 |
| [CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS](#a_005) | 3 |
| [SUMMARY](#a_006) | 4 |
| [THE OFFERING](#a_007) | 6 |
| [DETERMINATION OF OFFERING PRICE](#a_008) | 8 |
| [DISTRIBUTIONS](#a_009) | 8 |
| [RISK FACTORS](#a_010) | 9 |
| [USE OF PROCEEDS](#a_011) | 21 |
| [PLAN OF DISTRIBUTION](#a_012) | 23 |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_013) | 29 |
| [BUSINESS](#a_014) | 34 |
| [MANAGEMENT](#a_015) | 47 |
| [MANAGEMENT COMPENSATION](#a_016) | 50 |
| [CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS](#a_017) | 52 |
| [SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITY HOLDERS](#a_018) | 53 |
| [DESCRIPTION OF SECURITIES](#a_019) | 55 |
| [SHARES ELIGIBLE FOR FUTURE SALE](#a_020) | 58 |
| [MATERIAL U.S. FEDERAL TAX CONSIDERATIONS](#a_021) | 59 |
| [ERISA AND RELATED CONSIDERATIONS](#a_022) | 66 |
| [LEGAL MATTERS](#a_00023) | 69 |
| [EXPERTS](#a_00024) | 69 |
| [WHERE YOU CAN FIND MORE INFORMATION](#a_00025) | 69 |
| [INDEX TO CONSOLIDATED FINANCIAL STATEMENTS](#a_00026) | F-1 |

---

We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where such offers and sales are permitted. You should rely only on the information contained in this Offering Circular. We have not authorized anyone to provide you with any information other than the information contained in this Offering Circular. The information contained in this Offering Circular is accurate only as of its date, regardless of the time of its delivery or of any sale or delivery of our securities. Neither the delivery of this Offering Circular nor any sale or delivery of our securities shall, under any circumstances, imply that there has been no change in our affairs since the date of this Offering Circular. This Offering Circular will be updated and made available for delivery to the extent required by the federal securities laws. You should not assume that the information contained in this Offering Circular is accurate as of any date later than the date hereof or such other dates as are stated herein or as of the respective dates of any documents or other information incorporated herein by reference.

In this Offering Circular, unless the context indicates otherwise, references to "***Tranquil***", "***Tranquil Healthcare***" "***we***," the "***Company***," "***our***" and "***us***" refer to the activities of and the assets and liabilities of the business and operations of Tranquil Healthcare Fund I, LLC, or as applicable, Tranquil Healthcare, Inc., which was our predecessor company prior to completing a holding company reorganization structure and conversion into a limited liability company. Reference to "***Manager***", "***Tranquil Holdings***", or "***Tranquil Healthcare Holdings***" refers to our Tranquil Healthcare Holdings, Inc. which is the sole holder of our outstanding Common Shares.

i

 **IMPORTANT INFORMATION ABOUT THIS OFFERING CIRCULAR**

Please carefully read the information in this Offering Circular and any accompanying offering circular supplements, which we refer to collectively as the Offering Circular. You should rely only on the information contained in this Offering Circular. We have not authorized anyone to provide you with different information. This Offering Circular may only be used where it is legal to sell these securities. You should not assume that the information contained in this Offering Circular is accurate as of any date later than the date hereof or such other dates as are stated herein or as of the respective dates of any documents or other information incorporated herein by reference.

This Offering Circular is part of an offering statement that we filed with the SEC, using a continuous offering process. Periodically, as we make material investments, update the Aggregate Loan Amount or have other material developments, we will provide an offering circular supplement that may add, update or change information contained in this Offering Circular. Any statement that we make in this Offering Circular will be modified or superseded by any inconsistent statement made by us in a subsequent offering circular supplement. The offering statement we filed with the SEC includes exhibits that provide more detailed descriptions of the matters discussed in this Offering Circular. You should read this Offering Circular and the related exhibits filed with the SEC and any offering circular supplement, together with additional information contained in our annual reports, semi-annual reports and other reports and information statements that we will file periodically with the SEC. See the section entitled "Additional Information" below for more details.

The offering statement and all supplements and reports that we have filed or will file in the future can be read at the SEC website, www.sec.gov, or on the our website, http://www.tranquil.healthcare.com. The contents of the website (other than the offering statement, this Offering Circular and the appendices and exhibits thereto) are not incorporated by reference in or otherwise a part of this Offering Circular.

Our Manager and those selling shares on our behalf in this Offering are permitted to make a determination that the purchasers of shares in this Offering are "qualified purchasers" in reliance on the information and representations provided by the shareholder regarding the shareholder's financial situation. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov.

**MARKET AND INDUSTRY DATA**

This Offering Circular contains information concerning our industry, our business and the markets for our services to be provided to medical clinics, including data regarding the estimated size of such markets. We obtained the industry, market and similar data set forth in this Offering Circular from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe our internal research is reliable, such research has not been verified by any third party.

 **STATE LAW EXEMPTION AND PURCHASE RESTRICTIONS**

Our Class A Preferred Shares are being offered and sold only to "qualified purchasers" (as defined in Regulation A). As a Tier 2 offering pursuant to Regulation A, this offering is exempt from state law "Blue Sky" review, subject to meeting certain state filing requirements and complying with certain anti-fraud provisions, to the extent that our Class A Preferred Shares offered hereby are offered and sold only to "qualified purchasers" or at a time when our Class A Preferred Shares are listed on a national securities exchange. "Qualified purchasers" include: (i) "accredited investors" under Rule 501(a) of Regulation D and (ii) all other investors so long as their investment in our Class A Preferred Shares does not represent more than 10% of the greater of their annual income or net worth (for natural persons), or 10% of the greater of annual revenue or net assets at fiscal year-end (for non-natural persons). However, our Class A Preferred Shares are being offered and sold only to those investors that are within the latter category (i.e., investors whose investment in our Class A Preferred Shares does not represent more than 10% of the applicable amount), regardless of an investor's status as an "accredited investor". Accordingly, we reserve the right to reject any investor's subscription in whole or in part for any reason, including if we determine in our sole and absolute discretion that such investor is not a "qualified purchaser" for purposes of Regulation A.

To determine whether a potential investor is an "accredited investor" for purposes of satisfying one of the tests in the "qualified purchaser" definition, the investor must be a natural person:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1. who has an individual net worth, or joint net worth with the person's spouse, that exceeds $1,000,000 at the time of the purchase, excluding the value of the primary residence of such person; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. who has earned income exceeding $200,000 in each of the two most recent years or joint income with a spouse exceeding $300,000 for those years and a reasonable expectation of the same income level in the current year; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3. who has certain professional certifications, designations or credentials or other credentials issued by an accredited educational institution, as designated by the SEC; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4. who, with respect to investments in a private fund, are "knowledgeable employees" of the fund, as defined in the Investment Company Act of 1940.

The list above is non-exhaustive; prospective investors should review Rule 501 of Regulation D for more details on whether they are an "accredited investor." If the investor is not a natural person, different standards apply. See Rule 501 of Regulation D for more details.

For purposes of determining whether a potential investor is a "qualified purchaser", annual income and net worth should be calculated as provided in the "accredited investor" definition under Rule 501 of Regulation D. In particular, net worth in all cases should be calculated excluding the value of an investor's home, home furnishings and automobiles.

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

Some of the statements under "[Summary](#a_006)", "[Risk Factors](#a_010)", "[Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_013)", "[Business](#a_014)" and elsewhere in this Offering Circular constitute forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "should", "will" and "would" or the negatives of these terms or other comparable terminology.

You should not place undue reliance on forward-looking statements. The cautionary statements set forth in this Offering Circular, including in "Risk Factors" and elsewhere, identify important factors which you should consider in evaluating our forward-looking statements. These factors include, among other things, may include statements about our:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· business
 strategy;

· our
 ability to successfully compete in highly competitive markets, specifically in the TMS and behavioral health financing market;

· our
 expectations regarding financial performance, including but not limited to revenue, achieving or maintaining profitability, ability
 to generate or maintain positive cashflow and other results of operations;

· our
 expectations regarding future operating performance, including but not limited to our expectations regarding the success of our operating
 partner;

· The
 ability of our operating partners to successfully run their businesses and generate sufficient revenue to repay our loans with interest
 and pay for our consulting services;

· our
 expectations regarding our competitors, including their ability to raise capital;

· our
 anticipated investments in clinics, and the effect of these investments on our results of operations;

· our
 estimates regarding our capital requirements and expenses, including for the (i) retention of qualified personnel to provide consulting
 services and (ii) loans to our operating partners;

· anticipated
 technology trends and developments and our ability to address those trends and developments;

· the
 size of our addressable markets, market share, category positions, and market trends;

· our
 ability and each of our operating partner's ability to identify, recruit, and retain skilled personnel, including key members
 of their senior management;

· our
 ability to effectively manage our growth and maintain and improve our corporate culture;

· our
 ability and each of our operating partner's ability to successfully build and expand their operations, including to new markets;

· our
 ability and each of our operating partner's ability to successfully comply with regulatory requirements, licensing requirements,
 insurance reimbursements for mental health services, and existing and new federal and state healthcare laws in jurisdictions where
 we intend to operate;

· the
 availability of capital to grow our business, which we will need in order to implement our business plan;

· our
 ability to pay distributions to the holders of our Shares;

· our
 ability to prevent disturbances, including cybersecurity incidents, to our information technology systems;

· our
 ability to implement, maintain, and improve our internal control over financial reporting.

Although the forward-looking statements in this Offering Circular are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as maybe be required by law, to re-issue this Offering Circular or otherwise make public statements updating our forward-looking statements.

**SUMMARY**

 *This summary highlights selected information contained elsewhere in this Offering Circular. This summary is not complete and does not contain all the information that you should consider before deciding whether to invest in our Class A Preferred Shares. You should carefully read the entire Offering Circular, including the risks associated with an investment in the Company discussed in the "[Risk Factors](#a_010)" section of this Offering Circular, before making an investment decision. Some of the statements in this Offering Circular are forward-looking statements. See the section entitled "[Cautionary Statement Regarding Forward-Looking Statements](#a_005)."*

***Company Information***

Tranquil Healthcare Fund I, LLC. ("the Company", "Tranquil Healthcare", "Tranquil", "we" and "us") was incorporated as Tranquil Healthcare, Inc. (the "Predecessor Corporation") under the laws of the State of Delaware on October 21, 2025. In connection with a holding company reorganization, the Predecessor Corporation was converted into a Delaware limited liability company and became the wholly owned subsidiary of Tranquil Healthcare Holdings, Inc. (the "Manager"). The holding company reorganization was completed on March 3, 2026 (the "Reorganization"). As a result of the reorganization, the Manager holds all of the outstanding voting stock of the Company.

 ***Our Structure***

![](structure.jpg)

 ***Our Business***

We a recently organized Delaware limited liability company formed to partner with companies and their management teams ("Operators") and develop wellness clinics that provide services and treatments focused on Transcranial Magnetic Stimulation ("TMS") to the customer / patient ("Clinics"). We anticipate our partnering activities will consist of: (i) originating, investing in, and managing a portfolio of commercial loans and (ii) providing business and strategic consulting services to both Clinics that we finance and other wellness clinics.

Transcranial Magnetic Stimulation is a non-invasive neuromodulation therapy used primarily to treat mental health disorder, particularly in patients who have not responded adequately to conventional pharmacologic treatments. The therapy uses magnetic pulses to stimulate targeted regions of the brain associated with mood regulation. Since receiving regulatory clearance in the United States in 2008 for treatment-resistant depression, TMS has become an increasingly accepted clinical intervention within psychiatry.

In the United States, demand for TMS is driven by the large prevalence of major depressive disorder and the significant proportion of patients who do not respond to medication. Approximately 21 million adults experience at least one major depressive episode each year, and roughly one-third of patients with depression do not achieve adequate relief from standard antidepressant therapy. This treatment-resistant population forms the core clinical market for TMS therapy.

From an investment perspective, TMS treatment centers represent a growing segment within outpatient behavioral healthcare services. Clinics typically generate revenue through repeated treatment sessions over several weeks, creating recurring revenue streams once equipment and trained staff are in place. The industry remains fragmented, with many clinics operated by independent psychiatric practices, suggesting potential opportunities for consolidation or regional platform development. We believe that by providing financing, in the way of loans, as well as consulting services, the Company will be able to enhance the operational performance of Clinics and improve the likelihood of us generating greater returns on a risk-adjusted basis.

 ***Our Manager***

Tranquil Healthcare Holdings, Inc. ("Manager"), as our manager, will oversee and direct our day-to-day operations. In overseeing our operations, the Manager will use its own employees as well as retain consultants and experienced personnel both at the Manager level or Company level. Pursuant to our operating agreement ("Operating Agreement"), the Manager is entitled to make substantially all of the decisions regarding the Company operations and holds all of the voting securities of the Company, subject to certain limitations. Accordingly, all decisions related to our commercial loans as well as substantially all of the governance of the Company and its Members, will be subject to the sole discretion of the Manager.

 ***Our Operating Agreement***

Investors purchasing Class A Preferred Shares in this offering will be bound by and subject to the terms of the Operating Agreement, a copy of the form of which is attached to this Offering Circular as Exhibit 2.2.

 ***Our Offices***

We use the offices of the Manager, located at 18200 Von Karman, Suite 850, Irvine, CA 92612, Phone: 646-902-4953, Email: <u>invest@tranquil.healthcare.</u> We maintain a website at http://www.tranquil.healthcare. We do not incorporate the information on or accessible through our website into this Offering Circular, and you should not consider any information on, or that can be accessed through, our website to be a part of this Offering Circular.

**THE OFFERING**

---

| | |
|:---|:---|
| **Issuer or Company:** | Tranquil Healthcare Fund I, LLC, a Delaware limited liability company. |
| **Securities offered:** | The Company will offer Class A Preferred Shares - See "[Description Securities](#a_019)" below for further information regarding the Class A Preferred Shares. <br>We intend to sell a maximum of (i) 5,000,000 Class A Preferred Shares at an offering price of $10.00 per share (the "Offered Shares"), and (ii) up to 500,000 incentive Class A Preferred Shares ("Incentive Shares"). For each Investor purchasing at least $100,000 of Offered Shares (the "Incentive Threshold"), such Investor will receive such number of Incentive Shares equal to ten percent (10%) of the number of Offered Shares purchased (See "[Plan of Distribution](#a_012)").  |
| **Price per Class A Preferred Share:** | $10.00 |
| **Minimum Investment Amount:** | The minimum investment amount per investor is $2,500 (250 Class A Preferred Shares). We reserve the right to reject any subscription. However, we may revise the minimum investment amount in the future or elect to waive the minimum purchase requirements on a case-by-case basis in our sole discretion. Subscriptions will be accepted on a rolling basis and, once received, are irrevocable by investors but can be rejected by us prior to acceptance. |
| **Number of Class A Preferred Shares outstanding before the offering** | Prior to this offering, there are no shares of Class A Preferred Shares outstanding. |
| **Number of shares of Class A Preferred Shares outstanding after the offering:** | 5,500,000 shares, if the maximum amount of Offered Shares are sold and assuming all Investors meet the Incentive Threshold. Such number of Class A Preferred Shares outstanding after the offering excludes Class A Preferred Shares underlying $325,000 in outstanding convertible notes that are convertible into approximately 36,920 Class A Preferred Shares as of March 3, 2026 (based on a conversion price of $10.00 per share). |
| **Investment Restrictions:** | Generally, no sale may be made to you in this Offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, you are encouraged to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, you are encouraged to refer to *www.investor.gov*. |
| **Maximum offering amount:** | $50,000,000 consisting of 5,000,000 Class A Preferred Shares with an offering price of $10.00 per share, excluding any applicable Incentive Shares (See "[Plan of Distribution](#a_012)"). |
| **Subscribing Online:** | After the qualification by the SEC of the offering statement of which this Offering Circular is a part, the Offering will be conducted through our website whereby investors will receive, review, execute and deliver subscription agreements electronically and make payment of the purchase price. For additional information, see "Plan of Distribution Subscription Procedures." |

---

---

| | |
|:---|:---|
| **Voting Rights**: | The Class A Preferred Shares will not be entitled to vote on any matter, except for (i) certain amendments to the Operating Agreement that would disproportionately and adversely affect the Class A Preferred Shares, (ii) the determination to dissolve or wind up the Company, (iii) the appointment of a replacement Manager in the event the Manager resigns or is otherwise dissolved (bankruptcy etc.), and (iv) other matters required by Delaware law. <br>Accordingly, the Manager, as the sole holder of the Common Shares will have control over all other matters to be voted on by the Members of the Company. <br>|
| **Member Distributions:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If and when declared by the Manager, all distributions made by the Company, if any, will be subject to the following preference (the "Distributions"): <br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) First, to the holders of the Class A Preferred Shares until each Member holding Class A Preferred Shares has received cumulative Distributions equal to an annual, non-compounded, eight percent (8%) return on the original purchase price paid for such Class A Preferred Shares; and <br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ii) Then: (a) seventy percent (70%) to holders of Class A Preferred Shares and (b) thirty percent (30%) to holders of the Common Shares. <br>There can be no assurances if and when the Manager will make any Distributions, or if the Company will have sufficient free cash flows from its operations to make any Distributions. <br>|
| **Closing:** | There is offering has no minimum amount. The Company may close the entire offering as it accepts investor subscriptions on a rolling basis. We will offer Class A Preferred Shares in this offering for a period of twelve (12) months from the date of commencement of this offering after qualification or until we raise the maximum amount being offered, whichever occurs earlier. If any of the Class A Preferred Shares remain unsold as of the conclusion of the offering, such shares shall remain unissued by the Company. The Company reserves the right to terminate the offering for any reason at any time prior to the final closing. |
| **Trading Market:** | As of the date of this Offering Circular, there is no trading market for any of our securities, and we cannot assure you that a trading market will develop. We have not applied to list our securities on any national securities exchange. |
| **Use of proceeds:** | If we sell all of the Class A Preferred Shares being offered, our proceeds, (excluding our estimated offering expenses and any funds deposited in the Reserve Account to be used to return capital for the Distributions) will be $50,000,000. We expect to use the majority of the net proceeds to provide commercial loans for the purchase of equipment and the build out and marketing expenses related to the development of the Clinics. The remaining proceeds will be used for working capital and other general operational purposes. Please see "[Use of Proceeds](#a_011)" for further information. |
| **Transfer Restrictions:** | The Class A Preferred Shares may be transferred (i) pursuant to an Involuntary Transfer (as defined in the Operating Agreement), (ii) via a trading market approved by the Company, if one ever develops or (iii) pursuant to approval by the Company in writing. We do not currently plan to list the Class A Preferred Shares on any National Stock Exchange. There is no public market for the Class A Preferred Shares, and one may never develop. Certain states also impose additional statutory restrictions on secondary trading of shares purchased in the Offering, which may further restrict the transferability of the Class A Preferred Shares. Prospective investors are urged to consult their own legal advisors with respect to secondary trading in the Class A Preferred Shares. <br>|
| **Risk factors:** | Investing in our Class A Preferred Shares involves a high degree of risk. See the section entitled "[Risk Factors](#a_010)" for a discussion of factors you should carefully consider before deciding to invest. |

---

 **DETERMINATION OF OFFERING PRICE**

Our Manager established the offering price of our Class A Preferred Shares on an arbitrary basis. Because the offering price is not based upon any independent valuation, the offering price may not be indicative of the proceeds that you would receive upon liquidation.

 **DISTRIBUTIONS**

We do not expect to declare any Distributions until the proceeds from this offering are invested and generating operating cash flow from payments of interest and principal on the loans in our portfolio no sooner than following the conclusion of this offering. Once we begin to make Distributions, we expect that our Manager will make Distributions from time to time from our cash flow which we anticipate will be derived from payments of interest and principal from the loans in our portfolio and any applicable consulting fees after the payment of our expenses and liabilities and allocating reasonable cash reserves.

Any Distributions we make will be at the discretion of our Manager, and will be based on, among other factors, our present and reasonably projected future cash flow. Distributions will be paid to Members as of the record dates declared by the Manager.

Holders of our Class A Preferred Shares will be entitled to an 8% annualized preference on Distributions. Pursuant to such preference, in the event the Manager declares a distribution, 100% of the distribution will be allocated to Class A Preferred Shares until the holders have received an annualized return of 8%. In the event additional Distributions are made after such time, cash available for Distributions will be made 70% to the holders of the Class A Preferred Shares and 30% to the holders of our Common Shares.

We have agreed to allocate 8% of the proceeds from this offering to a Reserve Account, which will be maintained as a contingency reserve to make payments to the Class A Preferred Shares as Distributions. Such funds held in the Reserve Account will be classified as restricted cash, and may, at the discretion of the Manager, be invested by the Company in cash equivalents. Our Distributions generally will constitute a return of capital to the extent that they exceed our current and accumulated earnings and profits as determined for U.S. federal income tax purposes. To the extent that a Distribution is treated as a return of capital for U.S. federal income tax purposes, it will reduce a holder's adjusted tax basis in the holder's Shares, and to the extent that it exceeds the holder's adjusted tax basis, it will be treated as gain resulting from a sale or exchange of such Shares.

Notwithstanding the Reserve Account, there can be no assurance that the Manager will declare a Distribution at any time or that even if made, they will be sufficient to pay holders of the Class A Preferred Shares the annual preference or result in the return of their investment.

**RISK FACTORS**

 *An investment in our Class A Preferred Shares involves a high degree of risk. You should carefully consider the following risk factors, together with the other information contained in this Offering Circular, before purchasing our securities. Any of the following factors could harm our business, financial condition, results of operations or prospects, and could result in a partial or complete loss of your investment. Some statements in this Offering Circular, including statements in the following risk factors, constitute forward-looking statements. Please refer to the section entitled "[Cautionary Statement Regarding Forward-Looking Statements](#a_005)".*

 **Risks Related to this Offering and Our Class A Preferred Shares**

 ***There is no existing market for our Class A Preferred Shares and we cannot predict whether one will develop to provide you with adequate liquidity to sell your Class A Preferred Shares at prices equal to or greater than the price you paid in this offering.***

There is no public market for our Class A Preferred Shares and we have not applied to list or quote our securities on any market, exchange or interdealer quotation system. We cannot predict the extent to which investor interest in our Company will lead to the development of an active trading market or otherwise or how liquid that market might become. If an active trading market does not develop, you may not be able to sell the Class A Preferred Shares that you buy. The purchase price for the Class A Preferred Shares was determined by us and may not be representative of the value of the Company.

 ***If our Class A Preferred Shares become quoted, the market price of our Class A Preferred Shares may fluctuate, and you could lose all or part of your investment.***

The offering price for our Class A Preferred Shares was arbitrarily set by our Manager and may not be indicative of prices that would prevail on any national securities exchange, the OTC Markets or an alternative market if a market developed. If a market does develop, the value of our Class A Preferred Shares could decline.

Some of the factors that could negatively affect our share price or result in fluctuations in our share price if a market does develop, include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· our operating and financial
 performance with respect to our operations;

· semi-annual
 variations in our financial indicators, such as net income per share, net income and revenues;

· the public reaction
 to our press releases, our other public announcements and our filings with the SEC;

· our failure to meet
 revenue, reserves, or earnings estimates;

· our ability to make
 Distributions on our Class A Preferred Shares;

· our ability to pay our
 obligations as they come due;

· changes in accounting
 principles, policies, guidance, interpretations or standards;

· additions or departures
 of our Manager's key personnel;

· actions by our Members;

· general market conditions;

· domestic and international
 economic, legal and regulatory factors unrelated to our performance; and

· the realization of any
 risks describes under this "Risk Factors" section.

 ***Holders of our Class A Preferred Shares may not replace the Manager and have limited ability to influence decisions regarding our business.***

  ****

Pursuant to the terms of our Operating Agreement, the assets, affairs, and business of the Company are managed exclusively by our Manager, Tranquil Healthcare Holdings, Inc. The Manager is also the holder of 100% of our Common Shares. Holders of Class A Preferred Shares do not have the right to remove the Manager, and may only vote in limited circumstances, such as amendments to our Operating Agreement that are adverse to the Class A Preferred Members, the decision to wind up or dissolve the Company, to appoint a replacement Manager after a resignation or dissolution of the Manager, or as required by applicable law.

All Common Shares, which are the only voting shares, are owned by the Manager. As a result, the Manager has the ability to exercise unilateral control over all significant Company decisions, including operational matters, strategic direction, financings, amendments to governing documents (subject to applicable limitations), and the timing and amount of any distributions.

Because the Manager controls all voting power, holders of Class A Preferred Shares will have limited ability to influence the Company's management, policies, or strategic decisions. Investors must rely entirely on the judgment and discretion of the Manager, whose interests may not always align with those of the Class A Preferred holders.

 ***As a non-listed company conducting an exempt offering under Regulation A, we are not subject to many corporate governance requirements applicable to publicly listed companies.***

  ****

Because we are conducting an offering pursuant to Regulation A and our securities are not listed on a national securities exchange, we are not subject to many of the corporate governance requirements that apply to issuers listed on the NYSE, Nasdaq, or other national securities exchanges. For example, we are not required to maintain a board of directors composed of independent members or to establish independent audit, compensation, or nominating committees.

Instead, the Company is managed exclusively by our Manager, which owns 100% of our Common Shares and controls the voting power of the Company with respect to substantially all matters. As a result, investors will not receive the same level of corporate governance protections, oversight, or procedural safeguards that are afforded to stockholders of companies listed on national securities exchanges.

 ***The Manager has authority to determine compensation for its personnel, and we are required to reimburse such costs, which may reduce cash available for Distributions.***

  ****

Under the terms of the Operating Agreement and the Management Agreement, the Manager has broad authority to manage the Company's affairs, including determining the compensation, bonuses, benefits, and other remuneration paid to its personnel, including senior executives such as Tyler Ehler, who serves as its Chief Executive Officer. The Company is obligated to reimburse the Manager for compensation and related expenses incurred in connection with managing and operating the Company.

The Manager may increase the salaries, bonuses, equity incentives, or other forms of compensation payable to its personnel without obtaining the approval of the Company's members holding Class A Preferred Shares. Because these amounts are reimbursable expenses of the Company under the Management Agreement, any such increases will directly reduce the cash available to the Company for operations and Distributions.

Holders of Class A Preferred Shares do not have approval rights over compensation arrangements for the Manager's personnel and will not have the ability to influence or limit such compensation decisions. As a result, the Manager may establish compensation levels that holders of Class A Preferred Shares may believe are excessive or not aligned with the Company's performance.

In addition, because the Manager controls both the determination of compensation and the decision whether to declare Distributions, conflicts of interest may arise between maximizing compensation paid to the Manager's personnel and maximizing returns to investors. Any increase in reimbursable compensation expenses could materially reduce or eliminate funds otherwise available for Distributions and adversely affect the value of your investment.

Investors must rely on the integrity and business judgment of the Manager with respect to compensation decisions.

  ****

 ***Our Manager has broad discretion as to the selection of Clinics, Operators, and the use of the net proceeds from this offering.***

As described in the Use of Proceeds Section of this Offering Circular, we intend to use the majority of the proceeds from this Offering to (i) provide working capital loans for the buildout, development, operations, and purchase or lease of equipment for up to 40 Clinics and (ii) provide consulting services for up to 40 Clinics. The Company has currently entered into one (1) term sheet (only binding with respect to exclusivity) with DGR Health Services LLC ("DGR") to develop, market and consult on up to 40 Clinics for TMS. Our Manager will have broad discretion in the application of the net proceeds designated for use to provide loans and consulting services to the Clinics. Since Class A Preferred Shares will benefit from the growth and success of the Clinics through Distributions or an increase in value of your investment, you will be reliant on the Manager spending such proceeds efficiently. The Manager may spend a portion or all of the net proceeds from this offering in ways that holders of our Class A Preferred Shares may not desire or that may not yield a significant return or any return at all. The failure by our Manager to apply these funds effectively could harm our business, the value of your Class A Preferred Shares, and the Distributions you will be entitled to if and when declared by the Manager. Please see "Use of Proceeds" below for more information.

As a result, any future Distributions are uncertain and subject to the discretion of the Manager.

 ***Distributions to the Class A Preferred Shares depend on the performance of Clinics operated by third parties, over which we have no control, and are subject to the discretion of the Manager.***

Holders of our Class A Preferred Shares are entitled to receive Distributions if and when declared by the Manager and after satisfaction of our obligations to creditors and other senior obligations in the event of a liquidation or sale of the Company (see "[Description of Securities](#a_019) — Distributions"). There is no assurance that any Distributions will be made.

Our ability to make Distributions will depend largely on the financial performance of the Clinics to which we make loans and provide consulting services. The Clinics are operated by third-party Operators, including entities such as DGR, and we do not control their day-to-day management, operational decisions, financial policies, staffing, or business strategy. If the Clinics fail to achieve or maintain profitability, experience operational disruptions, default on loans, or suspend operations, our revenues may decline and our ability to generate cash flow could be materially and adversely affected. As of the date hereof, we have not entered into any binding agreement with any Operator and we have not currently funded loans to any Clinic.

Our business model also depends on our ability to raise sufficient capital to fund loans to Clinics and to support consulting operations. If we are unable to raise sufficient capital in this offering, our ability to originate loans, expand our consulting services, or support Clinic relationships may be limited, which could reduce our revenue and cash flow.

In addition, we are obligated to pay fees and expenses to the Manager pursuant to the Management Agreement. Such items include, but are not limited to, personnel compensation, overhead, insurance, legal and accounting fees, and other operational costs. Certain of these expenses will be incurred regardless of whether the Clinics are profitable. The Management Agreement may reduce the amount of cash otherwise available for Distributions.

The Manager holds all of the voting shares of the Company, except in limited circumstances, and therefore has substantial discretion over our operations, financial decisions, and the timing and amount of any Distributions. Because the Manager controls whether Distributions are declared and also receives fees under the Management Agreement, potential conflicts of interest may arise. There can be no assurance that the Manager will determine to make Distributions or that the fees and expenses payable under the Management Agreement will be favorable to holders of Class A Preferred Shares.

As a result of the foregoing, the timing, amount, and occurrence of any Distributions are uncertain, and investors should not rely on receiving regular or predictable returns on their investment.

 ***The holders of Class A Preferred Shares will have limited voting rights.***

  ****

The Company is managed by its Manager. Holders of the Class A Preferred Shares will not participate in the management or control of the Company and will not have general voting rights with respect to the Company's operations, business decisions, or strategic direction.

Pursuant to the Operating Agreement, holders of Class A Preferred Shares will have limited voting rights solely in specified circumstances, including (i) the approval of a liquidation or dissolution of the Company, (ii) amendments to the Operating Agreement that would materially and adversely affect the rights, preferences, or privileges of the Class A Preferred Shares, and (iii) the appointment of a successor Manager in the limited circumstance that the existing Manager resigns or otherwise ceases to exist as an entity. Outside of these limited protective provisions, holders of Class A Preferred Shares will not have the ability to vote on or approve matters relating to the Company's business, capital raising activities, incurrence of indebtedness, compensation arrangements, related-party transactions, or other operational decisions.

The Manager has broad authority to control the Company's affairs, including decisions regarding investments, loans and consulting services to Clinics, consulting arrangements, fees payable under the Management Agreement, the timing and amount of any Distributions, and whether to pursue additional financings or strategic transactions. Because the Manager controls these decisions and the holders of the Class A Preferred Shares have only limited protective voting rights, the Manager may make decisions that differ from, or conflict with, the interests of the Members holding Class A Preferred Shares.

This concentration of control procedures the ability of holders of Class A Preferred Shares to influence Company decisions, may delay or prevent transactions that such holders believe are favorable, and may adversely affect the value of their investment. Investors in the Class A Preferred Shares have rights in the Company that are primarily economic in nature and that they will not have meaningful governance influence over the Company.

 ***If we raise only a limited amount of proceeds in this Offering, we may be able to develop only a small number of Clinics, which would limit potential returns and prevent us from achieving economics of scale.***

  ****

A substantial portion of the proceeds from the sale of the Class A Preferred Shares will be used to finance the development of up to an anticipated forty (40) Clinics in collaboration with DGR or other potential Operators. The number of Clinics we are able to develop with the Operators will depend on the amount of capital raised in this Offering. If we raise only a limited amount of proceeds, we may be able to develop only a few Clinics, or none at all, which will likely reduce the frequency and amount of Distributions, if any.

 ***The interests of the Manager, its principals and its other affiliates may conflict with the interests of the Members holding Class A Preferred Shares.***

The Operating Agreement grants the Manager broad authority and discretion over the management, control, and operations of the Company. The Manager and its principals and affiliates may have interests that differ from or conflict with the interests of holders of the Class A Preferred Shares. Since the Class A Preferred Shares do not control the Company and have only limited protective voting rights, they will have limited ability to influence decisions in situations involving conflicts of interest.

Potential conflicts of interest include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· The
 Manager, its principals, and their affiliates may form, invest in, manage, operate, or otherwise
 participate in other entities, whether or not such businesses are competitive with or similar
 to our business. Neither the Operating Agreement, nor the Management Agreement prohibit the
 Manager or its affiliates from engaging in competing activities.

&nbsp;&nbsp;&nbsp;&nbsp;· The
 Manager, its principals, and their affiliates are not required to present business opportunities
 to the Company or to disgorge any profits, fees, or compensation earned from other ventures
 in which they participate. Investors in the Class A Preferred Shares will not have any right
 to participate in or share in the returns of any other business activities conducted by the
 Manager or its affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;· The
 Manager and its principals are not required to devote all, or any specified portion, of their
 time to the Company's affairs and may devote substantial time and resources to other
 business interests. This could reduce the time and attention devoted to our operations.

&nbsp;&nbsp;&nbsp;&nbsp;· The
 Manager is entitled to receive fees and reimbursement of expenses pursuant to the Management
 Agreement. Because such fees are paid regardless of the profitability of the Clinics or the
 Company, and because Distributions are made only from available cash and at the discretion
 of the Manager, conflicts may arise between maximizing fees and maximizing Distributions.

&nbsp;&nbsp;&nbsp;&nbsp;· The
 Company may enter into transactions with the Manager or its affiliates, including service
 arrangements or other agreements. Such transactions may not be negotiated on an arm's-length
 basis, and Members holding Class A Preferred Shares will not have approval rights over such
 arrangements.

 ***Our Operating Agreement limits the liability of our Manager and provides broad indemnification rights, which may restrict the remedies available to Members.***

  ****

Our Operating Agreement provides that the Manager will not be liable to the Company or the Members for actions taken in connection with Company affairs except in cases involving actual fraud, gross negligence, willful misconduct, bad faith, breach of fiduciary duty, reckless disregard of duty, or intentional and material breach of the Operating Agreement. The Company has also agreed to indemnify the Manager and other protected persons to the fullest extent permitted by law, subject to similar exceptions.

In addition, the Operating Agreement permits the Manager and its affiliates to engage in other business activities, including activities that may compete with the Company, without being deemed in breach of duty solely by reason of such activities. As a result of these provisions, Members may have more limited remedies against the Manager than would exist in the absence of such contractual limitations.

 ***The tax treatment of an investment in the Company is complex, uncertain and subject to change.***

  ****

We currently intend to be treated as a partnership for U.S. federal income tax purposes. As a partnership, we generally would not be subject to entity-level U.S. federal income tax. Instead, our taxable income, gain, loss and deductions would be allocated to our Members, and Members would be required to report such items on their individual tax returns, regardless of whether we make cash distributions.

If the Company were treated as a "publicly traded partnership" within the meaning of Section 7704 of the Internal Revenue Code (including as a result of the existence of a secondary market or the substantial equivalent thereof for our Class A Preferred Shares), the Company would generally be treated as a corporation for U.S. federal income tax purposes unless an exception applies. If we were treated as a corporation, we would be subject to entity-level U.S. federal income tax on our taxable income, and distributions to Members could be treated as taxable dividends to the extent of earnings and profits, resulting in potential double taxation.

In addition, our Manager has discretion, subject to applicable law, to cause the Company to elect to be treated as a corporation for U.S. federal income tax purposes. Any such change in tax classification could materially and adversely affect the amount and timing of cash distributions to Members and the after-tax return on an investment in the Company.

Tax laws are complex and subject to change, and the IRS could challenge our intended tax treatment. Members are urged to consult their own tax advisors regarding the tax consequences of an investment in the Company.

***By purchasing Class A Preferred Shares in this offering, you are bound by the arbitration provision contained in our subscription agreement which limit your ability to bring class action lawsuits or seek remedy on a class basis, including with respect to securities law claims.***

By purchasing shares in this offering, Investors agree to be bound by the arbitration provision contained in our subscription agreement (the "Arbitration Provision"). Such Arbitration Provision applies to claims under the U.S. federal securities laws and to all claims that are related to the Company, including with respect to this offering, our Class A Preferred Shares, and our ongoing operations, among other matters, and limit the ability of investors to bring class action lawsuits or similarly seek remedy on a class basis.

By agreeing to be subject to the Arbitration Provision, you are severely limiting your rights to seek redress against us in court. For example, you may not be able to pursue litigation for any claim in state or federal courts against us, our Manager, or their respective directors or officers, including with respect to securities law claims, and any awards or remedies determined by the arbitrators may not be appealed. In addition, arbitration rules generally limit discovery, which could impede your ability to bring or sustain claims, and the ability to collect attorneys' fees or other damages may be limited in the arbitration, which may discourage attorneys from agreeing to represent parties wishing to commence such a proceeding.

Specifically, the Arbitration Provision provides that either party may, at its sole election, require that the sole and exclusive forum and remedy for resolution of a claim be final and binding arbitration. We have not determined whether we will exercise our right to demand arbitration but reserve the right to make that determination on a case-by-case basis as claims arise. In this regard, the Arbitration Provision is similar to a binding arbitration provision as we are likely to invoke the Arbitration Provision to the fullest extent permissible.

Any arbitration brought pursuant to the Arbitration Provision must be conducted in the State of Delaware. The term "Claim" as used in the Arbitration Provision is very broad and includes any past, present, or future claim, dispute, or controversy involving you (or persons claiming through or connected with you), on the one hand, and us (or persons claiming through or connected with us), on the other hand, relating to or arising out of your subscription agreement, and/or the activities or relationships that involve, lead to, or result from any of the foregoing, including (except an individual Claim that you may bring in Small Claims Court or an equivalent court, if any, so long as the Claim is pending only in that court) the validity or enforceability of the Arbitration Provision, any part thereof, or the entire subscription agreement. Claims are subject to arbitration regardless of whether they arise from contract; tort (intentional or otherwise); a constitution, statute, common law, or principles of equity; or otherwise. Claims include (without limitation) matters arising as initial claims, counter-claims, cross-claims, third-party claims, or otherwise. The scope of the Arbitration Provision is to be given the broadest possible interpretation that will permit it to be enforceable. We believe that the Arbitration Provision is enforceable under federal law, the laws of the State of Delaware, or under any other applicable laws or regulations. However, the issue of enforceability is not free from doubt and to the extent that one or more of the provisions in our subscription agreement with respect to the Arbitration Provision or otherwise requiring you to waive certain rights were to be found by a court to be unenforceable, we would abide by such decision.

As a result of these arbitration provisions, you and our other members may be subject to increased costs in bringing a claim, limited access to information and you may also be subject to other imbalances of resources between us and our members. These provisions may also discourage you and other members, including those who may purchase securities upon resale by any initial purchaser in an aftermarket or otherwise, from bringing claims at all and will limit your ability to bring a claim in a judicial forum that you find favorable.

Further, potential Investors should consider that our subscription agreement restricts the ability of our Members to bring class action lawsuits or to similarly seek remedy on a class basis, unless otherwise consented to by us. These restrictions on the ability to bring a class action lawsuit are likely to result in increased costs, both in terms of time and money, to individual investors who wish to pursue claims against us.

BY AGREEING TO BE SUBJECT TO THE ARBITRATION PROVISION, INVESTORS WILL NOT BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

 ***By purchasing the Class A Preferred Shares in this offering, you are bound by the jury waiver provisions contained in our subscription agreement, which require you to waive your right to a trial by a jury for those matters that are not otherwise subject to the arbitration provisions, including with respect to securities law claims.***

By purchasing Class A Preferred Shares in this offering, Investors agree to be bound by the jury waiver provisions contained in our subscription agreement and our Operating Agreement. Such jury waiver provisions apply to claims under the U.S. federal securities laws and to all claims that are related to the Company, including with respect to this Offering, our Class A Preferred Shares, our holdings, our ongoing operations and the management of our investments, among other matters, and means that you are waiving your rights to a trial by jury with respect to such claims.

We believe that the jury waiver provisions are enforceable under federal law, the laws of the State of Delaware, or under any other applicable laws or regulations. However, the issue of enforceability is not free from doubt and to the extent that one or more of the provisions in our subscription agreement or our Operating Agreement with respect to the jury waiver provisions were to be found by a court to be unenforceable, we would abide by such decision.

BY AGREEING TO BE SUBJECT TO THE JURY WAIVER PROVISIONS, INVESTORS WILL NOT BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

***By purchasing Class A Preferred Shares in this offering, you are bound by the provisions contained in our subscription agreement and Operating Agreement that require you to waive your rights to request to review and obtain information relating to the Company, including, but not limited to, names and contact information of our Members.***

By purchasing Class A Preferred Shares in this offering, Investors agree to be bound by the provisions contained in our subscription agreement (the "Waiver Provision"). The Waiver Provision limits the ability of our Members to make a request to review and obtain information relating to and maintained by the Company, including, but not limited to, names and contact information of our Members, information listed in Section 18-305 of the Delaware Limited Liability Company Act, as amended, and any other information deemed to be confidential by the Manager in its sole discretion. While the intent of the Waiver Provision is to protect your personally identifiable information from being disclosed pursuant to Section 18-305, by agreeing to be subject to the Waiver Provision, you are severely limiting your right to seek access to the personally identifiable information of other Members, such as names, addresses and other information about Members and the Company that the Manager deems to be confidential. As a result, the Waiver Provision could impede your ability to communicate with other Members, and such provisions, on their own, or together with the effect of the Arbitration Provision, may impede your ability to bring or sustain claims against the Company, including under applicable securities laws.

We believe that the Waiver Provision is enforceable under federal law, the laws of the State of Delaware, or under any other applicable laws or regulations. However, the issue of enforceability is not free from doubt and to the extent that one or more of the provisions in our subscription agreement and Operating Agreement, with respect to the Waiver Provision were to be found by a court to be unenforceable, we would abide by such decision.

BY AGREEING TO BE SUBJECT TO THE WAIVER PROVISION, INVESTORS WILL NOT BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

**Risks Relating to Our Financial Condition**

 ***We have a limited operating history, have not generated any revenue to date, have limited cash, and there is substantial doubt about our ability to continue as a going concern.***

 ****

As of March 3, 2026, we had no revenue and very limited operations. Future losses are likely to occur until we are able to generate revenue from the origination of loans in connection with the opening of Clinics (by third party Operators). Prior to the commencement of this offering, have accrued approximately $91,500 in organization and offering related costs. We currently do not have sufficient liquidity to fund our operating expenses, pursue our business plan, or make Distributions to Members. As of the date of this Offering Circular, we have minimal cash on hand.

We expect to continue to incur losses for the foreseeable future as we seek to implement our business model and begin generating revenue from commercial loans and consulting services to Operators of Clinics to whom we anticipate providing our consulting services. Our ability to achieve profitability will depend on a number of factors, including our ability to raise sufficient capital in this offering, successfully originating our first loans to fund and launch the first Clinics with our Operator partners, and enable our operating partners to achieve profitable operations.

While we intend to use a portion of the proceeds from this Offering to finance these activities, there can be no assurance that we will raise capital in amounts sufficient to implement our business plan or achieve profitable operations. If we are unable to obtain sufficient funding, we may be required to delay or scale back our business plans, reduce expenses, seek additional financing on unfavorable terms, or cease operations. Any such developments could materially and adversely affect the value of your investment. Accordingly, an investment in our Class A Preferred Shares is highly speculative and involves a substantial risk of loss. Investors should be prepared to lose all or a substantial portion of their investment. As a result of these, among other factors, our financial statements for the year ended October 31, 2025, include an explanatory paragraph in Note 2 Going Concern, indicating that there is substantial doubt about our ability to continue as a going concern.

***Our existing financial resources are insufficient to meet our planned operating expenses, and we will need to raise additional capital to finance our anticipated operations.***

 ****

We currently have no sources of revenue and limited cash to meet our anticipated operating expenses. As a result, we are dependent on obtaining additional financing to fund our anticipated operations. In the short term, unless we are able to raise capital through the offering of debt and/or equity, we will be unable to meet our anticipated obligations or continue executing on our business plan. Over the longer term, we expect to seek additional funding through the sale of equity or debt securities, including the Class A Preferred Shares being offered pursuant to this Offering Circular. However, there can be no assurances that we will be able to obtain financing on acceptable terms, or at all.

  **

 ***We have accrued substantial expenses related to our formation, initial operations and this offering.***

  **

As of March 3, 2026, we have accrued expenses of $91,500. These expense include legal and accounting expenses, as well as accrued compensation related to our employees. If we are not able to raise sufficient capital in this offering, these accrued expenses will constitute a large portion of the monies raised which would significantly decrease the amount of capital available for future operations (See "[Use of Proceeds](#a_011)" in this Offering Circular).

 ***Our Manager has expressed concerns about our ability to continue as a going concern.***

The Manager, through its management team, has expressed concern about our ability to continue as a going concern based on the absence of any revenue, and our need for additional financing to fund all of our operations. It is not possible at this time for us to predict with assurance the potential success of our business. The revenue and income potential of our proposed business and operations are unknown. If we cannot continue as a viable entity, we may be unable to continue our operations, and you may lose some or all of your investment in our Class A Preferred Shares.

 ***Our financial results are likely to fluctuate based on the performance of independent Clinic operators.***

Our revenues depend in large part on the timing and profitability of the Clinics and the Operators that receive our commercial loans and consulting services. As these borrowers will be independent operators of the Clinics, their success depends on factors largely outside of our control, including their ability to secure locations, hire medical professionals, attract patients, and comply with healthcare regulations. Delays in Clinic openings, underperformance of operators, or defaults on loan obligations could cause our future revenues to vary significantly from period to period. In addition, our term sheet with DGR, our anticipated initial Operator of the Clinics, contemplates payment of our consulting services as a percentage of EBITDA of each Clinic. Accordingly, our ability to derive revenue from such consulting services will be dependent on the performance of the Operator of the applicable Clinic(s).

Other factors, such as broader economic conditions, changes in patient demand for behavioral-health or TMS-related services, and our ability to retain key employees and operator relationships, may also affect our results. As a result, our operating performance may fluctuate substantially between periods, and future results could differ materially from expectations.

**Risks Relating to Our Business and Industry**

 ***Our future agreements with Operators may not be entered into on favorable terms, and delays or adverse developments in our Clinic expansion could materially impact our business plan.***

Our business plan depends on us entering into agreements to provide consulting services with newly developed Clinics managed by DGR or other Operators. We have not yet entered into definitive agreements with respect to any Clinic and the Company is still in the early stages of development. There can be no assurance that such Clinics will be opened as anticipated, will generate enough revenue to pay the interest and principal on our loans, achieve commercial success, or we will be able to negotiate agreements on terms that we currently anticipate. Market conditions, increased competition, changes in healthcare reimbursement rates, or regulatory scrutiny could prevent our anticipated Clinics from generating significant revenue, which would result in less fees to the Company for consulting services, which would materially harm our financial condition and ability to implement our business plan.

 **

***Although we seek to structure our relationships to comply with healthcare laws, regulators could view aspects of our model—non-medical operators hiring physicians for certain services, as non-compliant in some jurisdictions.***

 **

Our Operators are not professional corporations and may contract with physicians or other licensed professionals to deliver services required by law for particular treatments. We intend to make every effort to design our future agreements (e.g., management, loans, and consulting arrangements) to respect state restrictions on the corporate practice of medicine, fee-splitting, supervision, advertising, and fair-market-value standards. Nevertheless, interpretations vary by state and over time regulators or courts could determine that an operator's engagement of physicians, or our economics with the operator, results in improper control of clinical practice or unlawful sharing of professional fees. We may need to modify agreements, change pricing, or restructure relationships, which could increase costs or reduce revenues.

 ****

 ***We anticipate entering into secured and unsecured loan arrangements in connection the Operators of the Clinics which will expose us to credit, collateral, and recovery risks.***

In connection with our partnerships with Operators, we anticipate entering into secured or unsecured loan arrangements. The structure, amount, priority, maturity, interest rate, covenants, and collateral (if any) of such loans will vary depending on the specific transaction, market conditions, borrower profile, and business objectives at the time the loan is made.

As a result, certain loans may involve greater credit risk than others. Secured loans may be collateralized by assets such as equipment or other clinic-related assets, while other loans may be unsecured. The value, liquidity, and enforceability of any collateral may be uncertain and could decline over time, particularly if the underlying clinic operations underperform or cease operations. Medical and clinic-related equipment, in particular, may be specialized, subject to rapid technological obsolescence, regulatory constraints, or limited resale markets, which could materially impair recovery values.

There can be no assurance that borrowers will satisfy their repayment obligations, that we will be able to enforce our rights in a timely or cost-effective manner, that any pledged collateral will be sufficient to cover outstanding amounts owed, or that we will be able to successfully foreclose upon, repossess, or liquidate such collateral at values sufficient to prevent losses. In addition, enforcement proceedings may be subject to delays, legal defenses, bankruptcy proceedings, regulatory limitations, or other factors beyond our control.

Further, we may have limited ability to monitor or control the manner in which Operators utilize loan proceeds. If borrowed funds are misallocated, used inefficiently, or deployed in projects that do not improve clinic operations or profitability, the financial performance of the Clinic(s) may deteriorate, thereby increasing credit risk and the potential for loss to our Company.

Accordingly, our lending activities may result in partial or total losses of principal and interest, which could materially and adversely affect our financial condition, results of operations, and ability to make Distributions to Members.

 **

***Changes in healthcare regulation or enforcement priorities could require us and our operators to adjust contract terms, supervision models, or economics.***

 **

State and federal requirements for physician involvement, supervision, facility licensing, and marketing of healthcare services evolve over time and vary by jurisdiction. New rules or guidance could restrict the use of non-medical operators, alter supervision requirements for specific treatments, or limit permissible financial arrangements. We and our operators may need to renegotiate agreements, modify economics to meet fair-market-value standards, or implement additional compliance controls, any of which could increase costs or reduce demand for our offerings.

***We depend on our management team and the management teams of our clinic operating partners, and the loss of key personnel could materially harm our business.***

 ****

Our success depends heavily on (i) the leadership and strategic direction of our Manager, and specifically its Chief Executive Officer, Tyler Ehler, and other key consultants and personnel, and (ii) the business and operational capabilities of the management teams of the independent Clinic Operators with whom we intend to partner. We will rely on these Operators to recruit, train, and manage qualified staff, contract with medical professionals when required, and operate their Clinics profitably.

Our Manager, currently has an employment agreement with Mr. Ehler, which is an at-will employment agreement and may be terminated at any time. The loss of Mr. Ehler or other key members of our Manager could disrupt our operations and slow our growth. Similarly, we have limited control over the personnel decisions of third-party Clinic Operators. If a Clinic Operator experiences turnover or loses experienced management, its Clinics may fail to achieve or maintain profitability, which could reduce or delay payments owed to us for consulting services. Any such events could materially and adversely affect our revenues, results of operations, and growth prospects, including our ability to make Distributions to the Members.

 **

 ***Our future success depends on our Manager's ability to attract, hire, and retain additional qualified personnel as we grow.***

  **

As we expand our operations and the number of Clinics we finance, our ability to continue scaling will depend our Manager hiring and retaining additional qualified personnel as needed. As our business grows, we, through our Manager, will need to expand our management, finance, operations, compliance, and business-development teams to manage a growing portfolio of loans and consulting engagements. Competition for experienced professionals in the healthcare services and finance sectors is intense, and our Manager may not be able to attract or retain the personnel we need at reasonable cost, or at all.

Failure to recruit and retain skilled employees and executives could slow our growth, reduce our ability to service our Clinic partners effectively, and limit our capacity to identify and onboard new operators. If we cannot build and maintain a strong team as we scale, our ability to execute our business strategy and achieve profitability could be materially and adversely affected.

 **

 ****

 **

 ****

***Natural disasters and other events beyond our control could materially adversely affect us.***

Natural disasters or other catastrophic events may cause damage or disruption to our operations including the ability for our operators to run their clinics and treat patients and thus could have a strong negative effect on us. Our business operations are subject to interruption by natural disasters, fire, power shortages, pandemics and other events beyond our control.

 ***Our business depends on the ability of our third-party Clinic Operators receiving adequate reimbursement from health insurers, and changes in reimbursement policies or FDA determinations could materially harm their ability to pay us and, as a result, adversely affect our business.***

A substantial portion of the revenues generated by the third-party Clinic Operators that we intend to finance or support depends on their ability to obtain reimbursement from private health insurers and government healthcare programs for the services they provide to patients. If these Operators are unable to secure or maintain adequate reimbursement levels for their treatments—particularly for TMS procedures, they may experience significant reductions in revenue and cash flow, which could impair their ability to meet their financial obligations to us under our anticipated credit facility loans, equipment leases, or consulting agreements. Any such reduction in reimbursement, delay in payments, or denial of coverage could adversely affect the ability of these Operators to service their indebtedness or make payments owed to us, which in turn could have a material adverse effect on our business, financial condition, and results of operations.

 ***We do not currently maintain managers' and officers' liability insurance, and our indemnification obligations may be limited and could reduce funds available for operations.***

  ****

We do not presently maintain managers' and officers' liability insurance covering our Manager or other protected persons. As a result, such persons may, under certain circumstances, be personally exposed to claims arising from their service to the Company.

Our Operating Agreement provides for exculpation and indemnification of the Manager and other protected persons to the fullest extent permitted by Delaware law, subject to certain exceptions, including for acts involving actual fraud, gross negligence, willful misconduct, bad faith, breach of fiduciary duty, reckless disregard of duty, or intentional and material breach of the Operating Agreement. However, there can be no assurance that such contractual protections will be sufficient to cover all potential claims, expenses, or liabilities.

In addition, our indemnification obligations may require us to advance expenses or reimburse significant legal costs incurred by the Manager or other protected persons, which could reduce funds otherwise available for operations or distributions to Members.

 ***If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, current and potential Members could lose confidence in our financial reporting, which would harm our business.***

 ****

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our brand and operating results could be harmed.

Under our Operating Agreement, the Manager has exclusive authority and discretion over the management and control of the Company's business and affairs, including financial reporting processes and the design and implementation of internal controls. Members, including holders of Class A Preferred Shares, have limited voting rights and no direct role in overseeing management, internal control systems, or financial reporting policies. We do not maintain an independent board of directors or independent audit committee to provide oversight of our financial reporting practices.

As a result, investors must rely substantially on the judgment, integrity, and performance of the Manager and its designated officers and personnel, with respect to internal controls. We may in the future identify material weaknesses or areas requiring improvement in our internal control systems, and we cannot assure you that measures implemented to address such issues will be effective. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could result in material misstatements, regulatory scrutiny, or a loss of investor confidence, which could materially and adversely affect our business, financial condition, and ability to make Distributions to Members.

 ***Distributions may reduce a Member's tax basis, and Members may recognize taxable income even if no cash distributions are made.***

  ****

We intend to be treated as a partnership for U.S. federal income tax purposes. As a result, Members generally will be allocated their distributive share of our taxable income, gain, loss, and deduction, regardless of whether we make cash Distributions.

Distributions from the Company generally will not be taxable to a Member to the extent of such Member's adjusted tax basis in its Class A Preferred Shares, but instead will reduce such Member's adjusted tax basis. To the extent a Distribution exceeds a Member's adjusted tax basis, such excess generally will be treated as taxable gain from the sale or exchange of such Shares.

Because taxable income is allocated to Members whether or not cash is distributed, it is possible that a Member could incur a U.S. federal income tax liability in respect of allocated income without receiving sufficient cash Distributions to pay such taxes. See "[Material U.S. Federal Tax Considerations](#a_021)."

  **

 ***We may issue the Class A Preferred Shares on a public, permissionless blockchain, which presents risks that would not be present on a private or permissioned blockchain or if the Company or its transfer agent maintained the books and records offline.***

  **

Because the blockchain is open and publicly viewable, all transaction data — including wallet addresses, transaction amounts, and transfer history — is permanently visible to any party. While wallet addresses are pseudonymous and do not by themselves identify Member holding Class A Preferred Shares, this level of transparency would not exist on a permissioned blockchain and could present privacy concerns for Members. Technology-based solutions for privacy-preserving identity verification, including zero-knowledge proofs, are being developed but are not yet fully mature.

Additionally, because public, permissionless blockchains are used by a wide range of participants for different purposes — including purposes that may be illegal or subject to regulatory scrutiny — the Company's association with a public blockchain network could create reputational risk or invite increased regulatory attention, regardless of the Company's own lawful use of the technology. This could cause investors to hesitate to invest in the Class A Preferred Shares linked to blockchain technology, which could impact the participation of potential investors and negatively impact the potential liquidity and value of the Shares.

 ***In the event the Company's book and records are maintained on the blockchain , the blockchain transaction records are the sole official records of ownership of its tokens / shares and will control in the event of any discrepancy. The Transfer Agent will maintain a copy of the block-chain as a duplicate record only.***

  ****

In the event the Company's books and records on maintained on the blockchain, records of ownership and secondary transfers of tokens or shares between holders, which the Company refers to as ''peer-to-peer'' transactions, would be maintained on a blockchain network with secondary records solely on the book-entry records of the Transfer Agent. The Transfer Agent is regulated by the SEC and the blockchain records will constitute the only official shareholder records for our token / Shares and govern the record ownership of our tokens / Shares in all circumstances. Tokens / Shares are ''ERC 721 Protocol'' digital tokens that are transferable between approved accounts in peer-to-peer transactions on a blockchain network approved by the Transfer Agent. Such tokens will be created, held, distributed, maintained, and deleted by the Transfer Agent, and not by the Company. The Transfer Agent will use the ERC 721 Standard (which can interface with various blockchain networks' programming standards) to program any relevant compliance-related transfer restrictions that would traditionally have been printed on a paper stock certificate onto ''smart contracts'' (computer programs written to the relevant blockchain), which will allow the smart contract to impose the relevant conditions on the transfer of the tokens / Shares. One example of such coding is a restriction on to whom tokens / Shares may be transferred. Tokens cannot be created or deleted by any entity other than the Transfer Agent.

 **

***Cautionary Note***

 **

We have sought to identify what we believe to be the most significant risks to our business, but we cannot predict whether, or to what extent, any of such risks may be realized nor can we guarantee that we have identified all possible risks that might arise. Investors should carefully consider all of such risk factors before making an investment decision with respect to our Class A Preferred Shares.

**USE OF PROCEEDS**

If we sell all of the Offered Shares, our gross proceeds will be $50,000,000. The figures below are estimates only and the actual costs may differ. The precise amounts that we will devote to each of the following items, and the timing of expenditures, will vary depending on numerous factors. As of the date of this Offering Circular, we have not sold any securities pursuant to this offering.

To account for a varying potential use of funds from the low to high ends of this range, the following table represents management's best estimate of the uses of gross proceeds. We provide a summary of the proceeds, excluding offering expenses at the maximum raise amount, as well as at the 25%, 50%, and 75% intervals. Although we are providing the summaries below, the offering has no minimum amount. Accordingly, we could receive less than the minimum amount depicted in the summary. All amounts in this table are based on estimated amounts outstanding on March 3, 2026, except as specifically stated otherwise.

---

| | |
|:---|:---|
| **If 100% of the Shares are sold:** <br> **Planned Actions** |<br> **Estimated Cost to Complete** |
| Loan / Line of Credit for: |  |
| &nbsp;&nbsp;&nbsp; Purchase / Rental of Equipment for 40 Clinics | $24000000 |
| &nbsp;&nbsp;&nbsp; Buildout expenses for 40 Clinics | 4000000 |
| &nbsp;&nbsp;&nbsp; Initial working capital for Clinics | 12000000 |
| Marketing Costs of this Offering | 2500000 |
| Repayment of Convertible Promissory Notes | 370000 |
| Reserve Account deposits\* | 4000000 |
| Repayment of accrued liabilities | 91500 |
| Working Capital and General Corporate Purposes | 3038500 |
| **TOTAL** | $50000000 |

---

---

| | |
|:---|:---|
| **If 75% of the Shares are sold:**<br>**Planned Actions** |<br>**Estimated Cost to Complete** |
| Loan / Line of Credit for: |  |
| &nbsp;&nbsp;&nbsp; Purchase / Rental of Equipment for 30 Clinics | $18000000 |
| &nbsp;&nbsp;&nbsp; Buildout expenses for 30 Clinics | 3000000 |
| &nbsp;&nbsp;&nbsp; Initial working capital for 30 Clinics | 9000000 |
| Marketing Costs of this Offering | 1875000 |
| Repayment of Convertible Promissory Notes | 370000 |
| Reserve Account deposits\* | 3000000 |
| Repayment of accrued liabilities | 91500 |
| Working Capital and General Corporate Purposes | 1210400 |
| **TOTAL** | $**37500000** |

---

---

| | |
|:---|:---|
| **If 50% of the Shares are sold:**<br>**Planned Actions** |<br>**Estimated Cost to Complete** |
| Loan / Line of Credit for: |  |
| &nbsp;&nbsp;&nbsp; Purchase / Rental of Equipment for 20 Clinics | $12000000 |
| &nbsp;&nbsp;&nbsp; Buildout expenses for 20 Clinics | 2000000 |
| &nbsp;&nbsp;&nbsp; Initial working capital for 20 Clinics | 6000000 |
| Marketing Costs of this Offering | 1250000 |
| Repayment of Convertible Promissory Notes | 370000 |
| Reserve Account deposits\* | 2000000 |
| Repayment of accrued liabilities | 91500 |
| Working Capital and General Corporate Purposes | 1288500 |
| **TOTAL** | $**25000000** |

---

---

| | |
|:---|:---|
| **If 25% of the Shares are sold:**<br>**Planned Actions** |<br>**Estimated Cost to Complete** |
| Loan / Line of Credit for: |  |
| &nbsp;&nbsp;&nbsp; Purchase / Rental of Equipment for 9 Clinics | $5400000 |
| &nbsp;&nbsp;&nbsp; Buildout expenses for 9 Clinics | 900000 |
| &nbsp;&nbsp;&nbsp; Initial working capital for 9 Clinics | 2700000 |
| Marketing Costs of this Offering | 625000 |
| Repayment of Convertible Promissory Notes | 370000 |
| Reserve Account deposits\* | 1000000 |
| Repayment of accrued liabilities | 91500 |
| Working Capital and General Corporate Purposes | 1413500 |
| **TOTAL** | $**12500000** |

---

\* Our Manager has the right to invest such Reserve Account funds in cash equivalents, at its discretion.

As indicated in the table above, if we sell only 25%, 50% or 75% of the Offered Shares in this Offering, we would expect to use the resulting proceeds for the same purposes as we would use the proceeds from the sale of 100% of the Offered Shares, and in approximately the same proportions, until such time as such use of proceeds would leave us without working capital reserve. At that point we would expect to modify our use of proceeds by limiting our expansion, leaving us with the working capital reserve indicated. There is no guarantee that we will be able to sell the minimum amount of 25% summarized above.

The use of proceeds also assumes that the holders of $325,000 in principal of our Convertible Notes (which are convertible into Class A Preferred Shares) elect to not convert their Convertible Notes and instead are repaid the entire principal plus accrued interest and bridge fees (calculated through March 3, 2026 with respect to amounts due under the Convertible Notes). In the event that the holders elect to convert any portion of the Convertible Notes, the additional unused proceeds are anticipated to be used for general working capital.

The expected use of proceeds from this Offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with respect to working capital, may vary significantly depending on numerous factors. The precise amounts that we will devote to each of the foregoing items, and the timing of expenditures, will vary depending on numerous factors. As a result, our management will retain broad discretion over the allocation of the proceeds from this offering.

In the event we do not sell all of the Class A Preferred Shares being offered, we may sell Class A Preferred Shares through other channels in order to support the intended use of proceeds indicated above. If we secure additional equity funding, investors in this offering would be diluted. In all events, there can be no assurance that additional financing would be available to us when wanted or needed and, if available, on terms acceptable to us.

 

 

 

 

**PLAN OF DISTRIBUTION**

This Offering Circular is part of an Offering Statement that we filed with the SEC, using a continuous offering process. Periodically, as we have material developments, we will provide an Offering Circular supplement that may add, update or change information contained in this Offering Circular. Any statement that we make in this Offering Circular will be modified or superseded by any inconsistent statement made by us in a subsequent Offering Circular supplement. The Offering Statement we filed with the Securities and Exchange Commission ("SEC") includes exhibits that provide more detailed descriptions of the matters discussed in this Offering Circular. You should read this Offering Circular and the related exhibits filed with the SEC and any Offering Circular supplement, together with additional information contained in our annual reports, semi-annual reports and other reports and information statements that we will file periodically with the SEC.

**Exchange Listing**

As of the date of this Offering Circular, there is no trading market for any of our securities, and we cannot assure you that a trading market will develop. We have not applied to list our securities on any national securities exchange.

**Pricing of the Offering**

Prior to this Offering, there has been no public market for the Offered Shares. The public offering price was determined by the Manager.

**Offering Period and Expiration Date**

This Offering will start on or after the qualification date and will terminate on the earlier of (a) twelve (12) months from the date this Offering Circular is qualified for sale by the SEC (which date may be extended for an additional 90 days in our sole discretion); (b) the date when all Offered Shares have been sold; or (c) the date on which this Offering is earlier terminated by us, in our sole discretion.

The Company may extend this Offering for an additional time period unless the Offering is completed or otherwise terminated by us, or unless we are required to terminate by application of Regulation A of the JOBS Act. Funds received from Investors will be counted towards the Offering only if the form of payment, such as a check or wire transfer, clears the banking system and represents immediately available funds held by us prior to the termination of the subscription period, or prior to the termination of the extended subscription period if extended by the Company.

**Incentive Shares**

Certain Investors in this Offering are eligible to receive Incentive Shares in addition to the Offered Shares subscribed for as part of the Offering, effectively discounting the price per share offered. To qualify for the receipt of Incentive Shares, an Investor is required to purchase at least $100,000 of Offered Shares in one closing, referred to as the Incentive Threshold. Upon meeting the Incentive Threshold, such applicable Investor will receive, as part of their investment, such number of additional Class A Preferred Shares equal to ten percent (10.0%) of the Offered Shares purchased by such Investor. Incentive Shares will be granted at the applicable closing only upon such Investor meeting the Incentive Threshold for such closing and such investment will not aggregate with purchases of Offered Shares in any other closing.

**Broker Dealers**

The Company will not initially sell the Offered Shares through commissioned broker-dealers, but may do so after the commencement of the Offering. Any such arrangement will add to our expenses in connection with the Offering. If we engage one or more commissioned sales agents or underwriters, we will supplement this Form 1-A to describe the arrangement.

**Subscription Procedures**

If you decide to subscribe for our Offered Shares in this Offering, you should review your subscription agreement. A copy of the form of subscription agreement is attached to this Offering Circular as Exhibit 4.1. Completed and signed subscription documents shall be either mailed directly to the Company at Tranquil Healthcare Fund I, LLC, 18200 Von Karman Ave. Suite 850, Irvine CA 92612, or sent via electronic correspondence at: <u>invest@tranquil.healthcare.</u> Since there is no minimum amount to complete a closing under this Offering, the Company may immediately deposit the proceeds from accepted subscription agreements into the Company's bank account, and subject to the requirement to deposit eight percent (8.00%) of subscriptions in the Reserve Account to be maintained as a contingency reserve for Distributions (which may be invested, at management's discretion, into cash equivalents), the Company may use such proceeds in accordance with the Use of Proceeds.)

You shall deliver funds by either check, ACH deposit, wire transfer, or such other consideration as the Manager deems appropriate, pursuant to the instructions set forth in the subscription agreement. Upon confirmation that a subscriber's funds have cleared, confirmation that your subscription has been accepted will be sent to you within 48 hours of the applicable closing electronically.

Any potential Investor will have ample time to review the subscription agreement, along with their counsel, prior to making any final investment decision. We shall only deliver such subscription agreement upon request after a potential Investor has had ample opportunity to review this Offering Circular.

 ***Agreement to be Bound by the Operating Agreement***

By purchasing Class A Preferred Shares, you will be admitted as a member of our Company and will be bound by the provisions of, and deemed to be a party to the Operating Agreement.

**Acceptance of Subscriptions**

Upon our receipt of a subscription agreement and payment, we will countersign the subscription agreement and issue the Class A Preferred Shares subscribed at the applicable closing. Once you submit the subscription agreement, you may not revoke or change your subscription or request your subscription funds. All accepted subscription agreements are irrevocable, and the Company will not return any funds to subscribers regardless of the volume of sales in any applicable closing.

Investors must further comply with the "Investor Suitability Standards" set forth below.

**Investor Suitability Standards**

As a Tier 2 Regulation A offering, Investors must comply with the 10% limitation to investment in the offering, as prescribed in Rule 251. Under Rule 251 of Regulation A, non-accredited, non-natural Investors are subject to the investment limitation and may only invest funds which do not exceed 10% of the greater of the purchaser's revenue or net assets (as of the purchaser's most recent fiscal year end). A non-accredited, natural person may only invest funds which do not exceed 10% of the greater of the purchaser's annual income or net worth (please see below on how to calculate your net worth).

NOTE: For the purposes of calculation, "Net Worth" is defined as the difference between total assets and total liabilities. This calculation must exclude the value of your primary residence and may exclude any indebtedness secured by your primary residence (up to an amount equal to the value of your primary residence). In the case of fiduciary accounts, net worth and/or income suitability requirements may be satisfied by the beneficiary of the account or by the fiduciary, if the donor or grantor is the fiduciary and the fiduciary directly or indirectly provides funds for the purchase of the Offered Shares.

In order to purchase Offered Shares and prior to the acceptance of any funds from an Investor, an Investor will be required to represent, to the Company's satisfaction, that it is either an accredited Investor or is in compliance with the ten percent (10%) of net worth or annual income limitation on investment in this offering. We urge all Investors to review Rule 251 of Regulation A to ensure compliance.

The only Investor in this offering exempt from this limitation is an "Accredited Investor," as defined under Rule 501 of Regulation D. If you meet one of the following tests you qualify as an Accredited Investor:

(i) You are a natural person who has had individual income in excess of $200,000 in each of the two most recent years, or joint income with your spouse in excess of $300,000 in each of these years, and have a reasonable expectation of reaching the same income level in the current year;

(ii) You are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase the Shares (please see below on how to calculate your net worth);

(iii) You are an executive officer or general partner of the issuer or a management team or executive officer of the general partner of the issuer;

(iv) You are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, the Code, a corporation, a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the Shares, with total assets in excess of $5,000,000;

(v) You are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended, the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered under the Investment Company Act of 1940, as amended, the Investment Company Act, or a business development company as defined in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development company as defined in the Investment Advisers Act of 1940;

(vi) You are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor;

(vii) You are a trust with total assets in excess of $5,000,000, your purchase of the Shares is directed by a person who either alone or with his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were not formed for the specific purpose of investing in the Shares;

(viii) You are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has assets in excess of $5,000,000; or

(ix) You are an investment professional in good standing holding the general securities representative license (Series 7), the investment adviser representative license (Series 65), or the private securities offerings representative license (Series 82).

 **No Certificates**

We currently do not anticipate issuing certificates with respect to the Offered Shares. Instead, we intend that our Class A Preferred Shares will be recorded and maintained with our transfer agent, in book-form. Each investor will be provided with an account from our Transfer Agent for tracking its investment and for the issuance of all Distributions.

 **Advertising, Sales and other Promotional Materials**

In addition to this Offering Circular, subject to limitations imposed by applicable securities laws, we expect to use additional advertising, sales and other promotional materials in connection with this offering. These materials may include information relating to this offering, the past performance of our Manager and its officers, directors and its affiliates, articles and publications concerning the clinics and the industry, or public advertisements and audio-visual materials, in each case only as authorized by us. In addition, the sales material may contain certain quotes from various publications without obtaining the consent of the author or the publication for use of the quoted material in the sales material. Although these materials will not contain information in conflict with the information provided by this Offering Circular and will be prepared with a view to presenting a balanced discussion of risk and reward with respect to our common shares, these materials will not give a complete understanding of this Offering, us or our Class A Preferred Shares and will only be made available consistent with the requirements of Rule 255 of Regulation A. This Offering is made only by means of this Offering Circular and prospective investors must read and rely on the information provided in this Offering Circular in connection with their decision to invest in our common shares.

 **How to Subscribe**

 *Investor Account*

When one subscribes to this Offering, the Investor will go through a Know Your Customer ("KYC") process such that an account can be automatically set-up on our Transfer Agent's platform, that is controlled directly by the subscriber.

Each investor may transfer funds into its account at the Transfer Agent by authorizing an electronic transfer using the ACH network from the investor's designated and verified bank account (or other means that may be permitted by the transfer agent) to its funding account. Any distributions we make on our Class A Preferred Shares will also be deposited directly into your funding account. Each investor can view its cash positions in their self-custodied account at the Transfer Agent, through an "Investor Dashboard".

 *Subscription Procedures*

Investors seeking to purchase our Class A Preferred Shares who satisfy the "qualified purchaser" standards should proceed as follows:

&nbsp;&nbsp;&nbsp;&nbsp;· Read
 this entire Offering Circular and any supplements accompanying this Offering Circular.

&nbsp;&nbsp;&nbsp;&nbsp;· Electronically
 complete and execute a copy of the subscription agreement. A specimen copy of the subscription
 agreement, including instructions for completing it, is included in this Offering Circular
 as Exhibit 4.1.

&nbsp;&nbsp;&nbsp;&nbsp;· Complete
 Client onboarding including KYC and establishing an account with our Transfer Agent.

&nbsp;&nbsp;&nbsp;&nbsp;· Transfer
 funds into the Transfer Agent for the purchase of the Class A Preferred Shares.

By executing the subscription agreement and paying the total purchase price for our Class A Preferred Shares subscribed for, each investor agrees to accept the terms of the subscription agreement and attests that the investor meets the minimum standards of a "qualified purchaser", and that such subscription for Class A Preferred Shares, to the extent not an "Accredited Investor" (as defined in Rule 501) does not exceed 10% of the greater of such investor's annual income or net worth (for natural persons), or 10% of the greater of annual revenue or net assets at fiscal year-end (for non-natural persons). Subscriptions will be binding upon investors but will be effective only upon our acceptance and we reserve the right to reject any subscription in whole or in part.

We will offer the Class A Preferred Shares in this Offering for a period of twelve (12) months from the date of commencement of this Offering after qualification or until we raise the maximum amount being offered, whichever occurs earlier, but there is No guarantee that any amount of our preferred shares will be sold. This Offering will commence within two (2) days of the date of qualification by the SEC. We reserve the right to terminate or extend the Offering for any reason at any time. Subscriptions will be accepted on a rolling basis and, once received, are irrevocable by investors. Subscriptions will be binding upon investors and will be accepted or rejected by us at our discretion.

To the extent that the funds are not ultimately received by us or are subsequently withdrawn by the subscriber, the subscription agreement will be considered terminated, and the subscriber will not be entitled to any Class A Preferred Shares subscribed for or distributions that may have accrued.

An investor must transfer funds held in its Transfer Agent account to its own bank account to utilize the funds in any way other than investment in our Class A Preferred Shares. Upon request, our Transfer Agent, will transfer funds back to an investor's verified bank account by ACH transfer, provided that such funds are not irrevocably committed to the purchase of our Class A Preferred Shares or otherwise irrevocably committed through the T7X Platform. An investor may transfer funds out of its T7X Platform account at any time by accessing their Investor Dashboard and selecting "request withdrawal". Funds withdrawn will be released and made available in the investor's funding account typically within 48 hours. Investors may withdraw uncommitted funds by accessing their Investor Dashboard on the T7X Platform and selecting the option to move uncommitted funds held in the T7X account back to their personal bank account. This transfer typically takes three to five business days to complete.

 *Minimum Purchase Requirements*

You must initially purchase at least 250 Class A Preferred Shares in this Offering, or $2,500 based on the current per share price. If you have satisfied the applicable minimum purchase requirement, any additional purchase must be in amounts of at least $10. However, in certain instances, and in our sole discretion, we may revise the minimum purchase requirements in the future or elect to waive the minimum purchase requirement, such as for individuals who participate in different plans established by our Manager.

**Arbitration Provision**

By purchasing Class A Preferred Shares in this offering, Investors agree to be bound by the Arbitration Provisions contained in our subscription agreement and our Operating Agreement. Such Arbitration Provisions apply to claims under the U.S. federal securities laws and to all claims that are related to the Company, including with respect to this offering, our Class A Preferred Shares, and our ongoing operations, among other matters, and limit the ability of investors to bring class action lawsuits or similarly seek remedy on a class basis.

By agreeing to be subject to the Arbitration Provisions contained in our subscription agreement and our Operating Agreement, you are severely limiting your rights to seek redress against us in court. For example, you may not be able to pursue litigation for any claim in state or federal courts against us, our Manager, or their respective directors or officers, including with respect to securities law claims, and any awards or remedies determined by the arbitrators may not be appealed. In addition, arbitration rules generally limit discovery, which could impede your ability to bring or sustain claims, and the ability to collect attorneys' fees or other damages may be limited in the arbitration, which may discourage attorneys from agreeing to represent parties wishing to commence such a proceeding.

Specifically, under the Arbitration Provisions, either party may, at its sole election, require that the sole and exclusive forum and remedy for resolution of a claim be final and binding arbitration. We have not determined whether we will exercise our right to demand arbitration but reserve the right to make that determination on a case by case basis as claims arise. In this regard, the Arbitration Provisions are similar to a binding arbitration provision as we are likely to invoke the Arbitration Provisions to the fullest extent permissible. The Arbitration Provisions apply to claims under the U.S. federal securities laws and to all claims that are related to the Company, including with respect to this offering, our holdings, our Class A Preferred Shares, and our ongoing operations, among other matters.

Any arbitration brought pursuant to the Arbitration Provisions must be conducted in the State of Delaware. The term "Claim" as used in the Arbitration Provisions is very broad and includes any past, present, or future claim, dispute, or controversy involving you (or persons claiming through or connected with you), on the one hand, and us (or persons claiming through or connected with us), on the other hand, relating to or arising out of your subscription agreement, and/or the activities or relationships that involve, lead to, or result from any of the foregoing, including (except an individual Claim that you may bring in Small Claims Court or an equivalent court, if any, so long as the Claim is pending only in that court) the validity or enforceability of the Arbitration Provisions, any part thereof, or the entire subscription agreement. Claims are subject to arbitration regardless of whether they arise from contract; tort (intentional or otherwise); a constitution, statute, common law, or principles of equity; or otherwise. Claims include (without limitation) matters arising as initial claims, counter-claims, cross-claims, third-party claims, or otherwise. The scope of the Arbitration Provisions is to be given the broadest possible interpretation that will permit it to be enforceable. We have no reason to believe that the Arbitration Provisions are not enforceable under federal law, the laws of the State of Delaware, or under any other applicable laws or regulations. However, to the extent that one or more of the provisions in our subscription agreement or our Operating Agreement with respect to the Arbitration Provisions or otherwise requiring you to waive certain rights were to be found by a court to be unenforceable, we would abide by such decision.

As a result of these arbitration provisions, you and our other Members may be subject to increased costs in bringing a claim, limited access to information and you may also be subject to other imbalances of resources between us and our Members. These provisions may also discourage you and other members, including those who may purchase securities upon resale by any initial purchaser in an aftermarket or otherwise, from bringing claims at all and will limit your ability to bring a claim in a judicial forum that you find favorable.

Before purchasing shares, a potential Investor must acknowledge, understand, and agree that: (a) arbitration is final and binding on the parties; (b) the parties are waiving their right to seek remedies in court, including the right to jury trial; (c) pre-arbitration discovery is generally more limited than and potentially different in form and scope from court proceedings; (d) the Arbitration Award is not required to include factual findings or legal reasoning and any party's right to appeal or to seek modification of a ruling by the arbitrators is strictly limited; and (e) the panel of arbitrators may include a minority of persons engaged in the securities industry. The Arbitration Provisions limit the rights of an investor to many legal remedies and rights otherwise available.

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF**

**FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*You should read the following discussion and analysis of our financial condition and results of our operations together with our consolidated financial statements and the notes thereto appearing elsewhere in this Offering Circular. This discussion contains forward-looking statements reflecting our current expectations, whose actual outcomes involve risks and uncertainties. Actual results and the timing of events may differ materially from those stated in or implied by these forward-looking statements due to a number of factors, including those discussed in the sections entitled "Risk Factors", "Cautionary Statement Regarding Forward-Looking Statements" and elsewhere in this Offering Circular. Please see the notes to our Financial Statements for information about our Critical Accounting Policies and Recently Issued Accounting Pronouncements.*

**Overview**

We were incorporated as Tranquil Healthcare, Inc. under the laws of the State of Delaware on October 21, 2025. On March 3, 2026, we completed a holding company reorganization, which resulted in us converting from a corporate structure to a limited liability structure and we became the wholly owned subsidiary of our Manager.

 **<u>Pro Forma Financial Information</u>**

The following pro forma equity statement presents the Company's members' equity as of October 31, 2025, on a pro forma basis to give effect to the conversion, share exchange, and subsequent issuance of LLC Shares of the Company as if these events had occurred as of that date. The pro forma information is presented for illustrative purposes only and does not purport to represent what the actual equity position would have been had the transactions occurred on October 31, 2025, nor does it project the Company's equity position for any future date.

![](image_001.jpg)

The pro forma adjustments consist solely of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Recasting the historical common stock issuance from 625,000 shares ($625 par value) to 847,000 shares ($847 par value) to reflect the actual pre-conversion shares outstanding that were exchanged.

· Adjusting the subscription receivable from ($25) to ($247) to maintain the net contributed capital at $600 (consistent with historical cash proceeds).

· Reflecting the additional 153,000 Common Shares issued to the Manager with no par value or additional paid-in capital impact (as this was a non-cash issuance to complete the 1,000,000-share ownership structure under Manager, with no change in total equity).

The pro forma total members' equity / (deficit) of ($75,750) remains unchanged from the historical stockholders' deficit, as the adjustments are structural in nature and reflect only the recapitalization to the post-conversion LLC equity structure.

On March 3, 2026, in connection with the reorganization of the issuer from a corporation to a limited liability company, we issued a total of 847,000 shares of Common Stock in exchange for 847,000 shares of Tranquil Healthcare, Inc. common stock. Following the transaction, the Predecessor Company's shareholders collectively owned 100% of our issued and outstanding Common Stock.

On March 3, 2026, all of the holders of our Common Shares entered into a purchase agreement with Tranquil Healthcare Holdings, Inc., the Issuer's manager ("Manager") whereby all of our members sold their Common Shares for shares of the Manager. As a result of the transaction, the Issuer became the wholly owned subsidiary of the Manager who owns 100% of Issuer issued and outstanding Common Shares.

**Plan of Operation for the Next Twelve Months**

We believe that if fully subscribed, the proceeds of this Offering will satisfy its 12 month cash requirements for both providing the necessary capital for the opening and operating up to 40 Clinics by our third party Operators, subject to executing definitive agreements with such Operators. If the Company desires to expand to more Clinics, it may have to raise additional funds in the next twelve months. There can be no assurances that we fund or partner with any Clinics in the next 12 months.

As we begin funding Clinics and expanding operations, our Manager may make significant changes in the number of its employees, primarily within the accounting department and possibly with additional consulting expertise to support our business and operational needs. It would be our responsibility to reimburse the Manager for such additional expenses pursuant to the Management Agreement.

 **Loans**. The Company intends to make substantial investments in the form of commercial loans to Operators for such Operators to build out, develop, purchase equipment for, and market the Clinics.

 **Marketing and sales.** Given that we anticipate opening up to 40 Clinics with DGR, pursuant to our term sheet with DGR, DGR will bear the costs of marketing and we expect minimal marketing with the exception of the costs marketing this Offering.

 **Consulting Services**. It is anticipated that we will enter into consulting arrangements with our Operators whereby we will be entitled to a portion of the profitability of each Clinic. For example, our term sheet with DGR contemplates that we will receive 10% of EBITDA for each Clinic. We believe that as the Clinics become more successful and profitable, our fees derived from consulting services will increase. As there is already a non-binding term sheet in place with our anticipated initial operating partner to open up to 40 Clinics and all of the costs of marketing the Clinics is borne by the operating partner, the Company expects minimal marketing with the exception of the costs marketing this Offering

 **Cost of revenue**. The Company expects to have relatively small cost of revenues primarily consisting of the cost of reimbursing our Manager for providing consulting services to our Operators, as well as compensation to Manager personnel, legal, accounting, and other ancillary expenses.

**Research and development**. The Company expects to have minimal research and development costs. It will rely on its management team, operating partners and advisors to assist with the sourcing and evaluation of the newest growing technologies. It will not be developing any technologies internally.

 **General and administrative**. The majority of our general and administrative expenses will consist of payments to our Manager to cover salaries, and bonuses for certain of our executives, board members and advisory board members. In addition, general and administrative expenses include legal, financial and corporate communication services. The Company expects to incur substantial expenses in marketing the current Offering. Further, the Company expects to incur significant general and administrative expenses in the following areas:

· Accounting,
 including audit, accounting, and tax compliance-related costs;

· Transfer Agent fees;

· Investor relations and
 news dissemination, including maintaining and updating a planned website and disseminating news releases; and

· Manager fees, including
 executive officer salaries, and other consulting fees.

**RESULTS OF OPERATIONS**

***From inception October 21, 2025 through to the period ended October 31, 2025***

The following table sets forth information showing the components of net loss from inception October 31, 2025 through the period ended October 31, 2025:

---

| | |
|:---|:---|
|  | **From inception (October 21, 2025)**<br>**through to the period ended**<br>**October 31, 2025** |
| **Revenues** | $**–** |
| **Cost of revenues** | **–** |
| **Gross profit** | **–** |
| **Operating expenses** | **76350** |
| **Loss from operations and before income taxes** | **(76350)** |
| **Income tax expense** | **–** |
| **Net loss** | $**(76350)** |
| **Basic and diluted - loss per common share** | $**(0.12)** |
| **Basic and diluted - weighted average common shares outstanding** | **625000** |

---

During the period from inception October 21, 2025 through to the period ended October 31, 2025, revenues were $0.

Cost of sales were $– period from inception October 21, 2025 through to the period ended October 31, 2025.

Gross profits were $– and $– during the period from inception October 21, 2025 through to the period ended October 31, 2025.

Operating expenses were $76,350 for the period from inception October 21, 2025 through to the period ended October 31, 2025 and is largely comprised of a signing bonus for our CEO $40, 0000 professional fees $32,350 and the $4,000 balance for travel expense and other administrative expenses.

Loss from operations was $76,350 for the period from inception October 21, 2025 through to the period ended October 31, 2025.

Other (expenses) was - for the period from inception October 21, 2025 through to the period ended October 31, 2025.

Net loss for the period from inception October 21, 2025 through to the period ended October 31, 2025 was $76,350.

**LIQUIDITY AND CAPITAL RESOURCES**

The following table summarizes the cash flows from inception through to the period ended October 31, 2025:

---

| | | |
|:---|:---|:---|
|  | **From inception (October 21, 2025)** | **From inception (October 21, 2025)** |
|  | **through to the period ended** | **through to the period ended** |
|  | **October 31, 2025** | **October 31, 2025** |
| **Operating Activities** |  |  |
| **Investing Activities** |  |  |
| **Financing Activities** |  | 600 |

---

During the period from inception October 21, 2025 through to the period ended October 31, 2025 net cash provided by operating activities was zero.

During the period from inception October 21, 2025 through to the period ended October 31, 2025, we used zero net cash from investing activities.

During the period from inception October 21, 2025 through to the period ended October 31, 2025, the Company had $600 net cash provided by financing activities. The cash provided from financing activities is attributable to the proceeds from the initial purchase of founders stock.

At October 31, 2025, we had current assets of $600, current liabilities of $76,350, working capital deficit of $75,750 and an accumulated deficit of $76,350.

We presently have limited and expensive available credit, and do not have bank financing or other external sources of liquidity. We will need to obtain additional capital in order to expand operations and become profitable. In order to obtain capital, we may need to sell additional shares of our common stock or borrow funds from private lenders. There can be no assurance that we will be successful in obtaining additional funding. We will still need additional capital in order to continue operations until we are able to achieve positive operating cash flow. Additional capital is being sought, but we cannot guarantee that we will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, Members may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.

**OFF-BALANCE SHEET ARRANGEMENTS**

We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, results of operations, liquidity, or capital expenditures.

**Recent Financing Transactions**

*<u>Convertible Note</u>*

From November 5 through November 7, 2025, the Company entered into a $300,000 of Convertible Notes with six individual accredited investors ("Note Holders"). The Note matures in 1 year from issuance and carries a 15% annual interest rate along with a 10% fixed bridge fee paid at exit. The Company must offer to repay the Convertible Notes, accumulated interest and bridge fees upon raising $3 million in this Offering. The Note Holders have the right to convert their Convertible Notes, accumulated interest and bridge fees into the Class A Preferred Shares at any time prior to repayment. In addition, the Company issued 22,000 shares of its common stock in connection with the loans underlying the Convertible Notes.

**Quantitative and Qualitative Disclosures about Market Risk**

In the ordinary course of our business, we are not exposed to market risk of the sort that may arise from changes in interest rates or foreign currency exchange rates, or that may otherwise arise from transactions in derivatives.

The preparation of financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company's significant estimates and assumptions include the fair value of the Company's common stock, stock-based compensation, the recoverability and useful lives of long-lived assets, and the valuation allowance relating to the Company's deferred tax assets.

**Contingencies**

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company's management, in consultation with its legal counsel as appropriate, assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company, in consultation with legal counsel, evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates a potentially material loss contingency is not probable, but is reasonably possible, or is probable, but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

**BUSINESS**

**Company Information**

We incorporated as Tranquil Healthcare, Inc. as a corporation under the laws of the State of Delaware on October 21, 2025. In connection with a holding company reorganization, we converted into a Delaware limited liability company and became the wholly owned subsidiary of our Manager. The holding company reorganization was completed on March 3, 2026. As a result of the reorganization, the Manager holds all the outstanding voting stock of the Company.

 ***Our Structure***

![](structure.jpg)

 ***Our Business***

We a recently organized Delaware limited liability company formed to partner with management teams and develop wellness clinics that provide services and treatments focused on Transcranial Magnetic Stimulation in the Clinics. We anticipate our partnering activities will consist of: (i) originate, invest in and manage a portfolio of commercial loans and (ii) providing business and strategic consulting services to Clinics which we finance as well as other wellness clinics.

 ***Our Manager***

Our Manager manages our day-to-day operations through its Board of Directors, officers and consultants. The Manager's Board of Directors is currently made up of (i) Tyler Ehler, who also serves as the Manager's chief executive officer, and (ii) Jeff Campbell. The Manager will additionally retain consultants with experience in medical equipment, medical devices, medical financing, and social media marketing. Pursuant to the Operating Agreement of the Company, the Manager makes substantially all of the decisions of the Company and holds all of the voting securities of the Company, except in certain limited circumstances. Accordingly, all decisions related to the consulting services and agreements with Operators will be subject to the discretion of the Manager.

Our Manager has assembled a group of executives and advisors that have expertise in medical equipment, direct-to-consumer marketing, financing, strategic positioning, biopharma and healthcare businesses, and healthcare reimbursement dynamics. We intend to leverage these skillsets to partner with organizations (the "Operators") that build, develop, and operate the Clinics, including retaining necessary medical and nonmedical personnel. We intend to enter into agreements with Operators in order to provide such Operators with the following services: (i) secured and or unsecured commercial loans pursuant to a revolving line of credit for the buildout, startup costs, equipment purchase or rentals, and marketing of each Clinic and (ii) consulting services related the operations and marketing of each Clinic, which will include marketing strategies, new Clinic expansion analysis and opportunities, new product development, and general business consulting. On October 28, 2025, we entered into a term sheet with DGR Health Services, LLC ("DGR"), a company with management experience in operating Clinics related to TMS, mental health, and psychiatric support services. The term sheet includes a binding 180-day exclusivity period to enter definitive agreements to provide our services for up to forty (40) Clinics in the United States. We have chosen to initially partner with DGR because, their management has operated over 35 clinics in the United States related to TMS, mental health, and psychiatric support services. We are also considering entering into similar arrangements with other potential Operators to provide our loans and services. In addition, from November 6, 2025 through February 11, 2026, we loaned DGR $150,000 in the form of a promissory note for the initial buildout of the first proposed Clinic, which is anticipated to be in Florida. The note matures in one (1) year from issuance, has a 10% interest rate and 10% bridge / exit fee upon repayment, and will automatically be exchanged into a future revolving credit facility, if and when entered into with DGR.

Pursuant to our loans and consulting services, we anticipate receiving the following compensation from Operators based on our term sheet with DGR, subject to executing definitive agreements with DGR, for which there can be no assurances or guarantees: (i) interest from our commercial loans to Operators, anticipated to be 10% per annum ("Loan Interest"), and (ii) after deducting certain Operator management fees, 10% of the Earnings Before Interest, Taxes, Depreciation, and Amortization ("EBITDA") generated by each Clinic that we provide consulting services to ("Management Fees"). In addition, as described in our term sheet with DGR, upon the sale of one or more Clinic (each a "Clinic Sale,") we anticipate receiving repayment of any outstanding commercial loans associated with that Clinic and accrued interest along with 10% of the net proceeds from such Clinic Sale, which is anticipated to be defined as the gross proceeds less any repayment of any outstanding commercial loans, interest and fees directly associated with such sale. In the event that Clinic Sales result in aggregate gross proceeds of $500 million or more, then the Manager will be entitled to the following: (i) a one-time bonus payment of $15 million dollars in cash and (ii) if such gross proceeds exceed $800 million, then an additional one-time bonus payment of $5 million dollars in cash

 **Management Agreement**

On March 3, 2026, we entered into a management agreement with the Manager (the "Management Agreement"). Pursuant to the terms of the Management Agreement, the Manager will determine whether to employ personnel that provide services for the benefit of our Company, including employees, directors, consultants, and all work related to identification of Operators and the loans and consulting services directly with the Manager or with us. To the extent incurred, the Manager is entitled to reimbursement of such salaries, fees, third party expenses for consultants, insurance, legal, investor relations, and any other direct costs and expenses incurred on behalf of the Company. If Manager serves as a manager, operator, or owner of other business enterprises, Manager shall act in good faith to allocate and proportionately share any shared or overlapping costs among the Company and such other enterprises in a fair and reasonable manner. Notwithstanding, nothing will preclude the Company from retaining the services of certain service providers directly, at its discretion.

The Manager does not receive any selling commissions or dealer manager fees in connection with the offer and sale of our Class A Preferred Shares. See "Management Compensation" for a more detailed explanation of the fees and expenses payable to the Manager.

 **Consulting Agreement**

On December 1, 2025 ("Start Date"), we entered into a consulting agreement with OCIFG, Inc. ("OCIFG"). Pursuant to the agreement, OCIFG will provide us with a variety of consulting services related to our business. These consulting services include: advising on strategic alternatives and business positioning; supporting business development initiatives including the evaluation of potential Clinic partners; facilitating introductions to professional service providers; reviewing and updating investor presentations and corporate materials on a monthly basis; providing industry and company analysis including financial models; and supporting visibility and thought leadership initiatives including conference attendance. We agreed to pay OCIFG an aggregate of $250,000 consisting of (i) $25,000 at the Start Date, (ii) $25,000 before 60 days after Start Date, (iii) $50,000 before 120 days after Start Date, (iv) $50,000 before 180 days after Start Date, (v) $50,000 before 240 days after Start Date, and (vi) $50,000 before 300 days after Start Date. Notwithstanding, we have the right to defer payments if the Company determines that there is insufficient available cash to make such payment(s). The agreement may be terminated by either party on thirty (30) days written notice.

 **Operating Agreement**

In the event that you purchase Class A Preferred Shares pursuant to this offering, you will be bound by, and subject to, the terms of the Operating Agreement, a copy of the form of which is attached to this Offering Circular as Exhibit 2.2.

 *Distributions* 

Pursuant to the Company's Operating Agreement, the Manager will determine if and when distributions are made to the Members. The Company will deposit 8.00% of the proceeds from this offering into a segregated restricted account, which will be maintained as a contingency reserve ("Reserve Account") to make distributions to the Members holding Class A Preferred Shares. Such funds held in the Reserve Account will be classified as restricted cash and may, at the discretion of the Manager, be invested by the Company in cash equivalents.

All distributions of cash to be made by the Company, at the discretion of Manager, will be subject to the following (collectively, the "Distributions"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) First, the Class A Preferred Shares shall receive one hundred percent (100%) of Distributions until each Member holding Class A Preferred Shares has received cumulative Distributions equal to an annual, non-compounded, eight percent (8%) return on the original purchase price paid for such Class A Preferred Shares, calculated from the date of issuance and prorated for partial years. Any such portion not distributed in any year shall continue to accrue and remain unpaid until satisfied; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ii) Thereafter, all additional Distributions, shall be distributed (1) seventy percent (70%) to the Class A Preferred Shares and (2) thirty percent (30%) to the Common Shares.

There can be no assurances if and when the Manager will make Distributions, or if the Company will have sufficient free cash flows from its loans and consulting services in order for Distributions to be made.

Our Distributions generally will constitute a return of capital to the extent that they exceed our current and accumulated earnings and profits as determined for U.S. federal income tax purposes. To the extent that a distribution is treated as a return of capital for U.S. federal income tax purposes, it will reduce a holder's adjusted tax basis in the holder's Shares, and to the extent that it exceeds the holder's adjusted tax basis, it will be treated as gain resulting from a sale or exchange of such Shares.

 *Voting Rights*

Pursuant the Operating Agreement, the Class A Preferred Shares will not vote on any matter, except for (i) certain amendments to the Operating Agreement that would disproportionately and adversely affect the Class A Preferred Shares, (ii) the determination to dissolve or wind up the Company, (iii) the appointment of a replacement Manager in the event the Manager resigns or is otherwise dissolved (bankruptcy etc.), and (iv) other matters required by Delaware law.

Accordingly, the Manager, as the sole holder of the Common Shares will have control over all other matters to be voted on by the Members of the Company.

 *Dissolution*

Upon any of the following to occur, the Company will commence winding up (each, a "Dissolution Event"): (i) the vote of the Members (each class voting separately), with Manager approval, (ii) the insolvency or bankruptcy of the Company, (iii) the occurrence of a Fundamental Transaction (as defined in the Operating Agreement, but generally an acquisition of the Company), or (iv) the entry of a decree of judicial dissolution under Section 18-801 of the Delaware Limited Liability Company Act. In the event of a Dissolution Event, the Distributions will be the same as those described above in the section entitled "Distributions" after payment of all creditors and liabilities have been made.

 *Other Governance Matters*

Other than the limited Class A Preferred Share voting rights described above, the Operating Agreement vests most other decisions relating to our assets and to the business of our Company, including decisions relating to acquisitions, originations and dispositions, the issuance of securities in our Company, in the Manager. See "Management" for more information about the rights and responsibilities of our Manager.

 **Our Offices**

We use the offices of the Manager, located at 18200 Von Karman, Suite 850, Irvine, CA 92612, Phone: 646-902-4953, Email: <u>invest@tranquil.healthcare.</u> We maintain a website at http://www.tranquil.healthcare. We do not incorporate the information on or accessible through our website into this Offering Circular, and you should not consider any information on, or that can be accessed through, our website to be a part of this Offering Circular.

 **Transfer Agent** 

The Company has engaged T7X Equities, Inc. to act as transfer agent for the Class A Preferred Shares. The Class A Preferred Shares will be issued and maintained in book-entry form on a digital ledger platform administered by the transfer agent. The digital record evidencing ownership will not be tradeable on any securities exchange or alternative trading system unless separately registered or qualified and in compliance with applicable securities laws.

**Business Plan**

We are initially focused on partnering with DGR, as our first anticipated Operator, to build a network of forty (40) Clinics that deliver advanced interventional psychiatry treatments. We will not provide any medical services or operate any Clinic. We will be providing our commercial loans and consulting services to Operators, whose Clinics will primarily provide psychiatry and mental health services, including the core service of TMS. TMS is a non-invasive, FDA-approved and EU-approved neuromodulation therapy.<sup>1</sup> TMS utilizes magnetic fields and pulses to stimulate specific nerve cells within the brain. TMS has been used in the US to improve the symptoms of major depressive disorder (MDD).<sup>1</sup> The US FDA has approved TMS for treating Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD) and smoking cessation. In the EU, TMS has received CE certification for MDD, OCD, Alzheimer's Disease, Autism Spectrum Disorder, Chronic Pain and Migraines, Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Parkinsons Disease, and Multiple Sclerosis.

In a multisite study of over 1,700 patients treating Major Depressive Disorder, a single course of treatment consisting of 30 sessions over six weeks resulted in an over 80% response rate and over 65% remission rate.<sup>2</sup> In another study, approximately 60% of patients saw complete remission of their symptoms, with a greater number of sessions leading to higher remission rates, consistent with other results.<sup>3</sup>

________________

<sup>1</sup> Mayo Clinic. Transcranial Magnetic Stimulation (TMS)

<sup>2</sup> Tendler, A et al. "Deep TMS H1 Coil treatment for depression: Results from a large post-marketing data analysis", *Psychiatry Research, 324*, Article 115179. https://doi.org/10.1016/j.psychres.2023.115179

<sup>3</sup> *Id.* 

We are attempting to build an efficient platform company designed to capture the fragmented growth of the advanced psychiatry market. We believe that most existing TMS clinics operate as single-location practices dependent on referrals from the individual clinician whose office houses the TMS equipment, creating a ceiling on patient volume and limiting scalability beyond that clinician's existing patient base. By contrast, subject to necessary capital requirements, we intend to provide: turnkey financing for buildout and start-up costs in the form of loans, which are anticipated to include long-term medical equipment financing for Clinic operations, and ongoing Consulting Services tied to Operator EBITDA, which together, we believe, will create durable, contractually-based revenue streams. Given our team's expertise in digital and social media marketing, we aim to assist Clinics in reducing their patient acquisition costs and thus increase profitability. We believe that this model can be replicated across many Clinics throughout the United States by giving an Operator access to consistent equipment, capital, and consulting services, to efficiently scale their Clinics.

Provided that we enter into definitive agreements with DGR, we anticipate that the first Clinics that we will partner on will be in high-density urban markets with a demand for behavioral health services with initial target locations in Florida, Pennsylvania, Virginia and New Jersey and potential additional expansion into California. Notwithstanding, no definitive agreements have been entered into with respect to the lease or buildout of any Clinic as of the date of this Offering Circular.

**Transcranial Magnetic Stimulation (TMS)**

We will not be providing any medical services, as all medical decisions, patient selection, treatment parameters, and clinical operations are managed solely by licensed clinicians employed by our operating partners. The success of our business will be tied to the ability of the Operators to effectively run Clinics that provide TMS services.

TMS was first introduced in 1985 by Dr. Anthony Barker and colleagues in Sheffield, England. Originally developed as a tool for non-invasive brain mapping, TMS evolved over the following decades into a powerful therapeutic intervention for neuropsychiatric conditions.<sup>4</sup>

In 2008, the U.S. Food and Drug Administration (FDA) approved the first TMS device for the treatment of major depressive disorder (MDD) in adults who had not responded to at least one antidepressant. Since then, TMS has gained FDA clearance for additional indications including obsessive-compulsive disorder (OCD) and smoking cessation and has been adopted by psychiatric providers worldwide.<sup>5 6</sup>

The European Union has approved TMS for similar uses and has recognized its efficacy in treating a broad range of brain-related disorders including Alzheimer's, Parkinson's, PTSD, Stroke Rehabilitation, Autism, Multiple Sclerosis, Chronic Pain and Tinnitus. <sup>4 6 7</sup> These indications are not FDA-approved in the United States.

*Safety Profile*

TMS is reported in research as a safe interventional treatment in psychiatry. Unlike pharmaceutical options, TMS is non-invasive and non-systemic, meaning it does not require surgery, incisions, or sedation, and it does not enter the bloodstream. As a result, it avoids the common side effects associated with antidepressants such as weight gain, sexual dysfunction, and cognitive dulling. <sup>7 8</sup>

The most common side effects of TMS are mild and transient, including scalp discomfort or headache during treatment sessions. These typically resolve after the first few sessions. <sup>9 10</sup>

______________________

<sup>4</sup> Ingenia. (2025). *Transcranial Magnetic Stimulation.*

<sup>5</sup> U.S. Food and Drug Administration (FDA). (2008). *FDA Clearance of rTMS Device for Major Depressive Disorder*

<sup>6</sup> Practical Psychiatry. (2020). *Transcranial Magnetic Stimulation: A Clinical Review*

<sup>7</sup> Rossi, S., et al. (2021). *Safety and recommendations for TMS use in healthy subjects and patient populations. Clinical Neurophysiology*, 132(1), 269-306

<sup>8</sup> Lefaucheur, J.-P., et al. (2022). *TMS Intervention and Non-serious Adverse Events*

<sup>9</sup> George, B.Q., et al. (2025). *Usage and equity of transcranial magnetic stimulation in the United States. Brain Stimulation: Journal of the American Society for Neuromodulation*, S1935-861X(25)00198-6

<sup>10</sup> Rapinesi, C., et al. (2022). *Evaluating the safety profile of connectome-based rTMS.* Acta Neuropsychiatrica

Serious adverse events—such as seizures—are extremely rare, occurring in less than 0.1% of patients in standard TMS protocols, and occurs under high-risk conditions such as improper use or pre-existing neurological conditions. Among seizures reported to date, they have been self-limited at time of stimulation. <sup>11 12</sup>

TMS has been thoroughly vetted through clinical trials and real-world usage, with estimates at more than 20 million treatment sessions delivered globally since 2009. <sup>13</sup>

*TMS vs. Medication: An Alternative for Depressed Patients*

TMS represents a shift in how clinicians can approach treatment-resistant conditions: it offers patients a non-invasive, drug-free alternative with minimal side effects and some patients have experienced durable therapeutic benefits.

While antidepressant medications remain the first-line treatment for mood disorders, these limitations have contributed to growing patient interest in other forms of therapeutic modalities such as TMS. We cannot predict whether our Operators will be able to successfully capitalize on this opportunity.

*Clinical Limitations of Medication*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Treatment-resistant depression is common**: It is estimated that at least 30% of persons with depression experience treatment resistant depression
 (TRD), that is, an inadequate response to a minimum of two antidepressants. <sup>14 15 16</sup>

· **High side-effect burden**: Common side effects include weight gain, sexual dysfunction, emotional blunting, and insomnia—often leading to poor compliance or early dropout. <sup>17 18 19 20</sup>

· **Delayed onset**:
 Some patients require 4–8 weeks to show a meaningful response, delaying relief and risking patient disengagement. <sup>21
 22</sup>

 *Potential Advantages of TMS for Certain Patients*

 

· **Minimal side effects**: TMS side effects are localized (e.g., mild scalp discomfort, occasional headache) and transient, with studies not showing systemic impact. <sup>23 24</sup>

· **Fast-acting and durable**: Many patients begin to see improvements within 3 weeks, and benefits can persist over time for most patients. <sup>25</sup>

· **Non-pharmacological**:
 TMS provides a clinically validated treatment pathway for patients who have not responded to, or cannot tolerate, pharmacological
 treatments. <sup>26</sup> This allows for potential expansion of the addressable patient population for our Clinic Operators

_______________________

<sup>11</sup> TMS Lab. *Clinical Safety of rTMS*

<sup>12</sup> MHC (Meridian). *Seizure Risk with rTMS*

<sup>13</sup> Carpenter, L. L., Philip, Noah. (2020). *American Journal of Psychiatry.* DOI: 10.1176/appi.ajp.2020.20060844

<sup>14</sup> Greden, J.F. (2001). *Treatment-resistant depression: prevalence and strategies*

<sup>15</sup> Quitkin, F.M., et al. (2000)

<sup>16</sup> Thase, M.E., et al. (1996)

<sup>17</sup> Treadway, M.T., et al. (2020)

<sup>18</sup> Mayo Clinic: Antidepressants and weight gain: what causes it?

<sup>19</sup> WebMD. *Coping with side effects of depression treatment*

<sup>20</sup> Wichniak, et al. (2017) doi: 10.2174/138161212803523608

<sup>21</sup> Papakostas, G.I., et al. (2018)

<sup>22</sup> Quitkin, F.M., et al. (2000)

<sup>23</sup> Lefaucheur, J.-P., et al. (2022). *TMS Intervention and Non-serious Adverse Events*

<sup>24</sup> George, B.Q., et al. (2025). *Usage and equity of transcranial magnetic stimulation in the United States. Brain Stimulation: Journal of the American Society for Neuromodulation*, S1935-861X(25)00198-6

<sup>25</sup> Garnaat, et al. (2020) *Updates on Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder*, doi: 10.1016/j.psc.2018.04.006

<sup>26</sup> Lysik, et al (2025) *Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathway, doi:* 10.1007/s11357-025-01615-8

Notwithstanding the foregoing, TMS requires multiple in-person treatment sessions, and may not be effective for all patients. Individual patient outcomes vary.

**Revenue Model**

Our revenue model is designed to generate recurring, contract-based income from the Operators that manage and operate the Clinics. We will not provide medical services directly. Instead, we expect to earn revenue through two primary sources:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Working Capital Loans*.
 We plan to provide secured and unsecured commercial loans to the Clinics to cover build-out costs, start-up expenses, equipment purchases
 and / or rentals and marketing activities. We will earn interest income and receive repayment of principal under those credit facilities.
 We anticipate offering our initial loans to Operators at an interest rate of 10% per annum.

2. *Consulting Services.* We will provide operational and marketing based consulting services to our Operators. We have entered into a term sheet with DGR, our
first anticipated Operator to receive a Management Fees.

We estimate that each Clinic will require approximately $1 million in total start-up capital, consisting of roughly $600,000 for equipment, $100,000 for build-out costs, and $300,000 for working capital. We anticipate that it will take approximately twelve (12) months of operation before a Clinic reaches full capacity.

TMS is reimbursed by most major U.S. insurance carriers, including Medicare and most private insurers, for FDA-approved indications. Medicaid also covers the treatment in select states for FDA-approved indications. Accordingly, we believe that our Operators will be able to derive revenues and achieve profitability through the operation of their Clinics, resulting in revenue and payment to us.

**Initial Operating Partner**

The initial Clinics are expected to be operated by DGR, who have experience in management of clinics and are an established clinic operator, with extensive backgrounds in TMS, behavioral health, and brain-wellness clinic operations. DGR's founders have launched more than 30 TMS clinics across six (6) states and oversaw treatment for more than 600+ TMS patients per day.

On October 28, 2025, we entered into a term sheet with DGR that provides for a binding 180-day exclusivity period to negotiate and execute definitive agreements under which DGR will operate up to 40 Clinics for which we will provide our loans and services.

Under the anticipated agreements, we expect to provide approximately to $1 million per Clinic in funding through commercial loans. DGR will be responsible for all clinical operations, regulatory compliance, staffing, and patient care. In return, we will receive fixed monthly lease payments for the equipment, interest and principal payments on monies loaned, and a percentage of EBITDA for Consulting Services.

We have additionally loaned DGR $150,000 for working capital to begin development of the first Clinics as described in the term sheet with DGR.

**Clinic Marketing**

Once we partner with an Operator, they will be primarily responsible for marketing and patient acquisition for the respective Clinics. Based on DGR's prior experience, DGR uses direct-to-consumer digital marketing strategies; including targeted online advertising and social-media outreach in order to identify potential patients and schedule consultations.

Through our consulting arrangements, we intend to advise DGR, and other Operators, if applicable, on optimizing these marketing efforts, drawing on our management team's expertise in social-media and digital advertising. Our goal is to help Operators improve patient-acquisition efficiency and overall Clinic profitability.

**Operational Team**

The success of Tranquil is dependent on the success of its Operators, which will initially consist of only DGR. Accordingly, DGR's management team's ability to successfully operate and grow the Clinics will be vital in the success of our business model.

The current management team of DGR consists of:

*<u>Randy Syrop</u>* is Chief Executive Officer of DGR and has been the CEO of a number of leading TMS based brain wellness clinics including Complete Mind Care of PA (CMC) and Success TMS. Mr. Syrop created more than 30 clinics across six states.

 *<u>Dr. George Chu</u>* is the Chief Financial Officer of DGR and has been partners with Mr. Syrop at both CMC and Success TMS. Dr. Chu has a PhD. in Clinical Psychology from Adelphi University and an MBA from Wharton School of Finance at the University of Pennsylvania. Dr. Chu's combined clinical and financial background provides DGR with expertise in both the operational and business aspects of TMS clinic management.

 *<u>Dr. Kevin D. Moore, MD, DFAPA</u>* is the Chief Medical Officer of DGR. Dr. Kevin Moore is a board-certified psychiatrist with added qualifications in Forensic and Addiction Psychiatry. A retired U.S. Navy Captain, Dr. Moore has held senior roles including Commanding Officer of multiple naval hospitals and Force Medical Officer for Naval Forces Japan. He has extensive experience in providing TMS to patients and brings decades of leadership and clinical expertise to his role as Chief Medical Officer for DGR. He is licensed in 20+ states including PA, NJ, VA and TX and will assist DGR in entering new markets.

**<br> Market Opportunity**

The demand for advanced, non-invasive mental health treatments in the United States continues to grow. Nearly one in five U.S. adults experiences a mental illness each year, with over 50 million people affected by conditions such as depression, anxiety, PTSD, and related disorders. <sup>27 28</sup> Many patients seek alternatives to traditional pharmacological and psychotherapy treatments as traditional treatments – primarily antidepressant medication and psychotherapy treatments – often fail to provide sufficient relief for a significant subset of patients. TMS has emerged as a clinically validated, FDA-cleared treatment for major depressive disorder, obsessive-compulsive disorder, and smoking cessation.<sup>29</sup> TMS is reimbursed by most commercial insurers and Medicare. It is also covered by Medicaid in select states. Notwithstanding, we believe overall penetration of TMS therapy remains low, primarily due to limited clinic capacity, uneven physician adoption, and weak marketing reach at the local practice level. However, industry analysts believe the market will continue to grow, driven by broader insurance coverage, increasing clinician adoption, and rising public awareness.<sup>30</sup>

We believe these trends create a strong environment for our business model, which combines financing and operational consulting to enable experienced Operators, such as DGR to open new Clinics quickly and cost-effectively.

_____________________

<sup>27</sup> National Institute of Mental Health (NIMH). *Mental Illness Statistics.* 2022

<sup>28</sup> National Alliance on Mental Illness (NAMI). *Mental Health By the Numbers*

<sup>29</sup> The Cleveland Clinic - https://my.clevelandclinic.org/health/treatments/17827-transcranial-magnetic-stimulation-tms.

<sup>30</sup> Mordor Intelligence - https://www.mordorintelligence.com/industry-reports/transcranial-magnetic-stimulator-marke

**Market Analysis**

According with our discussions with potential Operators, each Clinic is anticipated to be able to treat approximately 400 distinct patients annually at full capacity. Even if all 40 planned Clinics operated simultaneously, their combined capacity of about 16,000 patients per year would represent only a small fraction of the eligible patient population within our initial target states. Notwithstanding, there can be no assurance any Clinics will operate at full capacity or be able to adequately source patients sufficiently to maintain their operations. The substantial gap between patient demand and available treatment capacity highlights the scalability of our model and the long-term opportunity to expand through additional Operator partnerships and new Clinic locations.

**Competition**

The U.S. TMS market remains highly fragmented and evolving. While patient awareness and clinical adoption of TMS for depression and other behavioral-health indications have increased in recent years, the majority of providers continue to operate as single-location or small multi-clinic businesses with limited access to capital, marketing infrastructure, and scalable management systems. Historically, TMS has been delivered primarily through hospitals or psychiatrist offices, where patient engagement and throughput are constrained. Despite broad insurance coverage for TMS, overall access remains limited relative to the size of the addressable patient population.

Competition in our market exists at multiple levels. First, we compete indirectly with other TMS clinic operators, including both independent providers and larger groups seeking to expand regionally or nationally. These operators may have existing relationships with equipment manufacturers or established referral networks that enable them to grow without outside support.

Second, we face competition from companies that supply capital, equipment, or operational services to behavioral-health and TMS clinics. These include TMS device manufacturers such as Neuronetics, Inc. (NASDAQ: STIM) and BrainsWay Limited Ltd. - ADR (NASDAQ: BWAY), which offer equipment placement, financing, and marketing support to clinics, as well as companies and private investors that provide medical equipment leasing, practice-management, or consulting services to behavioral-health operators. Both of these companies have significantly greater capital resources than us.

We believe our model is differentiated in that we do not operate clinics directly. Instead, we provide financing, equipment, and consulting resources to independent Clinic Operators who manage daily operations and contract with licensed medical professionals as needed. This approach allows us to scale across multiple geographies and operators without assuming the regulatory burdens associated with clinical practice. Our ability to compete effectively will depend on the success of our partners in operating profitable clinics, our ability to source and support high-quality operators, and our continued access to capital at competitive terms.

**Government Regulation**

Although we do not provide medical, behavioral-health, or other clinical services, the Clinics with which we intend to partner, are subject to extensive federal, state, and local regulation. These laws govern the delivery of healthcare services, the use of medical equipment, billing and reimbursement, patient privacy, and the qualifications of licensed professionals. Because our business model depends on the success and compliance of independent Operators of Clinics, changes in these laws, or the way regulators interpret or enforce them, could materially affect our operations.

*Healthcare Practice and Licensing Laws*

 

Each Clinic Operator is responsible for ensuring that any physicians or other licensed professionals who perform services using our leased equipment hold the appropriate state licenses and operate within their lawful scope of practice. Many states have "corporate practice of medicine" restrictions that prohibit non-medical entities from owning, controlling, or profiting from medical practices. We intend to structure our relationships with Clinic Operators through consulting, leasing, and financing agreements designed to comply with these restrictions. Nevertheless, regulatory authorities could view certain aspects of our arrangements as inconsistent with applicable laws, which could require us or our operators to modify or restructure our agreements.

*Fee-Splitting and Anti-Kickback Statutes*

Federal and state laws, including the federal Anti-Kickback Statute and analogous state statutes, prohibit the offering or receipt of remuneration for patient referrals or the ordering of healthcare services reimbursed by government or private payers. In addition, many states restrict "fee-splitting" arrangements between physicians and non-physicians. While our agreements are intended to comply with these rules, any determination that our economics with operators constitute prohibited remuneration could result in penalties, repayment obligations, or the need to modify our business model.

*Data Privacy and Security*

Clinic operators that collect, store, or transmit patient health information must comply with the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and applicable state privacy laws. Although Tranquil does not directly handle protected health information, we may receive certain broad data regarding a Clinic for consulting purposes. If such information were deemed to include protected health information, we could be required to enter into business-associate agreements and adopt additional safeguards to maintain compliance.

*Equipment and Facility Compliance*

TMS and other medical devices are regulated by the U.S. Food and Drug Administration ("FDA") and must be used in accordance with cleared indications and manufacturer requirements. Our equipment-leasing activities depend on device manufacturers maintaining FDA clearances and on Operators using devices consistent with those clearances. Clinics are also subject to state facility, zoning, and safety regulations that can affect build-out timelines and costs.

 *Reimbursement and Coverage*

 

TMS is currently reimbursed by Medicare and most major commercial insurers for FDA-cleared indications. However, reimbursement policies are subject to change at any time by government and private payors. Reductions in reimbursement rates, the imposition of additional prior authorization requirements, or coverage denials could reduce patient access to TMS services and directly impair the revenue and profitability of our Operator partners, which would in turn adversely affect our ability to have our commercial loans repaid and derive revenue from our consulting services.

*Future Regulatory Developments*

Healthcare laws and enforcement priorities continue to evolve. Future legislative or regulatory changes—such as new restrictions on non-medical ownership of clinics, increased scrutiny of management or financing arrangements, or modifications to reimbursement policies—could require us and our operators to alter contractual relationships, increase compliance costs, or limit growth opportunities. We monitor regulatory developments and intend to adjust our business practices as needed; however, we cannot predict the timing or impact of future regulatory actions.

 *Equal Credit Opportunity Act (ECOA)* 

ECOA prohibits lenders from discriminating against any credit applicant — including business loan applicants — on the basis of race, color, religion, national origin, sex, marital status, age, or receipt of public assistance. For commercial loans, lenders must provide adverse action notices when declining credit, though the timing and detail requirements are relaxed for large commercial borrowers (gross revenues exceeding $1 million). Personal guarantors on commercial loans are also protected as credit applicants. Wellness center owners from protected classes are entitled to equal treatment in all aspects of the credit transaction, including pricing and terms.

 *Office of Foreign Assets Control (OFAC) Compliance*

Lenders are required to screen all loan applicants, beneficial owners, and related parties against OFAC's Specially Designated Nationals (SDN) list and other sanctions lists. Extending credit to a sanctioned person or entity is prohibited and may result in civil or criminal penalties. This obligation applies regardless of loan size or transaction type, including commercial loans to wellness centers.

 *Fair Credit Reporting Act (FCRA)*

FCRA governs the use of consumer credit reports in lending decisions. When a lender pulls the personal credit report of a wellness center owner or guarantor as part of the commercial loan underwriting process, FCRA requirements are triggered. These include obtaining permissible purpose, providing adverse action notices if credit is denied based in whole or in part on information in a credit report, and complying with accuracy and dispute resolution obligations. Business credit reports are not subject to FCRA, but personal guarantor reports are.

 *Flood Disaster Protection Act / National Flood Insurance Program (NFIP)*

If the commercial loan is secured by real property located in a Special Flood Hazard Area (SFHA), the lender is required to notify the borrower, ensure that flood insurance is obtained in an amount sufficient to cover the loan balance (up to the NFIP maximum), and maintain that insurance for the life of the loan. This applies to wellness centers located in or near flood zones. Lenders must conduct a flood zone determination prior to loan closing.

 *Uniform Commercial Code (UCC) — Article 9*

UCC Article 9 governs secured transactions where personal property (equipment, inventory, accounts receivable, fixtures) serves as collateral for a commercial loan. For a wellness center, this would typically cover spa equipment, fitness equipment, medical/therapeutic devices, accounts receivable from insurance or membership fees, and other business assets. Lenders must properly perfect their security interest by filing a UCC-1 financing statement with the appropriate state authority to establish priority over other creditors.

 *State Usury and Lending Laws*

Most states impose caps on interest rates for commercial loans, though many states have enacted exemptions for loans above certain thresholds or to corporate borrowers. Lenders must comply with the usury laws of the applicable jurisdiction, which is typically determined by where the loan is made or where the borrower is located. Some states also impose licensing requirements on commercial lenders and have enacted their own fair lending statutes. Florida, for example, has its own commercial lending statutes under Chapter 687, Florida Statutes.

 *Americans with Disabilities Act (ADA)* 

While the ADA does not directly regulate the lending transaction itself, it is relevant to lender due diligence. Wellness centers open to the public must comply with ADA Title III accessibility requirements for their physical facilities. A lender evaluating the creditworthiness of a wellness center may consider the borrower's ADA compliance posture, as outstanding ADA violations could expose the business to litigation liability that affects its ability to repay.

**Seasonality**

We expect only limited seasonality in our business as patients are being treated by Clinics run by Operators on a year round basis.

**Employees**

As of March 3, 2026, we have no full time employees. Our Manager, Tranquil Healthcare Holdings, Inc. has one (1) full time employee, its Chief Executive Officer, Tyler Ehler. We do not anticipate retaining additional personnel, but plan to utilize the employees, legal service providers, accountants, and other consultants of either our Manager, or those who we retain directly.

**Legal Proceedings**

We may from time to time be involved in various claims and legal proceedings of a nature we believe are normal and incidental to our business. These matters may include product liability, intellectual property, employment, personal injury caused by our employees, and other general claims. We will accrue for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. We are not presently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

**Description of Property**

*Corporate Office*

Our offices are located at 18200 Von Karman, Suite 850, Irvine, CA 92612, Phone: 646-902-4953, Email: <u>invest@tranquil.healthcare.</u> We maintain a website at http://www.tranquil.healthcare. We do not incorporate the information on or accessible through our website into this Offering Circular, and you should not consider any information on, or that can be accessed through, our website to be a part of this Offering Circular.

 ***Arbitration Provision***

Under the Arbitration Provision contained in our Operating agreement, either party may, at its sole election, require that the sole and exclusive forum and remedy for resolution of a claim be final and binding arbitration. We have not determined whether we will exercise our right to demand arbitration but reserve the right to make that determination on a case by case basis as claims arise. In this regard, the Arbitration Provision is similar to a binding arbitration provision as we are likely to invoke the Arbitration Provision to the fullest extent permissible. The Arbitration Provision applies to claims under the U.S. federal securities laws and to all claims that are related to the Company, including with respect to this offering, our holdings, our Class A Preferred Shares, and our ongoing operations, among other matters.

Any arbitration brought pursuant to the Arbitration Provision must be conducted in the State of Delaware. The term "Claim" as used in the Arbitration Provision is very broad and includes any past, present, or future claim, dispute, or controversy involving you (or persons claiming through or connected with you), on the one hand, and us (or persons claiming through or connected with us), on the other hand, relating to or arising out of your subscription agreement, and/or the activities or relationships that involve, lead to, or result from any of the foregoing, including (except an individual Claim that you may bring in Small Claims Court or an equivalent court, if any, so long as the Claim is pending only in that court) the validity or enforceability of the Arbitration Provision, any part thereof, or the entire subscription agreement. Claims are subject to arbitration regardless of whether they arise from contract; tort (intentional or otherwise); a constitution, statute, common law, or principles of equity; or otherwise. Claims include (without limitation) matters arising as initial claims, counter-claims, cross-claims, third-party claims, or otherwise. The scope of the Arbitration Provision is to be given the broadest possible interpretation that will permit it to be enforceable. Based on discussions with and research performed by the Company's counsel, we believe that the Arbitration Provision is enforceable under federal law, the laws of the State of Delaware, or under any other applicable laws or regulations. However, the issue of enforceability is not free from doubt and to the extent that one or more of the provisions in our subscription agreement or our operating agreement with respect to the Arbitration Provision or otherwise requiring you to waive certain rights were to be found by a court to be unenforceable, we would abide by such decision.

As a result of these arbitration provisions, you and our other Members may be subject to increased costs in bringing a claim, limited access to information and you may also be subject to other imbalances of resources between us and our Members. These provisions may also discourage you and other members, including those who may purchase securities upon resale by any initial purchaser in an aftermarket or otherwise, from bringing claims at all and will limit your ability to bring a claim in a judicial forum that you find favorable.

Before purchasing Class A Preferred Shares, a potential Investor must acknowledge, understand, and agree that: (a) arbitration is final and binding on the parties; (b) the parties are waiving their right to seek remedies in court, including the right to jury trial; (c) pre-arbitration discovery is generally more limited than and potentially different in form and scope from court proceedings; (d) the Arbitration Award is not required to include factual findings or legal reasoning and any party's right to appeal or to seek modification of a ruling by the arbitrators is strictly limited; and (e) the panel of arbitrators may include a minority of persons engaged in the securities industry. The Arbitration Provision limits the rights of an investor to many legal remedies and rights otherwise available. See the Section of this Offering Circular entitled - "How to Subscribe—Arbitration Provision."

BY AGREEING TO BE SUBJECT TO THE ARBITRATION PROVISION IN OUR OPERATING AGREEMENT, INVESTORS WILL NOT BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

**MANAGEMENT**

 **Our Manager**

Pursuant to a Management Agreement entered into by us and the Manager on March 3, 2026, our Manager controls and is responsible for directing the management of our business, managing our day-to-day affairs, and providing our commercial loans and consulting services to Operators. A majority of the outstanding capital stock of the Manager is owned by Tyler Ehler, the CEO and chairman of the board of directors of the Manager, and Jeff Campbell, the other director of the Manager. Pursuant to our Operating Agreement and Management Agreement, we have agreed to indemnify the Managers and its affiliated persons for their services under the Operating Agreement and Management Agreement, subject to certain exceptions, including for acts involving actual fraud, gross negligence, willful misconduct, bad faith, breach of fiduciary duty, reckless disregard of duty, or intentional and material breach of the Operating Agreement. The Manager and its officers and directors are not required to devote all of their time to our business and are only required to devote such time to our affairs as their duties require.

 **Responsibilities of our Manager pursuant to the Operating Agreement and Management Agreement**

The responsibilities of our Manager, as contained in the Operating Agreement and Management Agreement, include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· All
 day to day operational decisions, including the development, acquisition, financing, and
 disposition of Clinic-related loans and services;

&nbsp;&nbsp;&nbsp;&nbsp;· Provide,
 to the extent necessary, the commercial loans and consulting services to Operators of Clinics,
 if and when applicable;

&nbsp;&nbsp;&nbsp;&nbsp;· The
 declaration, timing, and amount of any Distributions to Members;

&nbsp;&nbsp;&nbsp;&nbsp;· Entry
 into, amendment, or termination of material agreements, including lending arrangements, management
 agreements, and service provider contracts;

&nbsp;&nbsp;&nbsp;&nbsp;· The
 incurrence of indebtedness and determination of capital structure;

&nbsp;&nbsp;&nbsp;&nbsp;· The
 issuance of additional Class A Preferred Shares (subject to applicable securities laws);

&nbsp;&nbsp;&nbsp;&nbsp;· Appointment
 and removal of Officers and delegation of authority to such Officers, if any;

&nbsp;&nbsp;&nbsp;&nbsp;· Financial
 reporting policies and internal control procedures;

&nbsp;&nbsp;&nbsp;&nbsp;· Selection
 of accountants, legal counsel, and other professional advisors;

&nbsp;&nbsp;&nbsp;&nbsp;· Approval
 of mergers, consolidations, restructurings, or other fundamental transactions, subject to
 the terms of the Operating Agreement and votes of Members, as applicable;

&nbsp;&nbsp;&nbsp;&nbsp;· Amendment
 of the Management Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;· Determination
 of reserves and use of Company funds;

&nbsp;&nbsp;&nbsp;&nbsp;· Approval
 of Transfers of Shares, to the extent required under the Operating Agreement.

 **Management Team**

The Company does not currently have a Board of directors or any officers. The Company is managed by its Manager, Tranquil Healthcare Holdings, Inc. The following table sets forth information regarding our Manager's executive officers, directors and significant employees, including their ages as of March 3, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Age** | **Term of Office** | **Position** | **Approximate hours per week for part-time employees** |
| Tyler Ehler | 37 | Oct 2025 – Current | Chief Executive Officer, Chief Financial Officer, President, Secretary, and Chairperson of the Board of Tranquil Healthcare Holdings, Inc. | Full Time |
| Jeff Campbell | 53 | Oct 2025 – Current | Director of Tranquil Healthcare Holdings, Inc. | 10 |

---

The principal occupations for each of our current executive officers and directors are as follows:

 ***<u>Tyler Ehler</u>*** -Mr. Ehler currently serves as chief executive officer, chief financial officer, president, and secretary of our Manager, Tranquil Healthcare Holdings, Inc. He held such similar positions at our Company since its incorporation through the holding company reorganization in March 2026. Mr. Ehler has more than a decade of experience in healthcare, biotechnology, and capital markets, with a focus on corporate strategy and investor engagement. He most recently served as Head of Investor Relations at I-Mab from June 2021 to February 2025. (NASDAQ: IMAB), where he oversaw global communications with institutional investors and analysts and supported strategic financing initiatives. Prior to that, he held senior investor relations leadership roles at KBP Biosciences from February 2020 to June 2021. Prior to working at KBP, he served in various capacities at other biopharmaceutical companies, where he was responsible for fundraising strategy, capital markets positioning, and corporate communications. Earlier in his career, Mr. Ehler worked in institutional equity sales, advising investors on healthcare and macroeconomic strategy. Mr. Ehler holds a Bachelor of Science degree in Biomedical Sciences from McGill University and a Master of Arts in International Relations & Economics from the Johns Hopkins University School of Advanced International Studies (SAIS). Mr. Ehler's experience in investor relations, healthcare, biotechnology, and capital raising qualify him to serve on the Board of Directors of our Manager.

 ***<u>Jeff Campbell</u>*** – Mr. Campbell is a senior level executive who brings over 25 years of hands-on branded response experience. Since March 2023, he has been serving CMO and on the board of directors for RealDefense, LLC, which develops and markets security, privacy and productivity software and services for consumers and small businesses. Since July 2025, he has also been serving as executive chairman for Adapti, Inc., a publicly traded company that integrates sports and influencer management by leveraging artificial intelligence (OTC: ADTI). Previously, from March 2019 to February 2023, he served as the CRO of Fitlab, the first platform to connect all aspects of one's fitness lifestyle, bringing immersive experiences whenever, wherever and however one trains. From Beginning in 2015 through 2017 he served as CEO of Geographic Farming, a media company focused on localized lead generation services for real estate agents, which was sold to the venture firm, RenRen. From In 2013 through August 2015, he served as President of UFC FIT, a joint venture between New Evolution Ventures, and the UFC. UFC Fit provided both at-home workouts, and a streaming content platform for its traditional gym members. He also served as the Executive Vice President of SENSA from 2009 through August 2013, where he oversaw customer acquisition and retention. During his tenure, his team was nominated for Marketer of the Year by the Direct Response Marketing Alliance for 2011, 2012, 2013, and won in 2012. Mr. Campbell received a BA from the University of California, Berkeley, and an MBA from the University of California Los Angeles. Mr. Campbell's experience in managing consumer products, including fitness devices, as well as marketing expertise, qualify him to serve on the Board of Directors of our Manager.

None of our Manager's executive officers or members of its board directors has been involved in any of the following proceedings during the past ten (10) years:

1. any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

2. any conviction in a criminal proceeding or being subject to a pending criminal proceedings (excluding traffic violations and other minor offenses);

3. being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or

4. being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

**Family Relationships**

There are no family relationships between any of the Predecessor Corporation's or our Manager's, officers and directors.

**Involvement in Certain Legal Proceedings**.

None of the following events have occurred during the past five years and which are material to an evaluation of the ability or integrity of any director or executive officer of our Manager or the Predecessor Corporation: (1) A petition under the federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing; or (2) Such person was convicted in a criminal proceeding (excluding traffic violations and other minor offenses).

 **Indemnification of our Manager and Others**

Our Operating Agreement provides for exculpation and indemnification of the Manager and other protected persons to the fullest extent permitted by Delaware law, subject to certain exceptions, including for acts involving actual fraud, gross negligence, willful misconduct, bad faith, breach of fiduciary duty, reckless disregard of duty, or intentional and material breach of the Operating Agreement. However, there can be no assurance that such contractual protections will be sufficient to cover all potential claims, expenses, or liabilities.

 **Term and Removal of the Manager**

Our operating agreement provides that our Manager will serve as our manager for an indefinite term, but that our Manager may resign at any time. The Manager may not be removed by the Members for any reason. In the event of a resignation of the Manager or the Manager's dissolution as a result of bankruptcy or other reason, the Class A Preferred Members may elect a new Manager.

**Board Composition** 

We do not have a Board of Directors and the Manager makes decisions typically made by a Board of Directors of a corporation. The Manager has a Board of Directors consisting of Tyler Ehler and Jeff Campbell – see "Management Team" above.

**Non-Employee Board Compensation Policy**

Our Predecessor Corporation adopted, effective October 28, 2025, a Non-Employee Director Compensation Policy. Upon completion of the Reorganization, this policy was materially adopted by the Board of Directors of the Manager. For further information regarding the policy, see the section below entitled "Management Compensation".

**Code of Business Conduct and Ethics**

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions, which would be our Manager. The code of business conduct and ethics is posted on our website at: tranquil.healthcare.

 **MANAGEMENT COMPENSATION**

The following table sets forth the cash compensation (including cash bonuses) paid or accrued, and equity awards granted, by us for the year ended October 31, 2025, to our Executive Officers and Directors. Notwithstanding, subsequent to our fiscal year end, on March 3, 2026, the Company completed a holding company reorganization and the Company was converted into a limited liability company. Subsequent to the conversion into a limited liability company, the Company adopted an Operating Agreement and entered into a Management Agreement with the Manager. Accordingly, as of the date hereof, the personnel listed below serve as officers and board members for the Manager and not for the Company. The below compensation includes compensation both accrued and/or paid by us or on behalf of the manager.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Capacities in which** <br> **compensation was received**  | **Cash** <br> **Compensation** <br> **($)**  | **Other** <br> **Compensation** <br> **($)**  | **Total** <br> **Compensation** <br> **($)**  |
| Tyler Ehler <sup>(1)</sup> | CEO, CFO, President, Secretary of Predecessor Corporation and the Manager post Reorganization | 40000 <sup>(2)</sup> | – | 40000 |
| Jeff Campbell <sup>(3)</sup> | Board of Directors of Predecessor Corporation and the Manager post Reorganization |  | – |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Mr. Ehler has served
 as the Company's CEO, CFO, President, Secretary and Chairman of the Board since its incorporation in October 2025. As described
 below under "Employment Agreements", Mr. Ehlers entered into and at will employment agreement with our Manager dated
 3, 2026.

(2) Prior to entering into
 the employment agreement with the Manager, Mr. Ehler served as our CEO and was entitled to a base salary of $120,000 per annum beginning
 November 1, 2025 and a one-time signing bonus of $40,000. Pursuant to the employment agreement with our Manager, he earns an annual
 salary of $120,000 per annum. The Company currently owes Mr. Ehler $30,000 in accrued but unpaid salary. Further, we are required
 to reimburse Manager for amounts paid and payable to Mr. Ehler beginning on the effective date of his employment with the Manager.

(3) Mr. Campbell previously
 served on our Board of Directors prior to the holding company reorganization and he now serves as a member of the board of Directors
 of the Manager. Mr. Campbell is entitled to compensation under the Manager's non-employee director compensation policy as described
 below under "Director Compensation", which we are required to reimburse amounts paid and payable under the Manager's
 director compensation policy. Mr. Campbell was not entitled to any amounts for the year ended October 31, 2025.

**Employment Agreements**

*Tyler Ehler Employment Agreement*

 

On March 3, 2026, the Manager entered into an employment agreement Mr. Ehler (the "Employment Agreement") for Mr. Ehler to serve as CEO, CFO, President, and Secretary of the Manager. Pursuant to the Employment Agreement, Mr. Ehler is entitled to a base salary of $120,000 per year (the "Base Salary"). Mr. Ehler will also be eligible to receive discretionary bonuses, if and when declared by the Board of Directors of the Manager.

In the event that the Manager terminates Mr. Ehler's employment without "Cause", death, or "Permanent Disability", then the Manager will be required to pay a severance of three (3) months of the Base Salary the in effect at the time of termination.

Mr. Ehler also entered into a standard confidential information and invention assignment agreement.

All compensation due and payable to Mr. Ehler by the Manager per the Employment Agreement will be subject to reimbursement by the Company pursuant to the Management Agreement.

 **Management Agreement**

For a description of the costs and fees anticipated under the Management Agreement, see the section of this Offering Circular entitled "Business" – "Management Agreement" above.

**Director Compensation**

<u>Non-Employee Director Compensation Policy</u>

Effective October 28, 2025, the Board of Directors of our predecessor company adopted a non-employee director compensation policy (the "Policy"). The Policy was subsequently adopted by the Manager in connection with the holding company reorganization in March of 2026 ("Manager Policy"). Pursuant to the Manager Policy, each member of the Board of Directors of the Manager, that is not an employee or consultant of the Manager or the Company (each, an "Eligible Director") is entitled to the following compensation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) Upon joining the Board of Directors, a right to purchase up to 100,000 shares of the Manager's common stock ("Initial Director Shares"), at a price per share equal to the fair market value of one (1) share of common stock, as determined by the Board of Directors, which of such Initial Director Shares, 25,000 fully vest on the purchase date and the remaining 75,000 Initial Director shares are subject to repurchase by the Company, with 25,000 Initial Director Shares vesting on each yearly anniversary of the grant date. In the event that an Eligible Director ceases to serve on the Board of Directors, the Manager will have the right to purchase any Initial Director Shares that were purchased and have not vested at a price per share equal to the price paid for such applicable Initial Director Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ii) Beginning on the date that the Company sells equity securities resulting in net cash proceeds of at least $300,000, each Eligible Director will begin receiving quarterly payments of $15,000 per quarter for service on the Board of Directors of Manager. Eligible Directors' cash payments will be prorated for any partial quarter of service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iii) Eligible Directors will be eligible to receive ad hoc grants from time to time, if and when determined by the Board of Directors of Manager.

With respect to the foregoing Manager Policy, we will be required to reimburse the Manager for cash fees paid to their directors pursuant to the Manager Policy. The Company did not incur any cash fees to a director under the Policy prior to the reorganization.

**Stock Option Plan and other Employee Benefits Plans**

The Company does not maintain a Stock Option Plan or other Employee Benefit Plans.

**Overview of Compensation Program**

Neither us, nor our Manager maintain a Compensation Committee. Until a formal committee is established, the Manager's Board of Directors has responsibility for establishing, implementing and continually monitoring adherence with the Company's compensation philosophy.

**CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS**

*Transactions*

1. On October
 28, 2025, our Predecessor Corporation sold our CEO, Tyler Ehler, 400,000 shares of common stock at a price per share of $0.001. Of
 the shares purchased, 300,000 are subject to a repurchase option by the Company at $0.001 per share. On each one (1) year anniversary
 of the purchase date, an additional 100,000 shares will vest and no longer be subject to repurchase, subject to Mr. Ehler continuing
 to be a service provider to the Company. The shares purchased were subsequently exchanged for shares of capital stock of the Manager
 in the holding company reorganization.

2. On November 7, 2025,
 as part of a consulting agreement, our Predecessor Corporation sold Johan (Thijs) Spoor, 200,000 shares of common stock at a price
 per share of $0.001. Of the shares purchased, 150,000 are subject to a repurchase option by the Company at $0.001 per share. On each
 one (1) year anniversary of the purchase right grant, an additional 50,000 shares will vest and no longer be subject to repurchase,
 subject to Mr. Spoor continuing to act as a consultant. The shares purchased were subsequently exchanged for shares of capital stock
 of the Manager in the holding company reorganization.

3. On October 28, 2025,
 pursuant to our non-employee director compensation policy, our Predecessor Corporation sold Jeff Campell, 200,000 shares of common
 stock at a price per share of $0.001. Of the shares purchased, 150,000 are subject to a repurchase option by the Company at $0.001
 per share. On each one (1) year anniversary of the purchase right grant, an additional 50,000 shares will vest and no longer be subject
 to repurchase, subject to Mr. Campbell continuing to serve on the Board. The shares purchased were subsequently exchanged for shares
 of capital stock of the Manager in the holding company reorganization

4. On March 3, 2026, we entered into a management
 agreement with the Manager (the "Management Agreement"). Pursuant to the terms of the Management Agreement, the Manager
 will employ personnel that provide services for the benefit of our Company, including employees, directors, consultants, and all
 work related to identification of Operators and the making the commercial loans and providing the clinical services. In addition,
 the Company will be required to pay certain bonus payments to the Manager upon the Clinics selling for aggregate gross proceeds of
 more than $500 million. In exchange, the Manager will be entitled to reimbursement of such salaries, fees, third party expenses for
 consultants, insurance, legal, investor relations, and any other direct costs and expenses incurred on behalf of the Company. Notwithstanding,
 the Company retains the right to directly hire consultants and other service providers. With respect to Manager, Tyler Ehler serves
 as CEO and Chairman of the Board and Jeff Campbell serves on the Board. Each of Mr. Ehler and Campbell served as directors of the
 Predecessor Corporation. Mr. Ehler and Campbell collectively own approximately 70.50% of the Manager and because the Company reimburses
 the Manager for compensation and other expenses incurred under the Management Agreement, payments made by the Company to the Manager
 will be economically beneficial to Mr. Ehler and Mr. Campbell as controlling owners, officers, and directors of the Manager. The
 terms of the Management Agreement were not negotiated at arm's length with an unaffiliated third party. As a result, conflicts
 of interest may arise, including with respect to the amount of compensation paid to personnel, the allocation of expenses between
 the Company and other affiliated entities, and the overall cost structure of the Company.

 **SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITY HOLDERS**

The following table sets forth the beneficial ownership of our common stock as of March 3, 2026 by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· each equity holder known
 by us to beneficially own more than 5% of the Manager's or our outstanding common shares;

· our Manager and each
 of its directors;

· each of the named executive
 officers of our Manager; and

· all of the Manager's
 directors and executive officers as a group.

We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally provide that a person is the beneficial owner of securities if such person has or shares the power to vote or direct the voting of securities, or to dispose or direct the disposition of securities. A security holder is also deemed to be, as of any date, the beneficial owner of all securities that such security holder has the right to acquire within 60 days after such date through (i) the exercise of any option or warrant, (ii) the conversion of a security, (iii) the power to revoke a trust, discretionary account or similar arrangement, or (iv) the automatic termination of a trust, discretionary account or similar arrangement. Except as disclosed in the footnotes to this table and subject to applicable community property laws, we believe that each person identified in the table has sole voting and investment power over all of the shares shown opposite such person's name. For purposes of this table below, given that the Manager manages all operations of our business and holds 100% of the Common Shares, which are the primary voting shares, we have disclosed ownership of the Manager where indicated.

 **<u>Common Shares</u>**

 *Tranquil Healthcare Fund I, LLC*

Percentage ownership in the Company in the following table is based on 1,000,000 Common Shares outstanding as of March 3, 2026.

---

| | | | |
|:---|:---|:---|:---|
| **Title of Class** | **Amount and nature of beneficial ownership <sup>(2)</sup>** | **Amount and nature of beneficial ownership acquirable** | **Percent of class <sup>(3)</sup>** |
| Common Shares Tranquil Healthcare Holdings, Inc. <sup>(4)</sup> | 1000000 | – | 100% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Beneficial Ownership
 is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment
 power with respect to securities. Common Shares subject to options, warrants, or convertible debt currently exercisable or convertible,
 or exercisable or convertible within 60 days of March 3, 2026 are deemed outstanding for computing percentage of the person holding
 such option or warrant but are not deemed outstanding for computing the percentage of any person. Percentages are based on a total
 of 1,000,000 Common Shares outstanding March 3, 2026 including all shares held for vesting, and the shares issuable upon exercise
 of options, warrants exercisable, and debt convertible on or within 60 days of March 3, 2026.

(2) Unless otherwise stated
 in a specific footnote, all shares are held directly by beneficial owners.

(3) The number of Common
 Shares outstanding used in computing the percentages is 1,000,000.

(4) See Table below regarding
 ownership of Tranquil Healthcare Holdings, Inc., our Manager. The Address of Tranquil Healthcare Holdings, Inc. is 18200 Von Karman
 Ave., Suite 850, Irvine CA, 92612.

 *Tranquil Healthcare Holdings, Inc.*

---

| | | | |
|:---|:---|:---|:---|
| **Title of Class** | **Amount and nature of beneficial ownership <sup>(2)</sup>** | **Amount and nature of beneficial ownership acquirable** | **Percent of class <sup>(3)</sup>** |
| Common Stock, par value $0.001 Tyler Ehler <sup>(4)</sup> | 200000 | – | 47.00% |
| Common Stock, par value $0.001 Jeff Campbell <sup>(5)</sup> | 100000 | – | 23.50% |
| Common Stock, par value $0.001 Johan Spoor <sup>(6)</sup> | 100000 | – | 23.50% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Beneficial Ownership
 is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment
 power with respect to securities. Common Stock subject to options, warrants, or convertible debt currently exercisable or convertible,
 or exercisable or convertible within 60 days of March 3, 2026 are deemed outstanding for computing percentage of the person holding
 such option or warrant but are not deemed outstanding for computing the percentage of any person. Percentages are based on a total
 of 423,500 shares of Common Stock outstanding March 3, 2026 including all shares held for vesting, and the shares issuable upon exercise
 of options, warrants exercisable, and debt convertible on or within 60 days of March 3, 2026.

(2) Unless otherwise stated
 in a specific footnote, all shares are held directly by beneficial owners.

(3) The number of Common
 Shares outstanding used in computing the percentages is 423,500.

(4) Mr. Ehler serves as
 the CEO, CFO, Secretary, and Chairman of the Board of Directors of Tranquil Healthcare Holdings, Inc. The Address of such beneficial
 owner is 18200 Von Karman Ave., Suite 850, Irvine CA, 92612.

(5) Mr. Campbell serves
 on the Board of Directors of Tranquil Healthcare Holdings, Inc. The Address of such beneficial owner is 18200 Von Karman Ave., Suite
 850, Irvine CA, 92612.

(6) Mr. Spoor serves as
 a consultant to Tranquil Healthcare Holdings, Inc. The Address of such beneficial owner is 18200 Von Karman Ave., Suite 850, Irvine
 CA, 92612.

**DESCRIPTION OF SECURITIES**

The following is a summary of the rights of our Shares as provided in our certificate of organization and Operating Agreement, as amended to date. For more detailed information, please see our certificate of organization and Operating Agreement, which have been filed as exhibits to the Offering Statement of which this Offering Circular is a part.

**General**

Market capital structure:

 **Current Capitalization**

---

| | | | |
|:---|:---|:---|:---|
| **Security** | **Authorized <sup>(1)</sup>** | **Outstanding** | **Voting Rights** |
| Common Shares | 1000000 | 1000000 | 1 vote / share |
| Class A Preferred Shares | 10000000 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0 <sup>(2)</sup> | None <sup>(3)</sup> |

---

(1) As of March
 3, 2026, the Company had authorized (i) 1,000,000 Common Shares and (ii) 10,000,000 Class A Preferred Shares.

(2) Excludes Class A Preferred
 Shares issuable upon conversion of $325,000 in principal of outstanding convertible promissory notes that convert at $10.00 per share.

(3) The Class A Preferred
 Shares vote in certain limited circumstances, such as (i) certain amendments to the Operating Agreement that would disproportionately
 and adversely affect the Class A Preferred Shares, (ii) the determination to dissolve or wind up the Company, (iii) the appointment
 of a replacement Manager in the event the Manager resigns or is otherwise dissolved (bankruptcy etc.), and (iv) other matters required
 by Delaware law.

 **Capitalization After the Offering**

---

| | | | |
|:---|:---|:---|:---|
| **Security** | **Authorized <sup>(1)</sup>** | **Outstanding** | **Voting Rights** |
| Common Shares | 1000000 | 1000000 | 1 vote / share |
| Class A Preferred Shares | 10000000 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5500000 <sup>(2)</sup> | None <sup>(3)</sup> |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) As of March 3, 2026,
 the Company had authorized (i) 1,000,000 Common Shares and (ii) 10,000,000 Class A Preferred Shares.

(2) Assumes that all Offered
 Shares are sold in the Offering and that all investors purchasing shares in this Offering meet the Incentive Threshold. Excludes
 Class A Preferred Shares issuable upon conversion of $325,000 in principal of convertible promissory notes that convert at $10.00
 per share.

 **<u>Class A Preferred Shares</u>**

Pursuant to the Operating Agreement, the Company is authorized to issue 10,000,000 Class A Preferred Shares. The Class A Preferred Shares have the rights, preferences, and privileges described below.

(a) <u>Designation and Amount</u>. 10,000,000 Class A Preferred Shares are authorized under the Operating Agreement.

(b) <u>Closings</u>. Since there is no minimum offering amount, the Company may immediately deposit the proceeds from accepted subscription agreements into the Company's bank account.

(c) <u>Voting.</u> Pursuant the Operating Agreement, the Class A Preferred Shares will not vote on any matter, except for (i) certain amendments to the Operating Agreement that would disproportionately and adversely affect the Class A Preferred Shares, (ii) the determination to dissolve or wind up the Company, (iii) the appointment of a replacement Manager in the event the Manager resigns or is otherwise dissolved (bankruptcy etc.), and (iv) other matters required by Delaware law.

Accordingly, the Manager, as the sole holder of the Common Shares will have control over all other matters to be voted on by the Members of the Company.

(d) <u>Distributions.</u>

Pursuant to the Company's Operating Agreement, the Manager will determine if and when distributions are made to the Members. The Company will deposit 8.00% of the proceeds from this offering into a segregated restricted account, which will be maintained as a contingency reserve ("Reserve Account") to make Distributions to the Members holding Class A Preferred Shares, which have a preference over the Common Shares. Such funds held in the Reserve Account will be classified as restricted cash and may, at the discretion of the Manager, be invested by the Company in cash equivalents.

All Distributions of cash to be made by the Company, at the discretion of Manager, will be subject to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) First, the Class A Preferred Shares shall receive one hundred percent (100%) of Distributions until each Member holding Class A Preferred Shares has received cumulative Distributions equal to an annual, non-compounded, eight percent (8%) return on the original purchase price paid for such Class A Preferred Shares, calculated from the date of issuance and prorated for partial years. Any such portion not distributed in any year shall continue to accrue and remain unpaid until satisfied; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ii) Thereafter, all additional Distributions, shall be distributed (1) seventy percent (70%) to the Class A Preferred Shares and (2) thirty percent (30%) to the Common Shares.

There can no assurances if and when the Manager will make Distributions, or if the Company will have sufficient free cash flows from its commercial loans and consulting services in order for Distributions to be made.

Our Distributions generally will constitute a return of capital to the extent that they exceed our current and accumulated earnings and profits as determined for U.S. federal income tax purposes. To the extent that a distribution is treated as a return of capital for U.S. federal income tax purposes, it will reduce a holder's adjusted tax basis in the holder's Shares, and to the extent that it exceeds the holder's adjusted tax basis, it will be treated as gain resulting from a sale or exchange of such Shares.

(e) <u>Dissolution</u>.

Upon any of the following to occur, the Company will commence winding up (each, a "Dissolution Event"): (i) the vote of the Members (each class voting separately), with Manager approval, (ii) the insolvency or bankruptcy of the Company, (iii) the occurrence of a Fundamental Transaction (as defined in the Operating Agreement, but generally an acquisition of the Company), or (iv) the entry of a decree of judicial dissolution under Section 18-801 of the Delaware Limited Liability Company Act. In the event of a Dissolution Event, the Distributions will be made on the same terms as those described above in the section entitled "Distributions" after payment of all creditors and liabilities have been made.

As of March 3, 2026, the Company had no Class A Preferred Shares outstanding.

 **<u>Common Shares</u>**

The Common Shares represent the equity ownership interests in the Company held by the Manager. The Common Shares are subordinate in certain respects to the Class A Preferred Shares with respect to Distributions and liquidation preferences, as described above.

The Common Shares are not being offered pursuant to this Offering Circular.

 **Management and Voting Rights**

The Company is a manager-managed limited liability company. Except as otherwise required by the Delaware Limited Liability Company Act or as expressly provided in the Operating Agreement, the holder of Common Shares has the exclusive authority to vote on all matters submitted to members of the Company.

The Manager currently holds all of the Common Shares, as a result, controls the management, direction, and policies of the Company. Holders of the Class A Preferred Shares have limited protective voting rights only in specified circumstances, as described elsewhere in this Offering Circular.

 **Distributions**

Distributions to holders of Common Shares may be declared by the Manager from legally available funds and in accordance with the Operating Agreement. The Common Shares receive Distributions along with the Class A Preferred Shares as described above under the description of Class A Preferred Shares, including in the event of a liquidation.

 **Transfer Restrictions**

The Common Shares are non-transferable by Manager, except in connection with an acquisition of the Company.

As of March 3, 2026 the Company had 1,000,000 Common Shares outstanding, all of which are owned by the Manager.

 **Transfer Agent** 

The Company has engaged T7X Equities, Inc. to act as transfer agent for the Class A Preferred Shares. The Class A Preferred Shares will be issued and maintained in book-entry form on a digital ledger platform administered by the transfer agent. The digital record evidencing ownership will not be tradeable on any securities exchange or alternative trading system unless separately registered or qualified and in compliance with applicable securities laws.

 **SHARES ELIGIBLE FOR FUTURE SALE / TRANSFER RESTRICTIONS**

The Class A Preferred Shares offered hereby are being issued pursuant to Regulation A under the Securities Act. Securities issued in a qualified Regulation A offering are not "restricted securities" for purposes of Rule 144; however, any resale of the Class A Preferred Shares must comply with applicable federal and state securities laws.

Transfers of Class A Preferred Shares are also subject to the restrictions contained in the Company's Operating Agreement. Except for transfers effected on a Trading Market approved in writing by the Company, any transfer of Class A Preferred Shares requires the prior written approval of the Company, which may be granted or withheld in the Company's sole discretion. Any attempted transfer in violation of the Operating Agreement will be null and void.

There is currently no public trading market for the Class A Preferred Shares, and there can be no assurance that an approved Trading Market will develop. As a result, investors should expect to hold their Class A Preferred Shares indefinitely.

 **MATERIAL U.S. FEDERAL TAX CONSIDERATIONS** 

The following is a discussion of material U.S. federal income tax considerations relating to the purchase, ownership and disposition of our Class A Preferred Shares by Holders (as defined below) as of the date hereof. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the "Code"), U.S. Treasury Regulations promulgated or proposed thereunder, and all administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect, or to different interpretation.

The U.S. federal income taxation of partnerships and partners is extremely complex, involving, among other things, significant issues as to the character, timing of realization and sourcing of gains and losses. This discussion does not address all of the U.S. federal income tax considerations that may be relevant to specific Holders in light of their particular circumstances or to Holders subject to special treatment under U.S. federal income tax law (such as banks, insurance companies, dealers in securities or other Holders that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities, retirement plans, regulated investment companies, real estate investment trusts, certain former citizens or residents of the United States or Holders that hold our Class A Preferred Shares as part of a straddle, hedge, conversion or other integrated transaction) or U.S. Holders that have a "functional currency" other than the U.S. dollar. This discussion does not address any U.S. state or local or non-U.S. tax considerations or any U.S. federal estate (except as discussed below for Non-U.S. Holders), gift or alternative minimum tax considerations. **Prospective Investors are urged to consult their own tax advisors regarding the purchase, ownership and disposition of our Class A Preferred Shares with respect to their particular tax situations, including, in the case of prospective Holders subject to special treatment under U.S. federal income tax laws, with reference to any special issues that the purchase, ownership and disposition of our Class A Preferred Shares may raise for such persons.** The activities of a Holder unrelated to such Holder's status as a member of the Company may affect the tax consequences to such Holder of an investment in the Company.

As used in this discussion, the term "U.S. Holder" means a beneficial owner of a Class A Preferred Share that, for U.S. federal income tax purposes, is (i) an individual who is a citizen or resident of the United States, (ii) a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia, (iii) an estate, the income of which is subject to U.S. federal income tax regardless of its source, or (iv) a trust (x) with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions or (y) that has in effect a valid election under applicable U.S. Treasury Regulations to be treated as a U.S. person. As used in this discussion, the term "Non-U.S. Holder" means a beneficial owner of a Class A Preferred Share that is neither a U.S. Holder nor a partnership for U.S. federal income tax purposes, and the term "Holder" means a U.S. Holder or a Non-U.S. Holder.

If an entity treated as a partnership for U.S. federal income tax purposes invests in our Class A Preferred Shares, the U.S. federal income tax considerations relating to such investment will depend in part upon the status and activities of such entity and the particular partner. Any such entity should consult its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners relating to the purchase, ownership and disposition of our Class A Preferred Shares.

PERSONS CONSIDERING AN INVESTMENT IN OUR CLASS A PREFERRED SHARES SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. INCOME, ESTATE AND OTHER TAX CONSIDERATIONS RELATING TO THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR CLASS A PREFERRED SHARES IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES.

 **Taxation of Our Company**

 ***Taxation of the Company.*** We expect that we will be treated as a partnership for U.S. federal income tax purposes and not as an association or publicly traded partnership subject to tax as a corporation. As a partnership, we generally will not be subject to U.S. federal income tax. Instead, each Holder that is subject to U.S. tax will be required to take into account its distributive share, whether or not distributed, of each item of our income, gain, loss, deduction or credit. See "—Taxation of U.S. Holders of Class A Preferred Shares".

An entity that would otherwise be classified as a partnership for U.S. federal income tax purposes may nonetheless be taxable as a corporation if it is a "publicly traded partnership", unless an exception applies. An entity that would otherwise be classified as a partnership is a publicly traded partnership if (i) interests in the partnership are traded on an established securities market or (ii) interests in the partnership are readily tradable on an alternative exchange or the substantial equivalent thereof. We may eventually be publicly traded for purposes of these rules.

A publicly traded partnership will, however, be treated as a partnership, and not as a corporation, for U.S. federal income tax purposes, if (x) 90% or more of such partnership's gross income during each taxable year consists of "qualifying income" and (y) such partnership is not required to register as an investment company under the Investment Company Act of 1940, as amended (the "1940 Act"). We refer to this exception as the "qualifying income exception." Qualifying income generally includes certain interest income, dividends, real property rents, gains from the sale or other disposition of real property, gains from the sale or other disposition of capital assets or other property held for the production of income that otherwise constitutes qualifying income and certain other forms of investment income.

We intend to operate such that we will meet the qualifying income exception in each taxable year. We do not expect that the Company will earn any income in any taxable year other than qualifying income including (x) interest income with respect to commercial loans made by the Company to the Operators and (y) Distributions, at the discretion of the Manager or upon dissolution / sale of the Company. At present, we do not expect to seek a ruling from the U.S. Internal Revenue Service (the "IRS") with respect to our treatment as a partnership for U.S. federal income tax purposes and no assurance can be given that the IRS will not take a contrary position.

If we fail to meet the qualifying income exception (other than a failure that is determined by the IRS to be inadvertent and that is cured within a reasonable time after discovery) or if we are required to register under the 1940 Act, we will be treated as if, on the first day in which we fail to meet the qualifying income exception or are required to register under the 1940 Act, we had transferred all of our assets, subject to our liabilities, to a newly formed corporation in exchange for stock of such corporation, and then distributed the stock to the Holders in liquidation of their interests in us. This deemed contribution and liquidation should generally be tax-free to the Holders so long as we do not have liabilities in excess of the tax basis of our assets at such time. Thereafter, we would be treated as a corporation for U.S. federal income tax purposes.

If we were treated as a corporation in any taxable year, our items of income, gain, loss, deduction and credit would be reflected our tax return, rather than the returns of our Holders subject to U.S. tax, and we would be subject to U.S. corporate income tax on our taxable income. Distributions of cash or other property to a Holder with respect to our Class A Preferred Shares generally would be treated as a dividend to the extent such distribution was paid from our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), or in the absence of earnings and profits, as a tax-free return of capital to the extent of such Holder's adjusted tax basis in such Class A Preferred Share, and then as capital gain. Accordingly, treatment as a corporation could materially reduce a Holder's after-tax return and thus could result in a substantial reduction of the value of our Class A Preferred Shares.

The remainder of this discussion assumes that we will be treated as a partnership for U.S. federal income tax purposes.

 **Taxation of U.S. Holders of Shares**

Below is a discussion of material U.S. federal income tax considerations applicable to U.S. Holders of our Class A Preferred Shares.

 ***Taxation of Holders of Shares on Our Profits and Losses.*** As a partnership for U.S. federal income tax purposes, we generally will not be subject to U.S. federal income tax. Instead, each Holder that is subject to U.S. tax will be required to take into account its distributive share, whether or not distributed, of each item of our income, gain, loss, deduction or credit. It is possible that in any year, a Holder's tax liability arising from the Company could exceed the Distributions made by the Company to such Holder. The Company will file a U.S. federal partnership information return reporting its operations for each year and provide a U.S. Internal Revenue Service Schedule K-1 to each Holder. However, Holders may not receive such Schedule prior to when their tax return reporting obligations become due and may need to file for extensions or file based on estimates.

In addition to regular U.S. federal income tax, certain U.S. Holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their "net investment income," which may include all or a portion of any interest income we earn that is allocable to such U.S. Holder.

 ***Allocation of Profits and Losses.*** For each of our fiscal years, each Holder's allocable share of our items of income, gain, loss, deduction or credit will be determined by our Operating Agreement, *provided* such allocations either have "substantial economic effect" or are determined to be in accordance with such Holder's interest in the Company. We believe that for U.S. federal income tax purposes, such allocations will be given effect as being in accordance with such Holder's interest in the Company and we intend to prepare tax returns based on such allocations. If the allocations provided by our Operating Agreement were successfully challenged by the IRS, the resulting allocations to a particular Holder for U.S. federal income tax purposes may be less favorable than the allocations set forth in our Operating Agreement.

Section 706 of the Internal Revenue Code provides that items of partnership income and deductions must be allocated between transferors and transferees of shares. We will apply certain assumptions and conventions in an attempt to comply with applicable rules and to report income, gain, loss, deduction and credit to Holders in a manner that reflects such Holders' beneficial shares of our items. These conventions are designed to more closely align the receipt of cash and the allocation of income between Holders of Class A Preferred Shares, but these assumptions and conventions may not conform with all aspects of existing Treasury Regulations. If the IRS successfully challenges our conventions, our items of income, gain, loss, deduction or credit may be reallocated among the Holders of Class A Preferred Shares to the possible detriment of certain Holders. The Manager is authorized to revise our method of allocation between transferors and transferees (as well as among Holders whose interests otherwise could vary during a taxable period).

 ***Adjusted Tax Basis of Class A Preferred Shares.*** A Holder's initial tax basis in its Class A Preferred Shares will generally equal the amount such Holder paid for the Class A Preferred Shares plus such Holder's allocable share of our liabilities, if any. A Holder's adjusted tax basis will be increased by such Holder's share of items of our income and gain and any increase in such Holder's share of our liabilities. A Holder's adjusted tax basis will be decreased, but not below zero, by distributions from us, such Holder's allocable share of items of our deductions and losses and by any decrease in such Holder's allocable share of our liabilities.

Holders who purchase our Class A Preferred Shares in separate transactions must combine the basis of those Class A Preferred Shares and maintain a single adjusted tax basis for all of those Class A Preferred Shares. Upon a sale or other disposition of less than all of the Class A Preferred Shares held by such Holder, a portion of that tax basis must be allocated to the Class A Preferred Shares sold.

 ***Restrictions on Deductibility of Expenses and Other Losses***. A Holder may deduct its allocable share of our losses (if any) for U.S. federal income tax purposes only to the extent of such Holder's adjusted tax basis in the Class A Preferred Shares it is treated as holding at the end of the taxable year in which the losses occur. If the recognition of a Holder's allocable share of our losses would reduce its adjusted tax basis for its Class A Preferred Shares below zero, the recognition of such losses by such Holder would be deferred to subsequent taxable years and will be allowed if and when such Holder has sufficient tax basis so that such losses would not reduce such Holder's adjusted tax basis below zero. In addition, the "at-risk" rules and the limitation on "excess business losses" could limit the deductibility of losses allocable to a Holder. We do not expect to generate income or losses from "passive activities" for purposes of Section 469 of the Internal Revenue Code. Therefore, income allocated by us to a Holder may not be offset by the Section 469 passive losses of such Holder and losses allocated to a Holder generally may not be used to offset Section 469 passive income of such Holder.

It is anticipated that our expenses generally will be investment expenses treated as miscellaneous itemized deductions, rather than trade or business expenses, with the result that any individual who is a Holder (either directly or through a Holder that is a partnership or other pass-through entity) will not be permitted to claim a U.S. federal income tax deduction for such expenses for taxable years beginning before January 1, 2026 and thereafter may be limited in his or her ability to claim a U.S. federal income tax deduction for such expenses.

In general, neither we nor any Holder may deduct organizational expenses. We may elect to amortize any organizational expenses ratably over fifteen years, or we may elect to capitalize such expenses. No deduction is allowed for offering expenses, including placement fees.

 ***Treatment of Distributions.*** For U.S. federal income tax purposes, distributions of cash by us generally will not be taxable to a U.S. Holder to the extent of such U.S. Holder's adjusted tax basis in its Class A Preferred Shares. Any cash distributions in excess of a U.S. Holder's adjusted tax basis generally will be considered to be gain from the sale or exchange of our Class A Preferred Shares. Under current law, such gain generally will be capital gain and will be long-term capital gain if such U.S. Holder has held such Class A Preferred Share for more than one year at the time of such distribution, subject to certain exceptions.

 ***Disposition of Class Shares.*** A U.S. Holder generally will recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of our Class A Preferred Shares in an amount equal to the difference, if any, between the amount realized on the sale, exchange or other disposition and such U.S. Holder's adjusted tax basis in such Class A Preferred Share. A U.S. Holder's adjusted tax basis will be adjusted for this purpose by its allocable share of our income or loss for the year of such sale or other disposition. Any gain or loss so recognized generally will be capital gain or loss and will be long-term capital gain or loss if such Holder has held such Class A Preferred Share for more than one year at the time of such sale, exchange or other disposition. Net long-term capital gain of certain non-corporate U.S. Holders generally is subject to preferential rates of tax. The deductibility of capital losses is subject to limitations.

Holders who purchase our Class A Preferred Shares at different times and intend to sell all or a portion of the Class A Preferred Shares within a year of their most recent purchase are urged to consult their tax advisors regarding the application of certain "split holding period" rules to them and the treatment of any gain or loss as long-term or short-term capital gain or loss. For example, a selling Holder may use the actual holding period of the portion of its transferred Class A Preferred Shares, *provided* such Class A Preferred Shares are divided into identifiable Class A Preferred Shares with ascertainable holding periods, the selling Holder can identify the portion of the Class A Preferred Shares transferred, and the selling Holder elects to use the identification method for all sales or exchanges of our Class A Preferred Shares.

 ***Controlled Foreign Corporations.*** In general, a corporation organized outside the United States is treated as a controlled foreign corporation ("CFC") for U.S. federal income tax purposes in any taxable year in which more than 50% of (i) the total combined voting power of all classes of stock of such non-U.S. corporation entitled to vote or (ii) the total value of the stock of such non-U.S. corporation is owned (or is considered as owned) by "U.S. Shareholders" on any day during the taxable year of such non-U.S. corporation. A "U.S. Shareholder" with respect to a non-U.S. corporation is any U.S. person that owns (or is treated as owning) 10% or more of the total combined voting power of all classes of stock of the non-U.S. corporation entitled to vote or 10% or more of the total value of such non-U.S. corporation's stock.

 ***Passive Foreign Investment Companies.*** In general, a corporation organized outside the United States is treated as a passive foreign investment company ("PFIC") for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of its gross income is "passive income" or (ii) on average at least 50% of the value of its assets is attributable to assets that produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents and gains from commodities transactions and from the sale or exchange of property that gives rise to passive income. In determining whether a non-U.S. corporation is a PFIC, a pro rata portion of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) generally is taken into account.

 **Taxation of Non-U.S. Holders of Class A Preferred Shares**

Below is a discussion of material U.S. federal income tax considerations applicable to Non-U.S. Holders of our Class A Preferred Shares and does not purport to address all of the U.S. federal income tax consequences that may be applicable to any particular Non-U.S. Holder. This discussion does not address the tax consequences of purchasing, holding or disposing of our Class A Preferred Shares to Non-U.S. Holders subject to special rules under U.S. federal income tax laws, such as non-U.S. governments and their controlled entities, non-U.S. pension plans, trusts, former U.S. citizens or residents and individual Non-U.S. Holders that have a "tax home" in the United States. The discussion assumes that a Non-U.S. Holder is not and will not be engaged in a trade or business within the United States, has and will have no U.S. source income apart from its investment in our Class A Preferred Shares, and, in the case of a Non-U.S. Holder that is an individual, has not been (and will not be) present in the United States for 183 days or more in any taxable year.

 ***Interest, Dividends, Etc***. A Non-U.S. Holder is subject to U.S. federal withholding tax at the rate of 30% (or at a lower rate if provided by an applicable tax treaty and the Non-U.S. Holder provides the documentation (generally, IRS Form W-8BEN or W-8BEN-E) required to claim benefits under such tax treaty to the applicable withholding agent) on its distributive share of any U.S. source interest (subject to certain exemptions), U.S. source dividends (including, in certain cases, dividend equivalent amounts) and certain other income received by us.

 ***Effectively Connected Income***. In general, a non-U.S. person that invests in an entity taxable as a partnership for U.S. federal income tax purposes that is (directly or through entities treated as disregarded from their owners or as partnerships for U.S. federal income tax purposes) "engaged in trade or business within the United States" is itself considered to be engaged in trade or business within the United States and is subject to U.S. federal income tax (including, possibly, in the case of a non-U.S. corporation, the "branch profits" tax), withholding and income tax return filing requirements with respect to its income effectively connected (or treated as effectively connected) with the U.S. trade or business ("ECI"). A non-U.S. person that fails to file a timely U.S. federal income tax return in respect of its ECI may subsequently be precluded from claiming deductions related to the ECI and may be subject to interest and penalties.

 ***U.S. Federal Estate Taxes for Non-U.S. Persons.*** Individual Non-U.S. Holders will be subject to U.S. federal estate tax on the value of U.S.-situs property owned at the time of their death. Our Class A Preferred Shares that are owned or treated as owned by an individual Non-U.S. Holder at the time of such Non-U.S. Holder's death may be considered U.S.-situs property for U.S. federal estate tax purposes and may be subject to U.S. federal estate tax unless an applicable estate tax treaty provides otherwise. Prospective individual holders who are non-U.S. persons are urged to consult their tax advisors concerning the potential U.S. federal estate tax consequences with regard to our Class A Preferred Shares.

 **Administrative Matters**

 ***Tax Elections.*** The Manager will have the authority to act on our behalf with respect to tax audits and certain other tax matters and to make such elections under the Internal Revenue Code and other relevant tax laws as the Manager deems necessary or appropriate. Accordingly, our Manager can change our tax election in its sole and absolute discretion.

 ***Nominee Reporting.*** Persons who hold our Class A Preferred Shares as nominees for another person are required to furnish to us (i) the name, address and taxpayer identification number of the beneficial owner and the nominee; (ii) whether the beneficial owner is (1) a person that is not a U.S. person, (2) a foreign government, an international organization or any wholly owned agency or instrumentality of either of the foregoing, or (3) a tax exempt entity; (iii) the amount and description of Class A Preferred Shares held, acquired or transferred for the beneficial owner; and (iv) specific information including the dates of acquisitions and transfers, means of acquisitions and transfers, and acquisition costs for purchases, as well as the amount of net proceeds from sales. Brokers and financial institutions are required to furnish additional information, including whether they are U.S. persons and specific information on Class A Preferred Shares they acquire, hold or transfer for their own account. A penalty is imposed by the Internal Revenue Code for failure to report that information to us. The nominee is required to supply the beneficial owner of the Class A Preferred Shares with the information furnished to us.

 ***Taxable Year.*** We currently intend to use the October 31 as our taxable year end for U.S. federal income tax purposes.

 ***Partnership Audit Rules***. We or the Holders may have potential tax liability in the event of an adjustment imposed as a result of a tax audit by the IRS. An audit resulting in an adjustment to any item of our income, gain, loss, deduction or credit (or adjustment of the allocation of any such items among the Holders), and any tax (including interest and penalties) attributable to such adjustment, may be determined and collected at the Company level in the year of such adjustment. In that event of any adjustment at the Company level, under the Operating Agreement, the Manager will allocate such tax among the Holders as equitably determined by the Manager, and each Holder may be required to contribute to the Company the amount of such tax allocated to it. As a result, a Holder may bear liability for the adjustment in an amount that exceeds the taxes that the Holder (or its predecessor in interest) would have paid if the adjustment had been applied at the Holder level. Alternatively, the Manager may elect to send an adjusted Schedule K-1 to each person who was a Holder in the taxable year reviewed on audit (the "Push-Out Election"). In that event, each such person (whether a current or former Holder) may elect to pay any resulting tax (including interest and penalties) or, in the case of a person that is itself treated as a partnership or other flow-through vehicle for U.S. federal income tax purposes, such person may further push out the adjustment to the next tier of partners. Non-U.S. Holders may be required to file U.S. tax returns as a result of a Push-Out Election. There is some uncertainty regarding the interpretation and implementation of these partnership audit procedures.

 ***Treatment of Withholding Taxes.*** We will withhold and pay over any U.S. withholding taxes required to be withheld with respect to any Holder and will treat such withholding as a payment to such Holder. Such payment will be treated as a distribution to the extent that the Holder is then entitled to receive a cash distribution. To the extent that such payment exceeds the amount of any cash distribution to which such Holder is then entitled, such Holder shall be required to make prompt payment to us. Similar provisions would apply in the case of taxes withheld from a distribution to us.

 **

 ****

 **

 ****

 ***Information Reporting and Backup Withholding.*** If we are required to withhold any U.S. tax on distributions made to any Holder of Class A Preferred Shares, we will pay such withheld amount to the IRS. Amounts withheld generally will be reported annually to the IRS and to the Holders by the applicable withholding agent. Distributions made to a U.S. Holder may be subject to backup withholding, unless such U.S. Holder provides the appropriate documentation certifying that, among other things, its taxpayer identification number ("TIN") is correct, or otherwise establishes an exemption. Such U.S. Holder should use an IRS Form W-9 for this purpose. If such U.S. Holder does not provide its correct TIN and other required information or an adequate basis for exemption, payments made to such U.S. Holder will be subject to backup withholding (currently, at a rate of 24%) and such U.S. Holder may be subject to a penalty imposed by the IRS. Exempt U.S. Holders (including, among others, all corporations) are not subject to these information reporting and backup withholding requirements, provided that, if required, they properly demonstrate their eligibility for exemption. In order for a Non-U.S. Holder to avoid backup withholding, such Non-U.S. Holder should submit the appropriate version of IRS Form W-8, attesting to such Non-U.S. Holder's foreign status. The failure of such a Non-U.S. Holder to provide the appropriate IRS Form W-8 may result in backup withholding on some or all of the payments made to such Non-U.S. Holder. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a Holder's U.S. federal income tax liability if the required information is furnished by such Holder on a timely basis to the IRS.

If you do not timely provide us with IRS Form W-8 or IRS Form W-9, as applicable, or such form is not properly completed, we may become subject to U.S. backup withholding taxes in excess of what would have been imposed had we received certifications from all Holders. Such excess U.S. backup withholding taxes may be treated by us as an expense that will be borne by all Holders on a pro rata basis (where we are or may be unable to cost efficiently allocate any such excess withholding tax cost specifically to the Holders that failed to timely provide the proper U.S. tax certifications).

The proper application to us of rules for withholding under Section 1441 of the Internal Revenue Code (applicable to certain dividends, interest and similar items) is unclear. Because the documentation we receive may not properly reflect the identities of Holders at any particular time (in light of possible sales of Class A Preferred Shares), we may over-withhold or under-withhold with respect to a particular Holder. For example, we may impose withholding, remit that amount to the IRS and thus reduce the amount of a distribution paid to a Non-U.S. Holder. It may be determined, however, that the corresponding amount of our income was not properly allocable to such Non-U.S. Holder, and the withholding should have been less than the actual withholding. Such Non-U.S. Holder would be entitled to a credit against such Non-U.S. Holder's U.S. tax liability for all withholding, including any such excess withholding, but if the withholding exceeded the Non-U.S. Holder's U.S. tax liability, the Non-U.S. Holder would be required to apply for a refund to obtain the benefit of the excess withholding. Similarly, we may fail to withhold on a distribution, and it may be determined that the corresponding income was properly allocable to a Non-U.S. Holder and withholding should have been imposed. In that event, we may determine to pay the under-withheld amount to the IRS, and we may treat such under-withholding as an expense that will be borne by all partners on a pro rata basis (since we may be unable to allocate any such excess withholding tax cost to the relevant Non-U.S. Holder).

 **Reportable Transactions**

If the U.S. federal tax rules relating to "reportable transactions" are applicable to us (or any of the transactions undertaken by us), Holders that are required to file U.S. federal income tax returns (and, in some cases, certain direct and indirect interest holders of certain Holders) would be required to disclose to the IRS information relating to the Company and our transactions, and to retain certain documents and other records related thereto. Although we do not believe that the purchase of our Class A Preferred Shares is a reportable transaction, there can be no assurance that the IRS will not take a contrary position. In addition, an interest in the Company could become a reportable transaction for Holders in the future, for example if we generate certain types of losses that exceed prescribed thresholds or if certain other events occur. It is also possible that a transaction undertaken by us will be a reportable transaction for Holders. Substantial penalties may be imposed on taxpayers who fail to comply with these laws.

In addition, other tax laws impose substantial excise taxes and additional reporting requirements and penalties on certain tax-exempt Investors (and, in some cases, the managers of tax-exempt investors) that are, directly or in some cases indirectly, parties to certain types of reportable transactions.

 **FATCA**

Under the Foreign Account Tax Compliance Act provisions of the Code and related U.S. Treasury guidance ("FATCA"), a withholding tax of 30% will be imposed in certain circumstances on (*i*) payments of certain U.S. source income (including interest and dividends) and gross proceeds from the sale or other disposition after December 31, 2018, of property that can produce U.S. source interest or dividends ("withholdable payments") and (*ii*) payments made after December 31, 2018 (or, if later, the date on which the final U.S. Treasury regulations that define "foreign passthru payments" are published) by certain foreign financial institutions (such as banks, brokers, investment funds or certain holding companies) ("FFIs") that are "attributable" to withholdable payments ("foreign passthru payments"). It is uncertain at present when payments will be treated as "attributable" to withholdable payments.

Although the application of FATCA to a sale or other disposition of an interest in an entity treated as a partnership for U.S. federal income tax purposes is unclear, it is possible that the gross proceeds from the sale or other disposition of an interest in the Company may be subject to tax under FATCA.

Each Holder should consult its own tax advisor regarding the application of FATCA to an investment in the Company.

 **Certain State, Local and Non-U.S. Tax Considerations**

The foregoing discussion does not address the U.S. state and local or non-U.S. tax consequences of the purchase, ownership and disposition of our Class A Preferred Shares. Holders may be subject to certain U.S. state and local and non-U.S. taxation, and tax return filing requirements, in the jurisdictions of our activities or investments. Holders may not receive the relevant tax information prior to when their tax return reporting obligations become due and may need to file for extensions. Prospective Holders are urged to consult their own tax advisors regarding U.S. state and local and non-U.S. tax matters.

 **ERISA AND RELATED CONSIDERATIONS**

The Employee Retirement Income Security Act of 1974, as amended ("ERISA"), is a broad statutory framework that governs most U.S. retirement and other U.S. employee benefit plans. ERISA and the rules and regulations of the Department of Labor (the "DOL") under ERISA contain provisions that should be considered by fiduciaries of employee benefit plans subject to the provisions of Title I of ERISA ("ERISA Plans") and their legal advisors. In particular, a fiduciary of an ERISA Plan should consider whether an investment in our Class A Preferred Shares (or, in the case of a participant-directed defined contribution plan (a "Participant-Directed Plan"), making our Class A Preferred Shares available for investment under the Participant-Directed Plan) satisfies the requirements set forth in Part 4 of Title I of ERISA, including the requirements that (1) the investment satisfy the prudence and diversification standards of ERISA, (2) the investment be in the best interests of the participants and beneficiaries of the ERISA Plan, (3) the investment be permissible under the terms of the ERISA Plan's investment policies and governing instruments and (4) the investment does not give rise to a non-exempt prohibited transaction under ERISA or Section 4975 of the Code.

In determining whether an investment in our Class A Preferred Shares (or making our shares available as an investment option under a Participant-Directed Plan) is prudent for ERISA purposes, a fiduciary of an ERISA Plan should consider all relevant facts and circumstances including, without limitation, possible limitations on the transferability of our Preferred shares, whether the investment provides sufficient liquidity in light of the foreseeable needs of the ERISA Plan (or the participant account in a Participant-Directed Plan), and whether the investment is reasonably designed, as part of the ERISA Plan's portfolio, to further the ERISA Plan's purposes, taking into consideration the risk of loss and the opportunity for gain (or other return) associated with the investment. It should be noted that we will invest our assets in accordance with the investment objectives and guidelines described herein, and that neither our Manager nor any of its affiliates has any responsibility for developing any overall investment strategy for any ERISA Plan (or the participant account in a Participant-Directed Plan) or for advising any ERISA Plan (or participant in a Participant-Directed Plan) as to the advisability or prudence of an investment in us. Rather, it is the obligation of the appropriate fiduciary for each ERISA Plan (or participant in a Participant-Directed Plan) to consider whether an investment in our Class A Preferred Shares by the ERISA Plan (or making such shares available for investment under a Participant-Directed Plan in which event it is the obligation of the participant to consider whether an investment in our Class A Preferred Shares is advisable), when judged in light of the overall portfolio of the ERISA Plan, will meet the prudence, diversification and other applicable requirements of ERISA.

Section 406 of ERISA and Section 4975 of the Code prohibit certain transactions involving the assets of an ERISA Plan, as well as those plans that are not subject to ERISA but that are subject to Section 4975 of the Code, such as individual retirement accounts ("IRAs") and non-ERISA Keogh plans (collectively with ERISA Plans, "Plans"), and certain persons (referred to as "parties in interest" for purposes of ERISA or "disqualified persons" for purposes of the Code) having certain relationships to Plans, unless a statutory or administrative exemption is applicable to the transaction. A party in interest or disqualified person who engages in a non-exempt prohibited transaction may be subject to non-deductible excise taxes and other penalties and liabilities under ERISA and the Code, and the transaction might have to be rescinded. In addition, a fiduciary who causes an ERISA Plan to engage in a non-exempt prohibited transaction may be personally liable for any resultant loss incurred by the ERISA Plan and may be subject to other potential remedies.

A Plan that proposes to invest in our preferred shares (or to make our shares available for investment under a Participant-Directed Plan) may already maintain a relationship with our Manager or one or more of its affiliates, as a result of which our Manager or such affiliate may be a "party in interest" under ERISA or a "disqualified person" under the Code, with respect to such Plan (e.g., if our Manager or such affiliate provides investment management, investment advisory or other services to that Plan). ERISA (and the Code) prohibits plan assets from being used for the benefit of a party in interest (or disqualified person). This prohibition is not triggered by "incidental" benefits to a party in interest (or disqualified person) that result from a transaction involving the Plan that is motivated solely by the interests of the Plan. ERISA (and the Code) also prohibits a fiduciary from using its position to cause the Plan to make an investment from which the fiduciary, its affiliates or certain parties in which it has an interest would receive a fee or other consideration or benefit. In this circumstance, Plans that propose to invest in our preferred shares should consult with their counsel to determine whether an investment in our preferred shares would result in a transaction that is prohibited by ERISA or Section 4975 of the Code.

If our assets were considered to be assets of a Plan (referred to herein as "Plan Assets"), our management might be deemed to be fiduciaries of the investing Plan. In this event, the operation of our Company could become subject to the restrictions of the fiduciary responsibility and prohibited transaction provisions of Title I of ERISA and/or the prohibited transaction rules of Section 4975 of the Code.

The DOL has promulgated a final regulation under ERISA, 29 C.F.R. § 2510.3-101 (as modified by Section 3(42) of ERISA, the "Plan Assets Regulation"), that provides guidelines as to whether, and under what circumstances, the underlying assets of an entity will be deemed to constitute Plan Assets for purposes of applying the fiduciary requirements of Title I of ERISA (including the prohibited transaction rules of Section 406 of ERISA) and the prohibited transaction provisions of Code Section 4975.

Under the Plan Assets Regulation, the assets of an entity in which a Plan or IRA makes an equity investment will generally be deemed to be assets of such Plan or IRA unless the entity satisfies one of the exceptions to this general rule. Generally, the exceptions require that the investment in the entity be one of the following:

&nbsp;&nbsp;&nbsp;&nbsp;· in
 securities issued by an investment company registered under the Investment Company Act;

&nbsp;&nbsp;&nbsp;&nbsp;· in
 "publicly offered securities", defined generally as interests that are "freely
 transferable", "widely held" and registered with the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;· in
 an "operating company" which includes "venture capital operating companies"
 and "real estate operating companies"; or

&nbsp;&nbsp;&nbsp;&nbsp;· in
 which equity participation by "benefit plan investors" is not significant.

The shares will constitute an "equity interest" for purposes of the Plan Assets Regulation, and the shares may not constitute "publicly offered securities" for purposes of the Plan Assets Regulation. In addition, the shares will not be issued by a registered investment company.

 *The 25% Limit.* Under the Plan Assets Regulation, and assuming No other exemption applies, an entity's assets would be deemed to include "plan assets" subject to ERISA on any date if, immediately after the most recent acquisition of any equity interest in the entity, 25% or more of the value of any class of equity interests in the entity is held by "benefit plan investors" (the "25% Limit"). For purposes of this determination, the value of equity interests held by a person (other than a benefit plan investor) that has discretionary authority or control with respect to the assets of the entity or that provides investment advice for a fee with respect to such assets (or any affiliate of such a person) is disregarded. The term "benefit plan investor" is defined in the Plan Assets Regulation as (a) any employee benefit plan (as defined in Section 3(3) of ERISA) that is subject to the provisions of Title I of ERISA, (b) any plan that is subject to Section 4975 of the Code and (c) any entity whose underlying assets include plan assets by reason of a plan's investment in the entity (to the extent of such plan's investment in the entity). Thus, while our assets would not be considered to be "plan assets" for purposes of ERISA so long as the 25% Limit is not exceeded. Our operating agreement provides that if benefit plan investors exceed the 25% Limit, we may redeem their interests at a price equal to the then current NAV per share. We intend to rely on this aspect of the Plan Assets Regulation.

 *Operating Companies.* Under the Plan Assets Regulation, an entity is an "operating company" if it is primarily engaged, directly or through a majority-owned subsidiary or subsidiaries, in the production or sale of a product or service other than the investment of capital. In addition, the Plan Assets Regulation provides that the term operating company includes an entity qualifying as a real estate operating company ("REOC") or a venture capital operating company ("VCOC"). An entity is a REOC if: (i) on its "initial valuation date and on at least one day within each annual valuation period", at least 50% of the entity's assets, valued at cost (other than short-term investments pending long-term commitment or distribution to investors) are invested in real estate that is managed or developed and with respect to which such entity has the right to substantially participate directly in management or development activities; and (ii) such entity in the ordinary course of its business is engaged directly in the management and development of real estate during the 12-month period. The "initial valuation date" is the date on which an entity first makes an investment that is not a short-term investment of funds pending long-term commitment. An entity's "annual valuation period" is a pre-established period not exceeding 90 days in duration, which begins No later than the anniversary of the entity's initial valuation date. Certain examples in the Plan Assets Regulation clarify that the management and development activities of an entity looking to qualify as a REOC may be carried out by independent contractors (including, in the case of a partnership, affiliates of the general partner) under the supervision of the entity. An entity will qualify as a VCOC if (i) on its initial valuation date and on at least one day during each annual valuation period, at least 50% of the entity's assets, valued at cost, consist of "venture capital investments", and (ii) the entity, in the ordinary course of business, actually exercises management rights with respect to one or more of its venture capital investments. The Plan Assets Regulation defines the term "venture capital investments" as investments in an operating company (other than a VCOC) with respect to which the investor obtains management rights.

If the 25% Limit is exceeded and we do not exercise our right to redeem benefit plan investors as described above, we may try to operate in a manner that will enable us to qualify as a VCOC or a REOC or to meet such other exception as may be available to prevent our assets from being treated as assets of any investing Plan for purposes of the Plan Assets Regulation. Accordingly, we believe, on the basis of the Plan Assets Regulation, that our underlying assets should not constitute "plan assets" for purposes of ERISA. However, no assurance can be given that this will be the case.

If our assets are deemed to constitute "plan assets" under ERISA, certain of the transactions in which we might normally engage could constitute a non-exempt "prohibited transaction" under ERISA or Section 4975 of the Code. In such circumstances, in our sole discretion, we may void or undo any such prohibited transaction, and we may require each investor that is a "benefit plan investor" to redeem their shares upon terms that we consider appropriate.

Prospective investors that are subject to the provisions of Title I of ERISA and/or Code Section 4975 should consult with their counsel and advisors as to the provisions of Title I of ERISA and/or Code Section 4975 relevant to an investment in our preferred shares.

As discussed above, although IRAs and non-ERISA Keogh plans are not subject to ERISA, they are subject to the provisions of Section 4975 of the Code, prohibiting transactions with "disqualified persons" and investments and transactions involving fiduciary conflicts. A prohibited transaction or conflict of interest could arise if the fiduciary making the decision to invest has a personal interest in or affiliation with our Company or any of its respective affiliates. In the case of an IRA, a prohibited transaction or conflict of interest that involves the beneficiary of the IRA could result in disqualification of the IRA. A fiduciary for an IRA who has any personal interest in or affiliation with our Company or any of its respective affiliates, should consult with his or her tax and legal advisors regarding the impact such interest may have on an investment in our shares with assets of the IRA.

Shares sold by us may be purchased or owned by investors who are investing Plan assets. Our acceptance of an investment by a Plan should not be considered to be a determination or representation by us or any of our respective affiliates that such an investment is appropriate for a Plan. In consultation with its advisors, each prospective Plan investor should carefully consider whether an investment in our Company is appropriate for, and permissible under, the terms of the Plan's governing documents.

Governmental plans, foreign plans and most church plans, while not subject to the fiduciary responsibility provisions of ERISA or the provisions of Code Section 4975, may nevertheless be subject to local, foreign, state or other federal laws that are substantially similar to the foregoing provisions of ERISA and the Code. Fiduciaries of any such plans should consult with their counsel and advisors before deciding to invest in our Class A Preferred Shares.

The DOL has issued a final regulation significantly expanding the concept of "investment advice" for purposes of determining fiduciary status under ERISA. The DOL recognized that transactions such as the mere offering of the shares to sophisticated Plans could be characterized as fiduciary investment advice under this new regulation absent an exception and that such potential for fiduciary status would not be appropriate in these contexts. Accordingly, the DOL provided an exception based upon satisfaction of certain factual conditions. As the final regulation became effective in April 2017, we may elect to ensure these conditions are satisfied in connection with the offering of the shares. Finally, fiduciaries of Plans should be aware that the Manager is not undertaking to provide impartial investment advice or to give advice in a fiduciary capacity in connection with the offering or purchase of shares and that the Manager has financial interests associated with the purchase of shares including the fees and other allocations and distributions they may receive from us as a result of the purchase of shares by a Plan.

 *Form 5500.* Plan administrators of ERISA Plans that acquire shares may be required to report compensation, including indirect compensation, paid in connection with the ERISA Plan's investment in shares on Schedule C of Form 5500 (Annual Return/Report of Employee Benefit Plan). The descriptions in this memorandum of fees and compensation, including the fees paid to the Manager, are intended to satisfy the disclosure requirement for "eligible indirect compensation", for which an alternative reporting procedure on Schedule C of Form 5500 may be available.

**LEGAL MATTERS**

Certain legal matters with respect to the shares of Class A Preferred Shares offered hereby will be passed upon by the Silvestre Law Group, P.C., whose address is 2629 Townsgate Rd., Suite 215, Westlake Village, CA 91361. Silvestre Law Group, or its attorneys, currently own an aggregate of 12,500 shares of the common stock of our Manager which is less than 3% of the total shares outstanding of our Manager.

**EXPERTS**

The financial statements of Tranquil Healthcare Fund I, LLC for the year ended October 31, 2025, included in this Offering Statement have been audited by Wahl Street Accountancy Corporation, an independent auditor, as stated in their report thereon and incorporated by reference in this Offering Statement, in reliance upon such report and upon the authority of said firm as experts in accounting and auditing.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC an Offering Statement on Form 1-A pursuant to Regulation A promulgated under the Securities Act with respect to the Class A Preferred Shares offered hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information set forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the Class A Preferred Shares offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained in this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering Statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the Offering Statement. Upon the qualification of the offering statement, we will become subject to the informational reporting requirements that are applicable to Tier 2 companies whose securities are qualified pursuant to Regulation A, and accordingly, we will file annual reports, semi-annual reports and other information with the SEC. You may read and copy this information at the SEC's Public Reference Room, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports, proxy statements and other information about issuers, including us, that file electronically with the SEC. The address of this site is <u>www.sec.gov</u>.

**Tranquil Healthcare, INC.**

**FINANCIAL STATEMENTS** 

**AS OF AND FROM INCEPTION OCTOBER 21, 2025 THROUGH TO THE PERIOD ENDED OCTOBER 31, 2025**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | Page |
| Financial Statements | F-1 |
| &nbsp;&nbsp;&nbsp;[Report of Independent Auditors](#a_024) | F-2 |
| &nbsp;&nbsp;&nbsp;[Balance Sheet at October 31, 2025 (audited)](#a_025) | F-4 |
| &nbsp;&nbsp;&nbsp;[Statement of Operations for the period from inception October 21, 2025 through to the period ended October 31, 2025 (audited)](#a_026) | F-5 |
| &nbsp;&nbsp;&nbsp;[Statement of Changes in Stockholders' Deficit for the period from inception October 21, 2025 through to the period ended October 31, 2025 (audited)](#a_027) | F-6 |
| &nbsp;&nbsp;&nbsp;[Statements of Cash Flows for the period from inception October 21, 2025 through to the period ended October 31, 2025 (audited)](#a_028) | F-7 |
| &nbsp;&nbsp;&nbsp;[Notes to the Financial Statements](#a_029) | F-8 - F-14 |

---

![](wahllogo.jpg)

**<u>Independent Auditor's Report</u>**

To the Board of Directors and Stockholders

Tranquil Healthcare Fund I, LLC (formerly Tranquil Healthcare, Inc.)

 ****

***Report on the Audit of the Financial Statements***

***Opinion***

We have audited the financial statements of Tranquil Healthcare Fund I, LLC (formerly Tranquil Healthcare, Inc.) (the "Company"), which comprise the balance sheet as of October 31, 2025, and the related statements of operations, changes in stockholders' deficit, and cash flows from inception (October 21, 2025) through to the period ended October 31, 2025, and the related notes to the financial statements. In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of October 31, 2025, and the results of its operations and its cash flows from inception (October 21, 2025) through to period then ended October 31, 2025 in accordance with accounting principles generally accepted in the United States of America.

 ****

***Basis for Opinion***

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Tranquil Healthcare Fund I, LLC (formerly Tranquil Healthcare, Inc.) and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

***Emphasis of Matter – Subsequent Events***

<br> As discussed in Note 7 to the financial statements, subsequent to December 31, 2025, the Company entered into multiple contracts: a consulting agreement, an agreement to convert from a c-corporation to a limited liability company, issuing common stock for units in the limited liability company and establish an operating agreement. Our opinion is not modified with respect to this matter.

 ****

***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for the next twelve months.

 **

 ****

 ****

 **

 ****

***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements. In performing an audit in accordance with GAAS, we:

· Exercise professional judgment and maintain professional skepticism throughout the audit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Identify and assess the risks of material misstatement of the financial statements, whether due to fraud
or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Obtain an understanding of internal control relevant to the audit in order to design audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control. Accordingly, no such opinion is expressed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting
estimates made by management, as well as evaluate the overall presentation of the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise
substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control–related matters that we identified during the audit.

Wahl Street Accountancy Corporation

Irvine, California

November 11, 2025, except for Note 7, as to which the date is March 16, 2026

**Tranquil Healthcare Fund I, LLC (formerly Tranquil Healthcare, Inc.)**

**BALANCE SHEET**

---

| | |
|:---|:---|
|  | **October 31, 2025** |
|  | **(audited)** |
| **ASSETS** |  |
| **Current Assets:** |  |
| &nbsp;&nbsp;&nbsp;**Cash** | $**600** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | **600** |
| **Total Assets** | $**600** |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |
| **Current Liabilities:** |  |
| &nbsp;&nbsp;&nbsp;**Accounts payable and accrued expenses** | $**76350** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Current Liabilities** | **76350** |
| **Stockholders' Deficit:** |  |
| &nbsp;&nbsp;&nbsp;**Preferred Stock, Series A, par value $0.001, authorized 10,000,000 and zero issued and outstanding as of October 31, 2025** | **–** |
| &nbsp;&nbsp;&nbsp;**Common stock, $0.001 par value, Authorized 2,000,000, 825,000 shares issued and outstanding at October 31, 2025** | **625** |
| &nbsp;&nbsp;&nbsp;**Subscription receivable** | **(25)** |
| &nbsp;&nbsp;&nbsp;**Additional paid-in capital** | **–** |
| &nbsp;&nbsp;&nbsp;**Accumulated deficit** | **(76350)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Stockholders' Deficit** | **(75750)** |
| **Total Liabilities and Stockholders' Deficit** | $**600** |

---

***The accompanying notes are an integral part of these financial statements.***

**Tranquil Healthcare Fund I, LLC (formerly Tranquil Healthcare, Inc.)**

**STATEMENT OF OPERATIONS**

**(AUDITED)**

---

| | |
|:---|:---|
|  | **From inception (October 21, 2025)**<br>**through to the period ended**<br>**October 31, 2025** |
| **Revenues** | $**–** |
| **Cost of revenues** | **–** |
| &nbsp;&nbsp;&nbsp;**Gross profit** | **–** |
| **Operating expenses** | **76350** |
| &nbsp;&nbsp;&nbsp;**Loss from operations and before income taxes** | **(76350)** |
| **Income tax expense** | **–** |
| **Net loss** | $**(76350)** |
| **Earnings per Share** | $**(0.06)** |

---

***The accompanying notes are an integral part of these financial statements***

**Tranquil Healthcare Fund I, LLC (formerly Tranquil Healthcare, Inc.)**

**STATEMENT OF CHANGES IN STOCKHOLDER'S DEFICIT**

**(AUDITED)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional Paid-In**<br>**Capital** | **Accumulated**<br>**Deficit** | **Total Stockholders' Equity/**<br>**(Deficit)** |
| **Balance, October 21 (Inception), 2025** |  | $**–** | **–** | $**–** | $**–** | $**–** | $**–** |
| **Share Issuance on October 28, 2025** |  | **–** | **625000** | **625** | **–** | **–** | **625** |
| **Subscription receivable** |  | **–** | **–** | **(25)** | **–** | **–** | **(25)** |
| **Net loss** |  | **–** | **–** | **–** | **–** | **(76350)** | **(76350)** |
| **Balance, October 31, 2025** |  | $**–** | **625000** | $**600** | $**–** | $**(76350)** | $**(75750)** |

---

***The accompanying notes are an integral part of these financial statements.***

**Tranquil Healthcare Fund I, LLC (formerly Tranquil Healthcare, Inc.)**

**STATEMENT OF CASH FLOWS**

**(AUDITED)**

---

| | |
|:---|:---|
|  | **From inception (October 21, 2025)**<br>**through to the period ended**<br>**October 31, 2025** |
| **Operating Activities:** |  |
| **Net loss** | $**(76350)** |
| **Adjustments to reconcile net loss to net cash used for operating activities:** |  |
| **Changes in operating assets and liabilities:** |  |
| &nbsp;&nbsp;&nbsp;**Accounts payable and accrued expenses** | **76350** |
| &nbsp;&nbsp;&nbsp;**Net cash used for operating activities** | **–** |
| **Investing Activities:** |  |
| &nbsp;&nbsp;&nbsp;**Net cash provided by investing activities** | **–** |
| **Financing Activities:** |  |
| &nbsp;&nbsp;&nbsp;**Founders stock issued for cash** | **625** |
| &nbsp;&nbsp;&nbsp;**Subscription receivable** | **(25)** |
| &nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | **600** |
| **Net increase in cash** | **600** |
| **Cash, beginning of period** | **–** |
| **Cash, end of period** | $**600** |
| **Supplemental disclosure of cash flow information** |  |
| &nbsp;&nbsp;&nbsp;**Cash paid for interest** | $**–** |
| &nbsp;&nbsp;&nbsp;**Cash paid for taxes** | $**–** |

---

***The accompanying notes are an integral part of these financial statements***

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO THE FINANCIAL STATEMENTS**

**NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION**

Tranquil Healthcare Fund I, LLC. (the "Company"), formerly known as Tranquil Healthcare, Inc. was incorporated in the State of Delaware on October 21, 2025. Subsequent to the completion of this audit, on March 3, 2026 the Company reincorporated as an LLC for tax purposes under the laws of the State of Delaware. Under the reincorporation, the Company changed its name to Tranquil Healthcare Fund I, LLC and appointed Tranquil Healthcare Holdings, Inc as its Manager. As part of the reorganization, it issued its Manager in total 1,000,000 shares of its Common Shares in exchange for all shares of Common Stock that were previously outstanding. All shareholders agreed to this change. The Company is a development-stage enterprise focused on healthcare-related services and solutions. Since inception, the Company has devoted substantially all of its efforts to establishing its legal structure, appointing officers, issuing founder equity, and incurring initial organizational, legal, and professional expenses.

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and include the accounts of the Company from the date of inception. The Company has elected a fiscal year ending October 31.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The summary of significant accounting policies presented below is designed to assist in understanding the Company's financial statements. Such financial statements and accompanying notes are a representation of the Company's management, who are responsible for integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("GAAP") in all material respects and have been consistently applied in preparing the accompany financial statements.

***Going Concern***

Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. As of October 31, 2025, the Company had an accumulated deficit of $76,350. The Company's continuation as a going concern is dependent on its ability to generate sufficient cash flows from operations to meet its obligations and/or obtain additional financing from its members or other sources, as may be required.

The Company's activities will necessitate significant uses of working capital beyond October 31, 2025. Additionally, the Company's capital requirements will depend on many factors, including the success of the Company's sales and the status of competitive products. The Company plans to continue financing its operations with cash received from financing activities and or affiliate funding.

While the Company strongly believes that its capital resources will be sufficient in the near term, there is no assurance that the Company's activities will eventually generate sufficient revenues to sustain its operations without additional capital or, if additional capital is needed, that such funds, if available, will be obtainable on terms satisfactory to the Company.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern; however, the above condition raises substantial doubt about the Company's ability to do so. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)** 

**Use of Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts. Actual results could differ from those estimates. As of October 31, 2025, no significant estimates were required due to the limited nature of operations.

**Cash and Cash Equivalents**

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of October 31, 2025, cash consists entirely of deposits in a U.S. banking institution, there are no cash equivalents.

**Revenue Recognition**

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when control of promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. As of October 31, 2025, the Company had no revenue-generating activities.

**Stock-Based Compensation**

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation. Equity instruments issued to non-employees for goods or services are measured at the fair value of the equity instruments issued at the grant date, unless the fair value of goods or services received is more reliably measurable. No stock-based compensation expense was recognized during the period, as all founder shares were issued for cash and subscription receivables (see Note 5).

**Income Taxes**

The Company accounts for income taxes under ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts and tax bases of assets and liabilities. A valuation allowance is established when it is more likely than not that some or all deferred tax assets will not be realized. As of October 31, 2025, the Company had a net operating loss carryforward of approximately $36,350 for federal and state income tax purposes. Due to the Company's early stage and lack of earnings history, a full valuation allowance has been recorded against the deferred tax asset.

***Financial Instruments***

The Company follows Accounting Standards Codification ("ASC") 820, "Fair Value Measurements and Disclosures" ("ASC 820"), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)** 

***Financial Instruments (continued)***

Level 1: Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2: Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3: Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company analyzed all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board's ("FASB") accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company's financial instruments consisted of cash, accounts payable and accrued expenses. The estimated fair value of these financial instruments approximates its carrying amount based on the short-term maturity of these instruments.

***Other Comprehensive Income***

The Company has analyzed paragraphs ASC 220-10-45-1 to ASC 220-10-45-10B and none of the items recorded in the income statement would qualify as Other Comprehensive Income.

**Net Loss per Share**

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share includes potentially dilutive securities, if any. For the period from inception through October 31, 2025, there were no potentially dilutive securities outstanding.

---

| | |
|:---|:---|
| Net loss | $(76350) |
| Weighted-average common shares outstanding (basic and diluted) | 625000 |
| Net loss per share (basic and diluted) | $(0.12) |

---

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)** 

**Lease Accounting**

For contracts entered into on or after October 1, 2019, the Company assesses at contract inception whether the contract is, or contains, a lease. Generally, it determines that a lease exists when (i) the contract involves the use of a distinct identified asset, (ii) obtains the right to substantially all economic benefits from use of the asset and (iii) it has the right to direct the use of the asset.

At the lease commencement date, the Company recognizes a right-of-use asset and a lease liability for all leases, except short-term leases with an original term of 12 months or less. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any prepayments to the lessor and initial direct costs, such as brokerage commissions, less any lease incentives received.

All right-of-use assets are periodically reviewed for impairment in accordance with standards that apply to long-lived assets. The lease liability is initially measured at the present value of the lease payments, discounted using an estimate of the Company's incremental borrowing rate for a collateralized loan with the same term as the underlying lease. The incremental borrowing rates used for the initial measurement of lease liabilities as of October 1, 2019, were based on the original lease terms.

Lease payments included in the measurement of lease liabilities consist of (i) fixed lease payments for the non-cancellable lease term, (ii) fixed lease payments for optional renewal periods where it is reasonably certain the renewal option will be exercised, and (iii) variable lease payments that depend on an underlying index or rate, based on the index or rate in effect at lease commencement. Real estate lease agreements may require variable lease payments that do not depend on an underlying index or rate, such as sales and value-added taxes, the Company's proportionate share of actual property taxes, insurance, common area maintenance, and utilities. The Company has adopted an accounting policy, as permitted by ASC 842, not to account for such payments as part of related lease payments. Consequently, such payments are recognized as operating expenses when incurred.

Lease expense for operating leases consists of the fixed lease payments recognized on a straight-line basis over the lease term plus variable lease payments as incurred. Amortization of the right-of-use asset for operating leases reflects amortization of the lease liability, any differences between straight-line expense and related lease payments during the accounting period, and any impairments. As of October 31, 2025 and through the date of this filing, the Company had no lease agreements.

***Litigation***

There are no pending, threatened or actual legal proceedings in which the Company is a party to.

***Recent Accounting Guidance Not Yet Adopted***

None.

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)** 

***Recent Accounting Guidance Adopted***

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. This ASU enhances the transparency and decision usefulness of income tax disclosures. It is designed to provide more detailed information about an entity's income tax expenses, liabilities, and deferred tax items, potentially affecting how companies report and disclose their income tax-related information. The ASU is effective for public business entities for annual periods beginning after December 15, 2024, including interim periods within those fiscal years. The Company is currently evaluating how this ASU will impact its financial statements and disclosures.

In November 2024, the FASB issued ASU 2024-03 "*Disaggregation of Income Statement Expenses,*" which requires the Company to disaggregate key expense categories such as employee compensation, depreciation and intangible asset amortization within its financial statements. ASU 2024-03 is effective for annuals periods beginning with the Company's fiscal year 2027, and interim periods within the Company's fiscal year 2028, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its financial statements and disclosures.

The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES**

Accounts payable and accrued expenses consist of the following as of October 31, 2025:

---

| | |
|:---|:---|
| Professional fees (legal, accounting, organizational, audit) | $32350.0 |
| Bonus to CEO | 40000.0 |
| Other accrued operating and administrative expenses | 4000.0 |
| Total accounts payable and accrued expenses | $76350.0 |

---

All amounts are payable on demand and non-interest-bearing.

**NOTE 4 – STOCKHOLDERS' DEFICIT**

Authorized Capital Preferred Stock: 10,000,000 shares authorized, $0.001 par value; non issued or outstanding.

Common Stock: 2,000,000 shares authorized, $0.001 par value; 625,000 shares issued and outstanding as of October 31, 2025.

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**NOTE 4 – STOCKHOLDERS' DEFICIT (Continued)**

Equity Transactions

On October 28, 2025, the Company issued 625,000 shares of common stock to the founders for $625 in cash, of which $25 remains unpaid and is recorded as a subscription receivable. No preferred stock has been issued.

The breakdown of the 625,000 shares of common stock is as follows: 400,000 shares relate to our CEO's employment agreement, 200,000 relates to one of our directors and 25,000 shares relates to our attorneys. Our attorneys have a Purchase Right clause in their contract with the Company that allows them to purchase up to 3% of founders stock at formation at par value.

Our CEO's shares vest immediately at 100,000 and each 100,000 shares will vest every 12 months.

On October 28, 2025 – Non-Employee Director Grant (Jeff Campbell) was issued 200,000 shares at $0.001 per share ($200 cash) under the Non-Employee Director Compensation Policy.

· 50,000 vested immediately.

· 150,000 vest over 3 years (50,000 annually).

· Unvested shares subject to repurchase at original price upon separation.

**NOTE 5 – RELATED PARTY TRANSACTIONS** 

On October 28, 2025, the Company entered into an employment agreement with Tyler Ehler to serve as Chief Executive Officer, Chief Financial Officer, President, and Secretary, commencing November 1, 2025.

Key terms include:

· Annual base salary: $120,000 (accrual begins November 1, 2025)

· One-time signing bonus: $40,000, earned upon execution and accrued as of October 31, 2025

· Right to purchase 400,000 shares of common stock at $0.001 per share (par value), with 100,000 shares
vesting immediately upon purchase and 300,000 vesting annually over three years.

Payment of salary and signing bonus is deferred until the Company raises at least $300,000 in equity or is deemed adequately capitalized by the Board.

As of October 31, 2025, $40,000 has been accrued related to the signing bonus. No compensation has been paid to Mr. Ehler during the period.

On October 28, 2025, as part of Mr. Campbell's director agreement he will be paid $15,000 per calendar quarter, pro-rated for partial quarters Commences only after the Company raises net proceeds ≥ $300,000 in a single equity transaction (the "Investment Threshold"). Unvested shares subject to repurchase at original price upon separation. The Company can award other share-based compensation to Mr. Campbell and other directors.

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**NOTE 6 – COMMITMENTS AND CONTINGENCIES**

Effective October 21, 2025, the Company entered into a binding term sheet with DGR Health Services, LLC ("DGR") for the development and management of up to 20 interventional psychiatry clinics.

Key binding terms include:

· Appointment of DGR as exclusive provider of management services

· Manager to provide administrative, billing, staffing, and operational support

· Company to provide per clinic: (i) up to $650,000 in equipment leasing, (ii) up to $650,000 revolving
credit for buildout and operations

· Manager entitled to: (i) 10% of gross revenue as overhead, (ii) 90% of Clinic EBITDA as management fee

As of October 31, 2025:

· No clinics have been established

· No funding has been provided

· No management fees or revenue-sharing obligations exist

The Company has no unconditional purchase obligations under this agreement. Future funding and fee obligations are contingent upon clinic development and revenue generation. The Company approved the Regulation A filing raise $50,000,000 to fund clinic development and revenue generation. As part of our consulting services, the Company will receive the following participation rights and liquidation preferences.

---

| | |
|:---|:---|
| **Dividend Rights:** | The Series A Preferred Stock will earn dividends (i) at the rate of 8% per annum from issuance and (ii) in an amount equal to 50% of the Management Fees received by the Company from the Series A Clinics, if any (collectively, the "Dividends"). All Dividends, to the extent legally permissible, will be paid in cash on January 31<sup>st</sup>, April 30<sup>th</sup>, July 31<sup>st</sup>, and October 31<sup>st</sup> of each year with the first such dividend for each investor equal to a partial payment based on the closing date of such investment. Such cash Dividends may be paid as a return of capital from the Reserve Account and then through the Company's profits, to the extent legally permissible under Delaware law. |
| **Liquidation Preference:** | In the event of any (i) liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, (ii) sale of substantially all of the assets or capital stock of the Company or (iii) the occurrence of a Series A Clinic Sale (each, a "Liquidation Event"), the Company will be required to redeem outstanding shares of Series A Preferred Stock ratably, at a price per share equal to the sum of (i) the stated value of the Series A Preferred Stock, (ii) all accrued but unpaid Dividends due, and (iii) 75% of the Tranquil Sales Proceeds after deducting the stated value of the Series A Preferred Stock and any management bonus paid for such sale ("Net Sales Proceeds"). Any redemption shall be made in compliance with Delaware law and subject to the Company's available funds and any contractual or regulatory restrictions then in effect. |

---

The terms above were effective as of October 31, 2025, subsequent to year end the Company capped the investment per clinic to $1,000,000 and does not include acquiring equipment on behalf of the clinic. The loan may be collateralized by the clinic equipment. As of March 16, 2026, pursuant to the reorganization into a limited liability company and adoption of the Company's operating agreement effective March 3, 2026, there are no dividend rights.

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**NOTE 7 – SUBSEQUENT EVENTS** 

The Company has evaluated subsequent events through November 11, 2025, the date the financial statements were available to be issued, and updated through to March 16, 2026 and noted the following:

**Issuance of Common Stock to Consultant**

Subsequent to October 31, 2025, the Company issued 200,000 shares of common stock to a consultant in exchange for advisory and business development services. The fair value of the shares on the grant date will be measured and recognized as stock-based compensation expense in the subsequent period. Unvested shares subject to repurchase at original price upon separation. Our CEO was paid $50,000 as compensation from November 1, 2026 through to the reporting date.

**Consulting Agreement**

On December 1, 2025 ("Start Date"), we entered into a consulting agreement with OCIFG, Inc. ("OCIFG"). Pursuant to the agreement, OCIFG will provide us with a variety of consulting services related to our business. These consulting services include: advising on strategic alternatives and business positioning; supporting business development initiatives including the evaluation of potential Clinic partners; facilitating introductions to professional service providers; reviewing and updating investor presentations and corporate materials on a monthly basis; providing industry and company analysis including financial models; and supporting visibility and thought leadership initiatives including conference attendance. We agreed to pay OCIFG an aggregate of $250,000 consisting of (i) $25,000 at the Start Date, (ii) $25,000 before 60 days after Start Date, (iii) $50,000 before 120 days after Start Date, (iv) $50,000 before 180 days after Start Date, (v) $50,000 before 240 days after Start Date, and (vi) $50,000 before 300 days after Start Date. Notwithstanding, we have the right to defer payments if the Company determines that there is insufficient available cash to make such payment(s). The agreement may be terminated by either party on thirty (30) days written notice. The Company made the first payment on December 8, 2025 for $25,000, the balance of OCIFG fees have been accrued through the reporting date.

**Convertible Promissory Notes**

Subsequent to October 31, 2025, the Company entered into convertible note agreements for aggregate principal of $325,000. The notes are convertible into preferred stock at a future date. It also includes 22,000 shares of common stock of the Company in connection with the financing, which where all subsequently exchanged for Common Shares of our Manager. This is part of a bridge financing with a maximum raise of $1 million that was approved by the board of directors of the Company on October 28, 2025.

From November 6, 2025 through February 16, 2026, we loaned DGR $150,000 in the form of a promissory note for the initial buildout of the first proposed Clinic, which is anticipated to be in Florida. The note matures in one (1) year from issuance, has a 10% interest rate and 10% bridge / exit fee upon repayment, and will automatically be exchanged into a future revolving credit facility, if and when entered into with DGR.

**Conversion from Corporation to an LLC**

On March 3, 2026 the Company reincorporated as an LLC for tax purposes under the laws of the State of Delaware. Under the reincorporation, the Company changed its name to Tranquil Healthcare Fund I, LLC and appointed Tranquil Healthcare Holdings, Inc. as its Manager. As part of the reorganization, it issued its Manager 1,000,000 Common Shares in exchange for all shares of Common Stock that was previously outstanding by the Predecessor Company. All shareholders approved this reincorporation.

**TRANQUIL HEALTHCARE FUND I, LLC (formerly Tranquil Healthcare, Inc.)**

**NOTES TO FINANCIAL STATEMENTS**

**Pro Forma Financial Information** 

The following pro forma equity statement presents the Company's members' equity as of October 31, 2025, on a pro forma basis to give effect to the conversion, share exchange, and subsequent issuance of LLC Shares of the Company as if these events had occurred as of that date. The pro forma information is presented for illustrative purposes only and does not purport to represent what the actual equity position would have been had the transactions occurred on October 31, 2025, nor does it project the Company's equity position for any future date.

The pro forma adjustments consist solely of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Recasting the historical common stock issuance from 625,000 shares ($625 par value) to 847,000 shares
($847 par value) to reflect the actual pre-conversion shares outstanding that were exchanged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Adjusting the subscription receivable from ($25) to ($247) to maintain the net contributed capital at
$600 (consistent with historical cash proceeds).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Reflecting the additional 153,000 Common Shares issued to the Manager with no par value or additional
paid-in capital impact (as this was a non-cash issuance to complete the 1,000,000-share ownership structure under Manager, with no change
in total equity).

The pro forma total members' equity / (deficit) of ($75,750) remains unchanged from the historical stockholders' deficit, as the adjustments are structural in nature and reflect only the recapitalization to the post-conversion LLC equity structure.

On March 3, 2026, in connection with the reorganization of the issuer from a corporation to a limited liability company, we issued a total of 847,000 shares of Common Stock in exchange for 847,000 shares of Tranquil Healthcare, Inc. common stock. Following the transaction, the Predecessor Company's shareholders collectively owned 100% of our issued and outstanding Common Stock.

On March 3, 2026, all of the holders of our Common Shares entered into a purchase agreement with Tranquil Healthcare Holdings, Inc., the Issuer's manager ("Manager") whereby all of our members sold their Common Shares for shares of the Manager. As a result of the transaction, the Issuer became the wholly owned subsidiary of the Manager who owns 100% of Issuer issued and outstanding Common Shares.

This pro forma information should be read in conjunction with the historical financial statements and notes thereto included elsewhere in this offering statement.

As of February 28, 2026, the Company has approximately $48,354 in cash.

**PART III — EXHIBITS**

Index to Exhibits

---

| | |
|:---|:---|
| Exhibit | Description |
| 2.1\* | [Certificate of Conversion and Certificate of Formation of Tranquil Healthcare Fund I, LLC](tranquil_ex0201.htm) |
| 2.2\* | [Operating Agreement of Tranquil Healthcare Fund I, LLC dated March 3, 2026](tranquil_ex0202.htm) |
| 2.3\* | [Certificate of Incorporation of Tranquil Healthcare Inc. (Predecessor Corporation)](tranquil_ex0203.htm) |
| 2.4\* | [Bylaws of Tranquil Healthcare, Inc. (Predecessor Corporation)](tranquil_ex0204.htm) |
| 3.1\* | [Form of Convertible Promissory Notes issued from November, 2025 through February 2026](tranquil_ex0301.htm) |
| 3.2\* | [Form of Note Purchase Agreement associated with Convertible Promissory Notes](tranquil_ex0302.htm) |
| 3.3\*+ | [Form of Employment Agreement between Tranquil Healthcare Holdings, Inc. and Tyler Ehler](tranquil_ex0303.htm) |
| 4.1\* | Form of Subscription Agreement for Class A Preferred Shares |
| 6.1\* | [Form of Partially Binding Term Sheet entered into by and between Tranquil Healthcare and DGR Health Services, LLC dated October 28, 2025](tranquil_ex0601.htm) |
| 6.2\*+ | [Form of Management Agreement between Tranquil Healthcare Holdings, Inc. and Tranquil Healthcare Fund I, LLC](tranquil_ex0602.htm) |
| 6.3\* | [Form of Consulting Agreement between OCIFG, Inc. and Tranquil Healthcare Fund I, LLC dated December 1, 2025](tranquil_ex0603.htm) |
| 11.1\* | Consent of Silvestre Law Group, P.C. (included in the opinion filed as Exhibit 12.1) |
| 12.1\* | [Legal Opinion of Silvestre Law Group, P.C.](tranquil_ex1201.htm) |
| 13.1 | Investor Presentation |
| 99.1\* | [Code of Ethics and Business Conduct](tranquil_ex9901.htm) |
| 99.2\*+ | [Tranquil Healthcare Holdings, Inc. Non-Employee Director Compensation Policy](tranquil_ex9902.htm) |

---

---

| | |
|:---|:---|
| + | Management contract or compensatory plan or arrangement. |
| \* | Filed herewith. |
| \*\* | Previously filed. |
| # | To be filed by amendment. |

---

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this Offering Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on March 16, 2026.

(Exact name of issuer as specified in its charter): <u>Tranquil Healthcare Fund I, LLC</u>

This Offering Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | |
|:---|:---|
| By (Signature and Title): | */s/ Tyler Ehler* |
|  | Tyler Ehler, Chief Executive Officer and Chief Financial Officer of the Manager – Tranquil Healthcare Holdings, Inc |

---

(Date): March 16, 2026

SIGNATURES OF BOARD OF DIRECTORS OF THE MANAGER:

---

| | |
|:---|:---|
| */s/ Tyler Ehler* | March 16, 2026 |
| Tyler Ehler, Chairman | Date |
| */s/ Jeff Campbell* | March 16, 2026 |
| Jeff Campbell, Director | Date |

---

## Ex1A-2A

**Exhibit 2.1**

![](image_004.jpg)

S t a t e o f D e l aware Se cr e t ary o f S t a t e Di visio n o f Co rp o r a ti o n s D e liv e r e d 0 8 : 4 3A M 03 / 03 / 2026 FIL E D 08 : 43A M 03 / 03 / 2026 S R 2026098 8 08 2 - F il e Nu m be r 103 7 4 698 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A CORPORATION TO A DELAWARE LIMITED LIABILITY COMPANY PURSUANT TO SECTION 18 - 214 OF THE DELAWARE LIMITED LIABILITY COMPANY ACT 1. The jurisdiction where the corporation was first formed is _ o _ e1 _ aw _ a _ re _ and the date the corporation first formed is October 21 , 2025 2. The jurisdiction immediately prior to filing this Certificate is_D_ei_aw _ a_re _ 3. The name of the corporation immediately prior to filing this Certificate is Tranquil Healthcare, Inc. 4. The name of the limited liability company as s e t forth in the Certificate of Formation is Tranquil Healthcare Fund I, LLC IN WITNESS WHEREOF, the undersigned have executed this C e rtificate on the 2nd day of March , A.D. _ 2 _ 02 _ 6 By : is / Tyler Ehler Authorized Person Name: T y lerEhler Print or Type

![](image_005.jpg)

STATE OF DELAWARE CERTIFICATE OF FORMATION OF LIMITED LIABILITY COMPANY The undersigned authorized person, desiring to form a limited liability company pursuant to the Limited Liability Company Act of the State of Delaware, hereby certifies as follows: 1. The name of the limited liability company is Tranquil Healthcare Fund I, LLC 2. The Registered Office of the limited liability company in the S t ate of Delaware is located at 2140 s . DuPont Hwy in the City of Camden , Zip Code 19934 (str e et) , . The name of the Registered Agent at such address upon whom process agains t this limited liability company may be served is _ P _ a r_ ac _ o _ rp _ 1n _ co _ rpo _ ra ted _ By : Isl Tyle r Eh l er Authori z ed Person N a me : T y ler Ehler Print or Type State of Delaware Secretary of Sta t e Div i sion of Corporations Delivered 08:4301 03 / 03 / 2026 FILED 08:43AM 03 / 03 /2 026 SR 20260988082 - File Number 10374698

## Ex1A-2A

**Exhibit 2.2**

OPERATING AGREEMENT

OF

TRANQUIL HEALTHCARE FUND I, LLC

Dated as of March 3, 2026

**Table of Contents**

Exhibit A Members, Capital Contributions, Shares <br> Exhibit B Rights, Preferences, and Privileges

LIMITED LIABILITY COMPANY OPERATING AGREEMENT<br> OF

TRANQUIL HEALTHCARE FUND I, LLC

This Limited Liability Company Operating Agreement (this "Agreement") of Tranquil Healthcare Fund I, LLC a Delaware limited liability company (the "Company"), is dated as of March 3, 2026, and is entered into by Tranquil Healthcare Holdings, Inc. ("Manager") and the Persons who are signatories to this Agreement ("Members") who are signatories to this Agreement.

R E C I T A L S:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The Company was formed as a limited liability company under the Delaware Act (as defined below) pursuant to the filing of (i) a certificate of conversion from a corporation to a limited liability company and (ii) the Certificate of Formation with the Secretary of State of the State of Delaware on March 3, 2026 in connection with the conversion of the Company from a Delaware corporation ("Predecessor Company") into a Delaware limited liability Company (the "Conversion").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Upon Conversion, the shareholders of the Predecessor Company became the Company's only members ("Initial Members");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. The Initial Members have authorized and approved this Agreement as the Company's operating agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Simultaneous with the execution of this Agreement, the Initial Members have agreed to exchange all of their respective membership interests in the Company for shares of capital stock of the Manager upon which time Manager will become the sole Member of the Company ("Subsequent Initial Member").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. The Company and the Manager, as Subsequent Initial Member, acknowledges the status of the Company, prior to the admission of one or more additional Persons (defined hereinafter) as Members, as a disregarded entity for U.S. federal income tax purposes whose U.S. federal income taxable attributes, if any, would be deemed attributed solely to the Subsequent Initial Member as its sole member; provided, however, owing to the contemplation of the imminent admission of one or more Persons as additional Members, upon such occurrence, the Company would be deemed to have become classified as a partnership for U.S. federal income tax purposes by default. Accordingly, this Agreement has been intentionally structured contemplating that eventuality, through its implementation of certain applicable concepts of U.S. federal partnership tax law, and prescription of certain processes and procedures incidental to such tax classification, that would become applicable only upon admission of such one or more Persons as additional Members.

NOW, THEREFORE, in consideration of the agreements and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Original Agreement is hereby amended and restated in its entirety to provide as set forth herein, and the Subsequent Initial Member hereby agrees as follows:

**ARTICLE I GENERAL PROVISIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Definitions</u>. For the purpose of this Agreement, the following terms shall have the following meaning

"**Adjustment Year**" has the meaning ascribed to said phrase under Section 6225(d)(2) of the Code.

"**Affiliate**" means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such Person. For the purposes of this definition, the term "controls," "is controlled by" or "under common control with" means, with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of such Person, whether through the ownership of voting securities, by contract or otherwise. No Member shall be deemed to be an "Affiliate" of the Company solely by reason of being a Member of the Company.

"**Agreement**" has the meaning set forth in the preamble.

"**Beneficial Owner**" of a security is a Person who directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of, such security and/or (ii) investment power, which includes the power to dispose, or to direct the disposition of, such security. The terms "Beneficially Own" and "Beneficial Ownership" shall have correlative meanings. Notwithstanding the forgoing, any determination as to whether a Person is a "Beneficial Owner" shall be determined in accordance with Section 13d-3(a) of the Securities Exchange Act, as amended. If such Person would be deemed a Beneficial Owner pursuant to Section 13, such Person shall be deemed a Beneficial Owner for purposes of this Agreement and, conversely, if such Person would not be deemed a Beneficial Owner pursuant to Section 13, such Person shall not be deemed a Beneficial Owner for purposes of this Agreement.

"**Business Day**" means Monday through Friday of each week, except that a legal holiday recognized as such by the government of the United States of America or the District of Columbia shall not be regarded as a Business Day.

"**Capital Account**" has the meaning set forth in Section 3.2(a).

"**Capital Contribution**" means with respect to any Member, the amount of cash and the initial gross fair market value (as determined by the Manager in its good faith discretion) of any other property contributed or deemed contributed to the capital of the Company by or on behalf of such Member, reduced by the amount of any liability assumed by the Company relating to such property and any liability to which such property is subject.

"**Certificate**" means a certificate (i) in book-form or (ii) in such other form as may be adopted by the Manager, issued by the Company evidencing ownership of one or more Shares.

"**Change in Tax Classification**" has the meaning set forth in Section 8.7.

"**Class A Preferred Member**" means a Member holding one or more Class A Preferred Shares.

"**Class A Preferred Shares**" shall have the meaning ascribed to it in Section 2.4(a).

"**Common Member**" means a Member holding one or more Common Shares.

"**Common Shares**" shall have the meaning ascribed to it in Section 2.4(a).

"**Code**" means the Internal Revenue Code of 1986, as amended from time to time.

"**Commission**" means the United States Securities and Exchange Commission.

"**Company**" has the meaning set forth in the preamble.

"**Delaware Act**" means the Chapter 18 of Subtitle II of Title 6 of the Delaware Code, referred to as the Delaware Limited Liability Company Act, as amended from time to time, and any successor thereto.

"**Depositary**" means a Person providing book-entry, clearance, settlement, custody, depository, transfer, recordkeeping, nominee, and related services similar to those provided by The Depository Trust Company or any successor securities depository, including (i) the immobilization of certificated securities, (ii) the maintenance of records reflecting the positions of the depository participants and the beneficial ownership of securities held through such participants, (iii) the electronic settlement of transfers of securities through book-entry movements, and (iv) such ancillary or related services as are necessary or customary to facilitate the issuance, transfer, clearance, settlement, and trading of securities through such depository.

"**DGCL**" means the General Corporation Law of the State of Delaware, 8 Del. C. Section 101, et seq., as amended, supplemented or restated from time to time, and any successor to such statute.

"**Dissolution Event**" has the meaning set forth in Section 6.1.

"**Distributions**" has the meaning set forth in Section 3.3(a).

"**Exchange Act**" means the Securities Exchange Act of 1934, as amended, supplemented or restated from time to time and any successor to such statute, and the rules and regulations promulgated thereunder.

"**Fair Value**" means, with respect to securities or any other assets, other than cash, the fair market value determined by the Manager.

"**Fiscal Year**" means each fiscal year of the Company (or portion thereof), which shall end on October 31; provided, however, that, upon Termination of the Company, "Fiscal Year" means the period from the January 1 immediately preceding such Termination to the date of such Termination.

"**Fundamental Transaction**" means any transaction pursuant to which, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization or any compulsory exchange pursuant to which the Common Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding Common Shares (not including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination).

"**Initial Members**" shall mean the set forth in the preamble.

"**Involuntary Transfer**" shall mean any Transfer of Shares, or proposed Transfer of Shares, (i) in the case of a Member who is a natural person, upon such Member's death or the entry by a court of competent jurisdiction adjudicating such Member incompetent to manage such Member's person or such Member's property; (ii) in the case of a Member that is a trust, the termination of the trust, (iii) in the case of a Member that is a partnership, the dissolution and commencement of winding up of the partnership; (iv) in the case of a Member that is an estate, the distribution by the fiduciary of the estate's interest in the Company; and (v) in the case of a Member that is a corporation, the filing of a certificate of dissolution, or its equivalent, for the corporation or the revocation of its charter.

"**IRS**" has the meaning set forth in Section 5.2(a).

"**Liabilities**" has the meaning set forth in Section 4.2(b).

"**Liquidating Trustee**" has the meaning set forth in Section 6.2(a).

"**Management Services Agreement**" has the meaning set forth in Section 2.1(b).

"**Manager**" has the meaning set forth in the preamble.

"**Member**" has the meaning set forth in the preamble and includes any Person later admitted to the Company as a Member.

"**Offering**" means the offering by the Company of Class A Preferred Shares for sale to the public pursuant to Regulation A under the Securities Act of 1933, as amended (the "Act") or, in any replacement offering of Class A Preferred Shares, as determined by the Manager in the event such Offering shall not proceed for any reason.

"**Officers**" has the meaning set forth in Section 2.2(a).

"**Partnership Representative**" has the meaning set forth in Section 5.2(a).

"**Person**" means an individual, a corporation, a company, a voluntary association, a partnership, a joint venture, a limited liability company, a trust, an estate, an unincorporated organization, a governmental authority or other entity.

"**Protected Person**" means: (i) the equity holders of the Manager; (ii) the Manager and its Affiliates; (iii) any Member; (iv) any Officer; or (v) any Person who serves at the request of the Manager on behalf of the Company as an officer, director, partner, member, stockholder or employee of any other Person.

"**Record Date**" means the date established by the Company for determining (a) the identity of the Record Holders entitled to notice of, or to vote at, any meeting of Members or entitled to exercise rights in respect of any lawful action of Members or (b) the identity of Record Holders entitled to receive any report or distribution or to participate in any offer.

"**Record Holder**" or "**holder**" means the Person in whose name such Shares are registered on the books of the Company or the Transfer Agent, as applicable, as of the opening of business on a particular Business Day.

"**Reviewed Year**" has the meaning ascribed to said phrase under Section 6225(d)(1) of the Code.

"**Share**" has the meaning set forth in Section 2.4(a).

"**Subsidiary**" means, with respect to any Person, any corporation, limited liability company, partnership, joint venture, association or other entity of which (a) more than fifty percent (50%) of the outstanding voting securities or voting interests are directly or indirectly owned by such Person, or (b) such Person otherwise has the power, directly or indirectly, to elect a majority of the board of directors or other governing body or to direct the management and policies of such entity, whether through ownership of voting securities, by contract, or otherwise.

"**Substitute Member**" means a Person who is admitted as a Member of the Company pursuant to Section 2.6 as a result of a Transfer of Shares to such Person.

"**Tax Proceeding**" has the meaning set forth in Section 5.2(a).

"**Termination**" means the date of the cancellation of the Certificate of Formation of the Company following the end of the Winding Up Period by the filing of a Certificate of Cancellation of the Company with the Secretary of State of the State of Delaware.

"**Trading Market**" means: (a) an exchange registered with the Commission under Section 6(a) of the Exchange Act or any successor thereto, (b) any established trading market, inter-dealer quotation system or (c) any alternative trading platform where the Class A Preferred Stock is traded, which for clarity may include the blockchain or other virtually distributed platform.

"**Transfer Agent**" means, with respect to any class of Shares, such bank, trust company or other Person (including the Company or one of its Affiliates) as shall be appointed from time to time by the Company to act as registrar and transfer agent for such class of Shares; provided that if no Transfer Agent is specifically designated for such class of Shares, the Manager or the Company shall act in such capacity.

"**Transfer**" means, with respect to a Share and the associated membership interest in the Company, a transaction by which the Record Holder of a Share assigns such Share to another Person who is or becomes a Member, and includes a sale, assignment, gift, exchange or any other disposition by law or otherwise, including any transfer upon foreclosure of any pledge, encumbrance, hypothecation or mortgage.

"**Treasury Regulations**" means the regulations of the U.S. Treasury Department issued pursuant to the Code.

"**Voting Member**" means a Member holding one or more Voting Shares.

"**Voting Shares**" means unless otherwise set forth in this Agreement, or otherwise required by the Delaware Act, the Common Shares.

"**Winding Up Period**" means the period from the Dissolution Event to the Termination of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <u>Name</u>. The name of the Company is "Tranquil Healthcare Fund I, LLC" All business of the Company shall be conducted under such name. The Manager may change the name of the Company at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <u>Principal Office</u>. The principal office of the Company shall be at a location as determined by the Manager either within or outside of the United States. The Company shall keep its books and records at its principal office.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <u>Registered Office and Registered Agent</u>. The street address of the registered office of the Company in the State of Delaware shall be as selected by the Manager. The Manager may elect to change the registered office and the registered agent of the Company at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <u>Term</u>. The Company was formed as a limited liability company on March 3, 2026, and shall continue its regular business activities until the Company is dissolved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <u>Purpose and Powers.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company is organized for the purposes of undertaking such activities as determined by the Manager, subject to the terms and conditions herein and of the Delaware Act, the Members, which are permitted by applicable law and engaging in activities incidental or ancillary thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall possess and may exercise all the powers and privileges granted by the Delaware Act or by any other law or by this Agreement, together with any powers incidental thereto, which are necessary or convenient to the conduct, promotion or attainment of the business, purposes or activities of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 <u>Power of Attorney</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each Member hereby constitutes and appoints the Manager, any of the Officers and, if a Liquidating Trustee shall have been selected pursuant to Section 6.2(a), the Liquidating Trustee (and any successor to the Liquidating Trustee by merger, transfer, assignment, election or otherwise) and each of their authorized officers and attorneys-in-fact, as the case may be, with full power of substitution, as his true and lawful agent and attorney-in-fact, with full power and authority in his name, place and stead, to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) execute, swear to, acknowledge, deliver, file and record in the appropriate public offices:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) all certificates, documents and other instruments (including this Agreement and the Certificate of Formation and all amendments or restatements hereof or thereof) that the Manager, Officers, or the Liquidating Trustee, determines to be necessary or appropriate to form, qualify or continue the existence or qualification of the Company as a limited liability company in the State of Delaware and in all other jurisdictions in which the Company may conduct business or own property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) all certificates, documents and other instruments that the Manager, Officers or the Liquidating Trustee, determines to be necessary or appropriate to reflect, in accordance with its terms, any amendment, change, modification or restatement of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) all certificates, documents and other instruments (including conveyances and a certificate of cancellation) that the Manager, Officers or the Liquidating Trustee determines to be necessary or appropriate to reflect the dissolution, liquidation and termination of the Company pursuant to the terms of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) all certificates, documents and other instruments relating to the admission, withdrawal, removal or substitution of any Member pursuant to, or other events described in, ARTICLE 2 or ARTICLE 3; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E) all certificates, documents and other instruments (including agreements and a certificate of merger) relating to a merger, consolidation or conversion of the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) execute, swear to, acknowledge, deliver, file and record all ballots, consents, approvals, waivers, certificates, documents and other instruments that the Manager, Officers or the Liquidating Trustee determines to be necessary or appropriate to (i) make, evidence, give, confirm or ratify any vote, consent, approval, agreement or other action that is made or given by the Members hereunder or is consistent with the terms of this Agreement or (ii) effectuate the terms or intent of this Agreement; provided, that when required by any provision of this Agreement that establishes a percentage of the Members or of the Members of any class or series required to take any action, the Manager, Officers or the Liquidating Trustee, may exercise the power of attorney made in this Section (ii)only after the necessary vote, consent, approval, agreement or other action of the Members or of the Members of such class or series, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Nothing contained in this Section 1.7 shall be construed as authorizing Officers, or the Liquidating Trustee, to amend, change or modify this Agreement except in accordance with Section 8.2 or as may be otherwise expressly provided for in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The foregoing power of attorney is hereby declared to be irrevocable and a power coupled with an interest, and it shall survive and, to the maximum extent permitted by law, not be affected by the subsequent death, incompetency, disability, incapacity, dissolution, bankruptcy or termination of any Member and the Transfer of all or any portion of such Member's Shares and shall extend to such Member's heirs, successors, assigns and personal representatives. Each such Member hereby agrees to be bound by any representation made by the Manager, Officers of the Company, or the Liquidating Trustee, acting in good faith pursuant to such power of attorney; and each such Member, to the maximum extent permitted by law, hereby waives any and all defenses that may be available to contest, negate or disaffirm the action of the Manager, officers of the Company, or the Liquidating Trustee, taken in good faith under such power of attorney in accordance with Section 1.7. Each Member shall execute and deliver to the Manager or officers of the Company, or the Liquidating Trustee, within 15 days after receipt of the request therefor, such further designation, powers of attorney and other instruments as any of such Manager, officers of the Company or the Liquidating Trustee determines to be necessary or appropriate to effectuate this Agreement and the purposes of the Company.

**ARTICLE II MANAGEMENT; MEMBERS AND SHARES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Rights and Duties of the Manager</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company is a manager-managed limited liability company. Except as otherwise expressly provided in this Agreement or as required by the Delaware Act, the Manager shall have complete and exclusive discretion in the management and control of the affairs and business of the Company, and shall possess all powers necessary, convenient or appropriate to carrying out the purposes and business of the Company, including doing all things and taking all actions necessary to carry out the terms and provisions of this Agreement. The Manager shall have full authority in its discretion to exercise, on behalf of and in the name of the Company, all rights and powers of a "manager" of a limited liability company under the Delaware Act necessary or convenient to carry out the purposes of the Company. The Manager will have the power to perform any acts, statutory or otherwise, with respect to the Company (including with respect to any Subsidiary of the Company) or this Agreement, which would otherwise be possessed by the Members under Delaware law, and the Members will have no power whatsoever with respect to the management of the business and affairs of the Company (including with respect to any Subsidiary of the Company) except as expressly provided herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall enter into a management services agreement with the Manager providing for the payment of costs and expenses as well as reasonably administrative overhead incurred by Manager in managing the day-to-day operations of the Company (the "Management Services Agreement"). The Manager may amend the Management Services Agreement at any time; provided that upon such amendment, the Manager will provide the Members with notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Subject to the terms and conditions herein, all decisions regarding the management and operations of the Company shall be made by the Manager, provided, however, that the Manager shall have all power and authority to take any and all actions necessary to effectuate the intent and purpose of the Management Services Agreement and the Manager may designate any Officers of the Company to have control or authority with respect to one or more decisions or areas of operation, and may include such limitations or restrictions on such power as they may deem reasonable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Officers</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) At any time, Manager may appoint and replace individuals as officers or agents of the Company ("Officers") with such titles as the Manager may determine on behalf of the Company with such power and authority as the Manager may delegate to such persons. Any number of offices may be held by the same person. Officers shall hold their offices for such terms as shall be determined from time to time by the Manager. Unless otherwise determined and set forth by the Manager and subject to the policies and procedures of the Company applicable to Officers and employees, each Officer shall have the powers, rights and obligations as are customarily held and exercised by other persons in similar positions in limited liability companies organized under the Delaware Act. The Officers shall hold office until their successors are chosen and qualified. Any Officer may be removed at any time, with or without cause, by the Manager. The Officers may also be officers or employees of other Persons. The Officers, to the extent of their powers set forth in this Agreement or otherwise vested in them by action of the Manager not inconsistent with this Agreement, are agents of the Company for the purpose of the Company's business and the actions of the Officers taken in accordance with such powers shall bind the Company. Except to the extent otherwise provided herein, each Officer shall have a fiduciary duty of loyalty and care as set forth in the Delaware Act. No Officer shall at any time serve as trustee in bankruptcy for any Affiliate of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Notwithstanding the foregoing, it shall be deemed not to be a breach of any duty (including any fiduciary duty) or any other obligation of any type whatsoever of the Manager or any officer or employee or any Affiliates of such Manager, officer or employee (other than any express obligation contained in any agreement to which such Person and the Company or any of its subsidiaries are parties) to engage in outside business interests and activities in preference to or to the exclusion of the Company or in direct competition with the Company. No Member or any other Person shall have any rights by virtue of the Manager or any officer's or employee's or any Affiliates of the Manager, officer or employee duties as the Manager, officer or employee or this Agreement in any business ventures of the Manager or any officer or employee or any Affiliates of the Manager, officer or employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Members</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) A Person shall be admitted as a Member and shall become bound by, and shall be deemed to have agreed to be bound by, the terms of this Agreement if such Person purchases or otherwise lawfully acquires any Share, and such Person shall become the Record Holder of such Share, in accordance with the provisions of this Agreement. A Member may be a Class A Preferred Member or Common Member, and, in such case, shall have the rights and obligations accorded to the Class A Preferred Shares and Common Shares, respectively. A Person may become a Record Holder without the consent or approval of any of the Members and without physical execution of this Agreement. A Person may not become a Member without acquiring a Share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The name and mailing address of each Member or such Member's representative shall be listed on the books and records of the Company maintained for such purpose by the Company or the Transfer Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as otherwise provided in the Delaware Act, the debts, obligations and liabilities of the Company, whether arising in contract, tort or otherwise, shall be solely the debts, obligations and liabilities of the Company; and the Members shall not be obligated personally for any such debt, obligation or liability of the Company solely by reason of being a Member of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Except to the extent expressly provided in this Agreement: (i) No Member shall be entitled to the withdrawal or return of any Capital Contribution, except to the extent, if any, that distributions made pursuant to this Agreement or upon dissolution of the Company may be considered as such by law and then only to the extent provided for in this Agreement; (ii) No Member shall have priority over any other Member either as to the return of Capital Contributions or as to profits, losses or distributions with respect to their applicable class of Shares; (iii) No interest shall be paid by the Company on Capital Contributions; and (iv) No Member, in its capacity as such, shall participate in the operation or management of the Company's business, transact any business in the Company's name or have the power to sign documents for or otherwise bind the Company by reason of being a Member.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Any Member shall be entitled to and may have business interests and engage in business activities in addition to those relating to the Company, including business interests and activities in direct competition with the Company. Neither the Company nor any of the other Members shall have any rights by virtue of this Agreement in any such business interests or activities of any Member.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <u>Shares; Membership Interests</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The total of the membership interests in the Company shall be divided into (i) Class A Preferred Shares having the rights and preferences as set forth herein (the "Class A Preferred Shares") and (ii) Common Shares having the rights and preferences as set forth herein ("Common Shares" and collectively with the Class A Preferred Shares, the "Shares" and each a "Share"). The number of Class A Preferred Shares shall be limited to 10,000,000 shares and the number of Common Shares shall be limited to 1,000,000 shares, all of which have been issued to the Manager. The Shares of the Members shall be as set forth on **<u>Exhibit A</u>** attached hereto, which may be updated as set forth herein. The name and mailing address and number of Shares owned of each Member or such Member's representative shall be listed on the books and records of the Company maintained for such purpose by the Company or the Transfer Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prior to the date hereof, the Initial Members have been issued 847,000 Common Shares representing 100% of the membership interests in the Company, in connection with the exchange of their capital stock in the Predecessor Company which collectively represented 100% of the issued and outstanding capital stock of the Predecessor Company. Upon execution of this Agreement, and the Initial Members exchange of their Common Shares, the Manager will have all of the rights and privileges of 100% of the membership interests in the Company, consisting of 1,000,000 Common Shares, afforded pursuant to this Agreement and applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding any provision to the contrary in this Agreement, the Manager shall have full power and authority to schedule one or more closings to issue Class A Preferred Shares and admit Members to the Company in accordance with the provisions of this Agreement. Any Person that acquires Class A Preferred Shares and is admitted as a Member of the Company after the date hereof, shall, in connection with such Member's acquisition of such Class A Preferred Shares, upon payment therefore, as determined by Manager, shall have the same rights, preferences, and privileges as all other Members with respect to the Class A Preferred Shares then outstanding and shall participate on an equal per share basis therewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <u>Certificates and Representations of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Shares may be recorded in book entry form or may be evidenced by certificates or electronic including a virtually distributed ledger, block-chain or crypto tokens or coins, or in any other form, as determined by the Manager as may be permitted by the Delaware Act. Notwithstanding anything contrary herein, unless the Manager shall determine otherwise in respect of one or more classes of Shares or as may be required by the Depository with respect to any specific class of Shares, Shares shall not be evidenced by physical Certificates. No Member shall have the right to require the Company to issue physical Certificates representing Shares for any reason, except as may be required by applicable law. If the Manager authorizes the issuance of Shares to any Person in the form of physical Certificates, the Company shall issue one or more Certificates in the name of such Person evidencing the number of such Shares being so issued. Certificates shall be executed on behalf of the Company by the Manager. If and to the extent a Transfer Agent has been appointed with respect to any class or series of Shares, No Certificate representing such class or series of Shares shall be valid for any purpose until it has been countersigned by the Transfer Agent; provided, however, that if the Manager elects to issue Shares in global form, the Certificates representing Shares shall be valid upon receipt of a certificate from the Transfer Agent certifying that the Shares have been duly registered in accordance with the directions of the Company. Any or all of the signatures required on the Certificate may be by facsimile. If any Officer or Transfer Agent who shall have signed or whose facsimile signature shall have been placed upon any such Certificate shall have ceased to be such officer or Transfer Agent before such Certificate is issued by the Company, such Certificate may nevertheless be issued by the Company with the same effect as if such Person were such officer or Transfer Agent at the date of issue. Certificates for any class or series of Shares shall be consecutively numbered and shall be entered on the books and records of the Company as they are issued and shall exhibit the holder's name and number and type of Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If any mutilated Certificate is surrendered to the Company or the Transfer Agent, the Manager or appropriate Officers on behalf of the Company shall execute, and the Transfer Agent shall countersign and deliver in exchange therefor, a new Certificate evidencing the same number and class or series of Shares as the Certificate so surrendered. The Manager or appropriate Officers on behalf of the Company shall execute, and the Transfer Agent shall countersign and deliver, a new Certificate in place of any Certificate previously issued if the Record Holder of the Certificate: (i) makes proof by affidavit, in form and substance satisfactory to the Company, that a previously issued Certificate has been lost, destroyed or stolen; (ii) requests the issuance of a new Certificate before the Company has notice that the Certificate has been acquired by a purchaser for value in good faith and without notice of an adverse claim; (iii) if requested by the Company, delivers to the Company a bond, in form and substance satisfactory to the Company, with surety or sureties and with fixed or open penalty as the Company may direct to indemnify the Company and the Transfer Agent against any claim that may be made on account of the alleged loss, destruction or theft of the Certificate; and (iv) satisfies any other reasonable requirements imposed by the Company. If a Member fails to notify the Company within a reasonable time after he has notice of the loss, destruction or theft of a Certificate, and a Transfer of the Shares represented by the Certificate is registered before the Company or the Transfer Agent receives such notification, the Member shall be precluded from making any claim against the Company or the Transfer Agent for such Transfer or for a new Certificate. As a condition to the issuance of any new Certificate under this Section, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Transfer Agent) reasonably connected therewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company shall be entitled to recognize the Record Holder as the owner of a Share and, accordingly, shall not be bound to recognize any equitable or other claim to or interest in such Share on the part of any other Person, regardless of whether the Company shall have actual or other notice thereof, except as otherwise provided by law or any applicable rule, regulation, guideline or requirement of any National Securities Exchange on which such Shares are listed for trading. Without limiting the foregoing, when a Person (such as a broker, dealer, bank, trust company or clearing corporation or an agent of any of the foregoing) is acting as nominee, agent or in some other representative capacity for another Person in acquiring and/or holding Shares, as between the Company on the one hand, and such other Persons on the other, such representative Person shall be the Record Holder of such Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <u>Registration and Transfer of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Any Transfer of any Shares shall only be completed subject to the compliance by the Member and the proposed transferee with all applicable laws; and furthermore, may only be completed in accordance with the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Other than (i) any Transfer of Shares which is an Involuntary Transfer or (ii) any Transfer that occurs on a Trading Market that has been approved by the Company in writing, and Transfer of Shares shall be subject to the prior written approval of the Company, which the Company may give or withhold in its sole discretion. The Common Shares are non-transferable after issuance to the Manager other than in connection with a Fundamental Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company shall keep or cause to be kept on behalf of the Company a register (which may be in electronic form) that will provide for the registration and Transfer of Shares. The Company may appoint a Transfer Agent to act as registrar and transfer agent for the purpose of registering any class of Shares and Transfers of such class of Shares as herein provided. For Shares represented by Certificates, upon surrender of a Certificate for registration of Transfer of any Shares evidenced by a Certificate, the Manager or appropriate Officers of the Company shall execute and deliver, and in the case of Shares for which a Transfer Agent has been appointed, the Transfer Agent shall countersign and deliver, in the name of the holder or the designated transferee or transferees, as required pursuant to the Record Holder's instructions, one or more new Certificates evidencing the same aggregate number and type of Shares as were evidenced by the Certificate so surrendered, provided that a transferor shall provide the address and facsimile number for each such transferee as set forth on ***<u>Exhibit A</u>*** at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company shall not recognize any Transfer of Shares evidenced by Certificates until the Certificates evidencing such Shares are surrendered for registration of Transfer. No charge shall be imposed by the Company for such Transfer; provided, that as a condition to the issuance of Shares, whether or not such Shares are evidenced by Certificates, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed with respect thereto. The Company's transfer agent may require a transferring shareholder to pay reasonable and customary fees in connection with any voluntary transfer of Class A Preferred Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) By acceptance of the Transfer of any Share, each transferee of a Share (including any nominee holder or an agent or representative acquiring such Shares for the account of another Person) (i) shall be admitted to the Company as a Substitute Member with respect to the Shares so Transferred to such transferee when any such Transfer or admission is reflected in the books and records of the Company or the Transfer Agent, as applicable, (ii) shall be deemed to agree to be bound by the terms of this Agreement, (iii) shall become the Record Holder of the Shares so transferred, (iv) grants powers of attorney to the Manager or the appropriate Officers of the Company and any Liquidating Trustee, as specified herein, and (v) makes the consents and waivers contained in this Agreement. The Transfer of any Shares and the admission of any new Member shall not constitute an amendment to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Nothing contained in this Agreement shall preclude electronic book-entry only Transfer of Shares or the settlement of any transactions involving Shares entered into through electronic systems maintained by the Manager on behalf of the Company, the Company, the Transfer Agent, facilities of the Depository or any Trading Market on which such Shares are listed for trading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Any Transfer or attempted Transfer of any Share(s) in contravention of this Agreement shall be absolutely null and void ab initio and of No force or effect, on or against the Company, any Member, any creditor of the Company or any claimant against the Company and may be enjoined, and shall not be recorded on the books and records of the Company. No distributions of cash or property of the Company shall be made to any transferee of any Share(s) which is/are Transferred in violation hereof, nor shall any such Transfer be registered on the books of the Company. The Transfer or attempted Transfer of any Share(s) in violation hereof shall not affect the Beneficial Ownership of such Share(s), and, notwithstanding such Transfer or attempted Transfer, the Member making such prohibited Transfer or attempted Transfer shall retain the right to vote, if any, and the right to receive liquidation proceeds and any other distributions with respect to the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <u>Voting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each Voting Share shall be entitled to and shall constitute one (1) vote. Except as otherwise set forth in this Agreement, the Voting Shares shall vote together as a single class on all matters submitted for approval of Members. Except as specifically set forth herein, unless such right to vote is specifically required and mandated by the Delaware Act or as set forth herein, the Class A Preferred Shares do not constitute Voting Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In determining any action or other matter to be undertaken by or on behalf of the Company, each Member shall be entitled to cast a number of votes equal to the number of Voting Shares that such Member holds, with the power to vote, at the time of such vote unless otherwise set forth in this Agreement. Unless otherwise set forth in this Agreement, or otherwise required by the Delaware Act, the taking of any action by the Company which required a vote of the Members as set forth above shall be authorized by the affirmative vote of a majority of the Voting Shares, subject to any approval of the Manager as required herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <u>Replacement of Manager</u>. In the event that (i) the Manager voluntarily resigns or (ii) the Manager is dissolved, liquidated, or adjudicated bankrupt, then the holders of the Class A Preferred Shares, voting together as a single class, shall have the right to appoint a successor Manager by the affirmative vote of a majority of the votes cast by the Class A Preferred Shares at any meeting called for such purpose. This Section does not grant the Class A Preferred Shares the right to remove the Manager for any reason.

**ARTICLE III CAPITAL CONTRIBUTIONS; CAPITAL ACCOUNT; DISTRIBUTIONS; ALLOCATIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Capital Contributions</u>. Persons seeking to become a Member shall be required to purchase or acquire Shares and make capital contributions in such forms and in such amounts and at such times as the Manager may require, if any, in its sole discretion (any, a "Capital Contribution") whereupon a capital account for a new Member will be established, and, if applicable, accreted, in the amount of such Member's Capital Contribution or based upon the Fair Value of property contributed, and the new Member shall be issued a number of Class A Preferred Shares as determined by the Manager, and the Manager shall update ***<u>Exhibit A</u>*** attached hereto accordingly. The provisions of this Section 3.1 are solely intended for the benefit of the Members and, to the fullest extent permitted by law, shall not be construed as conferring any benefit upon any creditor of the Company (and no such creditor shall be a third-party beneficiary of this Agreement). The Members shall have No duty or obligation to any creditor of the Company to make any contribution to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Capital Account</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) There shall be established for each Member on the books of the Company a capital account in accordance with Section 704 of the Code and the Treasury Regulations promulgated thereunder ("Capital Account").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At the close of each Fiscal Year, and at certain other periods, as in the case of a withdrawal or distribution, there shall be determined for each Member, such Member's closing Capital Account for such period which shall be determined by adjusting such Member's opening Capital Account for such period, as the case may be, as follows: (i) by increasing such Member's Capital Account by (A) such Member's allocable share of each item of the Company's income and gain for such period (allocated in accordance with Section 3.2(d)), and (B) the Capital Contributions, if any, made by such Member during such period and (ii) by decreasing such Member's Capital Account by (A) the amount of cash or the Fair Value of any property distributed in kind to such Member by the Company during such period and (B) such Member's allocable share of each item of the Company's loss and deduction for such period (allocated in accordance with Section 3.2(d)). Each Member's Capital Account shall be further adjusted with respect to any special allocations or adjustments pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In the event the Company is terminated during any period in accordance with ARTICLE 6, the closing Capital Accounts of the Members for such Fiscal Year then completed will be determined as of the date of termination of the Company in the manner provided in this Section 3.2.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) For each Fiscal Period, as of the end of such Fiscal Period, each item of income, deduction, gain or loss of the Company (determined in accordance with U.S. tax principles as applied to the maintenance of capital accounts) shall be allocated among the Capital Accounts of the Members in such manner that as closely as possible gives economic effect to the provisions of Section 3.3 and Section 6.2(b).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) If all or a portion of a Member's Shares are Transferred in accordance with the terms of this Agreement, the transferee shall succeed to the Capital Account of the transferor to the extent it relates to the Shares so transferred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <u>Distributions</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company, at the sole discretion of the Manager, in the event there are Available Funds, may make distributions thereof ("Distributions") to Members as set forth herein. "Available Funds" means the Company's gross cash receipts from operations, less the sum of: (1) payments of principal, interest, charges and fees pertaining to any of the Company's indebtedness; (2) costs and expenses incurred in the conduct of the Company's business; and (3) amounts reserved to meet the reasonable needs of the Company's business. Notwithstanding anything herein to the contrary, No Member may receive a Distribution to the extent that, after giving effect to the Distribution, all liabilities of the Company (other than to a Member on account of its Shares and liabilities for which the recourse of creditors is limited to specific property of the Company) exceed the Fair Value of the assets of the Company (except that property that is subject to a liability for which the recourse of the creditors is limited to such property shall be included in the assets of the Company only to the extent the Fair Value of such property exceeds that liability). In the event of a Distribution to a Member that would be deemed violative of applicable law, the applicable Member may be required to return such Distribution to the Company. Each Distribution in respect of any Shares shall be paid by the Company, directly or through the Transfer Agent or through any other Person or agent, only to the Record Holder of such Shares as of the Record Date set for such Distribution. Such payment shall constitute full payment and satisfaction of the Company's liability in respect of such payment, regardless of any claim of any Person who may have an interest in such payment by reason of an assignment or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If the Manager declares and determines to make any Distribution of cash or other assets to the Members, all such Distributions shall be made to the Members in accordance with the rights, preferences and obligations of the respective Shares are described in ***<u>Exhibit B</u>***.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as otherwise provided herein or as required by law, no Member shall be required to restore or repay to the Company any funds properly distributed to it pursuant to this Section 3.3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 Each item of income, gain, loss or deduction recognized by the Company shall be allocated among the Members for U.S. federal, state and local income tax purposes in the same manner that each such item is allocated to the Member's Capital Accounts pursuant to Section 3.2(d) or as otherwise provided herein, provided that the Manager may adjust such allocations as long as such adjusted allocations have substantial economic effect or are in accordance with the interests of the Members in the Company, in each case within the meaning of the Code and the Treasury Regulations. Tax credits and tax credit recapture shall be allocated in accordance with the Members' interests in the Company as provided in Treasury Regulations section 1.704-1(b)(4)(ii). Items of Company taxable income, gain, loss and deduction with respect to any property (other than cash) contributed to the capital of the Company or revalued shall, solely for tax purposes, be allocated among the Members, as determined by the Manager in accordance with Section 704(c) of the Code, so as to take account of any variation between the adjusted basis of such property to the Company for U.S. federal income tax purposes and its Fair Value at the time of contribution or revaluation, as the case may be. All of the Members agree that the Manager is authorized to select the method or convention, or to treat an item as an extraordinary item, in relation to any variation of any Member's interest in the Company described in section 1.706-4 of the Treasury Regulations in determining the Members' distributive shares of Company items. All matters concerning allocations for U.S. federal, state and local and non-U.S. income tax purposes, including accounting procedures, not expressly provided for by the terms of this Agreement shall be determined by the Manager in its sole discretion.

**ARTICLE IV LIABILITY; INDEMNIFICATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Liability of a Member</u>. The liability of each Member shall be limited as provided in the Delaware Act and as set forth in this Agreement. No Member shall be obligated to restore by way of Capital Contribution or otherwise any deficits in its Capital Account (if such deficits occur).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>Exculpation and Indemnification</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) No Protected Person shall be liable to the Company or any Manager or any other Member for any action taken or omitted to be taken by it or by other Person with respect to the Company, including any negligent act or failure to act, except in the case of a liability resulting from such Protected Person's own actual fraud, gross negligence, willful misconduct, bad faith, breach of fiduciary duty, reckless disregard of duty or any intentional and material breach of this Agreement or conduct that is subject of a criminal proceeding (where such Protected Person has reasonable cause to believe that such conduct was unlawful). With the prior consent of the Manager, which consent will not be unreasonably withheld, any Protected Person may consult with legal counsel and accountants with respect to Company affairs (including interpretations of this Agreement) and shall be fully protected and justified in any action or inaction which is taken or omitted in good faith, in reliance upon and in accordance with the opinion or advice of such counsel or accountants. In determining whether a Protected Person acted with the requisite degree of care, such Protected Person shall be entitled to rely on written or oral reports, opinions, certificates and other statements of the directors, officers, employees, consultants, attorneys, accountants and professional advisors of the Company selected with reasonable care; provided that No such Protected Person may rely upon such statements if it believed that such statements were materially false.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) To the fullest extent permitted by law, the Company shall indemnify, hold harmless, protect and defend each Protected Person against any losses, claims, damages or liabilities, including reasonable legal fees, costs and expenses incurred in investigating or defending against any such losses, claims, damages or liabilities or in enforcing a Protected Person's right to indemnification under this Agreement, and any amounts expended in respect of settlements of any claims approved by the Manager (collectively, "Liabilities"), to which any Protected Person may become subject:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) by reason of any act or omission or alleged act or omission (even if negligent) arising out of or in connection with the activities of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) by reason of the fact that it is or was acting in connection with the activities of the Company in any capacity or that it is or was serving at the request of the Company as a partner, shareholder, member, director, officer, employee, or agent of any Person;

unless, such Liability results from such Protected Person's own actual fraud, gross negligence, willful misconduct, bad faith, breach of fiduciary duty, reckless disregard of duty or intentional and material breach of this Agreement or conduct that is subject of a criminal proceeding (where such Protected Person has reasonable cause to believe that such conduct was unlawful).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Manager may, on behalf of the Company, reimburse (and/or advance to the extent reasonably required) each Protected Person for reasonable legal or other costs and expenses (as incurred) of such Protected Person in connection with investigating, preparing to defend or defending any claim, lawsuit or other proceeding relating to any Liabilities for which the Protected Person may be indemnified pursuant to this Section 4.2 and for all costs and expenses, including fees, expenses and disbursements of attorneys, reasonably incurred by such Protected Person in enforcing the indemnification provisions of this Section 4.2; provided, that such Protected Person executes a written undertaking to repay the Company for such reimbursed or advanced costs and expenses if it is finally judicially determined that such Protected Person is not entitled to the indemnification provided by this Section 4.2. Upon any liquidation of the Company, such reimbursements or advancement of expenses shall be reimbursed by the Company to the Manager prior to any other distributions hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The provisions of this Section 4.2 shall continue to afford protection to each Protected Person regardless of whether such Protected Person remains in the position or capacity pursuant to which such Protected Person became entitled to indemnification under this Section 4.2 and regardless of any subsequent amendment to this Agreement; provided, that, No such amendment shall reduce or restrict the extent to which these indemnification provisions apply to actions taken or omissions made prior to the date of such amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Any indemnification under this Section 4.2 or otherwise shall be paid out of and to the extent of the Company's assets only.

**ARTICLE V ACCOUNTING; FINANCIAL AND TAX MATTERS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Accounting Basis</u>. The Company shall use such method of accounting as may be determined by the Manager that is consistent with United States generally accepted accounting principles or such other accounting methods and conventions as the Manager may from time to time determine to be used in the preparation of the Company's tax returns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Tax Matters</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Manager (shall designate a Person as the partnership representative of the Company for purposes of Section 6223 of the Code ("Partnership Representative") and any similar provision under any state or local or non-U.S. tax laws, and such Person shall be responsible for acting as the liaison between the Company and the Internal Revenue Service ("IRS"). The Partnership Representative shall have the exclusive authority and discretion to determine all matters and shall be authorized to take any actions necessary with respect to preparing and filing any U.S. federal, state or local or non-U.S. tax returns of the Company, to make or cause the Company to make any elections required or permitted to be made by the Company under any provisions of the Code or any other applicable laws and has the sole authority under the Code to deal with the IRS regarding any audit, examination or investigation (including any judicial or administrative proceeding) of the Company by any U.S. federal, state or local or non-U.S. taxing authority ("Tax Proceeding") to the exclusion of all Members. At any time during an audit by the IRS of the Company, the Manager shall have the authority to remove, with or without cause, the Partnership Representative and appoint a replacement Partnership Representative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the Members consents to and agrees to become bound by all actions of the Partnership Representative, including any contest, settlement or other action or position which the Partnership Representative may deem proper under the circumstances. The Members specifically acknowledge, without limiting the general applicability of this Section 5.2, that the Partnership Representative will not be liable, responsible or accountable in damages or otherwise to the Company or any Member with respect to any action taken by it in its capacity as a Partnership Representative, except for bad faith, fraud, gross negligence, willful misconduct or breach of fiduciary duty. All reasonable out-of-pocket expenses incurred by the Partnership Representative in such capacity will be considered expenses of the Company for which the Partnership Representative will be entitled to full reimbursement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In connection with any Tax Proceeding, the Partnership Representative shall resolve each issue in the Tax Proceeding only in accordance with the affirmative accession of the Manager to the advice of the Partnership Representative made, either independently or in consultation with the Company's tax preparer, after appropriately articulating to it the issues involved and the dynamics of the impact upon the Company and the Members respective to any such proposed posture.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If, in connection with a Tax Proceeding, the IRS assesses a tax against the Company, the Partnership Representative, acting under Section 6225(c)(2) of the Code, may require all of the Members, or Persons who were previously Members as to an applicable Reviewed Year but not as of an applicable Adjustment Year, and the Persons signing this Agreement as a condition to becoming a Member hereby agree in such case, to file amended tax returns for the Reviewed Year and to pay their share of such assessed tax for such applicable period, in proportion to the share of partnership income or loss ascribed to each for such year, or, as necessary, upon such substantially similar allocation basis as the former basis of allocation may under then existing circumstances be required to be modified to address in a case in which the obligated Person would not as of such an applicable Adjustment Year then be a Member. This provision shall survive each Person's cessation as a Member of the Company or any amendment or termination of this Agreement for so long as a return of a Reviewed Year of the Company as to which any Person was a Member would be open to audit, and each Person signing this Agreement as a Member hereby agrees to indemnify the Company and the other Members from and against any amounts of assessed taxes as they would be otherwise obligated to pay in accordance with this Section 5.2, in a case in which such Person would not do so, as well as against all reasonable attorneys' fees and costs that would be incurred by the Company or such other one or more Members in the event undertakings, including legal proceedings, to enforce such obligation hereunder against such Person were commenced.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Members acknowledge that the Manager reserves the right to supplement or amend any applicable provisions of this Agreement, including as to this Section 5.2, to address such additional processes or procedures as may be indicated as such unresolved issues are prospectively addressed as to reasonably facilitate the Company's compliance with the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Members shall provide the Company with such information, which may be necessary or desirable in connection with preparing and filing tax elections or otherwise in connection with the compliance with applicable tax laws, including providing information in connection with Section 743 of the Code and elections permitted thereunder. The Manager shall cause to be prepared and filed all tax returns of the Company that are required for U.S. federal, state or local or non-U.S. tax purposes and shall make all determinations as to tax elections by the Company. The Company shall use reasonable efforts to furnish to all Members tax information as is reasonably required for U.S. federal, state and local income tax reporting purposes as soon as practicable following the end of the fiscal year. Each Member shall be required to report for all tax purposes consistently with such information provided by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Notwithstanding anything otherwise to the contrary herein, the Manager is authorized to take any action that may be required to cause the Company to comply with any withholding or other similar requirements established pursuant to the Code or any other provision of U.S. federal, state or local or non-U.S. tax law or otherwise. To the extent the Company is required to or elects to withhold and pay over or otherwise pay any withholding or other taxes payable, or required to be deducted, by the Company or any of its Affiliates pursuant to the Code or any provision of U.S. federal, state or local or non-U.S. tax law or otherwise, attributable to a Member (including taxes attributable to income or gain allocable to such Member) or resulting from such Member's participation in the Company or a Transfer to such Member, the Manager may treat the amount withheld as a distribution of cash pursuant to Section 3.4 to the extent such Member would have received a cash distribution but for such withholding or other taxes. To the extent that such payment exceeds the cash distribution that such Member would have received but for such withholding or other taxes, the Manager shall notify such Member as to the amount of such excess and such Member shall make a prompt payment to the Company of such amount by wire transfer, which payment shall not constitute a Capital Contribution of such Member.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <u>Waiver of Section 18-305 Rights</u>. Members hereby waive, to the fullest extent permitted by law, their rights to request to review and obtain information relating to and maintained by the Company, including, but not limited to, names and contact information of Members, information listed in Section 18-305 of the Delaware Act and any other information deemed to be confidential by the Company in its sole discretion. In addition, Members shall not seek to compel the Company to produce any information described in the preceding sentence or pursuant to any statutory scheme or provision. BY AGREEING TO BE SUBJECT TO THE WAIVER PROVISIONS, INVESTORS WILL NOT BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

**ARTICLE VI DISSOLUTION; WINDING UP; TERMINATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Dissolution</u>. The Company shall commence its winding up upon the first to occur of the following (the "Dissolution Event"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) upon the determination of a majority of each class of Shares, voting separately and with the approval of the Manager, at any time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the insolvency or bankruptcy of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the occurrence of a Fundamental Transaction; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the entry of a decree of judicial dissolution under Section 18-802 of the Delaware Act.

The Dissolution Event shall be effective on the day on which such event occurs and immediately thereafter the Company shall commence the Winding Up Period during which its affairs shall be wound up in accordance with Section 6.2and Section 6.3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Winding Up and Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon the occurrence of a Dissolution Event, the property and business of the Company shall be wound up by the Manager or, in the event of the unavailability of the Manager, by a Person designated as a liquidating trustee by the Manager (the Manager or such liquidating trustee, the "Liquidating Trustee"). Subject to the requirements of applicable law and the further provisions of this Section 6.2, the Liquidating Trustee shall have discretion in determining whether to sell or otherwise dispose of Company assets or to distribute the same in kind and the timing and manner of such disposition or distribution. While the Company continues to hold assets, the Liquidating Trustee may, in its discretion, expend funds, acquire additional assets and borrow funds. The Liquidating Trustee may also authorize the payment of fees and expenses reasonably required in connection with the winding up of the Company and any fees and expenses payable pursuant to any agreement to which the Company is party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Within a reasonable period of time following the occurrence of a Dissolution Event, after allocating all items of income, gain, loss or deduction pursuant to Section 3.4, the Company's assets (except for assets reserved pursuant to Section 6.3) shall be applied and distributed in the following manner and order of priority:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the claims of all creditors of the Company (including Members except to the extent not permitted by law) shall be paid and discharged other than liabilities for which reasonable provision for payment has been made; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to the Members in the same manner as Distributions under Section 3.3.

Notwithstanding anything to the contrary in this Agreement, liquidating distributions shall be made No later than the last to occur of (x) 90 days after the date of disposition (including pursuant to Section 6.3 of the last remaining asset of the Company and (y) the end of the Company's taxable year in which the disposition referred to in clause (x) shall occur.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Liquidating Trustee shall allocate securities for distribution in kind to the Members. Notwithstanding any other provision of this Agreement, the amount by which the Fair Value of any property to be distributed in kind to the Members (including property distributed in liquidation and property distributed pursuant to Section 3.3) exceeds or is less than the adjusted basis of such property shall, to the extent not otherwise recognized by the Company, be taken into account in computing income, gains and losses of the Company for purposes of crediting or charging the Capital Account of, and distributing proceeds to, the Members, pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) When the Liquidating Trustee has completed the winding up described in this Section 6.2, the Liquidating Trustee shall cause the Termination of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <u>Assets Reserved and Pending Claims</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If, upon the occurrence of a Dissolution Event, there are any assets that, in the judgment of the Liquidating Trustee, cannot be sold or distributed in kind without sacrificing a significant portion of the value thereof or where such sale or distribution is otherwise impractical at the time of the Dissolution Event, such assets may be retained by the Company if the Liquidating Trustee determines that the retention of such assets is in the best interests of the Members. Upon the sale of such assets or a determination by the Liquidating Trustee that circumstances no longer require their retention, such assets (at their Fair Value) or the proceeds from their sale shall be taken into account in computing Capital Accounts on winding up and amounts distributable pursuant to Section 6.2(b), and distributed in accordance with such value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If there are any claims or potential claims (including potential Company expenses in connection therewith) against the Company (either directly or indirectly, including potential claims for which the Company might have an indemnification obligation) for which the possible loss cannot, in the judgment of the Liquidating Trustee, be definitively ascertained, then such claims shall initially be taken into account in computing the Capital Accounts upon winding up and distributions pursuant to Section 6.2(b) at an amount estimated by the Liquidating Trustee to be sufficient to cover any potential loss or liability on account of such claims (including such potential Company expenses), and the Company shall retain funds (or assets) determined by the Liquidating Trustee in its discretion as a reserve against such potential losses and liabilities, including expenses associated therewith, and for any other Company purpose. The Liquidating Trustee may in its discretion obtain insurance or create escrow accounts or make other similar arrangements with respect to such losses and liabilities. Upon final settlement of such claims (including such potential Company expenses) or a determination by the Liquidating Trustee that the probable loss therefrom can be definitively ascertained, such claims (including such potential Company expenses) shall be taken into account in the amount at which they were settled or in the amount of the probable loss therefrom in computing the Capital Accounts on winding up and amounts distributable pursuant to Section 6.2(b), and any excess funds retained shall be distributed as such funds would be distributed under Section 6.2(b).

**ARTICLE VII MEMBER MEETINGS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <u>Member Meetings</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) There shall be no meetings of the Members unless called by the Manager or as otherwise specifically required by the Delaware Act. No Members or group of Members, acting in its or their capacity as Members, shall have the right to call a meeting of the Members.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All acts of Members to be taken hereunder shall be taken in the manner provided in this Agreement. If authorized by the Manager, and subject to such guidelines and procedures as the Manager may adopt, if a meeting of the Members is called Members and proxyholders not physically present at a meeting of Members may by means of remote communication participate in such meeting and be deemed present in person and vote at such meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) A majority of the Voting Shares present at such meeting, either in person or by proxy, and entitled to vote thereat, shall constitute a quorum for the purpose of such meeting, unless any such matter to be acted upon requires the approval of a majority of the Voting Shares. A majority of the Voting Shares present at such meeting, either in person or by proxy, and entitled to vote thereat, shall constitute a quorum for the purpose of such meeting. The Delaware Court of Chancery may issue such orders as may be appropriate, including orders designating the time and place of such meeting, the record date for determination of Members entitled to vote, and the form of notice of such meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) No Members or group of Members, acting in its or their capacity as Members, shall have the right to call a meeting of the Members.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <u>Notice of Meetings of Members</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Notice, stating the place, day and hour of any meeting of the Members, as determined by the Manager, and the purpose or purposes for which the meeting is called, as determined by the Manager, shall be delivered by the Company not less than 5 calendar days nor more than 60 calendar days before the date of the meeting, in a manner and otherwise in accordance with the terms herein to each Record Holder who is entitled to vote at such meeting. Such further notice shall be given as may be required by the Delaware Act or applicable federal law or any exchange on which any Shares are then listed. Only such business shall be conducted at a meeting of Members as shall have been brought before the meeting pursuant to the Company's notice of meeting. Any previously scheduled meeting of the Members may be postponed, and any meeting of the Members may be canceled, by resolution of the Manager upon public notice given prior to the date previously scheduled for such meeting of the Members.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Manager shall designate the place of meeting for any meeting of the Members, including a virtual meeting via telephonic conference. If no designation is made, the place of meeting shall be the principal office of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <u>Record Date</u>. For purposes of determining the Members entitled to notice of or to vote at a meeting of the Members, the Manager may set a Record Date, which shall not be less than 5 nor more than 60 days before the date of the meeting (unless such requirement conflicts with any rule, regulation, guideline or requirement of any National Securities Exchange on which the Shares are listed for trading, in which case the rule, regulation, guideline or requirement of such exchange shall govern). If no Record Date is fixed by the Manager, the Record Date for determining Members entitled to notice of or to vote at a meeting of Members shall be at the close of business on the day next preceding the day on which notice is given. A determination of Members of record entitled to notice of or to vote at a meeting of Members shall apply to any adjournment or postponement of the meeting; provided, however, that the Manager may fix a new Record Date for the adjourned or postponed meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <u>Adjournment</u>. When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting and a new Record Date need not be fixed, if the time and place thereof are announced at the meeting at which the adjournment is taken, unless such adjournment shall be for more than 30 days. At the adjourned meeting, the Company may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days or if a new Record Date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given in accordance with this ARTICLE VII.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <u>Waiver of Notice; Approval of Meeting</u>. Whenever notice to the Members is required to be given under this Agreement, a written waiver, signed by the Person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a Person at any such meeting of the Members shall constitute a waiver of notice of such meeting, except when the Person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Members need be specified in any written waiver of notice unless so required by resolution of the Manager. All waivers and approvals shall be filed with the Company records or made part of the minutes of the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <u>Quorum; Required Vote</u>. At any meeting of the Members, the holders of a majority of the Voting Shares entitled to vote represented in person or by proxy shall constitute a quorum unless any such action by the Members requires approval by holders of a greater percentage of Voting Shares entitled to vote, in which case the quorum shall be such greater percentage. The submission of matters to Members for approval shall occur only at a meeting of the Members duly called and held in accordance with this Agreement at which a quorum is present; provided, however, that the Members present at a duly called or held meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough Members to leave less than a quorum, if any action taken (other than adjournment) is approved by the required percentage of Shares entitled to vote specified in this Agreement. Any meeting of Members may be adjourned from time to time by the chairman of the meeting to another place or time, without regard to the presence of a quorum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 <u>Conduct of a Meeting; Member Lists</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Manager shall have full power and authority concerning the manner of conducting any meeting of the Members, including the determination of Persons entitled to vote, the existence of a quorum, the satisfaction of the requirements of this ARTICLE VII, the conduct of voting, the validity and effect of any proxies and the determination of any controversies, votes or challenges arising in connection with or during the meeting or voting. The Manager shall designate a Person to serve as chairman of any meeting and shall further designate a Person to take the minutes of any meeting. All minutes shall be kept with the records of the Company maintained by the Manager. The Manager may make such other regulations consistent with applicable law and this Agreement as it may deem advisable concerning the conduct of any meeting of the Members, including regulations in regard to the appointment of proxies, the appointment and duties of inspectors of votes, the submission and examination of proxies and other evidence of the right to vote.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) A complete list of Members entitled to vote at any meeting of Members, arranged in alphabetical order and showing the address of each such Member and the number of Shares registered in the name of such Member, shall be open to the examination of any Member, for any purpose germane to the meeting, during ordinary business hours, for a period of at least 10 days before the meeting, at the principal place of business of the Company. The Member list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any Member who is present.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <u>Action Without a Meeting</u>. On any matter that is to be voted on, consented to or approved by Members, the Members may take such action without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, shall be approved by the Members having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all Members entitled to vote thereon were present and voted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9 <u>Voting and Other Rights</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Only those Record Holders of Voting Shares on the Record Date set pursuant to Section 7.3 shall be entitled to notice of, and to vote at, a meeting of Members or to act with respect to matters as to which the holders of the Voting Shares have the right to vote or to act. All references in this Agreement to votes of, or other acts that may be taken by, the Voting Shares shall be deemed to be references to the votes or acts of the Record Holders of such Voting Shares on such Record Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) With respect to Voting Shares that are held for a Person's account by another Person (such as a broker, dealer, bank, trust company or clearing corporation, or an agent of any of the foregoing), in whose name such Voting Shares are registered, such other Person shall, in exercising the voting rights in respect of such Voting Shares on any matter, and unless the arrangement between such Persons provides otherwise, vote such Voting Shares in favor of, and at the direction of, the Person who is the Beneficial Owner, and the Company shall be entitled to assume it is so acting without further inquiry.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) No Members shall have any cumulative voting rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10 <u>Proxies and Voting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On any matter that is to be voted on by Members, the Members may vote in person or by proxy, and such vote may be made, or proxy may be granted in writing, by means of electronic transmission or as otherwise permitted by applicable law. Any such proxy shall be delivered in accordance with the procedure established for the relevant meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) For purposes of this Agreement, the term "electronic transmission" means any form of communication not directly involving the physical transmission of paper that creates a record that may be retained, retrieved and reviewed by a recipient thereof and that may be directly reproduced in paper form by such a recipient through an automated process. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to this paragraph may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Manager may, and to the extent required by law, shall, in advance of any meeting of Members, appoint one or more inspectors to act at the meeting and make a written report thereof. The Manager may designate one or more alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of Members, the chairman of the meeting may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. Every vote taken by ballots shall be counted by a duly appointed inspector or inspectors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) With respect to the use of proxies at any meeting of Members, the Company shall be governed by paragraphs (b), (c), (d) and (e) of Section 212 of the DGCL and other applicable provisions of the DGCL, as though the Company were a Delaware corporation and as though the Members were shareholders of a Delaware corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In the event that the Company becomes subject to Regulation 14A under the Exchange Act, pursuant to and subject to the provisions of Rule 14a-16 under the Exchange Act, the Company may, but is not required to, utilize a Notice of Internet Availability of Proxy Materials, as described in such rule, in conjunction with proxy material posted to an Internet site, in order to furnish any proxy or related material to Members pursuant to Regulation 14A under the Exchange Act.

**ARTICLE VIII MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <u>Addresses and Notices</u>. Any notice, demand, request, report or proxy materials required or permitted to be given or made to a Member under this Agreement shall be in writing and shall be deemed given or made when delivered in person or when sent by first class United States mail or by other means of written communication (including electronic communication) to the Member at the address described below. Any notice, payment or report to be given or made to a Member hereunder shall be deemed conclusively to have been given or made, and the obligation to give such notice or report or to make such payment shall be deemed conclusively to have been fully satisfied, upon sending of such notice, payment or report to the Record Holder of such Shares at his address as shown on the records of the Transfer Agent or delivered electronically as otherwise shown on the records of the Company (including on Exhibit A attached hereto), regardless of any claim of any Person who may have an interest in such Shares by reason of any assignment or otherwise. An affidavit or certificate of making of any notice, payment or report in accordance with the provisions of this Section 8.1 executed by the Company, the Manager or the Transfer Agent or the mailing organization shall be prima facie evidence of the giving or making of such notice, payment or report. If any notice, payment or report addressed to a Record Holder at the address of such Record Holder appearing on the books and records of the Transfer Agent or the Company is returned by the United States Postal Service marked to indicate that the United States Postal Service is unable to deliver it or is returned or there is a delivery failure through any electronic communication, such notice, payment or report and any subsequent notices, payments and reports shall be deemed to have been duly given or made without further mailing (until such time as such Record Holder or another Person notifies the Transfer Agent or the Company of a change in his address or electronic address, as applicable) if they are available for the Member at the principal office of the Company for a period of one year from the date of the giving or making of such notice, payment or report to the other Members. Any notice to the Company shall be deemed given if received by the Secretary at the principal office of the Company designated pursuant to the terms and conditions herein. The Manager and the Officers may rely and shall be protected in relying on any notice or other document from a Member or other Person if believed by it to be genuine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <u>Amendments; Waiver</u>. Except as otherwise expressly provided in this Agreement, any provision of this Agreement may be amended or waived only by an instrument in writing executed by the Manager and Members holding a majority of the Voting Shares, provided, however, any amendment which disproportionately and adversely affects the Class A Preferred Members, must be approved by the Class A Preferred Members holding a majority of the Class A Preferred Shares voting as a separate class. Notwithstanding the foregoing, the Manager may amend this Agreement and the schedules and exhibits hereto, without the approval of the Members (i) to evidence the joinder to this Agreement of a new Member of the Company; (ii) in connection with the Transfer of Shares; (iii) in connection with any issuance of Shares to the Manager or to any existing members, whether as a result of issuances to the Manager pursuant to the Management Services Agreement, or otherwise, (iv) as otherwise required to reflect Capital Contributions, distributions and similar actions hereunder; (v) to reflect the naming of new officers, members of the Manager or replacement of officers or managers of the Company; (vi) pursuant to Section 8.7, and (vii) any change the Manager deems necessary or appropriate to enable trading of membership interests. Notwithstanding the foregoing, the Manager is authorized to make such amendments to this Agreement as required in order to comply with any applicable law, including, without limitation, any securities law or tax law, whether currently in place or promulgated in the future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <u>Successors and Assigns</u>. This Agreement shall inure to the benefit of, and shall be binding upon, the successors and permitted assigns of the Members.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <u>No Waiver</u>. Except as set forth in Section 8.17 hereof with respect to forum selection, No failure or delay by any party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.5 <u>Survival of Certain Provisions</u>. The covenants and agreements set forth in Section 4.1, Section 4.2 and Section 5.2 shall survive the Termination of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.6 <u>Telephone Consumer Protection Act Consent</u>. Each Member expressly consents to receiving calls and messages, including auto-dialed and pre-recorded message calls, and SMS messages (including text messages) from the Manager, its affiliates, agents and others calling at their request or on their behalf, at any telephone numbers that the Member has provided to the Company (including any cellular telephone numbers). Member's cellular or mobile telephone provider will charge Member according to the type of plan Member carries. Any Member may unsubscribe from receiving text messages or promotional calls at any time by (i) replying STOP, STOPALL, UNSUBSCRIBE, CANCEL, END or QUIT to any text message such Member receives from the Company or (ii) email to investor@tranquil.healthcare. with one of the forgoing words in the subject line. Each Member acknowledges and consents that following such a request to unsubscribe, such Member may receive one final text message from the Company confirming such request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7 <u>Corporate Treatment</u>. The Manager shall use its reasonable best efforts to take such actions as are necessary or appropriate to preserve the status of the Company as a partnership for U.S. federal (and applicable state and local) income tax purposes. If, however, the Manager determines, in its sole discretion, for any reason (including the proposal, formally or informally, of legislation that could affect the Company's status as a partnership for U.S. federal and/or applicable state and local income tax purposes) that it is not in the best interests of the Company to be characterized as a partnership, the Manager may take whatever steps, if any, are needed to cause the Company to be or confirm that the Company will be treated as an association or as a publicly traded partnership taxable as a corporation for U.S. federal (and applicable state and local) income tax purposes, including by making an election to be taxed as a "C" corporation pursuant to the Code (a "Change in Tax Classification"), without any approval or vote of the Members required, and to make such filings, including without limitation, a Form 8832 with the IRS, and to undertake such actions as required to effect such Change in Tax Classification. At the time and following any Change of Tax Classification, the Manager shall have the right, without any approval or vote of the Members being required, to amend this Agreement as reasonably required to effect the Change in Tax Classification and to provide for the operations of the Company following such event. Notwithstanding anything in this Agreement to the contrary, in the event U.S. federal (and/or applicable state and local) income tax laws, rules or regulations are enacted, amended, modified or applied after the date hereof in such a manner as to require or necessitate that the Company No longer be treated as a partnership for U.S. federal (and/or applicable state and local) income tax purposes, then the first sentence of this Section 8.7 shall No longer apply.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8 <u>Section 7704(e) Relief</u>. In the event that the Manager determines the Company should seek relief pursuant to Section 7704(e) of the Code to preserve the status of the Company as a partnership for U.S. federal (and applicable state) income tax purposes, the Company and each Member shall agree to adjustments required by the tax authorities, and the Company shall pay such amounts as required by the tax authorities, to preserve the status of the Company as a partnership.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.9 <u>Electronic Information</u>. Each Member hereby agrees that all current and future notices, confirmations and other communications may be made by the Company via email, sent to the email address of record of the Member provided to the Company as changed or updated from time to time, without necessity of confirmation of receipt, delivery or reading, and such form of electronic communication is sufficient for all matters regarding the relationship between the Company and the Members except as otherwise required by law. If any such electronically sent communication fails to be received for any reason, including but not limited to such communications being diverted to the recipients spam filters by the recipients email service provider, or due to a recipient's change of address, or due to technology issues by the recipients service provider, the parties agree that the burden of such failure to receive is on the recipient and not the sender, and that the sender is under No obligation to resend communications via any other means, including but not limited to postal service or overnight courier, and that such communications shall for all purposes, including legal and regulatory, be deemed to have been delivered and received. Except as required by law, No physical, paper documents will be sent to Members, and a Member desires physical documents then such Member agrees to be satisfied by directly and personally printing, at such Member's own expense, the electronically sent communication(s) and maintaining such physical records in any manner or form that a Member desires.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.10 <u>Severability</u>. In case any provision in this Agreement shall be deemed to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.11 <u>Interpretation</u> The headings in this Agreement are inserted for convenience of reference only and shall not affect the interpretation of this Agreement. As used herein, masculine pronouns shall include the feminine and neuter, neuter pronouns shall include the masculine and the feminine, and the singular shall be deemed to include the plural. The use of the word "including" herein shall not be considered to limit the provision that it modifies but instead shall mean "including, without limitation."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.12 <u>No Third-Party Rights</u>. Except as expressly provided in this Agreement, this Agreement is intended solely for the benefit of the parties hereto and is not intended to confer any benefits upon, or create any rights in favor of, any Person other than the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.13 <u>Entire Agreement</u>. This Agreement constitutes the entire agreement of the Company, the Subsequent Initial Member and any Person who becomes a Member hereafter with respect to the matters described herein and supersedes any prior agreement or understanding among them with respect to such subject matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.14 <u>Rule of Construction</u>. The general rule of construction for interpreting a contract, which provides that the provisions of a contract should be construed against the party preparing the contract, is waived by the parties hereto. Each party acknowledges that such party was represented by separate legal counsel in this matter who participated in the preparation of this Agreement or such party had the opportunity to retain counsel to participate in the preparation of this Agreement but elected not to do so.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.15 <u>Authority</u>. Whenever in this Agreement or elsewhere it is provided that consent is required of, or a demand shall be made by, or an act or thing shall be done by or at the direction of, the Company, or whenever any words of like import are used, all such consents, demands, acts and things are to be made, given or done by the consent of the Manager or Person acting under the authority of the Manager, unless a contrary intention is expressly indicated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.16 <u>Governing Law</u>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the conflict of laws principles thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.17 <u>Arbitration</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Any party to this Agreement may, at its sole election, require that the sole and exclusive forum and remedy for resolution of a Claim be final and binding arbitration pursuant to this Section 8.17 (this "Arbitration Provision"). The arbitration shall be conducted in the State of Delaware. As used in this Arbitration Provision, "Claim" (or in the plural, "Claims") shall include any past, present, or future claim, dispute, or controversy involving a Member (or persons claiming through or connected with a Member), on the one hand, and the Company (or persons claiming through or connected with the Company), on the other hand, relating to or arising out of the subscription agreement to purchase Class A Preferred Shares, any Class A Preferred Shares, and/or the activities or relationships that involve, lead to, or result from any of the foregoing, including (except to the extent provided otherwise in the last sentence of sub-section (e) below) the validity or enforceability of this Arbitration Provision, any part thereof, or the entire Agreement. Claims are subject to arbitration regardless of whether they arise from contract; tort (intentional or otherwise); a constitution, statute, common law, or principles of equity; or otherwise. Claims include (without limitation) matters arising as initial claims, counter-claims, cross-claims, third-party claims, or otherwise. This Arbitration Provision applies to claims under the US federal securities laws and to all claims that that are related to the Company, including with respect to this offering, the Company's holdings (including the holdings of any Subsidiary), the Class A Preferred Shares, the Company's ongoing operations and the management of the Company's investments, among other matters. The scope of this Arbitration Provision is to be given the broadest possible interpretation that is enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The party initiating arbitration shall do so with the American Arbitration Association (the "AAA"). The arbitration shall be conducted according to, and the location of the arbitration shall be determined in accordance with, the rules and policies of the administrator selected, except to the extent the rules conflict with this Arbitration Provision or any countervailing law. In the case of a conflict between the rules and policies of the administrator and this Arbitration Provision, this Arbitration Provision shall control, subject to countervailing law, unless all parties to the arbitration consent to have the rules and policies of the administrator apply.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If the Company elects arbitration, the Company shall pay all the administrator's filing costs and administrative fees (other than hearing fees). If a Member elects arbitration, filing costs and administrative fees (other than hearing fees) shall be paid in accordance with the rules of the administrator selected, or in accordance with countervailing law if contrary to the administrator's rules. The Company shall pay the administrator's hearing fees for one full day of arbitration hearings. Fees for hearings that exceed one day will be paid by the party requesting the hearing, unless the administrator's rules or applicable law require otherwise, or a Member requests that the Company pay them and the Company agrees to do so. Each party shall bear the expense of its own attorney's fees, except as otherwise provided by law. If a statute gives a Member the right to recover any of these fees, these statutory rights shall apply in the arbitration notwithstanding anything to the contrary herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Within 30 days of a final award by the arbitrator, a party may appeal the award for reconsideration by a three-arbitrator panel selected according to the rules of the arbitrator administrator. In the event of such an appeal, an opposing party may cross-appeal within 30 days after notice of the appeal. The panel will reconsider de novo all aspects of the initial award that are appealed. Costs and conduct of any appeal shall be governed by this Arbitration Provision and the administrator's rules, in the same way as the initial arbitration proceeding. Any award by the individual arbitrator that is not subject to appeal, and any panel award on appeal, shall be final and binding, except for any appeal right under the Federal Arbitration Act (the "**FAA**"), and may be entered as a judgment in any court of competent jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company agrees not to invoke the right to arbitrate an individual Claim that a Member may bring in Small Claims Court or an equivalent court, if any, so long as the Claim is pending only in that court. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NO ARBITRATION SHALL PROCEED ON A CLASS, REPRESENTATIVE, OR COLLECTIVE BASIS (INCLUDING AS PRIVATE ATTORNEY GENERAL ON BEHALF OF OTHERS), EVEN IF THE CLAIM OR CLAIMS THAT ARE THE SUBJECT OF THE ARBITRATION HAD PREVIOUSLY BEEN ASSERTED (OR COULD HAVE BEEN ASSERTED) IN A COURT AS CLASS REPRESENTATIVE, OR COLLECTIVE ACTIONS IN A COURT.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Unless otherwise provided in this Agreement or consented to in writing by all parties to the arbitration, No party to the arbitration may join, consolidate, or otherwise bring claims for or on behalf of two or more individuals or unrelated corporate entities in the same arbitration unless those persons are parties to a single transaction. Unless consented to in writing by all parties to the arbitration, an award in arbitration shall determine the rights and obligations of the named parties only, and only with respect to the claims in arbitration, and shall not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) determine the rights, obligations, or interests of anyone other than a named party, or resolve any Claim of anyone other than a named party; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) make an award for the benefit of, or against, anyone other than a named party. No administrator or arbitrator shall have the power or authority to waive, modify, or fail to enforce this sub-section (f), and any attempt to do so, whether by rule, policy, arbitration decision or otherwise, shall be invalid and unenforceable. Any challenge to the validity of this sub-section (f) shall be determined exclusively by a court and not by the administrator or any arbitrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) This Arbitration Provision is made pursuant to a transaction involving interstate commerce and shall be governed by and enforceable under the FAA. The arbitrator will apply substantive law consistent with the FAA and applicable statutes of limitations. The arbitrator may award damages or other types of relief permitted by applicable substantive law, subject to the limitations set forth in this Arbitration Provision. The arbitrator will not be bound by judicial rules of procedure and evidence that would apply in a court. The arbitrator shall take steps to reasonably protect confidential information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) This Arbitration Provision shall survive:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) suspension, termination, revocation, closure, or amendments to this Agreement and the relationship of the parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the bankruptcy or insolvency of any party hereto or other party; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) any transfer of any Class A Preferred Share.

If any portion of this Arbitration Provision other than sub-section (e) is deemed invalid or unenforceable, the remaining portions of this Arbitration Provision shall nevertheless remain valid and in force. If arbitration is brought on a class, representative, or collective basis, and the limitations on such proceedings in sub-section (e) are finally adjudicated pursuant to the last sentence of sub-section (e) to be unenforceable, then No arbitration shall be had. In No event shall any invalidation be deemed to authorize an arbitrator to determine Claims or make awards beyond those authorized in this Arbitration Provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.18 <u>Waiver of Court & Jury Rights</u>. THE PARTIES ACKNOWLEDGE THAT THEY HAVE A RIGHT TO LITIGATE CLAIMS THROUGH A COURT BEFORE A JUDGE, BUT WILL NOT HAVE THAT RIGHT IF ANY PARTY ELECTS ARBITRATION PURSUANT TO THIS ARBITRATION PROVISION. THE PARTIES HEREBY KNOWINGLY AND VOLUNTARILY WAIVE THEIR RIGHTS TO LITIGATE SUCH CLAIMS IN A COURT UPON ELECTION OF ARBITRATION BY ANY PARTY. THE PARTIES HERETO WAIVE A TRIAL BY JURY IN ANY LITIGATION RELATING TO THIS AGREEMENT, THE CLASS A PREFERRED SHARES, OR ANY OTHER AGREEMENTS RELATED THERETO. BY AGREEING TO BE SUBJECT TO THE ARBITRATION PROVISIONS, INVESTORS WILL NOT BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.19 <u>Facsimile Signatures</u>. The use of facsimile signatures affixed in the name and on behalf of the transfer agent and registrar of the Company on certificates representing Shares is expressly permitted by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.20 <u>Counterparts</u>. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.

[Signatures appear on following page]

IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first written above.

---

| | |
|:---|:---|
| Subsequent Sole Member: Tranquil Healthcare Holdings, Inc. | Subsequent Sole Member: Tranquil Healthcare Holdings, Inc. |
| By: |  |
| Name: | Tyler Ehler |
| Title: | CEO |

---

All members now and hereafter admitted as Members of the Company, pursuant to powers of attorney now and hereafter executed in favor of, and granted and delivered to the Company or without execution hereof or thereof by purchasing or otherwise lawfully acquiring any Share, pursuant to Section 1.7.

Form of Counterpart Signature Page

The undersigned hereby accepts, and becomes a party to, the Limited Liability Company Operating Agreement (the "Agreement") of Tranquil Healthcare Fund I, LLC, a Delaware limited liability company (the "Company"), in connection with the acquisition of Shares (as defined in the Agreement) of the Company, and by its signature below signifies its agreement to be bound by the terms and conditions of the Agreement.

---

| | |
|:---|:---|
| Member Name: | Tranquil Healthcare Holdings, Inc. |
| By: |  |
| Name: | Tyler Ehler |
| Title: | CEO |
| Number of Shares: | 1000000 |

---

Agreed and Accepted:

---

| | |
|:---|:---|
| Tranquil Healthcare Fund I, LLC | Tranquil Healthcare Fund I, LLC |
| By: |  |
| Name: | Tyler Ehler |
| Title: | CEO of Tranquil Healthcare Holdings, Inc. |

---

**<u>Exhibit A</u>**

Members, Capital Contributions, Shares

<u>Member Name</u> <u>Address</u> <u>Capital Contribution</u> <u>Number of<br> Common<br> Shares</u> <u>Number of Class A Preferred Shares</u> <br> Tranquil Healthcare Holdings, Inc. 18200 Von Karman Ave. #850, Irvine, CA 92612 Founders Services 1,000,000 -

**<u>Exhibit B</u>**

**<u>Class A Preferred Shares and Common Shares Rights and Preferences</u>**

---

| | |
|:---|:---|
| Class of Units: | Class A Preferred Shares.<br> Common Shares. |
| Voting Rights: | The Class A Preferred Shares shall have no voting rights, except as set forth in the Agreement or by Delaware law.<br>The Common Shares will vote on all matters requiring a vote of the Members under the Agreement, as required by Delaware law. |
| Distributions: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) First, if and when declared by Manager, the Class A Preferred Shares shall receive one hundred percent (100%) of Distributions until each Member holding Class A Preferred Shares has received cumulative Distributions equal to an annual, non-compounded, eight percent (8%) return on the original purchase price paid for such Class A Preferred Shares; and<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Thereafter, all additional Distributions, if and when declared by the Manager, shall be distributed (a) seventy percent (70%) to holders of Class A Preferred Shares and (b) thirty percent (30%) to holders of the Common Shares. |
| Distributions on Dissolution, Liquidation or Winding Up: | Upon a Dissolution Event, the Class A Preferred Shares and Common Shares will receive Distributions in the same manner as set forth in the paragraph above entitled "Distributions". |
| All Other Rights and Preferences: | The Class A Preferred Shares shall be on a pari passu basis on all other matters, rights, preferences, and privileges with the Common Units. |
| Possible Dilution: | The Operating Agreement allows the Manager to sell or issue Class A Preferred Shares for consideration determined by the Manager. |

---

## Ex1A-2A

**Exhibit 2.3**

**CERTIFICATE OF INCORPORATION**

**OF**

**TRANQUIL HEALTHCARE, INC.**

**ARTICLE I**

The name of the corporation is Tranquil Healthcare, Inc. (the "<u>Corporation</u>").

**ARTICLE II**

The address of the Corporation's registered office in the state of Delaware is 2140 S. DuPont Hwy, in the city of Camden, county of Kent, Zip Code 19934. The name of its registered agent at such address is Paracorp Incorporated.

**ARTICLE III**

The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law ("<u>DGCL</u>").

**ARTICLE IV**

The authorized capital stock of the Corporation shall consist of: (i) Two Million (2,000,000) shares of Common Stock having a par value of $0.001 per share ("<u>Common Stock</u>") and (ii) Ten Million (10,000,000) shares of "blank check" Preferred Stock having a par value of $0.001 per share ("<u>Preferred Stock</u>"). Authority is hereby expressly granted to the board of directors ("<u>Board</u>") of the Corporation to fix by resolution or resolutions any of the designations, power, preferences and rights, and any of the qualifications, limitations or restrictions which are permitted by the DGCL in respect of any class or classes of Preferred Stock or any series of any class of Preferred Stock of the Corporation. Except as otherwise provided in any certificate of designations of any series of Preferred Stock, the number of authorized shares of the class of Common Stock or Preferred Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section 242(b)(2) of the DGCL.

**ARTICLE V**

The Corporation is to have a perpetual existence.

**ARTICLE VI**

The business and affairs of the Corporation shall be managed by or under the direction of the Board. Elections of directors need not be by written ballot unless otherwise provided in the Bylaws of the Corporation. In furtherance of and not in limitation of the powers conferred by the laws of the state of Delaware, the Board is expressly authorized to make, amend or repeal Bylaws of the Corporation.

**ARTICLE VII**

To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.

The Corporation shall indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director or officer of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as a director or officer at the request of the Corporation or any predecessor to the Corporation.

Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of the Corporation's Certificate of Incorporation inconsistent with this Article VII shall eliminate or reduce the effect of this Article VII in respect of any matter occurring, or any action or proceeding accruing or arising or that, but for this Article VII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.

**ARTICLE VIII**

To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which the DGCL permits the Corporation to provide indemnification) through bylaws provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the DGCL.

Any amendment, repeal or modification of the foregoing provisions of this Article VII shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.

**ARTICLE IX**

Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (A) any derivative action or proceeding asserting a claim on behalf of the Corporation, (B) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, employee or agent of the Corporation to the Corporation or the Corporation's stockholders, (C) any action or proceeding asserting a claim against the Corporation arising pursuant to any provision of the Delaware General Corporation Law or the Corporation's Certificate of Incorporation or Bylaws, (D) any action or proceeding asserting a claim as to which the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware, or (E) any action or proceeding asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.

**ARTICLE X**

The name and mailing address of the incorporator are as follows:

Dennis Gluck

2629 Townsgate Road #215

Westlake Village, CA 91361

<u>/s/ Dennis Gluck</u> 

By: Dennis Gluck

Its: Incorporator

Dated: October 20, 2025

## Ex1A-2B

**Exhibit 2.4**

**BYLAWS**

**OF**

**TRANQUIL HEALTHCARE, Inc.** 

**Article I** **<br> CORPORATE OFFICES**

1.1 REGISTERED OFFICE.

The registered office of Tranquil Healthcare, Inc. shall be as designated by the corporation's board of directors ("Board") as maybe determined from time to time or as set forth in its certificate of incorporation ("Certificate").

1.2 OTHER OFFICES.

The corporation's Board of Directors (the "<u>Board</u>") may at any time establish other offices at any place or places where the corporation is qualified to do business.

**Article II** **<br> MEETINGS OF STOCKHOLDERS**

2.1 PLACE OF MEETINGS.

Meetings of stockholders shall be held at any place within or outside the State of Delaware as designated by the Board. The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the Delaware General Corporation Law (the "<u>DGCL</u>"). In the absence of any such designation or determination, stockholders' meetings shall be held at the corporation's principal executive office.

2.2 ANNUAL MEETING.

The annual meeting of stockholders shall be held each year on a date and at a time designated by the Board. At the annual meeting, directors shall be elected and any other proper business may be transacted.

2.3 SPECIAL MEETING.

Unless otherwise required by law or the Certificate, special meetings of the stockholders may be called at any time, for any purpose or purposes, only by (i) the Board, (ii) the Chairman of the Board, (iii) the chief executive officer (or, in the absence of a chief executive officer, the president) of the corporation, or (iv) holders of more than twenty percent (20%) of the total voting power of the outstanding shares of capital stock of the corporation then entitled to vote.

If any person(s) other than the Board calls a special meeting, the request shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) be in writing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) specify the general nature of the business proposed to be transacted; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) be delivered personally or sent by registered mail or by facsimile transmission to the secretary of the
corporation.

Upon receipt of such a request, the Board shall determine the date, time and place of such special meeting, which must be scheduled to be held on a date that is within ninety (90) days of receipt by the secretary of the request therefor, and the secretary of the corporation shall prepare a proper notice thereof. No business may be transacted at such special meeting other than the business specified in the notice to stockholders of such meeting.

2.4 NOTICE OF STOCKHOLDERS' MEETINGS.

All notices of meetings of stockholders shall be sent or otherwise given in accordance with either Section 2.5 or Section 8.1 of these bylaws not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting, except as otherwise required by applicable law. The notice shall specify the place, if any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Any previously scheduled meeting of stockholders may be postponed, and, unless the Certificate provides otherwise, any special meeting of the stockholders may be cancelled by resolution duly adopted by a majority of the Board members then in office upon public notice given prior to the date previously scheduled for such meeting of stockholders.

Whenever notice is required to be given, under the DGCL, the Certificate or these bylaws, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate with the Secretary of State of Delaware, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.

Whenever notice is required to be given, under any provision of the DGCL, the Certificate or these bylaws, to any stockholder to whom (a) notice of two (2) consecutive annual meetings, or (b) all, and at least two (2) payments (if sent by first-class mail) of dividends or interest on securities during a twelve (12) month period, have been mailed addressed to such person at such person's address as shown on the records of the corporation and have been returned undeliverable, the giving of such notice to such person shall not be required. Any action or meeting which shall be taken or held without notice to such person shall have the same force and effect as if such notice had been duly given. If any such person shall deliver to the corporation a written notice setting forth such person's then current address, the requirement that notice be given to such person shall be reinstated. In the event that the action taken by the corporation is such as to require the filing of a certificate with the Secretary of State of Delaware, the certificate need not state that notice was not given to persons to whom notice was not required to be given pursuant to Section 230(b) of the DGCL.

The exception in subsection (a) of the above paragraph to the requirement that notice be given shall not be applicable to any notice returned as undeliverable if the notice was given by electronic transmission.

2.5 MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE.

Notice of any meeting of stockholders shall be given:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if mailed, when deposited in the United States mail, postage prepaid, directed to the stockholder at his
or her address as it appears on the corporation's records;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if electronically transmitted, as provided in Section 8.1 of these bylaws; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) otherwise, when delivered.

An affidavit of the secretary or an assistant secretary of the corporation or of the transfer agent or any other agent of the corporation that the notice has been given shall, in the absence of fraud, be *prima facie* evidence of the facts stated therein.

Notice may be waived in accordance with Section 7.13 of these bylaws.

2.6 QUORUM

Unless otherwise provided in the Certificate or required by law, stockholders representing one-third of the voting power of the issued and outstanding capital stock of the corporation, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. If such quorum is not present or represented at any meeting of the stockholders, then the chairman of the meeting, or the stockholders representing a majority of the voting power of the capital stock at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting from time to time until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed. The stockholders present at a duly called meeting at which quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.

2.7 ADJOURNED MEETING; NOTICE

When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place if any thereof, and the means of remote communications if any by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At the continuation of the adjourned meeting, the corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting in accordance with the provisions of Section 2.4 and 2.5 of these bylaws.

2.8 ADMINISTRATION OF THE MEETING

Meetings of stockholders shall be presided over by the chairman of the Board or, in the absence thereof, by such person as the chairman of the Board shall appoint, or, in the absence thereof or in the event that the chairman shall fail to make such appointment, any officer of the corporation elected by the Board. In the absence of the secretary of the corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.

The Board shall, in advance of any meeting of stockholders, appoint one (1) or more inspector(s), who may include individual(s) who serve the corporation in other capacities, including without limitation as officers, employees or agents, to act at the meeting of stockholders and make a written report thereof. The Board may designate one (1) or more persons as alternate inspector(s) to replace any inspector, who fails to act. If no inspector or alternate has been appointed or is able to act at a meeting of stockholders, the chairman of the meeting shall appoint one (1) or more inspector(s) to act at the meeting. Each inspector, before discharging his or her duties, shall take and sign an oath to faithfully execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspector(s) or alternate(s) shall have the duties prescribed pursuant to Section 231 of the DGCL or other applicable law.

The Board shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including without limitation establishing an agenda of business of the meeting, rules or regulations to maintain order, restrictions on entry to the meeting after the time fixed for commencement thereof and the fixing of the date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at a meeting (and shall announce such at the meeting).

2.9 VOTING.

The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section 2.11 of these bylaws, subject to Section 217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other voting agreements) of the DGCL.

Except as otherwise provided in the provisions of Section 213 of the DGCL (relating to the fixing of a date for determination of stockholders of record) or these bylaws, each stockholder shall be entitled to that number of votes for each share of capital stock held by such stockholder as set forth in the Certificate.

In all matters, other than the election of directors and except as otherwise required by law, the Certificate or these bylaws, the affirmative vote of a majority of the voting power of the shares present or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders. Directors shall be elected by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.

The stockholders of the corporation shall not have the right to cumulate their votes for the election of directors of the corporation.

2.10 STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING.

Unless otherwise restricted by the Certificate, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the corporation by delivery to its registered office, its principal place of business, or an officer or agent of the corporation having custody of the book in which minutes of proceedings of stockholders are recorded. Delivery made to the corporation's registered office shall be by hand or by certified or registered mail, return receipt requested. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall, to the extent required by law, be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the corporation.

2.11 RECORD DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING CONSENTS.

In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted and which shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting, nor more than sixty (60) days prior to any other such action.

If the Board does not fix a record date in accordance with these bylaws and applicable law:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders
shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of
business on the day next preceding the day on which the meeting is held.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The record date for determining stockholders entitled to consent to corporate action in writing without
a meeting, when no prior action by the Board is necessary, shall be the first day on which a signed written consent setting forth the
action taken or proposed to be taken is delivered to the corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The record date for determining stockholders for any other purpose shall be at the close of business on
the day on which the Board adopts the resolution relating thereto.

A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting.

2.12 PROXIES.

Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law and filed with the secretary of the corporation, but no such proxy shall be voted or acted upon after three (3) years from its date, unless the proxy provides for a longer period. A stockholder may also authorize another person or persons to act for him, her or it as proxy in the manner(s) provided under Section 212(c) of the DGCL or as otherwise provided under Delaware law. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 212 of the DGCL.

2.13 LIST OF STOCKHOLDERS ENTITLED TO VOTE.

The officer who has charge of the stock ledger of the corporation shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least ten (10) days prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the corporation's principal place of business.

In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting.

2.14 ADVANCE NOTICE OF STOCKHOLDER BUSINESS

Only such business shall be conducted as shall have been properly brought before a meeting of the stockholders of the corporation. To be properly brought before an annual meeting, business must be (a) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board, (b) otherwise properly brought before the meeting by or at the direction of the Board, or (c) a proper matter for stockholder action under the DGCL that has been properly brought before the meeting by a stockholder (i) who is a stockholder of record on the date of the giving of the notice provided for in this Section 2.14 and on the record date for the determination of stockholders entitled to vote at such annual meeting and (ii) who complies with the notice procedures set forth in this Section 2.14. For such business to be considered properly brought before the meeting by a stockholder such stockholder must, in addition to any other applicable requirements, have given timely notice in proper form of such stockholder's intent to bring such business before such meeting. To be timely, such stockholder's notice must be delivered to or mailed and received by the secretary of the corporation at the principal executive offices of the corporation not later than the close of business on the 90 <sup>th</sup> day, nor earlier than the close of business on the 120 <sup>th</sup> day, prior to the anniversary date of the immediately preceding annual meeting; provided, however, that in the event that no annual meeting was held in the previous year or the annual meeting is called for a date that is not within thirty (30) days before or after such anniversary date, notice by the stockholder to be timely must be so received not later than the close of business on the tenth (10 <sup>th</sup>) day following the day on which such notice of the date of the meeting was mailed or public disclosure of the date of the meeting was made, whichever occurs first.

To be in proper form, a stockholder's notice to the secretary shall be in writing and shall set forth:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the name and record address of the stockholder who intends to propose the business and the class or series
and number of shares of capital stock of the corporation which are owned beneficially or of record by such stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any proxy, contract, arrangement, understanding, or relationship pursuant to which such stockholder or
beneficial owner, if any, has a right to vote any shares of any security of the corporation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a description of all agreements, arrangements and understandings between such stockholder and beneficial
owner, if any, and any other person or persons (including their names) in connection with the proposal of such business by such stockholder,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) a representation that the stockholder is a holder of record of stock of the corporation entitled to vote
at such meeting and intends to appear in person or by proxy at the meeting to introduce the business specified in the notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) a brief description of the business desired to be brought before the annual meeting and the reasons for
conducting such business at the annual meeting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) any material interest of the stockholder in such business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) any other information that is required to be provided by the stockholder pursuant to Regulation 14A under
the Securities Exchange Act of 1934, as amended (the " <u>Exchange Act</u> ").

Notwithstanding the foregoing, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholder's meeting, stockholders must provide notice as required by, and otherwise comply with the requirements of, the Exchange Act and the regulations promulgated thereunder.

No business shall be conducted at the annual meeting of stockholders except business brought before the annual meeting in accordance with the procedures set forth in this Section 2.14. The chairman of the meeting may refuse to acknowledge the proposal of any business not made in compliance with the foregoing procedure.

2.15 ADVANCE NOTICE OF DIRECTOR NOMINATIONS

Only persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the corporation, except as may be otherwise provided in the Certificate with respect to the right of holders of Preferred Stock of the corporation to nominate and elect a specified number of directors. To be properly brought before an annual meeting of stockholders, or any special meeting of stockholders called for the purpose of electing directors, nominations for the election of director must be (a) specified in the notice of meeting (or any supplement thereto), (b) made by or at the direction of the Board (or any duly authorized committee thereof) or (c) made by any stockholder of the corporation (i) who is a stockholder of record on the date of the giving of the notice provided for in this Section 2.15 and on the record date for the determination of stockholders entitled to vote at such meeting and (ii) who complies with the notice procedures set forth in this Section 2.15.

In addition to any other applicable requirements, for a nomination to be made by a stockholder, such stockholder must have given timely notice thereof in proper written form to the secretary of the corporation. To be timely, a stockholder's notice to the secretary must be delivered to or mailed and received at the principal executive offices of the corporation, in the case of an annual meeting, in accordance with the provisions set forth in Section 2.14, and, in the case of a special meeting of stockholders called for the purpose of electing directors, not later than the close of business on the tenth (10th) day following the day on which notice of the date of the special meeting was mailed or public disclosure of the date of the special meeting was made, whichever first occurs.

To be in proper written form, a stockholder's notice to the secretary must set forth:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) as to each person whom the stockholder proposes to nominate for election as a director (i) the name, age,
business address and residence address of the person, (ii) the principal occupation or employment of the person, (iii) the class or series
and number of shares of capital stock of the corporation which are owned beneficially or of record by the person, (iv) a description of
all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons)
pursuant to which the nominations are to be made by the stockholder, and (v) any other information relating to such person that is required
to be disclosed in solicitations of proxies for elections of directors, or is otherwise required, in each case pursuant to Regulation
14A under the Exchange Act (including without limitation such person's written consent to being named in the proxy statement, if
any, as a nominee and to serving as a director if elected); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) as to such stockholder giving notice, the information required to be provided pursuant to Section 2.14.

Subject to the rights of any holders of Preferred Stock of the corporation, no person shall be eligible for election as a director of the corporation unless nominated in accordance with the procedures set forth in this Section 2.15. If the chairman of the meeting properly determines that a nomination was not made in accordance with the foregoing procedures, the chairman shall declare to the meeting that the nomination was defective and such defective nomination shall be disregarded.

2.16 DISCLOSURE BY STOCKHOLDERS OF HEDGED POSITIONS.

A notice submitted by a stockholder under Section 2.14 or 2.15 must describe, with respect to the stockholder and any Stockholder Associated Person, (i) any Derivative Instrument directly or indirectly beneficially owned by the stockholder or a Stockholder Associated Person, or any other direct or indirect opportunity for the stockholder or Stockholder Associated Person to profit or share in any profit derived from any increase or decrease in the value of shares of the corporation, (ii) any proportionate interest in shares of the corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which the stockholder or Stockholder Associated Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, (iii) any short interest in any security of the corporation (for purposes of this By-law a person shall be deemed to have a short interest in a security if such person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value of the subject security), (iv) any performance-related fees (other than an asset-based fee) that such stockholder or any Stockholder Associated Person is entitled to based on any increase or decrease in the value of shares of the corporation or Derivative Instruments, if any, and (v) any hedging or other transaction or series of transactions that has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including, without limitation, any put, short position or any borrowing or lending of shares) that has been made, the effect or intent of which is to mitigate loss to or manage risk of share price changes for, or to increase or decrease the voting power of, the stockholder or any Stockholder Associated Person with respect to any share of the corporation.

Definitions. As used in this Section 2.16 the following terms have the meanings indicated:

"Derivative Instrument" means an option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the corporation or with a value derived in whole or in part from the value of any class or series of shares of the corporation, whether or not such instrument or right is subject to settlement in the underlying class or series of shares of the corporation or otherwise.

"Stockholder Associated Person" of a stockholder means (i) any person controlling, controlled by, under common control with, or acting in concert with, the stockholder, (ii) any beneficial owner of shares of the corporation owned of record or beneficially by the stockholder, and (iii) any person controlling, controlled by or under common control with, a person that is a Stockholder Associated Person pursuant to clause (ii) of this definition.

**Article III** **<br> DIRECTORS**

3.1 POWERS.

Subject to the provisions of the DGCL and any limitations in the Certificate, the business and affairs of the corporation shall be managed and all corporate powers shall be exercised by or under the direction of the Board.

3.2 NUMBER OF DIRECTORS.

Subject to the rights of the holders of any series of Preferred Stock to elect directors under specified circumstances, the authorized number of directors shall be determined from time to time by resolution of the Board, provided the Board shall consist of at least one (1) member. No reduction of the authorized number of directors shall have the effect of removing any director before that director's term of office expires.

3.3 ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS.

Except as provided in Section 3.4 and Section 3.13 of these bylaws, directors shall be elected at each annual meeting of stockholders to hold office until the next annual meeting. Directors need not be stockholders unless so required by the Certificate or these bylaws. The Certificate or these bylaws may prescribe other qualifications for directors. Each director, including a director elected to fill a vacancy, shall hold office until such director's successor is elected and qualified or until such director's earlier death, resignation or removal.

All elections of directors shall be by written ballot or by written consent of the shareholders as provided for in Section 2.10 of these By-Laws, unless otherwise provided in the Certificate. If authorized by the Board, such requirement of a written ballot shall be satisfied by a ballot submitted by electronic transmission, provided that any such electronic transmission must be either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized.

3.4 RESIGNATION AND VACANCIES.

Any director may resign at any time upon written notice or by electronic transmission to the corporation.

Subject to the rights of the holders of any series of Preferred Stock of the corporation then outstanding and unless the Board otherwise determines, newly created directorships resulting from any increase in the authorized number of directors, or any vacancies on the Board resulting from the death, resignation, retirement, disqualification, removal from office or other cause shall, unless otherwise required by law, be filled by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board, or by a sole remaining director. When one or more directors resigns and the resignation is effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in this Section 3.4 in the filling of other vacancies.

3.5 PLACE OF MEETINGS; MEETINGS BY TELEPHONE.

The Board may hold meetings, both regular and special, either within or outside the State of Delaware.

Unless otherwise restricted by the Certificate or these bylaws, members of the Board, or any committee designated by the Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.

3.6 REGULAR MEETINGS.

Regular meetings of the Board may be held with at least five business days prior notice at such time and at such place as shall from time to time be determined by the Board.

3.7 SPECIAL MEETINGS; NOTICE.

Special meetings of the Board for any purpose or purposes may be called at any time by the chairman of the Board, the chief executive officer, a president, the secretary or any two directors. The person(s) authorized to call special meetings of the Board may fix the place and time of the meeting.

Notice of the time and place of special meetings shall be:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) delivered personally by hand, by courier or by telephone;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) sent by United States first-class mail, postage prepaid;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) sent by facsimile; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) sent by electronic mail,

directed to each director at that director's address, telephone number, facsimile number or electronic mail address, as the case may be, as shown on the corporation's records.

If the notice is (i) delivered personally by hand, by courier or by telephone, (ii) sent by facsimile or (iii) sent by electronic mail, it shall be delivered or sent at least twenty-four (24) hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall be deposited in the United States mail at least four days before the time of the holding of the meeting. Any oral notice may be communicated either to the director or to a person at the office of the director who the person giving notice has reason to believe will promptly communicate such notice to the director. The notice need not specify the place of the meeting if the meeting is to be held at the corporation's principal executive office nor the purpose of the meeting.

3.8 QUORUM.

Except as otherwise required by law or the Certificate, at all meetings of the Board, a majority of the authorized number of directors (as determined pursuant to Section 3.2 of these bylaws) shall constitute a quorum for the transaction of business, except to adjourn as provided in Section 3.11 of these bylaws. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may be otherwise specifically provided by statute, the Certificate or these bylaws.

A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors, if any action taken is approved by at least a majority of the directors present at that meeting.

3.9 WAIVER OF NOTICE

Whenever notice is required to be given under any provisions of the DGCL, the Certificate or these bylaws, a written waiver thereof, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting solely for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the directors, or members of a committee of directors, need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate or these bylaws.

3.10 BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING.

Unless otherwise restricted by the Certificate or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

3.11 ADJOURNED MEETING; NOTICE.

If a quorum is not present at any meeting of the Board, then a majority of the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.

3.12 FEES AND COMPENSATION OF DIRECTORS.

Unless otherwise restricted by the Certificate or these bylaws, the Board shall have the authority to fix the compensation of directors.

3.13 REMOVAL OF DIRECTORS.

Subject to the rights of the holders of any series of Preferred Stock then outstanding, any director or the entire Board may be removed from office at any time, with or without cause, by the affirmative vote of the holders of at least a majority of the voting power of the issued and outstanding shares of capital stock of the corporation then entitled to vote in the election of directors.

3.14 CORPORATE GOVERNANCE COMPLIANCE.

Without otherwise limiting the powers of the Board set forth in Section 3.1 and provided that shares of capital stock of the corporation are listed for trading on either The American Stock Exchange ("<u>AMEX</u>"), The Nasdaq National Market ("<u>NASDAQ</u>") or the New York Stock Exchange ("<u>NYSE</u>"), the corporation shall comply with the corporate governance rules and requirements of the AMEX, NASDAQ or the NYSE, as applicable.

**Article IV** **<br> COMMITTEES**

4.1 COMMITTEES OF DIRECTORS.

The Board may designate one or more committees, each committee to consist of one or more of the directors of the corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise such lawfully delegable powers and duties as the Board may confer. Each committee will comply with all applicable provisions of: the Sarbanes-Oxley Act of 2002, the rules and regulations of the Securities and Exchange Commission, and the rules and requirements of AMEX, NASDAQ or NYSE, as applicable, and will have the right to retain independent legal counsel and other advisers at the corporation's expense.

4.2 COMMITTEE MINUTES.

Each committee shall keep regular minutes of its meetings and report to the Board when required.

4.3 MEETINGS AND ACTION OF COMMITTEES.

Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Section 3.5 (place of meetings and meetings by telephone);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Section 3.6 (REGULAR MEETINGS.);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Section 3.7 (special meetings and notice);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Section 3.8 (QUORUM.);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Section 3.9 (WAIVER OF NOTICE);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Section 3.10 (action without a meeting); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Section 3.11 (adjournment and notice of adjournment).

with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the Board and its members.

Notwithstanding the foregoing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) the time of regular meetings of committees may be determined either by resolution of the Board or by resolution
of the committee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) special meetings of committees may also be called by resolution of the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) notice of special meetings of committees shall also be given to all alternate members, who shall have
the right to attend all meetings of the committee. The Board may adopt rules for the government of any committee not inconsistent with
the provisions of these bylaws.

4.4 AUDIT COMMITTEE

The Board may establish an Audit Committee whose principal purpose will be to oversee the corporation's and its subsidiaries' accounting and financial reporting processes, internal systems of control, independent auditor relationships and audits of consolidated financial statements of the corporation and its subsidiaries. The Audit Committee will also determine the appointment of the independent auditors of the corporation and any change in such appointment and ensure the independence of the corporation's auditors. In addition, the Audit Committee will assume such other duties and responsibilities as the Board may confer upon the committee from time to time. In the event of any inconsistency between this Section 4.4 and the Certificate, the terms of the Certificate will govern.

4.5 CORPORATE GOVERNANCE AND NOMINATING COMMITTEE

The Board may establish a Corporate Governance and Nominating Committee whose principal duties will be to assist the Board by identifying individuals qualified to become Board members consistent with criteria approved by the Board, to recommend to the Board for its approval the slate of nominees to be proposed by the Board to the stockholders for election to the Board, to develop and recommend to the Board the governance principles applicable to the corporation, as well as such other duties and responsibilities as the Board may confer upon the committee from time to time.

4.6 COMPENSATION COMMITTEE

The Board may establish a Compensation Committee whose principal duties will be to review employee compensation policies and programs as well as the compensation of the chief executive officer and other executive officers of the corporation, to recommend to the Board a compensation program for outside Board members, as well as such other duties and responsibilities as the Board may confer upon the committee from time to time. In the event of any inconsistency between this Section 4.6 and the Certificate, the terms of the Certificate will govern.

**Article V** **<br> OFFICERS**

5.1 OFFICERS

The officers of the corporation shall be a chief executive officer, one or more presidents (at the discretion of the Board), a chairman of the Board and a secretary. The corporation may also have, at the discretion of the Board, a vice chairman of the Board, a chief financial officer, a treasurer, one or more vice presidents, one or more assistant vice presidents, one or more assistant treasurers, one or more assistant secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws.

Any number of offices may be held by the same person.

5.2 APPOINTMENT OF OFFICERS

The Board shall appoint the officers of the corporation, except such officers as may be appointed in accordance with the provisions of Sections 5.3 of these bylaws, subject to the rights, if any, of an officer under any contract of employment. Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal. A failure to elect officers shall not dissolve or otherwise affect the corporation.

5.3 SUBORDINATE OFFICERS

The Board may appoint, or empower the chief executive officer and/or one or more presidents of the corporation, to appoint, such other officers and agents as the business of the corporation may require. Each of such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the Board may from time to time determine.

5.4 REMOVAL AND RESIGNATION OF OFFICERS.

Any officer may be removed, either with or without cause, by an affirmative vote of the majority of the Board at any regular or special meeting of the Board or, except in the case of an officer appointed by the Board, by any officer upon whom such power of removal may be conferred by the Board.

Any officer may resign at any time by giving written notice to the corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the corporation under any contract to which the officer is a party.

5.5 VACANCIES IN OFFICES.

Any vacancy occurring in any office of the corporation shall be filled by the Board or as provided in Section 5.2.

5.6 CHAIRMAN OF THE BOARD.

The Chairman of the Board shall be chosen from among the Directors. The Chairman of the Board shall have the power to call special meetings of the stockholders and of the Directors for any purpose or purposes, and he shall preside at all meetings of the Board of Directors, unless he shall be absent or unless he shall, at his election, designate the Vice Chairman, if one is elected, to preside in his stead. The Chairman of the Board shall advise and counsel the Chief Executive Officer and other officers of the Corporation and shall exercise such powers and perform such duties as shall be assigned to or required by him from time to time by the Board of Directors.

5.7 CHIEF EXECUTIVE OFFICER.

Subject to the control of the Board and any supervisory powers the Board may give to the chairman of the Board, the chief executive officer shall, together with the president or presidents of the corporation, have general supervision, direction, and control of the business and affairs of the corporation and shall see that all orders and resolutions of the Board are carried into effect. The chief executive officer shall, together with the president or presidents of the corporation, also perform all duties incidental to this office that may be required by law and all such other duties as are properly required of this office by the Board of Directors. The chief executive officer shall serve as chairman of and preside at all meetings of the stockholders. In the absence of the chairman of the Board, the chief executive officer shall preside at all meetings of the Board.

5.8 PRESIDENTS.

Subject to the control of the Board and any supervisory powers the Board may give to the chairman of the Board, the president or presidents of the corporation shall, together with the chief executive officer, have general supervision, direction, and control of the business and affairs of the corporation and shall see that all orders and resolutions of the Board are carried into effect. A president shall have such other powers and perform such other duties as from time to time may be prescribed for him or her by the Board, these bylaws, or the chairman of the Board.

5.9 VICE PRESIDENTS.

In the absence or disability of any president, the vice presidents, if any, in order of their rank as fixed by the Board or, if not ranked, a vice president designated by the Board, shall perform all the duties of a president. When acting as a president, the appropriate vice president shall have all the powers of, and be subject to all the restrictions upon, that president. The vice presidents shall have such other powers and perform such other duties as from time to time may be prescribed for them respectively by the Board, these bylaws, the chairman of the Board, the chief executive officer or, in the absence of a chief executive officer, one of more of the presidents.

5.10 SECRETARY.

The secretary shall keep or cause to be kept, at the principal executive office of the corporation or such other place as the Board may direct, a book of minutes of all meetings and actions of directors, committees of directors, and stockholders. The minutes shall show:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the time and place of each meeting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) whether regular or special (and, if special, how authorized and the notice given);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the names of those present at directors' meetings or committee meetings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the number of shares present or represented at stockholders' meetings; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) the proceedings thereof.

The secretary shall keep, or cause to be kept, at the principal executive office of the corporation or at the office of the corporation's transfer agent or registrar, as determined by resolution of the Board, a share register, or a duplicate share register showing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the names of all stockholders and their addresses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the number and classes of shares held by each;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the number and date of certificates evidencing such shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the number and date of cancellation of every certificate surrendered for cancellation.

The secretary shall give, or cause to be given, notice of all meetings of the stockholders and of the Board required to be given by law or by these bylaws. The secretary shall keep the seal of the corporation, if one be adopted, in safe custody and shall have such other powers and perform such other duties as may be prescribed by the Board or by these bylaws.

5.11 CHIEF FINANCIAL OFFICER

The chief financial officer shall keep and maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of the properties and business transactions of the corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings and shares. The books of account shall at all reasonable times be open to inspection by any director.

The chief financial officer shall deposit all moneys and other valuables in the name and to the credit of the corporation with such depositories as the Board may designate. The chief financial officer shall disburse the funds of the corporation as may be ordered by the Board, shall render to the chief executive officer or, in the absence of a chief executive officer, any president and directors, whenever they request it, an account of all his or her transactions as chief financial officer and of the financial condition of the corporation, and shall have other powers and perform such other duties as may be prescribed by the Board or these bylaws.

The chief financial officer may be the treasurer of the corporation.

5.12 TREASURER.

The treasurer shall keep and maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of the properties and business transactions of the corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings and shares. The books of account shall at all reasonable times be open to inspection by any director.

The treasurer shall deposit all moneys and other valuables in the name and to the credit of the corporation with such depositories as the Board may designate. The treasurer shall disburse the funds of the corporation as may be ordered by the Board, shall render to the chief executive officer or, in the absence of a chief executive officer, one or more of the presidents and directors, whenever they request it, an account of all his or her transactions as treasurer and of the financial condition of the corporation, and shall have other powers and perform such other duties as may be prescribed by the Board or these bylaws.

5.13 ASSISTANT SECRETARY.

The assistant secretary, or, if there is more than one, the assistant secretaries in the order determined by the Board (or if there be no such determination, then in the order of their election) shall, in the absence of the secretary or in the event of the secretary's inability or refusal to act, perform the duties and exercise the powers of the secretary and shall perform such other duties and have such other powers as may be prescribed by the Board or these bylaws.

5.14 ASSISTANT TREASURER.

The assistant treasurer, or, if there is more than one, the assistant treasurers, in the order determined by the Board (or if there be no such determination, then in the order of their election), shall, in the absence of the chief financial officer or treasurer or in the event of the chief financial officer's or treasurer's inability or refusal to act, perform the duties and exercise the powers of the chief financial officer or treasurer, as applicable, and shall perform such other duties and have such other powers as may be prescribed by the Board or these bylaws.

5.15 REPRESENTATION OF SHARES OF OTHER CORPORATIONS.

The chairman of the Board, the chief executive officer, any president, any vice president, the treasurer, the secretary or assistant secretary of this corporation, or any other person authorized by the Board, the chief executive officer, a president or a vice president, is authorized to vote, represent, and exercise on behalf of this corporation all rights incident to any and all shares or other equity interests of any other corporation or entity standing in the name of this corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.

5.16 AUTHORITY AND DUTIES OF OFFICERS.

In addition to the foregoing authority and duties, all officers of the corporation shall respectively have such authority and perform such duties in the management of the business of the corporation as may be designated from time to time by the Board.

**Article VI** **<br> RECORDS AND REPORTS**

6.1 MAINTENANCE AND INSPECTION OF RECORDS.

The corporation shall, either at its principal executive office or at such place or places as designated by the Board, keep a record of its stockholders listing their names and addresses and the number and class of shares held by each stockholder, a copy of these bylaws, as may be amended to date, minute books, accounting books and other records.

Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be maintained on any information storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases); provided that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, the records so kept comply with Section 224 of the DGCL. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to applicable law.

6.2 INSPECTION BY DIRECTORS.

Any director shall have the right to examine the corporation's stock ledger, a list of its stockholders, and its other books and records for a purpose reasonably related to his or her position as a director.

**Article VII** **<br> GENERAL MATTERS**

7.1 CHECKS; DRAFTS; EVIDENCES OF INDEBTEDNESS.

From time to time, the Board shall determine by resolution which person or persons may sign or endorse all checks, drafts, other orders for payment of money, notes or other evidences of indebtedness that are issued in the name of or payable to the corporation, and only the persons so authorized shall sign or endorse those instruments.

7.2 EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS.

Except as otherwise provided in these bylaws, the Board, or any officers of the corporation authorized thereby, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the corporation; such authority may be general or confined to specific instances.

7.3 STOCK CERTIFICATES; PARTLY PAID SHARES.

The shares of the corporation shall be represented by certificates, provided that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares, including being maintained on one or more electronic networks or databases (including distributed electronic networks or databases) in compliance with the DGCL. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the corporation. Any or all of the signatures on the certificate may be a facsimile or electronic signature. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue.

The corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, and upon the books and records of the corporation in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.

7.4 SPECIAL DESIGNATION ON CERTIFICATES.

If the corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, designations, preferences, and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the corporation shall issue to represent such class or series of stock; <u>provided</u> , <u>however</u> , that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements there may be set forth on the face or back of the certificate that the corporation shall issue to represent such class or series of stock a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences, and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.

7.5 LOST CERTIFICATES.

Except as provided in this Section 7.6, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the corporation and cancelled at the same time. The corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the corporation may require the owner of the lost, stolen or destroyed certificate, or such owner's legal representative, to give the corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.

7.6 CONSTRUCTION; DEFINITIONS.

Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term "person" includes both a corporation and a natural person.

7.7 DIVIDENDS.

The Board, subject to any restrictions contained in either (i) the DGCL, or (ii) the Certificate, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property, or in shares of the corporation's capital stock.

The Board may set apart out of any of the funds of the corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve.

7.8 FISCAL YEAR.

The fiscal year of the corporation shall be fixed by resolution of the Board and may be changed by the Board.

7.9 SEAL.

The corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.

7.10 TRANSFER OF STOCK.

Transfers of stock shall be made only upon the transfer books of the corporation kept at an office of the corporation or by transfer agents designated to transfer shares of the stock of the corporation. Except where a certificate is issued in accordance with Section 7.5 of these bylaws, an outstanding certificate for the number of shares involved shall be surrendered for cancellation before a new certificate is issued therefore. Upon surrender to the corporation or the transfer agent of the corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it shall be the duty of the corporation to issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction in its books.

7.11 STOCK TRANSFER AGREEMENTS.

The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes or series of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes or series owned by such stockholders in any manner not prohibited by the DGCL.

7.12 REGISTERED STOCKHOLDERS.

The corporation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) shall be entitled to recognize the exclusive right of a person registered on its books as the owner of
shares to receive dividends and to vote as such owner;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) shall be entitled to hold liable for calls and assessments on partly paid shares the person registered
on its books as the owner of shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) shall not be bound to recognize any equitable or other claim to or interest in such share or shares on
the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of
Delaware.

7.13 WAIVER OF NOTICE.

Whenever notice is required to be given under any provision of the DGCL, the Certificate or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting solely for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate or these bylaws.

7.14 CHARITABLE FOUNDATION.

The establishment by the corporation of a charitable foundation will require Board approval, as will contributions by the corporation to the foundation and disbursements by the foundation. The Board may delegate authority over the foundation to one or more persons who are not directors of the corporation with the approval of two-thirds of the members of the Board.

**Article VIII** **<br> NOTICE BY ELECTRONIC TRANSMISSION**

8.1 NOTICE BY ELECTRONIC TRANSMISSION.

Without limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the Certificate or these bylaws, any notice to stockholders given by the corporation under any provision of the DGCL, the Certificate or these bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the corporation. Any such consent shall be deemed revoked if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the corporation is unable to deliver by electronic transmission two consecutive notices given by the corporation
in accordance with such consent; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) such inability becomes known to the secretary or an assistant secretary of the corporation or to the transfer
agent, or other person responsible for the giving of notice.

However, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.

Any notice given pursuant to the preceding paragraph shall be deemed given:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to
receive notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented
to receive notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific
posting, upon the later of (A) such posting and (B) the giving of such separate notice; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) if by any other form of electronic transmission, when directed to the stockholder.

An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

8.2 DEFINITION OF ELECTRONIC TRANSMISSION.

An "electronic transmission" means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.

8.3 INAPPLICABILITY.

Notice by a form of electronic transmission shall not apply to Section 164 (failure to pay for stock; remedies), Section 296 (adjudication of claims; appeal), Section 311 (revocation of voluntary dissolution), Section 312 (renewal, revival, extension and restoration of certificate of incorporation) or Section 324 (attachment of shares of stock) of the DGCL.

**Article IX** **<br> INDEMNIFICATION OF DIRECTORS AND OFFICERS**

9.1 POWER TO INDEMNIFY IN ACTIONS, SUITS OR PROCEEDINGS OTHER THAN THOSE BY OR IN THE RIGHT OF THE CORPORATION.

Subject to Section 9.3 of this Article IX, the corporation shall indemnify, to the fullest extent permitted by the DGCL, as now or hereafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person (or the legal representative of such person) is or was a director or officer of the corporation or any predecessor of the corporation, or is or was a director or officer of the corporation serving at the request of the corporation as a director or officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person's conduct was unlawful.

9.2 POWER TO INDEMNIFY IN ACTIONS, SUITS OR PROCEEDINGS BY OR IN THE RIGHT OF THE CORPORATION

Subject to Section 9.3 of this Article IX, the corporation shall indemnify, to the fullest extent permitted by the DGCL, as now or hereafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person (or the legal representative of such person) is or was a director or officer of the corporation or any predecessor of the corporation, or is or was a director or officer of the corporation serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

9.3 AUTHORIZATION OF INDEMNIFICATION

Any indemnification under this Article IX (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification of the director or officer is proper in the circumstances because such person has met the applicable standard of conduct set forth in Section 9.1 or Section 9.2 of this Article IX, as the case may be. Such determination shall be made, with respect to a person who is a director or officer at the time of such determination, (i) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion or (iv) by the stockholders (but only if a majority of the directors who are not parties to such action, suit or proceeding, if they constitute a quorum of the board of directors, presents the issue of entitlement to indemnification to the stockholders for their determination). Such determination shall be made, with respect to former directors and officers, by any person or persons having the authority to act on the matter on behalf of the corporation. To the extent, however, that a present or former director or officer of the corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding described above, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection therewith, without the necessity of authorization in the specific case.

9.4 GOOD FAITH DEFINED

For purposes of any determination under Section 9.3 of this Article IX, to the fullest extent permitted by applicable law, a person shall be deemed to have acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe such person's conduct was unlawful, if such person's action is based on the records or books of account of the corporation or another enterprise, or on information supplied to such person by the officers of the corporation or another enterprise in the course of their duties, or on the advice of legal counsel for the corporation or another enterprise or on information or records given or reports made to the corporation or another enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the corporation or another enterprise. The term "another enterprise" as used in this Section 9.4 shall mean any other corporation or any partnership, joint venture, trust, employee benefit plan or other enterprise of which such person is or was serving at the request of the corporation as a director, officer, employee or agent. The provisions of this Section 9.4 shall not be deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed to have met the applicable standard of conduct set forth in Section 9.1 or 9.2 of this Article IX, as the case may be.

9.5 INDEMNIFICATION BY A COURT

Notwithstanding any contrary determination in the specific case under Section 9.3 of this Article IX, and notwithstanding the absence of any determination thereunder, any director or officer may apply to the Court of Chancery in the State of Delaware for indemnification to the extent otherwise permissible under Sections 9.1 and 9.2 of this Article IX. The basis of such indemnification by a court shall be a determination by such court that indemnification of the director or officer is proper in the circumstances because such person has met the applicable standards of conduct set forth in Section 9.1 or 9.2 of this Article IX, as the case may be. Neither a contrary determination in the specific case under Section 9.3 of this Article IX nor the absence of any determination thereunder shall be a defense to such application or create a presumption that the director or officer seeking indemnification has not met any applicable standard of conduct. Notice of any application for indemnification pursuant to this Section 9.5 shall be given to the corporation promptly upon the filing of such application. If successful, in whole or in part, the director or officer seeking indemnification shall also be entitled to be paid the expense of prosecuting such application.

9.6 EXPENSES PAYABLE IN ADVANCE

To the fullest extent not prohibited by the DGCL, or by any other applicable law, expenses incurred by a person who is or was a director or officer in defending any civil, criminal, administrative or investigative action, suit or proceeding shall be paid by the corporation in advance of the final disposition of such action, suit or proceeding; provided, however, that if the DGCL requires, an advance of expenses incurred by any person in his or her capacity as a director or officer (and not in any other capacity) shall be made only upon receipt of an undertaking by or on behalf of such person to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized in this Article IX.

9.7 NONEXCLUSIVITY OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES

The indemnification and advancement of expenses provided by or granted pursuant to this Article IX shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the Certificate, any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person's official capacity and as to action in another capacity while holding such office, it being the policy of the corporation that indemnification of the persons specified in Sections 9.1 and 9.2 of this Article IX shall be made to the fullest extent permitted by law. The provisions of this Article IX shall not be deemed to preclude the indemnification of any person who is not specified in Section 9.1 or 9.2 of this Article IX but whom the corporation has the power or obligation to indemnify under the provisions of the DGCL, or otherwise. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law.

9.8 INSURANCE

To the fullest extent permitted by the DGCL or any other applicable law, the corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was a director, officer, employee or agent of the corporation serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the corporation would have the power or the obligation to indemnify such person against such liability under the provisions of this Article IX.

9.9 CERTAIN DEFINITIONS

For purposes of this Article IX, references to "the corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors or officers, so that any person who is or was a director or officer of such constituent corporation, or is or was a director or officer of such constituent corporation serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, shall stand in the same position under the provisions of this Article IX with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued. For purposes of this Article IX, references to "fines" shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to "serving at the request of the corporation" shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director or officer with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the corporation" as referred to in this Article IX.

9.10 SURVIVAL OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES

The rights to indemnification and advancement of expenses conferred by this Article IX shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors, administrators and other personal and legal representatives of such a person.

9.11 LIMITATION ON INDEMNIFICATION

Notwithstanding anything contained in this Article IX to the contrary, except for proceedings to enforce rights to indemnification (which shall be governed by Section 9.5 hereof), the corporation shall not be obligated to indemnify any director or officer in connection with a proceeding (or part thereof) initiated by such person unless such proceeding (or part thereof) was authorized or consented to by the board of directors of the corporation.

9.12 INDEMNIFICATION OF EMPLOYEES AND AGENTS

The corporation may, to the extent authorized from time to time by the board of directors, provide rights to indemnification and to the advancement of expenses to employees and agents of the corporation similar to those conferred in this Article IX to directors and officers of the corporation.

9.13 EFFECT OF AMENDMENT OR REPEAL

Neither any amendment or repeal of any Section of this Article IX, nor the adoption of any provision of the Certificate or the bylaws inconsistent with this Article IX, shall adversely affect any right or protection of any director, officer, employee or other agent established pursuant to this Article IX existing at the time of such amendment, repeal or adoption of an inconsistent provision, including without limitation by eliminating or reducing the effect of this Article IX, for or in respect of any act, omission or other matter occurring, or any action or proceeding accruing or arising (or that, but for this Article IX, would accrue or arise), prior to such amendment, repeal or adoption of an inconsistent provision.

**Article X** **<br> FORUM FOR ADJUDICATION OF DISPUTES**

Unless the Corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation's stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Certificate of Incorporation or Bylaws (as either may be amended from time to time), or (iv) any action asserting a claim governed by the internal affairs doctrine shall be the Court of Chancery in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware).

If any action the subject matter of which is within the scope of the preceding sentence is filed in a court other than a court located within the State of Delaware (a "Foreign Action") in the name of any stockholder, such stockholder shall be deemed to have consented to (i) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the preceding sentence and (ii) having service of process made upon such stockholder in any such action by service upon such stockholder's counsel in the Foreign Action as agent for such stockholder.

**Article XI** **<br> MISCELLANEOUS**

11.1 PROVISIONS OF CERTIFICATE GOVERN

In the event of any inconsistency between the terms of these bylaws and the Certificate, the terms of the Certificate will govern.

11.2 AMENDMENT

The bylaws of the corporation may be adopted, amended or repealed by the corporation's Board. The fact that such power has been so conferred upon the Board shall not divest the stockholders of the power, nor limit their power to adopt, amend or repeal bylaws.

[Remainder of Page Intentionally Left Blank]

**TRANQUIL HEALTHCARE, Inc.** 

**a Delaware corporation**

**CERTIFICATE OF ADOPTION OF BYLAWS**

The undersigned hereby certifies that he or she is the duly elected, qualified, and acting Chief Financial Officer of Tranquil Healthcare, Inc., a Delaware corporation and that the foregoing bylaws, comprising twenty-two (22) pages, were adopted as the corporation's bylaws on October 28, 2025 by the corporation's board of directors as provided for in the corporations certificate of incorporation filed with the Delaware secretary of state.

IN WITNESS WHEREOF, the undersigned has hereunto set his or her hand this 28<sup>th</sup> day of October, 2025.

__________________________________

Tyler Ehler

Chief Financial Officer

## Ex1A-3

**Exhibit 3.1**

THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT (1) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN AVAIALBLE EXEMPTION FROM REGISTRATION**.**

---

| | |
|:---|:---|
| **Principal Amount $**_______ | **Issuance Date:** November [\*], 2025 |

---

**<u>CONVERTIBLE PROMISSORY NOTE</u>**

**FOR VALUE RECEIVED**, **Tranquil Healthcare, Inc.**, a Delaware corporation (hereinafter called the "Borrower"), hereby promises to pay to the order of [____________] or registered assigns (the "Holder"), the sum of [___] dollars <u>($[\*])</u> ("Principal Amount") together with any interest as set forth herein, on the one (1) year anniversary of the Issuance Date (the "<u>Maturity Date</u>"). This Convertible Promissory Note ("Note") is being issued pursuant to the Note Purchase Agreement ("NPA") entered into by and among Holders, Borrower, and certain other purchasers of convertible promissory notes (collectively, the "Pari Passu Notes"). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the NPA.

**ARTICLE I**

**REPAYMENT OF NOTE / INTEREST**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Interest Rate.</u> The unpaid Principal Amount of this Note will bear simple interest at the rate of fifteen percent (15%) per annum from the Issuance Date until paid in full or converted into capital stock pursuant to the terms hereof. Upon an Event of Default (as defined below), and while such Event of Default is continuing, this Note will bear simple interest on the unpaid Principal Amount (excluding interest and Bridge Fee) at the rate of the lesser of (i) eighteen percent (18%) per annum or (ii) the highest rate under Delaware Law ("<u>Default Interest</u>"). All interest shall be computed on the basis of a 365-day year. Interest shall commence accruing on the Issuance Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <u>Bridge Fee</u>. This Note shall also contain a bridge fee equal to ten percent (10%) of the Principal Amount regardless of the date of repayment / conversion (the "Bridge Fee").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <u>Payments</u>. Subject to Holder's optional right to convert his Note pursuant to Article II, the Principal Amount, all applicable accrued interest (including any Default Interest) and the Bridge Fee (collectively the "Outstanding Amounts") which are outstanding, will be due and payable in cash on the Maturity Date, unless required to be repaid sooner under the provisions of this Note. All payments due hereunder (to the extent not converted into Borrower capital stock in accordance with Article II) shall be made in lawful money of the United States of America and to all holders of Pari Passu Notes ratably. All payments shall be made at such address as the Holder provides to Borrower pursuant to the NPA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <u>Mandatory Prepayment</u>. Upon Borrower closing on at least $3,000,000 in net proceeds from capital raising transactions (excluding debt instruments) in a transaction or series of transactions with the same terms (a "Qualified Financing"), Borrower will be required to offer to prepay all Outstanding Amounts this Note and the Pari Passu Notes ratably. Upon a Qualified Financing, Borrower must deliver a notice of prepayment to the Holder (and holders of the Pari Passu Notes) pursuant to the notice requirements under the NPA, stating: (1) that the Borrower is prepaying the Note, and (2) the date of prepayment ("Prepayment Date") which shall be not more than ten (10) days from the date of the completion of the Qualified Financing. On the Prepayment Date, Borrower shall make payment of the Prepayment Amount (as defined below) to Holder (and the holders of the Pari Passu Notes), at an account / address to be confirmed in writing by Holder

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <u>Taxes Liens</u>. This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the Holder thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <u>Unsecured</u>. This Note is an unsecured obligation of Borrower, but shall rank senior in right of payment to all other unsecured indebtedness of the Borrower and will rank pari passu with any other future debt instrument having similar terms to this Note.

**ARTICLE II**

**CONVERSION RIGHTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Conversion</u>. At any time, the Holder shall have the right to convert all or any part of the Outstanding Amounts into fully paid and non-assessable shares of the Company's Series A Preferred Stock, when designated ("Preferred Stock") at a conversion price equal to the price of the Preferred Stock being offered in the Borrower's anticipated Regulation A offering (the "<u>Conversion Price</u>"). If no Preferred Stock has been designated or authorized by the Company, then the Note may only be repaid in cash and not converted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Method of Conversion</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Mechanics of Conversion</u>. As set forth in Section 2.1 hereof, the Outstanding Amounts may be converted by the Borrower by submitting a notice of conversion ("Notice of Conversion"), in the form attached hereto as **<u>Exhibit A</u>** (by facsimile or e-mail at any time).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Surrender of Note Upon a Discretionary or Conversion</u>. Upon conversion of the entire Outstanding Amount, the Holder shall be required to physically surrender this Note to the Borrower. The Holder and the Borrower shall maintain records showing the amounts so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion to the extent any Outstanding Amounts remain outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Delivery of Preferred Stock Upon Conversion</u>. Upon delivery by the Borrower of a Notice of Conversion as provided for in this Section 2.2, the Borrower shall issue and deliver or cause to be issued and delivered to the Holder the Preferred Stock electronically held for the Holder at the Borrower's transfer agent or its internal company records if no transfer agent has been retained. The Preferred Stock will be issued after receipt of the Notice of Conversion (and, solely in the case of conversion of the entire Outstanding Amount, surrender of this Note). Subject to Section 2.1, upon receipt of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Preferred Stock issuable upon such conversion, the outstanding Principal Amount and the amount of accrued and unpaid interest and Bridge Fee on this Note shall be reduced to reflect such conversion (to the extent not fully converted), and all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Preferred Stock Restrictions</u>. If this Note is converted, pursuant to this Article II, the Preferred Stock issuable upon conversion of this Note may not be sold or transferred except pursuant to applicable law, the certificate of designation of the Preferred Stock and Articles of Incorporation of Borrower, as amended (when filed and approved by the Wyoming Secretary of State, as applicable).

**ARTICLE III**

**EVENTS OF DEFAULT**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Events of Default</u>. Each of the following will constitute an event of default under this Note (each, an "Event of Default"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Failure to Pay the Outstanding Balance</u>. The Borrower fails to pay the principal, interest and any applicable costs and fees when due on this Note, whether on the Maturity Date or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Conversion and the Preferred Stock</u>. The Borrower fails to issue the Preferred Stock to the Holder pursuant to a conversion under Article II of this Note or announces or threatens in writing that it will not honor its obligation to do so upon exercise by the Holder of its conversion rights in accordance with the terms of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Breach of Covenants</u>. The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the NPA and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Breach of Representations and Warranties</u>. Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the NPA), shall be false in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Receiver or Trustee</u>. The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Bankruptcy</u>. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Liquidation</u>. Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

Upon the occurrence and during the continuation of any Event of Default and upon delivery of a written notice of default (a "Notice of Default") to the Borrower, and after providing a ten (10) business day opportunity to cure said Event of Default, the Note shall become immediately due and payable and the Borrower shall pay to the Holder, in full satisfaction of its obligations hereunder, an amount equal to the Outstanding Amounts. All such amounts shall immediately become due and payable, together with all costs, including, without limitation, legal fees and expenses, of collection.

**ARTICLE IV**

MISCELLANEOUS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Failure or Indulgence Not Waiver</u>. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>Notices</u>. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, e-mail or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

If to the Borrower, to:

Tranquil Healthcare, Inc.

18200 Von Karmen, Suite 850

Irvine, CA 92612

Attn: Tyler Ehler

Email: tyler@tranquil.healthcare

If to the Holder: Any notice to the Holder may be given by such means to the Holder at the address provided by the Holder pursuant to the NPA. Any Party may change the address to which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other party notice in the manner herein set forth

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <u>Amendments</u>. This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower a majority of the outstanding Principal Amount of all Pari Passu Notes, except that no Holder may be treated differently from other Holders pursuant to such amendment or waiver.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <u>Assignability</u>. This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an "accredited investor" (as defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <u>Cost of Collection</u>. If default is made in the payment of this Note, the Borrower shall pay the Holder hereof reasonable costs of collection, including reasonable attorneys' fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <u>Governing Law</u>. This Note shall be governed by and construed in accordance with the laws of the State of Delaware without regard to principles of conflicts of laws. The prevailing Party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each Party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such Party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

\*SIGNATURE PAGE TO FOLLOW\*

IN WITNESS WHEREOF, the Borrower has caused this Note to be signed in its name by its duly authorized officer.

**Tranquil Holdings, Inc.**

By: ______________________________

Tyler Ehler

Chief Executive Officer

Date: [_]

**Accepted and Agreed:**

**HOLDER**

**[________].**

By: ______________________________

Name: _____________

Date: [_]

 **EXHIBIT A -- NOTICE OF CONVERSION**

(To be sent in at time of conversion only)

The undersigned hereby elects to convert $_________________ of principal, interest, and the Bridge Fee (as defined in the Note) of the Convertible Promissory Note ("Note") into that number of Series A Preferred Stock to be issued pursuant to the conversion of the Note as set forth below, of Tranquil Holdings, Inc., a Delaware corporation (the "Borrower") according to the conditions of the Note on the following date: __________________.

The Borrower shall issue the number of shares of Series A Preferred Stock as set forth below with the transfer agent or at a custodian at the choice of the Holder in the name(s) specified immediately below (the "Holder") or, if additional space is necessary, on an attachment hereto:

HOLDER _______________________________ Phone __________________________________ <br> Address ________________________________ Email __________________________________ <br> _______________________________________ SSN/TIN _______________________________

Signature ____________________________

Date ________________________________

Dollar Amount to be Converted: $___________________

Conversion Price: ________________

Number of shares of Series A Preferred Stock to be issued: ___________

## Ex1A-3

**Exhibit 3.2**

**TRANQUIL HEALTHCARE, INC.**

**NOTE PURCHASE AGREEMENT**

This **NOTE PURCHASE AGREEMENT** (the "Agreement"), is made and entered into as of the respective date set forth opposite the name of the respective Purchaser (as hereinafter defined) on **Schedule A** attached hereto, by and among **TRANQUIL HEALTHCARE, INC.**, a Delaware corporation, with its address at 18200 Von Karmen, Suite 850, Irvine, CA 92612 (the "Borrower"), and T7X Assets, Inc, (the "Purchaser"). Capitalized terms not otherwise defined herein, shall have the meaning ascribed to them in the Note (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. **WHEREAS**, the Borrower and each Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "1933 Act"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. **WHEREAS**, each Purchaser desires to purchase and the Borrower desires to issue and sell, upon the terms and conditions set forth in this Agreement, convertible notes of the Borrower, in the form attached hereto as **Exhibit A**, in the principal amount set forth below such Purchaser's name on the signature page hereto (the "Note(s)"), convertible into shares of the Borrower's Series A Preferred Stock ("Series A Preferred Stock") (subject first to the requirements that (i) the Series A Preferred Stock is designated in the Certificate of Incorporation of Borrower and (ii) the first sale of Series A Preferred Stock occurs pursuant to a Regulation A Offering under the 1933 Act by Borrower (the "Series A Conditions"), upon the terms and subject to the limitations and conditions set forth in such Note.

**NOW THEREFORE**, the Borrower and each Purchaser severally (and not jointly) hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Purchase and Sale of Note.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>The Note and Approval</u>. On November 5, 2025, the Board of Directors of the Borrower ("Board") authorized the offer, sale and issuance of Notes in an aggregate principal amount of up to One Million Dollars ($1,000,000) ("Maximum Purchase Amount").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>The Closing</u>. The Borrower agrees to issue and sell to each Purchaser, and each Purchaser agrees to purchase the Note in the principal amount set forth on the signature page to this Agreement (the "Subscription Amount"). The purchase and sale shall take place on the date set forth on the signature page to this Agreement at a closing (each, a "Closing" and such date, the "Closing Date")) to be held at the offices of Silvestre Law Group at 2629 Townsgate Road #215, Westlake Village, CA 91361, at 12:00 p.m., Pacific time, or at such other time or place as may be mutually agreed upon by the Borrower and the Purchaser(s). Each Purchaser acknowledges that the Borrower may issue and sell Notes at one or more additional closings for a period of ninety (90) days after the date of the initial Closing, provided that the aggregate principal amount of all Notes sold at all Closings does not exceed the Maximum Purchase Amount. At Closing, Purchaser will deliver to the Borrower as payment in full for the Note to be purchased by Purchaser at the Closing, its Subscription Amount by one or more of the following: (i) wire transfer of funds to the Borrower per the wiring instructions attached hereto as **Schedule B** or (ii) exchange of outstanding indebtedness owed by the Borrower to such Purchaser, or (iii) a combination of (i) and (ii). At each Closing, the Borrower will issue and deliver to each Purchaser participating in such Closing, a duly executed Note in the principal amount of such Purchaser's Subscription Amount. The Borrower shall send such Note to the Purchaser at the address furnished to the Borrower for that purpose. The parties agree that the delivery of this Agreement and any other documents at the Closing may be effected by means of an exchange of signatures (including via email or facsimile of .pdf signatures).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Common Stock Incentive</u>. In addition to the Note, each Purchaser shall receive, as an equity incentive, 8,000 shares of the Company's Common Stock, par value $0.001 per share, for each $100,000 of Subscription Amount purchased under this Agreement, with the number of shares issuable for any lesser or greater Subscription Amounts to be calculated on a pro rata basis. The shares of common stock issuable hereunder will contain the Company's standard restricted legend.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Purchaser's Representations and Warranties.</u> Each Purchaser represents and warrants to the Borrower that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Investment Purpose</u>. As of the date hereof, the Purchaser is purchasing the Note and upon conversion of such Note, the shares of Series A Preferred Stock issuable thereunder (subject to the completion of the Series A Conditions); such shares of Series A Preferred Stock being collectively referred to herein as the "Conversion Shares" and, collectively with the Note and the shares of common stock issuable hereunder, the "Securities") for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Accredited Investor Status</u>. The Purchaser is an "accredited investor" as that term is defined in Rule 501(a) of Regulation D under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Reliance on Exemptions</u>. The Purchaser understands that the Securities have not been registered under the 1933 Act and are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Borrower is relying upon the truth and accuracy of, and the Purchaser's compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. <u>Information; Acknowledgement</u>. Purchaser has sufficient knowledge and experience in investing in companies similar to the Borrower in terms of the Borrower's stage of development so as to be able to evaluate the risks and merits of its investment in the Borrower and it is able to financially bear the risks thereof. Purchaser has made an investigation of the Borrower and its business as it deemed necessary and has had an opportunity to discuss and review the Borrower's business, management, and financial affairs as it deems necessary and had conducted due diligence on the Borrower and the Securities to the extent Purchaser deemed necessary and sufficient. Purchaser acknowledges and agrees that the Borrower: (i) is an early-stage company, (ii) has limited assets and cash reserves, and (iii) has incurred net losses to date. Additionally, Purchaser acknowledges that the Borrower is depending upon, among many other matters, (x) raising substantial additional funding to accomplish the Borrower's business strategy, even upon the successful issuance and sale of Notes; and (y) the Borrower may not be able to accomplish any of the foregoing or benefit from its business strategy, which could increase the Borrower's financing costs, dilute Purchaser's investment interests (in the event the Notes are converted into the Conversion Shares), affect the Borrower's business operations and/or force the Borrower to delay, reduce or abandon its business strategy or cease operations, in which case, the Note may be in default. Purchaser further acknowledges that the Conversion Shares will only be issuable in the event that the Borrower is able to complete the Series A Conditions, which may or may not occur.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. <u>Legends</u>. The Purchaser understands that the certificates evidencing the Securities shall bear a restrictive legend in substantially the following form:

"THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, PLEDGED, OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT (1) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN AVAIALBLE EXEMPTION FROM REGISTRATION."

The legend set forth above shall be removed and the Borrower shall, or shall cause its transfer agent to, issue a book-entry statement, or other digital confirmation (as authorized by the Borrower's Bylaws) without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act, or (b) such holder provides the Borrower with an opinion of counsel, reasonably satisfactory to the Borrower and its transfer agent (if applicable) that a public sale or transfer of such Security may be made without registration under the 1933 Act. The Purchaser agrees to sell all Securities, including those represented without legend, in compliance with applicable prospectus delivery requirements, to the extent applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. <u>Authorization; Enforcement</u>. Purchaser has full power and authority to enter into and perform this Agreement in accordance with its terms, and it was not organized for the specific purpose of acquiring the Note, and any securities issuable upon conversion of the Note. This Agreement has been duly executed and delivered on behalf of the Purchaser, and this Agreement constitutes a valid and binding agreement of the Purchaser enforceable in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Representations and Warranties of the Borrower</u>. The Borrower represents and warrants to the Purchaser that as of the date of each applicable Closing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Organization and Qualification</u>. The Borrower and each of its Subsidiaries (as defined below), if any, is a corporation or other entity, duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated or organized, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted. "Subsidiaries" means any corporation or other organization, whether incorporated or unincorporated, in which the Borrower owns, directly or indirectly, any equity or other ownership interest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Authorization; Enforcement</u>. (i) The Borrower has all requisite corporate power and authority to enter into and perform this Agreement, the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Borrower and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Board and no further consent or authorization of the Borrower, its Board, or its shareholders is required except for approvals required and related to the Series A Conditions, (iii) this Agreement has been duly executed and delivered by the Borrower by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the Borrower accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Borrower of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Capitalization</u>. As of November 1, 2025, the authorized common stock of the Borrower consists of (i) 2,000,000 authorized shares of common stock, par value $0.001 per share ("Common Stock") and (ii) 10,000,000 shares of preferred stock, par value $0.001 per share ("Preferred Stock"). As of November 1, 2025, the Borrower has (i) 825,000 shares of Common Stock issued and outstanding, (ii) no shares of Preferred Stock outstanding. All of such outstanding shares of capital stock are, or upon issuance, will be, duly authorized, validly issued, fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. <u>Issuance of Shares</u>. The Conversion Shares, upon completion of the Series A Conditions, will be duly authorized and, upon conversion of the Note in accordance with its respective terms, will be validly issued, fully paid and non- assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. <u>No Conflicts</u>. The execution, delivery and performance of this Agreement, the Note by the Borrower and the consummation by the Borrower of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Conversion Shares subject to the completion of the Series A Conditions) will not (i) conflict with or result in a violation of any provision of the Borrower's Certificate of Incorporation, as amended or Bylaws, as amended or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Borrower or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Borrower or its securities are subject) applicable to the Borrower or any of its Subsidiaries or by which any property or asset of the Borrower or any of its Subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect). The Borrower and its Subsidiaries, are conducting their business in violation of any law, ordinance or regulation of any governmental entity, except where such violation will not result in a Material Adverse Effect. "Material Adverse Effect" means any material adverse effect on (i) the business, operations, assets, or financial condition of the Borrower or its Subsidiaries, if any, taken as a whole, or (ii) the transactions contemplated by this Agreement or the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. <u>Absence of Litigation</u>. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Borrower or any of its Subsidiaries, threatened against or affecting the Borrower or any of its Subsidiaries, or their officers or directors in their capacity as such, that could have a Material Adverse Effect. The Borrower and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. <u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers' representations and warranties set forth in Section 2, neither the Borrower, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offering of the Securities to be integrated with prior offerings by the Borrower for purposes of (i) the 1933 Act that would require the registration of the Securities under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. <u>Breach of Representations and Warranties by the Borrower</u>. If the Borrower breaches any of the representations or warranties set forth in this Section 3, and such breach(es) are not cured within fifteen (15) days of the receipt of notice of such breach from Purchaser, then in addition to any other remedies available to the Purchaser pursuant to this Agreement, such breach(es) will be considered an Event of Default under Section 3.1 of the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Conditions to the Borrower's Obligation to Sell</u>. The obligation of the Borrower hereunder to issue and sell the Note to the Purchaser at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions thereto, provided that these conditions are for the Borrower's sole benefit and may be waived by the Borrower at any time in its sole discretion:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The Purchaser shall have executed this Agreement and delivered the same to the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The Purchaser shall have delivered the Subscription Amount in accordance with Section 1(b) above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The representations and warranties of the Purchaser shall be true and correct in all material respects as of the Closing Date (except for representations and warranties that speak as of a specific date), and the Purchaser shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Conditions to The Purchaser's Obligation to Purchase</u>. The obligation of the Purchaser hereunder to purchase the Note at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that these conditions are for the Purchaser's sole benefit and may be waived by the Purchaser at any time in its sole discretion:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The Borrower shall have executed this Agreement and delivered the samet o the Purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The Borrower shall have delivered to the Purchaser the duly executed Note (in such denominations as the Purchaser shall request) in accordance with Section 1(b) above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The representations and warranties of the Borrower shall be true and correct in all material respects as of the Closing Date (except for representations and warranties that speak as of a specific date) and the Borrower shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Borrower at or prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Governing Law; Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Governing Law</u>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to principles of conflicts of laws. The Borrower and each Purchaser waive trial by jury. The prevailing Party shall be entitled to recover from the other Party its reasonable attorney's fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each Party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement, the Note or any related document or agreement by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such Party at the address in effect for notices to it under this Agreement (Section 6(f)) and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Counterparts</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each Party and delivered to the other Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Headings</u>. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. <u>Severability</u>. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. <u>Entire Agreement; Amendments</u>. This Agreement, the Note, and the instruments referenced herein contain the entire understanding of the Parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Borrower nor such Purchaser makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by a majority of the then outstanding principal amounts under the Notes sold in all applicable Closings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. <u>Notices</u>. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile or electronic mail (email), addressed as set forth in the signature pages below or to such other address as such Party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile or email, with accurate confirmation generated by the transmitting facsimile machine or confirmation being sent via email, at the address, email address, or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be as set forth in the heading of this Agreement. Each Party shall provide notice to the other Party of any change in address.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. <u>Survival</u>. The representations and warranties of the Borrower and the agreements and covenants set forth in this Agreement shall survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Further Assurances</u>. Each Party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j. <u>No Strict Construction</u>. The language used in this Agreement will be deemed to be the language chosen by the Parties to express their mutual intent, and no rules of strict construction will be applied against any Party.

IN WITNESS WHEREOF, the undersigned Purchaser and the Borrower have caused this Agreement to be duly executed.

**TRANQUIL HEALTHCARE, INC.**

By: ______________________________

Name: Tyler Ehler

Title: Chief Executive Officer

Date: ____________________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Date funds cleared and accepted)

---

| |
|:---|
| **PURCHASER:** <br>**[_________]** |
| <br> Signature: |
| Name: |
| Address: |
| Phone: |
| Email: |
| SSN or TIN: |
| Date: |

---

Exact name securities should be issued to, if different from above: ______________________

Subscription Amount of Note: $_______________

**Exhibit A**

**Form of Convertible Note**

**SCHEDULE B**

**Wiring Instructions**

## Ex1A-3

**Exhibit 3.3**

**Tranquil Healthcare HOLDINGS, Inc.**

March 3, 2026

Tyler Ehler<br> Long Island City, NY

Re: **<u>EMPLOYMENT AGREEMENT</u>**

Dear Tyler Ehler:

On behalf of Tranquil Healthcare Holdings, Inc., a Delaware corporation (the "<u>Company</u>"), I am pleased to offer you the position of Chief Executive Officer, Chief Financial Officer, President, and Secretary of the Company. Your employment by the Company shall be governed by the following terms and conditions (this "<u>Agreement</u>"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **<u>Duties and Scope of Employment</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Position</u>.** For the term of your employment under this Agreement (your "<u>Employment</u>"), the Company agrees to employ you in the position of Chief Executive Officer, Chief Financial Officer, President, and Secretary. You will report to the Company's Board of Directors. You will be working virtually out of any place of your choosing. You will perform the duties and have the responsibilities and authority customarily performed and held by an employee in your position or as otherwise may be assigned or delegated to you by the Company's Board of Directors, including but not limited to overseeing and performing functions with respect to the Company's management agreement (the "<u>Management Agreement</u>") entered into with Tranquil Healthcare Fund I, LLC ("<u>Tranquil Fund</u>"), the Company's subsidiary, which shall include fund raising, investor relations, overseeing the Company's investments, and overseeing all reporting requirements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Obligations to the Company</u>.** During your Employment, you shall devote whatever efforts and time is required to fulfill your duties to the Company. It is anticipated that such time requirements will generally not be full time but on occasion might require your full time and attention. During your Employment, without the prior written approval of the Company's Board of Directors, which approval shall not be unreasonably withheld, you shall not render services in any capacity to any other person or entity and shall not act as a sole proprietor or partner of any other person or entity or own more than five percent of the stock of any director competitor of the Company. Notwithstanding the foregoing, you may serve on corporate, civic or charitable boards or committees, deliver lectures, fulfill speaking engagements, teach at educational institutions, or manage personal investments without such advance written consent, provided that such activities do not individually or in the aggregate interfere with the performance of your duties under this Agreement. You shall comply with the Company's policies and rules, as they may be in effect from time to time during your Employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **<u>No Conflicting Obligations</u>.** You represent and warrant to the Company that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations under this Agreement. In connection with your Employment, you shall not use or disclose any trade secrets or other proprietary information or intellectual property in which you or any other person has any right, title or interest and your Employment will not infringe or violate the rights of any other person. You represent and warrant to the Company that you have returned all property and confidential information belonging to any prior employer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **<u>Commencement Date</u>.** You shall commence Employment as of March 1, 2026 (the "<u>Start Date</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **<u>Cash and Incentive Compensation</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Salary</u>.** Beginning on the Start Date, the Company shall pay you as compensation for your services an initial base salary at a gross annual rate of $120,000. Such salary shall be payable in accordance with the Company's standard payroll procedures. The annual compensation specified in this subsection (a), together with any modifications in such compensation that the Company may make from time to time, is referred to in this Agreement as "<u>Base Salary</u>." The Board or any Compensation Committee of the Board shall review your Base Salary at least annually. Effective as of the date of any change to your Base Salary, the Base Salary as so changed shall be considered the new Base Salary for all purposes of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Payment Upon Sale of Clinics</u>**. As described in the Management Agreement, in the event that Tranquil Fund's clinics that it performs services for are sold and such sales result in a bonus payment to the Company, the Company will distribute such bonus payments to you ("<u>Bonus Clinic Payment</u>"). You agree that at the time the Bonus Clinic Payment is earned, if the Board has (i) one (1) independent director, such director will receive 17.5% of the Bonus Clinic Payment and if (ii) two (2) independent directors, or more, such directors will receive 35% of the Bonus Clinic Payments. You may distribute any additional amounts under the Bonus Clinic Payments to the Company's employees and consultants in your sole reasonable discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **<u>Discretionary Bonus</u>** The Board has the right to award you a discretionary bonus at any time that as determined by the Board (a "<u>Bonus</u>"). A Bonus may be based on, but not limited to, your performance, the qualification of a Form 1-A for Tranquil Fund, and other factors reasonably determined by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **<u>Vacation/PTO and Employee Benefits</u>.** During your Employment, you shall be eligible to accrue up to 20 days of paid vacation / paid time off, pro-rated for the remainder of any year, in accordance with the Company's vacation / paid time off policy, as it may be amended from time to time. During your Employment, you shall be eligible to participate in the employee benefit plans maintained by the Company and generally available to similarly situated employees of the Company, subject in each case to the generally applicable terms and conditions of the plan in question and to the determinations of any person or committee administering such plan. It is anticipated that the Company will not be offering any health insurance coverage to its employees unless required to do so by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **<u>Business Expenses</u>.** The Company will reimburse you for your necessary and reasonable business expenses incurred in connection with your duties hereunder upon presentation of an itemized account and appropriate supporting documentation, all in accordance with the Company's generally applicable policies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **<u>Termination</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Employment at Will</u>.** Your Employment shall be "at will," meaning that either you or the Company shall be entitled to terminate your Employment at any time and for any reason, with or without Cause. Any contrary representations that may have been made to you shall be superseded by this Agreement. This Agreement shall constitute the full and complete agreement between you and the Company on the "at-will" nature of your employment, which may only be changed in an express written agreement signed by you and a duly authorized officer or member of the Board of the Company. In the event that this Agreement is terminated for any reason, by you or the Company, you agree that you will immediately resign from the Board of Directors, to the extent you are serving on the Board of Directors at the time of termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Rights Upon Termination</u>.** Except as expressly provided in Section 6, upon the termination of your Employment, you shall only be entitled to the Accrued Obligations. As used herein "<u>Accrued Obligations</u>" means (i) the portion of your Base Salary that has accrued prior to any termination of your employment with the Company and has not yet been paid; (ii) to the extent required by law and the Company's policies, an amount equal to the value of your accrued but unused paid time off days; (iii) the amount of any expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed; (iv) any applicable Bonus previously awarded, but not paid and if the termination is not for "Cause". For clarity, upon your termination for Cause, you will not be eligible to receive any Bonus Clinic Payment if occurring after your termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **<u>Termination Benefits</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>General Release</u>.** Any other provision of this Agreement notwithstanding, subsection (b) below shall not apply unless and until (i) you have executed (and do not revoke) a full and complete general release of all claims in a form provided by the Company without alteration and (ii) you have returned all Company property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Severance Pay</u>.** If, during the term of this Agreement, the Company terminates your Employment for any reason other than Cause, death or Permanent Disability, then, in addition to the Accrued Obligations, the Company shall pay you severance pay at a rate equal to your Base Salary in effect at the time of termination of your Employment for a period of 3 months following the termination of your Employment (the "<u>Continuation Period</u>"). Such severance pay shall be paid in accordance with the Company's standard payroll procedures on the Company's payroll dates and shall be subject to all applicable withholdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **<u>Definition of "Cause</u>."** For all purposes under this Agreement, "<u>Cause</u>" shall mean:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any breach by you of this Agreement, the Confidential Information and Invention Assignment Agreement (as defined below) between you and the Company, or any other written agreement between you and the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any failure by you to comply with the Company's written policies or rules, as they may be in effect from time to time during your Employment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Your repeated failure to follow reasonable and lawful instructions from the Company's Board of Directors and your failure to cure such condition after receiving 20 days advance written notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Commission, conviction of, or a plea of "guilty" or "no contest" to, a felony under the laws of the United States or any State by you;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Your misappropriation of funds or property of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Neglect of your duties; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Any gross negligence or willful misconduct by you.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **<u>Definition of "Permanent Disability</u>."** For all purposes under this Agreement, "<u>Permanent Disability</u>" shall mean your inability to perform the essential functions of your position with or without reasonable accommodation for a period of 120 consecutive days because of your physical or mental impairment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **<u>Non-Solicitation</u>.** During the period commencing on the date of this Agreement and continuing until the first year anniversary of the date when your Employment terminated for any reason, you shall not directly or indirectly, personally or through others, solicit or attempt to solicit (on your own behalf or on behalf of any other person or entity) either (i) any employee or any consultant of the Company or any of the Company's affiliates or (ii) the business of any customer of the Company or any of the Company's affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **<u>Pre-Employment Conditions</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Confidentiality Agreement</u>.** Your acceptance of this offer and commencement of employment with the Company is contingent upon the execution, and delivery to the counsel of the Company, of the Company's Confidential Information and Invention Assignment Agreement, a copy of which is enclosed for your review and execution (the "<u>Confidentiality Agreement</u>"), prior to or on your Start Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Right to Work</u>.** For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your Start Date, or our employment relationship with you may be terminated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **<u>Successors</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Company's Successors</u>.** This Agreement shall be binding upon any successor (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company's business and/or assets. For all purposes under this Agreement, the term "<u>Company</u>" shall include any successor to the Company's business or assets that becomes bound by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Your Successors</u>.** This Agreement and all of your rights hereunder shall inure to the benefit of, and be enforceable by, your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **<u>Miscellaneous Provisions</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **<u>Indemnification</u>.** The Company shall indemnify you to the maximum extent permitted by applicable law and the Company's Bylaws with respect to your service and you shall also be covered under a directors and officers liability insurance policy paid for by the Company to the extent that the Company maintains such a liability insurance policy now or in the future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **<u>Notice</u>.** Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In your case, mailed notices shall be addressed to you at the home address that you most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **<u>Modifications and Waivers</u>.** No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by you and by an authorized officer of the Company (other than you). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **<u>Whole Agreement</u>.** No other agreements, representations or understandings (whether oral or written and whether express or implied) which are not expressly set forth in this Agreement have been made or entered into by either party with respect to the subject matter hereof. This Agreement and the Confidentiality Agreement contain the entire understanding of the parties with respect to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) **<u>Withholding Taxes</u>.** All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be withheld by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) **<u>Choice of Law and Severability</u>.** This Agreement shall be interpreted in accordance with the laws of the State of Delaware without giving effect to provisions governing the choice of law. If any provision of this Agreement becomes or is deemed invalid, illegal or unenforceable in any applicable jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the minimum extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision shall be stricken and the remainder of this Agreement shall continue in full force and effect. If any provision of this Agreement is rendered illegal by any present or future statute, law, ordinance or regulation (collectively, the "<u>Law</u>") then that provision shall be curtailed or limited only to the minimum extent necessary to bring the provision into compliance with the Law. All the other terms and provisions of this Agreement shall continue in full force and effect without impairment or limitation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) **<u>No Assignment</u>.** This Agreement and all of your rights and obligations hereunder are personal to you and may not be transferred or assigned by you at any time. The Company may assign its rights under this Agreement to any entity that assumes the Company's obligations hereunder in connection with any sale or transfer of all or a substantial portion of the Company's assets to such entity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) **<u>Counterparts</u>.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

*[Signature Page Follows]*

To indicate your acceptance of the Company's offer, please sign and date this letter in the space provided below and return it to me, along with a signed and dated original copy of the Confidentiality Agreement

Very truly yours,

Tranquil Healthcare HOLDINGS, Inc.

By: ___________________________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Signature)

Name: <u>Jeff Campbell</u> 

Title: <u>Director</u> 

ACCEPTED AND AGREED:

Tyler Ehler

________________________________________

<br> (Signature)

________________________________________

<br> Date

Attachment A: Confidential Information and Invention Assignment Agreement

**<u>ATTACHMENT A</u>**

**CONFIDENTIAL INFORMATION AND<br> INVENTION ASSIGNMENT AGREEMENT**

*(See Attached)*

## Ex1A-4

**Exhibit 4.1**

**FORM OF SUBSCRIPTION AGREEMENT**

**SUBSCRIPTION AGREEMENT**

**TRANQUIL HEALTHCARE FUND I, LLC**

*A DELAWARE LIMITED LIABILITY COMPANY*

This is a Subscription for

Class A Preferred Shares

of

Tranquil Healthcare Fund I, LLC ("***Tranquil***")

**THIS SUBSCRIPTION AGREEMENT** (this "***Agreement***" or this "***Subscription***") is made and entered into as of [**\*]**, by and between the undersigned (the "***Subscriber***", "***Investor***", or "***you***") and **Tranquil Healthcare Fund I, LLC**, a Delaware limited liability company ("***Tranquil***" or "***we***" or "***us***" or "***our***"), with reference to the facts set forth below.

WHEREAS, subject to the terms and conditions of this Agreement, the Subscriber wishes to irrevocably subscribe for and purchase (subject to acceptance of such subscription by Tranquil) certain Class A Preferred Shares and provided that Investor purchases $100,000 or more of Class A Preferred Shares in one closing, he or she will receive incentive shares equal to 10% of the Preferred Shares purchased ("***Preferred Shares"),***"), as set forth in Section 1 and on the signature page hereto, offered pursuant to the most recent Offering Circular of Tranquil (the "***Offering Circular***") qualified by the Securities and Exchange Commission (the "***SEC***").

NOW, THEREFORE, in order to implement the foregoing and in consideration of the mutual representations, warranties, covenants and agreements contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

**NOTICE REGARDING AGREEMENT TO ARBITRATE**

ALL INVESTORS ARE REQUIRED TO ARBITRATE ANY DISPUTE ARISING OUT OF THEIR INVESTMENT IN THE COMPANY. ALL INVESTORS FURTHER AGREE THAT THE ARBITRATION WILL BE BINDING AND HELD IN THE STATE OF DELAWARE. EACH INVESTOR ALSO AGREES TO WAIVE ANY RIGHTS TO A JURY TRIAL. OUT OF STATE ARBITRATION MAY FORCE AN INVESTOR TO ACCEPT A LESS FAVORABLE SETTLEMENT FOR DISPUTES. OUT OF STATE ARBITRATION MAY ALSO COST AN INVESTOR MORE TO ARBITRATE A SETTLEMENT OF A DISPUTE.

THESE DISPUTE RESOLUTION PROVISIONS APPLY IN ANY LITIGATION RELATING TO THIS SUBSCRIPTION AGREEMENT, OUR PREFERRED SHARES OR THE COMPANY, INCLUDING CLAIMS UNDER THE U.S. FEDERAL SECURITIES LAWS.

BY AGREEING TO BE SUBJECT TO THE ARBITRATION PROVISION CONTAINED IN OUR SUBSCRIPTION AGREEMENT (WHICH IS ALSO INCLUDED IN OUR OPERATING AGREEMENT), INVESTORS WILL NOT BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

**NOTICE REGARDING WAIVER** 

**OF** 

**SECTION 18-305 OF THE DELAWARE LIMITED LIABILITY COMPANY ACT**

BY AGREEING TO BE SUBJECT TO THE WAIVER PROVISIONS CONTAINED IN THIS AGREEMENT, INVESTORS WILL NOT BE DEEMED TO WAIVE TRANQUIL'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

1. <u>Subscription for and Purchase of the Preferred Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 Subject to the express terms and conditions of this Agreement, the Subscriber hereby irrevocably subscribes for and agrees to purchase the Preferred Shares in the amount of the purchase price (the "***Purchase Price***") set forth on the signature page to this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 Unless waived by Tranquil Healthcare Holdings, Inc., a Delaware corporation, Tranquil's manager (our "***Manager***"), the Subscriber must initially purchase at least $1,000 worth of Preferred Shares in this offering. There are no minimum subscription requirements when subscribing for additional Preferred Shares once the Subscriber has purchased the requisite minimum of $1,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 The offering of Preferred Shares is described in the Offering Circular, that is available through the online website platform <u>www.tranquil.healthcare</u> (the "***Site***"), as well as on the SEC's EDGAR website. Please read this Agreement, the Offering Circular, and Tranquil's Operating Agreement (the "***Operating Agreement***"). While they are subject to change, as described below, Tranquil advises you to print and retain a copy of these documents for your records. By signing electronically below, you agree to the following terms together with the Site's Terms and Conditions and Terms of Service and agree to transact business with us and to receive communications relating to the Preferred Shares electronically.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 Tranquil has the right to reject this Subscription in whole or in part for any reason. The Subscriber may not cancel, terminate or revoke this Agreement, which, in the case of an individual, shall survive his death or disability and shall be binding upon the Subscriber, his heirs, trustees, beneficiaries, executors, personal or legal administrators or representatives, successors, transferees and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 Once you make a funding commitment to purchase the Preferred Shares, it is irrevocable unless the subscription is rejected by Tranquil, or Tranquil otherwise determines not to consummate the transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 The undersigned has received and read a copy of the Operating Agreement and agrees that its execution of this Subscription Agreement constitutes its consent to such Operating Agreement, and, that upon acceptance of this Subscription Agreement by Tranquil, the undersigned will become a member of Tranquil as a holder of Preferred Shares. When this Subscription Agreement is countersigned by Tranquil, the Operating Agreement shall be binding upon the undersigned as of the settlement date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 The undersigned has carefully reviewed the arbitration notice set forth on the first page of this Agreement, Section 11 of this Agreement, and the arbitration risk factor disclosure on page [\*] of the Offering Circular. The undersigned hereby acknowledges, understands, and agrees that: (a) arbitration is final and binding on the parties; (b) the parties are waiving their right to seek remedies in court, including the right to jury trial; (c) pre-arbitration discovery is generally more limited than and potentially different in form and scope from court proceedings; (d) the Arbitration Award is not required to include factual findings or legal reasoning and any party's right to appeal or to seek modification of a ruling by the arbitrators is strictly limited; and (e) the panel of arbitrators may include a minority of persons engaged in the securities industry. Such arbitration provision limits the rights of an investor to some legal remedies and rights otherwise available.

2. <u>Purchase of the Preferred Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 The Subscriber understands that the Purchase Price is payable with the execution and submission of this Agreement, and accordingly, is submitting herewith to Tranquil the Purchase Price as agreed to by Tranquil on the Site.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 If Tranquil returns the Subscriber's Purchase Price to the Subscriber, Tranquil will not pay any interest to the Subscriber.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 If this Subscription is accepted by Tranquil, the Subscriber agrees to comply fully with the terms of this Agreement, the Preferred Shares and all other applicable documents or instruments of Tranquil, including the Operating Agreement. The Subscriber further agrees to execute any other necessary documents or instruments in connection with this Subscription and the Subscriber's purchase of the Preferred Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 In the event that this Subscription is rejected in full or the offering is terminated, payment made by the Subscriber to Tranquil for the Preferred Shares will be refunded to the Subscriber without interest and without deduction, and all of the obligations of the Subscriber hereunder shall terminate. To the extent that this Subscription is rejected in part, Tranquil shall refund to the Subscriber any payment made by the Subscriber to Tranquil with respect to the rejected portion of this Subscription without interest and without deduction, and all of the obligations of Subscriber hereunder shall remain in full force and effect except for those obligations with respect to the rejected portion of this Subscription, which shall terminate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 To the extent that the funds are not ultimately received by Tranquil or are subsequently withdrawn by the Subscriber, whether due to an ACH chargeback or otherwise, the Subscription Agreement will be considered terminated, and the Subscriber shall not be entitled to any shares subscribed for or dividends that may have accrued.

3. <u>Investment Representations and Warranties of the Subscriber</u>.

The Subscriber represents and warrants to Tranquil the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 The information that the Subscriber has furnished herein, including (without limitation) the information furnished by the Subscriber to Tranquil, upon signing up for the Site regarding whether Subscriber qualifies as (i) an "accredited investor" as that term is defined in Rule 501 under Regulation D promulgated under the Securities Act of 1933, as amended (the "***Act***") and/or (ii) a "qualified purchaser" as that term is defined in Regulation A promulgated under the Act, is correct and complete as of the date of this Agreement and will be correct and complete on the date, if any, that Tranquil accepts this subscription. Further, the Subscriber shall immediately notify Tranquil of any change in any statement made herein prior to the Subscriber's receipt of Tranquil's acceptance of this Subscription, including, without limitation, Subscriber's status as an "accredited investor" and/or "qualified purchaser". The representations and warranties made by the Subscriber may be fully relied upon by Tranquil and by any investigating party relying on them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 Reserved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 The Subscriber has the requisite power and authority to deliver this Agreement, perform his, her or its obligations set forth herein, and consummate the transactions contemplated hereby. The Subscriber has duly executed and delivered this Agreement and has obtained the necessary authorization to execute and deliver this Agreement and to perform his, her or its obligations herein and to consummate the transactions contemplated hereby. This Agreement, assuming the due execution and delivery hereof by Tranquil, is a legal, valid and binding obligation of the Subscriber enforceable against the Subscriber in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 At no time has it been expressly or implicitly represented, guaranteed or warranted to the Subscriber by Tranquil or any other person that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) A percentage of profit and/or amount or type of gain or other consideration will be realized as a result
of this investment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) That although the Preferred Shares are entitled to a cumulative preference on distribution, as described
in the Operating Agreement and Offering Circulate, such distribution may never be realized; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The past performance or experience on the part of Tranquil and/or its Manager does in any way indicate
the predictable or probable results of the ownership of the Preferred Shares or the overall Tranquil business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 The Subscriber has received this Agreement, the Offering Circular and the Operating Agreement. The Subscriber and/or the Subscriber's advisors, who are not affiliated with and not compensated directly or indirectly by Tranquil or an affiliate thereof, have such knowledge and experience in business and financial matters as will enable them to utilize the information which they have received in connection with Tranquil and its business to evaluate the merits and risks of an investment, to make an informed investment decision and to protect Subscriber's own interests in connection with the purchase of the Preferred Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 The Subscriber understands that the Preferred Shares being purchased are a speculative investment which involves a substantial degree of risk of loss of the Subscriber's entire investment in the Preferred Shares, and the Subscriber understands and is fully cognizant of the risk factors related to the purchase of the Preferred Shares. The Subscriber has read, reviewed and understood the risk factors set forth in the Offering Circular.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 The Subscriber understands that any forecasts or predictions as to Tranquil's performance are based on estimates, assumptions and forecasts that Tranquil believes to be reasonable but that may prove to be materially incorrect, and No assurance is given that actual results will correspond with the results contemplated by the various forecasts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 The Subscriber is able to bear the economic risk of this investment and, without limiting the generality of the foregoing, is able to hold this investment for an indefinite period of time. The Subscriber has adequate means to provide for the Subscriber's current needs and personal contingencies and has a sufficient net worth to sustain the loss of the Subscriber's entire investment in Tranquil.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 With respect non-accredited investor, the amount of Preferred Shares being purchased by the Subscriber does not exceed 10% of the greater of the Subscriber's annual income or net worth (for natural persons), or 10% of the greater of the Subscriber's annual revenue or net assets at fiscal year-end (for non-natural persons).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 The Subscriber has had an opportunity to ask questions of Tranquil or anyone acting on its behalf and to receive answers concerning the terms of this Agreement and the Preferred Shares, as well as about Tranquil and its business generally, and to obtain any additional information that Tranquil possesses or can acquire without unreasonable effort or expense, that is necessary to verify the accuracy of the information contained in this Agreement. Further, all such questions have been answered to the full satisfaction of the Subscriber.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 The Subscriber agrees to provide any additional documentation Tranquil may reasonably request, including documentation as may be required by Tranquil to form a reasonable basis that the Subscriber qualifies as an "accredited investor" as that term is defined in Rule 501 under Regulation D promulgated under the Act, or otherwise as a "qualified purchaser" as that term is defined in Regulation A promulgated under the Act, or as may be required by the securities administrators or regulators of any state, to confirm that the Subscriber meets any applicable minimum financial suitability standards and has satisfied any applicable maximum investment limits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 The Subscriber understands that no state or federal authority has scrutinized this Agreement or the Preferred Shares offered pursuant hereto, has made any finding or determination relating to the fairness for investment of the Preferred Shares, or has recommended or endorsed the Preferred Shares, and that the Preferred Shares have not been registered or qualified under the Act or any state securities laws, in reliance upon exemptions from registration thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13 The Subscriber understands that Tranquil has not been registered under the Investment Company Act of 1940. In addition, the Subscriber understands that Tranquil is not registered as an investment adviser under the Investment Advisers Act of 1940, as amended (the "***Advisers Act***").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14 The Subscriber is subscribing for and purchasing the Preferred Shares without being furnished any offering literature, other than the Offering Circular, the Operating Agreement and this Agreement, and such other related documents, agreements or instruments as may be attached to the foregoing documents as exhibits or supplements thereto, or as the Subscriber has otherwise requested from Tranquil in writing, and without receiving any representations or warranties from Tranquil or its agents and representatives other than the representations and warranties contained in said documents, and is making this investment decision solely in reliance upon the information contained in said documents and upon any investigation made by the Subscriber or Subscriber's advisors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.15 The Subscriber's true and correct full legal name, address of residence (or, if an entity, principal place of business), phone number, electronic mail address, United States taxpayer identification number, if any, and other contact information are accurately provided on signature page hereto. The Subscriber is currently a bona fide resident of the state or jurisdiction set forth in the current address provided to Tranquil. The Subscriber has no present intention of becoming a resident of any other state or jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.16 The Subscriber is subscribing for and purchasing the Preferred Shares solely for the Subscriber's own account, for investment purposes only, and not with a view toward or in connection with resale, distribution (other than to its shareholders or members, if any), subdivision or fractionalization thereof. The Subscriber has no agreement or other arrangement, formal or informal, with any person or entity to sell, transfer or pledge any part of the Preferred Shares, or which would guarantee the Subscriber any profit, or insure against any loss with respect to the Preferred Shares, and the Subscriber has no plans to enter into any such agreement or arrangement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.17 The Subscriber represents and warrants that the execution and delivery of this Agreement, the consummation of the transactions contemplated thereby and hereby and the performance of the obligations thereunder and hereunder will not conflict with or result in any violation of or default under any provision of any other agreement or instrument to which the Subscriber is a party or any license, permit, franchise, judgment, order, writ or decree, or any statute, rule or regulation, applicable to the Subscriber. The Subscriber confirms that the consummation of the transactions envisioned herein, including, but not limited to, the Subscriber's purchase of the Preferred Shares, will not violate any foreign law and that such transactions are lawful in the Subscriber's country of citizenship and residence.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.18 Tranquil's intent is to comply with all applicable federal, state and local laws designed to combat money laundering and similar illegal activities, including the provisions of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (the "***PATRIOT Act***").

For purposes of this Section 3.18, the following terms shall have the meanings described below:

"***Close Associate of a Senior Foreign Political Figure***" shall mean a person who is widely and publicly known internationally to maintain an unusually close relationship with the Senior Foreign Political Figure, and includes a person who is in a position to conduct substantial domestic and international financial transactions on behalf of the Senior Foreign Political Figure;

"***Foreign Shell Bank***" shall mean a Foreign Bank without a presence in any country;

"***Foreign Bank***" shall mean an organization that (i) is organized under the laws of a foreign country, (ii) engages in the business of banking, (iii) is recognized as a bank by the bank supervisory or monetary authority of the country of its organization or principal banking operations, (iv) receives deposits to a substantial extent in the regular course of its business, and (v) has the power to accept demand deposits, but does not include the U.S. branches or agencies of a foreign bank;

"***Non-Cooperative Jurisdiction***" shall mean any foreign country that has been designated as noncooperative with international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Task Force on Money Laundering, of which the U.S. is a member and with which designation the U.S. representative to the group or organization continues to concur;

"***Prohibited Investor***" shall mean a person or entity whose name appears on (i) the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign Assets Control; (ii) other lists of prohibited persons and entities as may be mandated by applicable law or regulation; or (iii) such other lists of prohibited persons and entities as may be provided to the Fund in connection therewith;

"***Related Person***" shall mean, with respect to any entity, any interest holder, director, senior officer, trustee, beneficiary or grantor of such entity; provided that in the case of an entity that is a publicly traded company or a tax qualified pension or retirement plan in which at least 100 employees participate that is maintained by an employer that is organized in the U.S. or is a U.S. government entity, the term "Related Person" shall exclude any interest holder holding less than 5% of any class of securities of such publicly traded company and beneficiaries of such plan;

"***Senior Foreign Political Figure***" shall mean a senior official in the executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government-owned corporation. In addition, a Senior Foreign Political Figure includes any corporation, business or other entity that has been formed by, or for the benefit of, a Senior Foreign Political Figure.

Subscriber hereby represents, covenants, and agrees that, to the best of Subscriber's knowledge based on reasonable investigation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) None of the Subscriber's funds tendered for the Purchase Price (whether payable in cash or otherwise)
shall be derived from money laundering or similar activities deemed illegal under federal laws and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) To the extent within the Subscriber's control, none of the Subscriber's funds tendered for
the Purchase Price will cause Tranquil or any of its personnel or affiliates to be in violation of federal anti-money laundering laws,
including (without limitation) the Bank Secrecy Act (31 U.S.C. 5311 et seq.), the United States Money Laundering Control Act of 1986 or
the International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001, and/or any regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) When requested by Tranquil, the Subscriber will provide any and all additional information, and the Subscriber
understands and agrees that Tranquil may release confidential information about the Subscriber and, if applicable, any underlying beneficial
owner or Related Person to U.S. regulators and law enforcement authorities, deemed reasonably necessary to ensure compliance with all
applicable laws and regulations concerning money laundering and similar activities. Tranquil reserves the right to request any information
as is necessary to verify the identity of the Subscriber and the source of any payment to the Fund. In the event of delay or failure by
the Subscriber to produce any information required for verification purposes, the subscription by the Subscriber may be refused.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Neither the Subscriber, nor any person or entity controlled by, controlling or under common control with
the Subscriber, any of the Subscriber's beneficial owners, any person for whom the Subscriber is acting as agent or nominee in connection
with this investment nor, in the case of a Subscriber which is an entity, any Related Person is:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a Prohibited Investor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) a Senior Foreign Political Figure, any member of a Senior Foreign Political Figure's "immediate
family", which includes the figure's parents, siblings, spouse, children and in-laws, or any Close Associate of a Senior Foreign
Political Figure, or a person or entity resident in, or organized or chartered under, the laws of a Non-Cooperative Jurisdiction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a person or entity resident in, or organized or chartered under, the laws of a jurisdiction that has been
designated by the U.S. Secretary of the Treasury under Section 311 or 312 of the PATRIOT Act as warranting special measures due to money
laundering concerns; or Bank without a physical presence in any country, but does not include a regulated affiliate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iv) a person or entity who gives Subscriber reason to believe that its funds originate from, or will be or have been routed through, an account maintained at a Foreign Shell Bank, an "offshore bank", or a bank organized or chartered under the laws of a Non-Cooperative Jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Subscriber hereby agrees to immediately notify Tranquil if the Subscriber knows, or has reason to
suspect, that any of the representations in this Section 3.18 have become incorrect or if there is any change in the information affecting
these representations and covenants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Subscriber agrees that, if at any time it is discovered that any of the foregoing anti-money laundering
representations are incorrect, or if otherwise required by applicable laws or regulations, Tranquil may undertake appropriate actions,
and the Subscriber agrees to cooperate with such actions, to ensure compliance with such laws or regulations, including, but not limited
to segregation and/or redemption of the Subscriber's interest in the Preferred Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19 The Subscriber represents and warrants that the Subscriber is either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Purchasing the Preferred Shares with funds that constitute the assets of one or more of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) an "employee benefit plan" as defined in Section 3(3) of the U.S. Employee Retirement Income
Security Act of 1974, as amended ("ERISA"), that is subject to Title I of ERISA;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) an "employee benefit plan" as defined in Section 3(3) of ERISA that is not subject to either
Title I of ERISA or Section 4975 of the Internal Revenue Code of 1986, as amended (the "Code") (including a governmental plan,
non-electing church plan or foreign plan). The Subscriber hereby represents and warrants that (a) its investment in Tranquil: (i) does
not violate and is not otherwise inconsistent with the terms of any legal document constituting or governing the employee benefit plan;
(ii) has been duly authorized and approved by all necessary parties; and (iii) is in compliance with all applicable laws, and (b) neither
Tranquil nor any person who manages the assets of Tranquil will be subject to any laws, rules or regulations applicable to such Subscriber
solely as a result of the investment in Tranquil by such Subscriber;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a plan that is subject to Section 4975 of the Code (including an individual retirement account);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) an entity (including, if applicable, an insurance company general account) whose underlying assets include
"plan assets" of one or more "employee benefit plans" that are subject to Title I of ERISA or "plans"
that are subject to Section 4975 of the Code by reason of the investment in such entity, directly or indirectly, by such employee benefit
plans or plans; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) an entity that (a) is a group trust within the meaning of Revenue Ruling 81-100, a common or collective
trust fund of a bank or an insurance company separate account and (b) is subject to Title I of ERISA, Section 4975 of the Code or both;
or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Not purchasing the Preferred Shares with funds that constitute the assets of any of the entities or plans described in Section 3.19(a)(i)
through 3.19(a)(v) above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.20 The Subscriber further represents and warrants that neither Subscriber nor any of its affiliates (a) have discretionary authority or control with respect to the assets of Tranquil or (b) provide investment advice for a fee (direct or indirect) with respect to the assets of Tranquil. For this purpose, an "affiliate" includes any person, directly or indirectly, through one or more intermediaries, controlling, controlled by, or under common control with the person and "control" with respect to a person other than an individual means the power to exercise a controlling influence over the management or policies of such person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.21 The Subscriber confirms that the Subscriber has been advised to consult with the Subscriber's independent attorney regarding legal matters concerning Tranquil and to consult with independent tax advisers regarding the tax consequences of investing through Tranquil. The Subscriber acknowledges that Subscriber understands that any anticipated United States federal or state income tax benefits may not be available and, further, may be adversely affected through adoption of new laws or regulations or amendments to existing laws or regulations. The Subscriber acknowledges and agrees that Tranquil is providing No warranty or assurance regarding the ultimate availability of any tax benefits to the Subscriber by reason of the Purchase.

4. <u>Tax Forms</u>. The Subscriber will complete an IRS Form W-9 or the appropriate Form W-8, which should be returned directly to us via the Site. The Subscriber certifies that the information contained in the executed copy (or copies) of IRS Form W-9 or appropriate IRS Form W-8 (and any accompanying required documentation), as applicable, when submitted to us will be true, correct and complete. The Subscriber shall (i) promptly inform us of any change in such information, and (ii) furnish to us a new properly completed and executed form, certificate or attachment, as applicable, as may be required under the Internal Revenue Service instructions to such forms, the Code or any applicable Treasury Regulations or as may be requested from time to time by us.

5. <u>No Advisory Relationship</u>. You acknowledge and agree that the purchase and sale of the Preferred Shares pursuant to this Agreement is an arms-length transaction between you and Tranquil. In connection with the purchase and sale of the Preferred Shares, Tranquil is not acting as your agent or fiduciary. Tranquil assumes No advisory or fiduciary responsibility in your favor in connection with the Preferred Shares or the corresponding project investments. Tranquil has not provided you with any legal, accounting, regulatory or tax advice with respect to the Preferred Shares, and you have consulted your own respective legal, accounting, regulatory and tax advisors to the extent you have deemed appropriate.

6. <u>Bankruptcy</u>. In the event that you file or enter bankruptcy, insolvency or other similar proceeding, you agree to use the best efforts possible to avoid Tranquil being named as a party or otherwise involved in the bankruptcy proceeding. Furthermore, this Agreement should be interpreted so as to prevent, to the maximum extent permitted by applicable law, any bankruptcy trustee, receiver or debtor-in-possession from asserting, requiring or seeking that (i) you be allowed by Tranquil to return the Preferred Shares to Tranquil for a refund or (ii) Tranquil be mandated or ordered to redeem or withdraw the Preferred Shares held or owned by you.

7. *<u>Miscellaneous Provisions.</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (without regard to the conflicts of laws principles thereof).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 All notices and communications to be given or otherwise made to the Subscriber shall be deemed to be sufficient if sent by electronic mail to such address as set forth for the Subscriber at the records of Tranquil (or that you submitted to us via the Site). You shall send all notices or other communications required to be given hereunder to Tranquil via email at investor@tranquil.healthcare (with a copy to be sent concurrently via prepaid certified mail to: 18200 Von Karman, Suite 850, Irvine, CA 92612, Attention: Investor Relations).

Any such notice or communication shall be deemed to have been delivered and received on the first business day following that on which the electronic mail has been sent (assuming that there is No error in delivery). As used in this Section, "business day" shall mean any day other than a day on which banking institutions in the State of Delaware are legally closed for business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 This Agreement, or the rights, obligations or interests of the Subscriber hereunder, may not be assigned, transferred or delegated without the prior written consent of Tranquil. Any such assignment, transfer or delegation in violation of this section shall be null and void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 The parties agree to execute and deliver such further documents and information as may be reasonably required in order to effectuate the purposes of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of each of the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 If one or more provisions of this Agreement are held to be unenforceable under applicable law, rule or regulation, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 In the event that either party hereto commences any suit, action or other proceeding to interpret this Agreement, or determines to enforce any right or obligation created hereby, then such party, if it prevails in such action, shall recover its reasonable costs and expenses incurred in connection therewith, including, but not limited to, reasonable attorney's fees and expenses and costs of appeal, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 This Agreement (including the exhibits and schedules attached hereto) and the documents referred to herein (including without limitation the Preferred Shares) constitute the entire agreement among the parties and shall constitute the sole documents setting forth terms and conditions of the Subscriber's contractual relationship with Tranquil with regard to the matters set forth herein. This Agreement supersedes any and all prior or contemporaneous communications, whether oral, written or electronic, between us.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9 This Agreement may be executed in any number of counterparts, or facsimile or email counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10 The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. The singular number or masculine gender, as used herein, shall be deemed to include the plural number and the feminine or neuter genders whenever the context so requires.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11 The parties acknowledge that there are No third-party beneficiaries of this Agreement, except for any affiliates of Tranquil that may be involved in the issuance or servicing of Preferred Shares on the Site, which the parties expressly agree shall be third party beneficiaries hereof.

8. <u>Consent to Electronic Delivery</u>. The Subscriber hereby agrees that Tranquil may deliver all notices, financial statements, valuations, reports, reviews, analyses or other materials, and any and all other documents, information and communications concerning the affairs of Tranquil and its investments, including, without limitation, information about the investment, required or permitted to be provided to the Subscriber regarding the Preferred Shares or hereunder by means e-mail or by posting on an electronic message board or by other means of electronic communication. Because Tranquil operates principally on the Internet, you will need to consent to transact business with us online and electronically. As part of doing business with us, therefore, we also need you to consent to our giving you certain disclosures electronically, either via the Site or to the email address you provide to us. By entering into this Agreement, you consent to receive electronically all documents, communications, notices, contracts, and agreements arising from or relating in any way to your or our rights, obligations or services under this Agreement (each, a "Disclosure"). The decision to do business with us electronically is yours. This document informs you of your rights concerning Disclosures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Scope of Consent*. Your consent to receive Disclosures and transact business electronically, and
our agreement to do so, applies to any transactions to which such Disclosures relate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *Consenting to Do Business Electronically*. Before you decide to do business electronically with
us, you should consider whether you have the required hardware and software capabilities described below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) *Hardware and Software Requirements*. In order to access and retain Disclosures electronically, you
must satisfy the following computer hardware and software requirements: access to the Internet; an email account and related software
capable of receiving email through the Internet; a web browser which is SSL-compliant and supports secure sessions; and hardware capable
of running this software.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) How to Contact Us Regarding Electronic Disclosures. You can contact us via email at investor@tranquil.healthcare
. You may also reach us in writing at the following address: 18200 Von Karman, Suite 850, Irvine, CA 92612 Attention: Investor Support.
You agree to keep us informed of any change in your email or home mailing address so that you can continue to receive all Disclosures
in a timely fashion. If your registered e-mail address changes, you must notify us of the change by sending an email to investor@tranquil.healthcare.
You also agree to update your registered residence address and telephone number on the Site if they change. You will print a copy of this
Agreement for your records, and you agree and acknowledge that you can access, receive and retain all Disclosures electronically sent
via email or posted on the Site.

9. <u>Consent to Electronic Delivery of Tax Documents</u>. Please read this disclosure about how we will provide certain documents that we are required by IRS to send to you ("Tax Documents") in connection with your Preferred Shares. A Tax Document provides important information you need to complete your tax returns. Tax Documents include Form 1099. Occasionally, we are required to send you CORRECTED Tax Documents. Additionally, we may include inserts with your Tax Documents. We are required to send Tax Documents to you in writing, which means in paper form. When you consent to electronic delivery of your Tax Documents, you will be consenting to delivery of Tax Documents, including these corrected Tax Documents and inserts, electronically instead of in paper form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Agreement to Receive Tax Documents Electronically*. By executing this Agreement on the Site, you
are consenting in the affirmative that we may send Tax Documents to you electronically, and acknowledging that you are able to access
Tax Documents from the site. If you subsequently withdraw consent to receive Tax Documents electronically, a paper copy will be provided.
Your consent to receive the Tax Documents electronically continues for every tax year until you withdraw your consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *How We Will Notify You That a Tax Document is Available*. You will receive an electronic notification
via email when your Tax Documents are ready for access on the Site. Your Tax Documents are maintained on the Site through at least October
15 of the applicable tax year, at a minimum, should you ever need to access them again.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) *Your Option to Receive Paper Copies*. To obtain a paper copy of your Tax Documents, you can print
one by visiting the Tranquil web site. You can also contact us at investor@tranquil.healthcare and request a paper copy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Withdrawal of Consent to Receive Electronic Notices*. You can withdraw your consent before the Tax
Document is furnished by mailing a letter including your name, mailing address, effective tax year, and indicating your intent to withdraw
consent to the electronic delivery of Tax Documents to:

Tranquil Healthcare Fund I, LLC

Attention: Investor Support

18200 Von Karman

Suite 850

Irvine, CA 92612

If you withdraw consent to receive Tax Documents electronically, a paper copy will be provided. Your consent to receive the Tax Documents electronically continues for every tax year until you withdraw your consent.

(e) *Termination of Electronic Delivery of Tax Documents*. We may terminate your request for electronic delivery of Tax Documents without your withdrawal of consent in writing in the following instances:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· You do not have a password for your Tranquil
account

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Your Tranquil account is closed

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· You were removed from the Tranquil account

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Your role or authority on the Tranquil account
changed in a manner that No longer allows you to consent to electronic delivery

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· We received three consecutive email notifications
that indicate your email address is No longer valid

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· We cancel the electronic delivery of Tax Documents

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) *You Must Keep Your E-mail Address Current With Us*. You must promptly notify us of a change of your
email address. If your mailing address, email address, telephone number or other contact information changes, you may also provide updated
information by contacting us at investor@tranquil.healthcare

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) *Hardware and Software Requirements*. In order to access and retain Tax Documents electronically,
you must satisfy the computer hardware and software requirements as set forth above in Section 8(c) of this Agreement. You will also need
a printer if you wish to print Tax Documents on paper, and electronic storage if you wish to download and save Tax Documents to your computer.

10. <u>LIMITATIONS ON DAMAGES</u>. IN NO EVENT SHALL TRANQUIL BE LIABLE TO THE SUBSCRIBER FOR ANY LOST PROFITS OR SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, EVEN IF INFORMED OF THE POSSIBILITY OF SUCH DAMAGES. THE FOREGOING SHALL BE INTERPRETED AND HAVE EFFECT TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, RULE OR REGULATION.

11. *<u>Arbitration</u>*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Either party may, at its sole election, require that the sole and exclusive forum and remedy for resolution
of a Claim be final and binding arbitration pursuant to this Section 11 (this "Arbitration Provision"). The arbitration shall
be conducted in the State of Delaware. As used in this Arbitration Provision, "Claim" shall include any past, present, or
future claim, dispute, or controversy involving you (or persons claiming through or connected with you), on the one hand, and Tranquil
(or persons claiming through or connected with Tranquil), on the other hand, relating to or arising out of this Agreement, the Site, and/or
the activities or relationships that involve, lead to, or result from any of the foregoing, including (except to the extent provided otherwise
in the last sentence of sub-section (e) below) the validity or enforceability of this Arbitration Provision, any part thereof, or the
entire Agreement. Claims are subject to arbitration regardless of whether they arise from contract; tort (intentional or otherwise); a
constitution, statute, common law, or principles of equity; or otherwise. Claims include (without limitation) matters arising as initial
claims, counter-claims, cross-claims, third-party claims, or otherwise. This Arbitration Provision applies to claims under the U.S. federal
securities laws and to all claims that that are related to Tranquil, including with respect to this offering, our holdings, the Preferred
Shares, our ongoing operations and the management of our investments, among other matters. The scope of this Arbitration Provision is
to be given the broadest possible interpretation that is enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The party initiating arbitration shall do so with the American Arbitration Association (the "AAA")
or JAMS. The arbitration shall be conducted according to, and the location of the arbitration shall be determined in accordance with,
the rules and policies of the administrator selected, except to the extent the rules conflict with this Arbitration Provision or any countervailing
law. In the case of a conflict between the rules and policies of the administrator and this Arbitration Provision, this Arbitration Provision
shall control, subject to countervailing law, unless all parties to the arbitration consent to have the rules and policies of the administrator
apply.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If we elect arbitration, we shall pay all the administrator's filing costs and administrative fees
(other than hearing fees). If you elect arbitration, filing costs and administrative fees (other than hearing fees) shall be paid in accordance
with the rules of the administrator selected, or in accordance with countervailing law if contrary to the administrator's rules.
We shall pay the administrator's hearing fees for one full day of arbitration hearings. Fees for hearings that exceed one day will
be paid by the party requesting the hearing, unless the administrator's rules or applicable law require otherwise, or you request
that we pay them and we agree to do so. Each party shall bear the expense of its own attorney's fees, except as otherwise provided
by law. If a statute gives you the right to recover any of these fees, these statutory rights shall apply in the arbitration notwithstanding
anything to the contrary herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Within 30 days of a final award by the arbitrator, a party may appeal the award for reconsideration by
a three-arbitrator panel selected according to the rules of the arbitrator administrator. In the event of such an appeal, an opposing
party may cross-appeal within 30 days after notice of the appeal. The panel will reconsider de novo all aspects of the initial award that
are appealed. Costs and conduct of any appeal shall be governed by this Arbitration Provision and the administrator's rules, in
the same way as the initial arbitration proceeding. Any award by the individual arbitrator that is not subject to appeal, and any panel
award on appeal, shall be final and binding, except for any appeal right under the Federal Arbitration Act (the "FAA"), and
may be entered as a judgment in any court of competent jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) We agree not to invoke our right to arbitrate an individual Claim that you may bring in Small Claims Court
or an equivalent court, if any, so long as the Claim is pending only in that court. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, No
ARBITRATION SHALL PROCEED ON A CLASS, REPRESENTATIVE, OR COLLECTIVE BASIS (INCLUDING AS PRIVATE ATTORNEY GENERAL ON BEHALF OF OTHERS),
EVEN IF THE CLAIM OR CLAIMS THAT ARE THE SUBJECT OF THE ARBITRATION HAD PREVIOUSLY BEEN ASSERTED (OR COULD HAVE BEEN ASSERTED) IN A COURT
AS CLASS REPRESENTATIVE, OR COLLECTIVE ACTIONS IN A COURT.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Unless otherwise provided in this Agreement or consented to in writing by all parties to the arbitration,
No party to the arbitration may join, consolidate, or otherwise bring claims for or on behalf of two or more individuals or unrelated
corporate entities in the same arbitration unless those persons are parties to a single transaction. Unless consented to in writing by
all parties to the arbitration, an award in arbitration shall determine the rights and obligations of the named parties only, and only
with respect to the claims in arbitration, and shall not (i) determine the rights, obligations, or interests of anyone other than a named
party, or resolve any Claim of anyone other than a named party, or (ii) make an award for the benefit of, or against, anyone other than
a named party. No administrator or arbitrator shall have the power or authority to waive, modify, or fail to enforce this sub-section
(f), and any attempt to do so, whether by rule, policy, arbitration decision or otherwise, shall be invalid and unenforceable. Any challenge
to the validity of this sub-section (f) shall be determined exclusively by a court and not by the administrator or any arbitrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) This Arbitration Provision is made pursuant to a transaction involving interstate commerce and shall be
governed by and enforceable under the FAA. The arbitrator will apply substantive law consistent with the FAA and applicable statutes of
limitations. The arbitrator may award damages or other types of relief permitted by applicable substantive law, subject to the limitations
set forth in this Arbitration Provision. The arbitrator will not be bound by judicial rules of procedure and evidence that would apply
in a court. The arbitrator shall take steps to reasonably protect confidential information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) This Arbitration Provision shall survive (i) suspension, termination, revocation, closure, or amendments
to this Agreement and the relationship of the parties; (ii) the bankruptcy or insolvency of any party hereto or other party; and (iii)
any transfer of any loan or Preferred Share or any amounts owed on such loans or notes, to any other party. If any portion of this Arbitration
Provision other than sub-section (e) is deemed invalid or unenforceable, the remaining portions of this Arbitration Provision shall nevertheless
remain valid and in force. If arbitration is brought on a class, representative, or collective basis, and the limitations on such proceedings
in sub-section (e) are finally adjudicated pursuant to the last sentence of sub-section (e) to be unenforceable, then No arbitration shall
be had. In No event shall any invalidation be deemed to authorize an arbitrator to determine Claims or make awards beyond those authorized
in this Arbitration Provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) You also acknowledge that the requirement to arbitrate disputes contained in this Section 11 and the waiver
of court and jury rights contained in Section 12 are also in our operating agreement and that subsequent holders of our Preferred Shares
will also be subject to such provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) BY AGREEING TO BE SUBJECT TO THE ARBITRATION PROVISION CONTAINED IN THIS AGREEMENT, INVESTORS WILL NOT
BE DEEMED TO WAIVE THE COMPANY'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

12. *<u>Waiver of Court & Jury Rights</u>*. THE PARTIES ACKNOWLEDGE THAT THEY HAVE A RIGHT TO LITIGATE CLAIMS THROUGH A COURT BEFORE A JUDGE, BUT WILL NOT HAVE THAT RIGHT IF ANY PARTY ELECTS ARBITRATION PURSUANT TO THIS ARBITRATION PROVISION. THE PARTIES HEREBY KNOWINGLY AND VOLUNTARILY WAIVE THEIR RIGHTS TO LITIGATE SUCH CLAIMS IN A COURT UPON ELECTION OF ARBITRATION BY ANY PARTY. THE PARTIES HERETO WAIVE A TRIAL BY JURY IN ANY LITIGATION RELATING TO THIS AGREEMENT, THE PREFERRED SHARES OR ANY OTHER AGREEMENTS RELATED THERETO.

13. *<u>Waiver of Section 18-305 Rights</u>*. By executing this agreement, you expressly and completely waive, to the fullest extent permitted by law, your rights to request to review and obtain information relating to and maintained by Tranquil, including, but not limited to, names and contact information of our members, information listed in Section 18-305 of the Delaware Limited Liability Company Act, as amended, and any other information deemed to be confidential by Tranquil in its sole discretion. In addition, by executing this agreement, you expressly agree not to seek to compel Tranquil to produce any information described in the preceding sentence or pursuant to any statutory scheme or provision. BY AGREEING TO BE SUBJECT TO THE WAIVER PROVISIONS, INVESTORS WILL NOT BE DEEMED TO WAIVE TRANQUIL'S COMPLIANCE WITH THE FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

14. *<u>Authority</u>*. By executing this Agreement, you expressly acknowledge that you have reviewed this Agreement and the Offering Circular for this particular subscription.

*[Signature page to follow]*

**IN WITNESS WHEREOF**, the Subscriber, or its duly authorized representative(s), hereby acknowledges that it has read and understood the risk factors set forth in the Offering Circular, and has hereby executed and delivered this Agreement, and executed and delivered herewith the Purchase Price, as of the date set forth above.

**THE SUBSCRIBER:**

Print Name of Subscriber: ________________________________________________________________

Description of Entity (if applicable): ________________________________________________________

EIN/SS: ________________________________________________________________________________

Signature of Subscriber: ___________________________________________________________________

Name of Person Signing on behalf of Subscriber: ______________________________________________

Title (if applicable): _______________________________________________________________________

Address of Subscriber: _____________________________________________________________________

______________________________________________________________________

______________________________________________________________________

Telephone: _______________________________________________________________________________

Email: ___________________________________________________________________________________

Number of Preferred Shares Purchased: _________________________________________________________

Number of Incentive Shares, if any: ____________________________________________________________

Purchase Price: _____________________________________________________________________________

(Signature Page to Subscription Agreement)

## Ex1A-6

**Exhibit 6.1**

**TERM SHEET**

This term sheet (the "<u>Term Sheet</u>") outlines proposed terms of a transaction between Tranquil Healthcare, Inc, a Delaware corporation ("<u>Company</u>"), and DGR Health Services, LLC ("<u>Manager</u>"). Each of Company and Manager will be referred to herein as a "<u>Party</u>", and collectively as the "<u>Parties</u>". The Parties intend that the provisions of ***Part B*** of this Term Sheet (the "<u>Binding Terms</u>") will be binding on and enforceable against each of them. Except for the Binding Terms: (a) none of the provisions of this Term Sheet shall constitute an obligation binding on any Party and all such provisions are subject to the completion of financial, commercial and legal due diligence satisfactory to the Parties; and (b) except with respect to the Binding Terms, there is no obligation on either Party until the execution and delivery of Definitive Agreements (as defined below).

<u>PART A: NON-BINDING TERMS</u> 

---

| | |
|:---|:---|
| **<u>Collaborative Agreement</u>** | **<u>Collaborative Agreement</u>** |
| **Overview:** | The Company develops advanced interventional psychiatry treatments, including Transcranial Magnetic Stimulation, a non-invasive, FDA- and EU-approved neuromodulation therapy. The Company plans on developing up to forty (40) clinics providing such services to consumers ("Clinic(s)"). Manager is experienced with managing clinics offering such services. Company and Manager desire to enter into collaborate arrangements for the development of such clinics (collectively, the "<u>Project</u>"). |
| **Company Contribution:** | With respect to the Project, the Company will provide: (i) equipment leasing to each Clinic in an amount up to $650,000, (ii) a revolving line of credit in an amount up to $650,000 to be used for general working capital purposes, and (iii) consulting services to each Clinic. |
| **Manager Contribution:** | With respect to the Project, Manager will provide Management Services (as defined below) for the Project pursuant to the terms of a Management Services agreement as further described herein. |
| **<u>Management Services Agreement</u>** | **<u>Management Services Agreement</u>** |
| **Management Service:** | Management services will include the provision of, or arranging for, a comprehensive range of administrative, business, facilities, equipment, information technology, infrastructure, management, laboratory and other support services required for the operation of the Clinics and Manager will be responsible for the sale of the Manager and / or Clinics to at third-party (collectively, "<u>Management Services</u>").<br>As part of the Management Services, Manager agrees to employ, on a full or part time basis, physicians who specialize in the provision of medical care, treatment, and goods and services relating to advanced interventional psychiatry treatments (collectively, "<u>Physicians</u>") or support staff who specialize in clinical services (collectively, "<u>Professional Services</u>"), and who are fully licensed and authorized to provide the Professional Services.<br>|
| **Exclusivity:** | During the term of the Project, the Company will appoint Manager as its sole and exclusive provider of Management Services, and Manager shall serve as the Company's sole and exclusive manager with respect to the Project. Manager also agrees to provide Management Services to the Company. |
| **Billing:** | Manager shall submit, process and collect all billings and claims for payment from and to patients and, as applicable, third party payors and fiscal intermediaries, for all goods, items, and services provided by Physicians to its patients at the Clinic (including any globally billed services or services involving a professional and/or technical component). Manager shall bill or cause to be billed all fees charged for Professional Services rendered by the Physicians and any nurse practitioners or physician assistants employed by or contracting with Manager (collectively, "<u>Non-Physician Practitioners</u>") for Professional Services provided at the Clinics. |

---

---

| | |
|:---|:---|
| **Collections:** | Manager shall: (i) collect all revenue from any source, including accounts receivable, due to the Clinics in connection with Manager's operations at the Clinics ("<u>Gross Revenue</u>"); (ii) receive all Gross Revenue on the Clinics' behalf, except, if applicable at any time, for Federal Healthcare Program (such as Medicare, Medicaid, and TRICARE) receivables; and (iii) take all legal actions necessary and required for and give satisfaction for monies due on accounts and to withdraw any legal actions pertaining to or arising out of Manager's or the Clinic's right to collect amounts owed. Manager will be responsible for keeping complete records on all collections.<br>|
| **Personnel:** | Manager will provide to the Clinics, the support services of non-clinical, clerical and administrative personnel who may be employed by Manager as applicable law permits who are necessary for the Clinics to furnish its services ("<u>Provider Support Personnel</u>"). Manager will ensure that all Provider Support Personnel shall be appropriately licensed as required under applicable law, shall perform all services within the scope of any applicable licenses and certifications, shall perform all services in accordance with all laws and with prevailing and applicable standards of care and in accordance with any policies adopted by the Company, Manager, or the Clinic(s).<br>Additionally, Manager shall provide to the Clinics the support services of licensed healthcare personnel, other than Physicians and Non-Physician Practitioners, each of whom will be directly employed by the Clinics, as applicable. Such personnel shall include, but not be limited to, medical assistants and registered nurses who may be employed by Manager as applicable law permits who are necessary for Provider to furnish its services ("<u>Licensed Support Personnel</u>"). Manager will ensure that all Licensed Support Personnel will be appropriately licensed as required under applicable law, shall perform all services within the scope of their licenses and certifications, shall perform all services in accordance with all laws and with prevailing and applicable standards of care.<br>|
| **Management Fees:** | As compensation for the Management Services provided by Manager, Manager will be entitled to (i) a corporate overhead charge equal to 10% of the gross revenues of each Clinic and (ii) ninety Percent (90%) of EBITDA generated by the operation of the Clinics (as determined by GAAP), as a management fee. |
| **<u>Equipment Lease:</u>** |  |
| **Master Equipment Lease:** | Company will provide the Project with a 10-year master equipment lease ("<u>Master Equipment Lease</u>") in an initial principal amount of up to $650,000 per Clinic. The Master Equipment Lease will be on commercially reasonable terms. At Maturity, the Equipment Lease and any accrued and unpaid rent shall become immediately due and payable and Manager shall, at that time, own such equipment.<br>|
| **Equipment:** | All equipment leased pursuant to the Master Equipment Lease (the "<u>Equipment</u>") will be used by Manager in connection with providing the Professional Services and Management Services at each Clinic. |
| **True Lease:** | The Parties intend that Master Equipment Lease constitute a true lease under applicable law and not a sale or financing arrangement. Company retains title to the Equipment at all times. Manager acquires no ownership, title, property, right, equity, or interest in the Equipment other than its leasehold interest solely as lessee subject to customary terms for similar transactions. |
| **Security Interest:** | In the event that the Master Equipment Lease is recharacterized under applicable law as a secured financing or a lease intended for security, Manager shall grant Company a first priority security interest in the Equipment and all proceeds thereof, to secure the payment of Manager's obligations under the Master Equipment Lease agreement. The Parties each agree to execute, acknowledge, deliver, file, and record, or cause to be executed, acknowledged, delivered, filed, and recorded such further documents (including without limitation UCC financing statements), and to do all such things and acts, necessary to ensure that such security interest would be a perfected first priority security interest under applicable law. |

---

---

| | |
|:---|:---|
| **Base Rent:** | The base rent for one (1) year for each piece of Equipment under the Master Equipment Lease will be equal to 10% of the capital cost of the Equipment to be paid on a monthly basis. |
| **Net Lease:** | The Parties intend that the Master Equipment Lease be a "net lease." In addition to the Base Rent, Manager will be responsible for maintaining, repairing and insuring the Equipment, as well as paying all applicable property taxes with respect to any Equipment. |
| **Change in Control:** | In the event of a change in control of any Clinic, the aggregate capital cost of the Equipment will immediately become due and payable. |
| **Other Conditions:** | The Master Equipment Lease will be subject to such representations, warranties and covenants as is customary in a transaction of this type. |
| **<u>Credit Facility</u>** |  |
| **Facility Amount:** | Up to $650,000 per Clinic. |
| **Term:** | Each draw down on the facility will have a term of 10 years, subject to normal and customary acceleration conditions ("Maturity"). At Maturity, the Credit Facility and any accrued and unpaid interest shall become immediately due and payable. |
| **Use of Proceeds:** | Advances from the Credit Facility will be used for expenses associated with the build-out of Clinic locations and for initial marketing and initial operating costs for each Clinic until it is operational.<br>|
| **Interest Rate:** | Interest on the facility will equal 10% per annum, will be calculated on a 365 day basis and be payable in arrears on a quarterly basis. |
| **Change in Control:** | In the event of a change of control of any Clinic, the aggregate amount of the draw-downs related to that Clinic will become due and payable.<br>|
| **<u>Company Consulting Services</u>** | **<u>Company Consulting Services</u>** |
| **Services:** | The Company will provide each Clinic with consulting services under individual consulting agreements. The services will include but not be limited to: (i) reviewing and providing recommendations regarding the Projects' direct to consumer marketing strategies, and providing assistance, if requested by Manager, with respect to implementation; (ii) reviewing and providing alternatives to advertising and social media outreach related to the Project and providing alternatives for purchasing such ads; (iii) undertaking a comprehensive review of markets to determine optimal location to open Clinics; (iv) assisting in a review of product expansion opportunities; (v) exploring opportunities for expanding insurance reimbursement related to the products and services provided by the Clinics; and (vi) general business consultation on an as requested basis (collectively "<u>Consulting Services</u>"). |
| **Consulting Fees:** | As compensation for the Consulting Services provided by the Company, the Company will be entitled to ten percent (10%) of the EBITDA generated by the Clinics, as a consulting fee. |
| **Change in Control:** | In the event of a change in control, the Company will be entitled to 10% of the net consideration (after deducting the return of the capital outlaws for the equipment and credit facility) received by the Manager or Clinics resulting from such transaction. In the event of a sale/change of control, all proceeds will be received within an escrow account controlled by the Company's counsel and distributed according to this agreement. |

---

---

| | |
|:---|:---|
| **<u>Intellectual Property</u>** | **<u>Intellectual Property</u>** |

| **<u>Other Terms & Agreements</u>** | **<u>Other Terms & Agreements</u>** |
| **Definitive <br> Agreement:** | The detailed terms and conditions of the arrangements outlined herein will be set forth in definitive agreements (the "<u>Definitive Agreements</u>"), with the understanding that the Definitive Agreements will contain, in addition to the items addressed above, certain representations and warranties, provisions regarding the protection, prosecution and enforcement of intellectual property rights, confidentiality and non-disclosure obligations, indemnification, certain operating and governance covenants, and conditions to effectiveness, that are customary for transactions of this kind. The Parties anticipate that the Definitive Agreements will include but not be limited to: (i) a management services agreement, (ii) a Master Equipment Lease, (iii) Manager Services agreement, and (iv) a Company consulting agreement. |
| **Reporting Requirements:** | The Manager shall provide the Company with monthly financial statements on the results of the Clinics. In addition, the Manager shall assist the Company with any financial information required by the Company to complete its own annual audit requirements and biannual accounting review. Company shall have the right to audit the books and records of the Manager on an annual basis if so desired.<br>|
| **Indemnification by Manager:** | Manager shall indemnify, defend, and hold harmless Company, its officers, directors, shareholders, agents, and affiliates (collectively, the "Company Indemnitees") from and against any and all losses, liabilities, claims, damages, costs, and expenses (including reasonable attorneys' fees) incurred by any Company Indemnitee arising out of or resulting from: (a) the clinical operations, medical practices, or healthcare services provided by Manager or its employees, agents, or contractors; (b) any violation of applicable healthcare laws or regulations, including but not limited to billing and collections practices, coding, or third-party payer requirements; and (c) any gross negligence, willful misconduct, or breach of this Agreement by Manager or its representatives. |
| **Indemnification by Company:** | Company shall indemnify, defend, and hold harmless Manager, its officers, managers, employees, and affiliates (collectively, the "Manager Indemnitees") from and against any and all losses, liabilities, claims, damages, costs, and expenses (including reasonable attorneys' fees) incurred by any Manager Indemnitee arising out of or resulting from: (a) Company's capital raising activities, investor representations, investor relations, securities filings or offerings, or the structure and terms of any financing provided to Manager; and (b) any gross negligence, willful misconduct, or breach of this Agreement by Company or its representatives. |
| **Working Capital:** | Manager shall provide for sufficient working capital reserves for Clinic operational expenses prior to distributions of EBITDA to Manager members. |

---

<u>PART B: BINDING TERMS</u>

---

| | |
|:---|:---|
| **Exclusivity:** | During the 180-day period commencing on the date of last signature of this Term Sheet, (as may be extended pursuant hereto, the "<u>Exclusivity Period</u>"), the Parties agree to negotiate in good faith to finalize and execute the Definitive Agreements and shall not, directly or indirectly, through any affiliate, officer, director, agent or otherwise, make, solicit, initiate or encourage submission of any proposal or offer from any third party (a "<u>Person</u>") relating to any transaction similar to the Project, the development and management of clinics or any other transaction that would effectively prohibit the Parties from negotiating the proposed transaction under this Term Sheet (each, a "<u>Proposal</u>"). Each Party agrees (i) to terminate immediately all ongoing contacts or negotiations, if any, with respect to any Proposal (except with the Parties hereto), and (ii) to promptly notify the other Party if any Proposal, or any inquiry or contact with any Person with respect thereto, is made, and shall provide the other Party with such information regarding such Proposal, inquiry or contact as such Party may request. |
| **Confidentiality:** | The Parties have entered into a Confidentiality Agreement dated October 28, 2025 (the "<u>Confidentiality Agreement</u>"). The contents of this Term Sheet and all Confidential Information (as defined in the Confidentiality Agreement) disclosed by the Parties in relation to this Term Sheet or the transactions contemplated hereunder will be subject to the Confidentiality Agreement. In addition, neither Party nor any of its affiliates will use the name of the other Party or any affiliate of the other Party in any manner, context or format (including reference on or links to websites, press releases, etc.) without obtaining in each instance the prior written consent of such other Party. For purposes of clarity, the Parties agree that Company will be required to disclose information relating to this Term Sheet pursuant to its Form 1-A Offering Circular for its Regulation A Offering with the SEC and Manager confirms and consents to such information herein being included. |
| **Expiration:** | This Term Sheet, if not mutually executed by the Parties, will expire at 12:01 a.m., Eastern Time on October 31, 2025. |
| **Governing <br> Law:** | The Definitive Agreements will be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof. Each Party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Term Sheet, the Definitive Agreements and any other transaction documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the County of Palm Beach, Florida. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the County of Palm Beach, State of Florida, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any provision contained in the Definitive Agreements), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.<br>|

---

**[Remainder of Page Intentionally Left Blank]**

**[Signature Page to Follow]**

**IN WITNESS WHEREOF**, the Parties have caused this Term Sheet to be executed by their duly authorized representatives as of October 28, 2025.

COMPANY: TRANQUIL HEALTHCARE, INC.

By:______________________________________

Name: Tyler Ehler

Title: CEO

Address: _________________________________

_________________________________

Facsimile: N/A

E-mail: ___________________________________

Attention: Tyler Ehler

MANAGER: DGR Health Services, LLC

By: ___________________________________

Name:_________________________________

Title: __________________________________

Address: _______________________________

_______________________________

Facsimile:_______________________________

E-mail: _________________________________

Attention: ______________________________

## Ex1A-6

**Exhibit 6.2**

**MANAGEMENT AGREEMENT**

This Management Agreement (this "**<u>Agreement</u>**") is entered into as of March 3, 2026, by and between Tranquil Healthcare Holdings, Inc., a Delaware corporation ("**<u>Manager</u>**") and Tranquil Healthcare Fund I, LLC, a Delaware limited liability company (the "**<u>Company</u>**"). Each party to this Agreement is referred to as a "**Party**" and collectively as the "**Parties**." Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Company's Operating Agreement dated as of the date hereof (as the same may be amended from time to time, the "**<u>Operating Agreement</u>**").

WHEREAS, the Company has been formed to originate and make commercial loans, provide consulting services, and advance credit to transcranial magnetic stimulation and mental health clinics ("**Business**");

WHEREAS, the Manager is designated as the manager of the Company and is responsible for managing the business and day-to-day operations of the Company, in the manner and on the terms set forth in the Operating Agreement;

WHEREAS, Manager has agreed to provide the Company with the personnel, services and resources necessary to carry out the Business in exchange for the payment to Manager of the reimbursement of all fees and expense incurred in providing the Services; and

WHEREAS, the Company and Manager intend to apply the services cost method (as described in Treasury Regulation Section 1.482-9(b)) to determine the arm's length charge for services provided under this Agreement.

NOW THEREFORE, The Company and the Manager hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Services</u>. Manager hereby agrees to provide the Company with the personnel, services and resources necessary for the Company to carry out its Business pursuant to the Operating Agreement, including, without limitation, the services and activities described on <u>Exhibit A</u> attached hereto (the "**<u>Services</u>**"), in consideration of the payment of the fees described in <u>Section 3</u> hereof, during the term of this Agreement. Manager hereby agrees not to take any actions in contravention of, or that could cause a breach of the Operating Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Term and Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Agreement shall commence on the date hereof and, unless sooner terminated in accordance with the terms hereof or by mutual written consent of the parties, shall remain in effect for so long as the Operating Agreement is in effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Manager may terminate this Agreement immediately upon written notice to the Company if the Company: (i) becomes the subject of a petition in bankruptcy which is not withdrawn or dismissed within 60 days thereafter; (ii) makes an assignment for the benefit of creditors; or (iii) breaches any material obligation under this Agreement and fails to cure such breach within 30 days after delivery of notice thereof by the Manager.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) Company may terminate this Agreement immediately upon written notice to the Manager if the Manager: (i) becomes the subject of a petition in bankruptcy which is not withdrawn or dismissed within 60 days thereafter; or (ii) makes an assignment for the benefit of creditors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Fees and Expenses</u>. The Company shall reimburse Manager for all Direct Costs and Overhead Costs incurred by Manager and its Affiliates on behalf of the Company or Manager, as applicable, under this Agreement. Costs and expenses incurred by the Manager on behalf of the Company shall be reimbursed monthly in cash to the Manager.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Direct Costs</u>. Direct Costs mean the sum of all internal and external costs incurred by the Company in providing the Services including, but not limited to, allocable salaries and wages, incentives, paid absences, payroll taxes, health care and retirement benefits, direct non-labor costs and similar expenses, and reimbursement of out-of-pocket third party costs and expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Overhead Costs</u>. Overhead Costs mean all internal and external indirect costs incurred by the Company in providing the Services and shall include (but are not limited to) general overhead and facilities charges (for example, office rent, depreciation, maintenance, utilities, and supplies).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Bonus Payment on Clinic Sale</u>. In connection with the Business, if any clinics that the Company provides services to through its third party operators sell and all such sales of clinics result in aggregate gross proceeds of $500 million or more, then the Manager will be entitled to the following: (i) a one-time bonus payment of $15 million dollars in cash and (ii) if such gross proceeds exceed $800 million, then an additional one-time bonus payment of $5 million dollars in cash.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Standard of Care</u>. Manager will use its commercially reasonable best efforts in the timely provision of the Services to be rendered hereunder and shall cooperate with the Company in connection with the provision of such Services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Representations and Warranties.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Manager hereby represents and warrants to the Company as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Manager is a corporation duly formed, validly existing and in good standing under the laws of the State of Delaware. Manager has the power and authority under its organizational documents to own and operate its assets and to carry on its business as proposed to be conducted, to execute, deliver and perform this Agreement and any other document, agreement, certificate and instrument that may be contemplated hereby to which it is a party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The execution and delivery by Manager of this Agreement and any other document, agreement, certificate and instrument that may be contemplated hereby to which it is a party, the performance by Manager of its obligations hereunder and thereunder have been duly authorized by all requisite corporate action on the part of Manager and will not violate any provision of law, any order of any court or other agency of government, the charter or bylaws of Manager or any other organizational document of Manager.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) This Agreement has been duly executed and delivered by Manager and constitutes the legal, valid and binding obligations of the Manager, enforceable against the Manager in accordance with its terms, except as the enforceability hereof may be limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors' rights generally or (b) applicable equitable principles (whether considered in a proceeding at law or in equity).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Manager has received and carefully reviewed a copy of the Operating Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company hereby represents and warrants to Manager as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company is a limited liability company duly formed, validly existing and in good standing under the laws of the State of Delaware. The Company has the power and authority under its organizational documents to own and operate its assets and to carry on its business as proposed to be conducted, to execute, deliver and perform this Agreement and any other document, agreement, certificate and instrument that may be contemplated hereby to which it is a party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The execution and delivery by the Company of this Agreement and any other document, agreement, certificate and instrument that may be contemplated hereby to which it is a party, the performance by the Company of its obligations hereunder and thereunder have been duly authorized by all requisite limited liability company action on the part of the Company and will not violate any provision of law, any order of any court or other agency of government, the certificate of formation of the Company or any other organizational document of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms, except as the enforceability hereof may be limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors' rights generally or (b) applicable equitable principles (whether considered in a proceeding at law or in equity).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Confidential Information</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Manager acknowledges that the information and knowledge obtained in the course of its performance of the Services relating to the Business (the "Confidential Information") are of a confidential nature. Manager shall, and shall ensure that its employees, use commercially reasonable efforts to take all actions necessary and appropriate to preserve the confidentiality of the Confidential Information and prevent (i) the disclosure of the Confidential Information to any person other than employees of Manager who have a need to know of it in order to perform their duties hereunder; and (ii) the use of the Confidential Information other than in connection with the performance of its duties hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The foregoing provision shall not apply to Confidential Information that (i) has been disclosed to the public by the Company, (ii) otherwise entered the public domain through lawful means, (iii) was or is disclosed to Manager by a third party which is not subject to an obligation of confidentiality to the Company, (iv) was known by Manager prior to its receipt from the Company, (v) was developed by Manager independently of any disclosures previously made by the Company, (vi) is required to be disclosed by Manager in connection with any judicial, administrative or other governmental proceeding involving the Company or the Manager, or any of their affiliates or employees (whether or not such proceeding involves third parties) relating to the Services or this Agreement, provided that Manager provide written notice to the Company, as soon as possible prior to such disclosure, unless notice would be unlawful, or (vii) is disclosed in good faith by Manager in the ordinary course of carrying out its duties hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Limitation on Liability; Indemnification</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Manager assumes no responsibility under this Agreement other than to render the Services called for hereunder in good faith. Manager and its Affiliates, and any of stockholders, officers, directors, employees, consultants and any person providing advisory or sub-advisory services to Manager, will not be liable to the Company or the Company's members, officers, directors, employees or consultants for any acts or omissions by any such Person (including errors that may result from ordinary negligence, such as errors in the investment decision making process or in the trade process) performed in accordance with and pursuant to this Agreement, except by reason of acts or omission constituting bad faith, willful misconduct, gross negligence or reckless disregard of their respective duties under this Agreement, as determined by a final non-appealable order of a court of competent jurisdiction. The Company shall, to the full extent lawful, reimburse, indemnify and hold harmless Manager, its Affiliates, and of its stockholders, managers, partners, personnel, officers, directors, employees, consultants and any person providing advisory or sub-advisory services to Manager (each, a "**Manager Indemnified Party**"), of and from any and all expenses, losses, damages, liabilities, demands, charges and claims of any nature whatsoever (including reasonable attorneys' fees and amounts reasonably paid in settlement) (collectively "Losses") incurred by the Manager Indemnified Party in or by reason of any pending, threatened or completed action, suit, investigation or other proceeding (including an action or suit by or in the right of the Company or its security holders) arising from any acts or omissions of such Manager Indemnified Party performed in good faith under this Agreement and not constituting bad faith, willful misconduct, gross negligence or reckless disregard of duties of such Manager Indemnified Party under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Manager shall, to the full extent lawful, reimburse, indemnify and hold harmless the Company, and the officers or members of the Company (each, a "**Company Indemnified Party**" and, together with a Manager Indemnified Party, an "**Indemnified Party**") of and from any and all Losses in respect of or arising from (i) any acts or omissions of Manager constituting bad faith, willful misconduct, gross negligence or reckless disregard of duties of Manager under this Agreement or (ii) any claims by Manager's employees relating to the terms and conditions of their employment by Manager.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In case any such claim, suit, action or proceeding (a "Claim") is brought against any Indemnified Party in respect of which indemnification may be sought by such Indemnified Party pursuant hereto, the Indemnified Party shall give prompt written notice thereof to the indemnifying party; provided, however, that the failure of the Indemnified Party to so notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have hereunder, except to the extent such failure actually materially prejudices the indemnifying party. Upon receipt of such notice of Claim (together with such documents and information from such Indemnified Party), the indemnifying party shall, at its sole cost and expense, in good faith defend any such Claim with counsel reasonably satisfactory to such Indemnified Party. The Indemnified Party will be entitled to participate but, subject to the next sentence, not control, the defense of any such action, with its own counsel and at its own expense. Such Indemnified Party may elect to conduct the defense of the Claim, if (i) such Indemnified Party reasonably determines that the conduct of its defense by the indemnifying party could be materially prejudicial to its interests, (ii) the indemnifying party refuses to assume such defense (or fails to give written notice to the Indemnified Party within ten (10) days of receipt of a notice of Claim that the indemnifying party assumes such defense), or (iii) the indemnifying party shall have failed, in such Indemnified Party's reasonable judgment, to defend the Claim in good faith. The indemnifying party may settle any Claim against such Indemnified Party without such Indemnified Party's consent, provided, that (i) such settlement is without any Losses whatsoever to such Indemnified Party, (ii) the settlement does not include or require any admission of liability or culpability by such Indemnified Party and (iii) the indemnifying party obtains an effective written release of liability for such Indemnified Party from the party to the Claim with whom such settlement is being made, which release must be reasonably acceptable to such Indemnified Party, and a dismissal with prejudice with respect to all claims made by the party against such Indemnified Party in connection with such Claim. The applicable Indemnified Party shall reasonably cooperate with the indemnifying party, at the indemnifying party's sole cost and expense, in connection with the defense or settlement of any Claim in accordance with the terms hereof. If such Indemnified Party is entitled pursuant to this <u>Section</u> 7 to elect to defend such Claim by counsel of its own choosing and so elects, then the indemnifying party shall be responsible for any good faith settlement of such Claim entered into by such Indemnified Party. Except as provided in the immediately preceding sentence, No Indemnified Party may pay or settle any Claim and seek reimbursement therefor under this Section 7.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The provisions of this Section 7 shall survive the expiration or earlier termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Assignment</u>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assignable or transferable by any party without the prior written consent of the other parties hereto, and any such unauthorized assignment or transfer will be void. This Agreement and all the provisions hereof shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Additional Documents</u>. From time to time after execution of this Agreement, the parties hereto will, without additional consideration, execute and deliver such further documents and take such further action as may be reasonably requested by any other party hereto in order to carry out the purposes of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Entire Agreement</u>. This Agreement contains the entire understanding between the parties and this Agreement supersedes any prior understandings and written or oral agreements between them respecting the subject matter of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Title and Headings</u>. Titles and headings to sections herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Notices</u>. All notices, requests and demands to or upon the respective Parties hereto to be effective shall be in writing, and, unless otherwise expressly provided herein, shall be deemed to have been duly given or made when delivered against receipt or upon actual receipt of (i) personal delivery, (ii) delivery by reputable overnight courier, (iii) delivery by electronic mail, or facsimile transmission or (iv) delivery by registered or certified mail, postage prepaid, return receipt requested, addressed as set forth on the signature pages to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Amendment</u>. The Manager may unilaterally amend this Agreement upon 15 days written notice to the Company and its Members.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Severability</u>. The provisions of this Agreement are severable, and in the event that any one or more provisions are deemed illegal or unenforceable the remaining provisions shall remain in full force and effect unless the deletion of such provision shall cause this Agreement to become materially adverse to either party, in which event the parties shall use reasonable commercial efforts to arrive at an accommodation that best preserves for the parties the benefits and obligations of the offending provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>GOVERNING LAW</u>. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE. EACH OF THE PARTIES HERETO IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF (I) THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE, OR (II) SOLELY TO THE EXTENT THERE IS NO APPLICABLE FEDERAL JURISDICTION OVER SUCH DISPUTE OR MATTER, IN THE STATE COURTS OF DELAWARE FOR THE PURPOSE OF ANY ACTION OR JUDGMENT RELATING TO OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY AND TO THE LAYING OF VENUE IN SUCH COURT.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. <u>WAIVER OF JURY TRIAL</u>*.* EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND, THEREFORE, EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. <u>Counterparts</u>. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, each of the parties hereto has executed this Management Agreement as of the date first written above.

---

| | | |
|:---|:---|:---|
| **COMPANY** | **COMPANY** | **COMPANY** |
| **Tranquil Healthcare Fund I, LLC** | **Tranquil Healthcare Fund I, LLC** | **Tranquil Healthcare Fund I, LLC** |
| By: |  |  |
|  | Name: | Tyler Ehler |
|  | Title: | CEO of Manager |
|  | Address: | 18200 Von Karman Ave. suite 850 |
|  |  | Irvine, CA 92612 |
|  | Email: |  |
| **MANAGER** | **MANAGER** | **MANAGER** |
| **Tranquil Healthcare Holdings, Inc.** | **Tranquil Healthcare Holdings, Inc.** | **Tranquil Healthcare Holdings, Inc.** |
| By: |  |  |
|  | Name: |  |
|  | Title: |  |
|  | Address: |  |
|  | Email: |  |

---

**EXHIBIT A**

<u>DESCRIPTION OF SERVICES</u>

Manager will provide the Company with the personnel, services and resources necessary for the Company to comply with its obligations and responsibilities under the Operating Agreement, which include responsibility for the day-to-day operations of the Company and performance of such services and activities relating to the Business of the Company, including but not limited to those services and activities described in Article II of the Operating Agreement and the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. oversight and management of banking activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. management of preparation and filing of SEC and other corporate filings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. financial, accounting and bookkeeping services, including retention of an auditor for the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. record-keeping, shareholder registrar, investor relations and regulatory compliance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. tax reporting services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. bill payment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. maintain the Company's stock ledger and coordinating activities of the Company transfer agent, escrow agent and related parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. underwriting of the Company's lending operations, including monitoring loans and payments due to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. provide consulting services as needed with respect to the Company's contractual relationships with clinic operators;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j. legal and professional transactional services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k. other transaction-related services, cost, payments and expenditures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l. administrative services in connection with liquidation or winding up of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m. managing litigation, judicial proceedings or arbitration, including the defense and or settlement of any claims (regardless of whether
or not the Issuer is named as a defendant or party in any such claim); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n. other non-routine or extraordinary services.

Notwithstanding anything contained herein, Company shall retain the right and ability to retain any third party service providers directly, at its discretion.

## Ex1A-6

**Exhibit 6.3**

**<u>CONSULTING AGREEMENT</u>**

This Agreement is made as of December 1, 2025 (the "Effective Date") by and between Tranquil Healthcare, Inc., a Delaware Corporation (together with its affiliates, the "Company") and OCIFG, Inc., a California Corporation ("Consultant") (each of Company and Consulting may be referred to individually as a "Party," or collectively as the "Parties").

**WHEREAS**, Consultant has experience with the types of advisory services set forth on ***<u>Exhibit A</u>*** hereto and is willing to provide such services to the Company; and

**WHEREAS**, Company wishes to obtain Consultant's advisory services, as requested by Company, on a non-exclusive basis.

**NOW, THEREFORE**, in consideration of the above recitals, the terms and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;**1.**  **<u>Definitions</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** "**Confidential Information**" means any non-public information relating to the services being provided pursuant to this Agreement, intellectual property, products, services, operations, plans or business of either Party and which either Party reasonably deems confidential, or would otherwise reasonably be understood to be confidential under the circumstances, regardless whether so labeled or the form of disclosure (including written, encoded, graphic, other tangible form, or oral) including, but not limited to, the following: trade secrets, know-how, formulae, inventions, patent applications, devices, techniques, processes, data, software programs, schematics, plans, machinery, designs, equipment, processes, pricing information, software source documents, contracts, customer and supplier lists, financial information, sales, manufacturing, and marketing plans, and information and business plans. For the avoidance of doubt, each Party shall at all times retain sole and exclusive title to all of its respective Confidential Information, except as expressly provided in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** "**Affiliate**" means, with respect to any Person, another person that directly or indirectly through one or more intermediaries, owns or controls, is owned or controlled by or is under common ownership or control with such first Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** "**Person**" means any human being, labor organization, partnership, association, joint venture, corporation, legal representative, trust, trustee, trustee in bankruptcy, receiver, government, governmental body, agency, authority, court or any other legal entity whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;**2.**  **<u>Services</u>** : As requested by Company, Consultant agrees to provide the services as described
on  ***<u>Exhibit A-1</u>*** hereto, as maybe amended from time to time, which may only be amended by a written amendment executed
by both Parties. Consultant also agrees to have up to one (1) weekly status report meeting with the Company, upon reasonable request by
the Company, to provide an update on the status of the services described in Exhibit A-1. Any materials developed by the Consultant will
be provided to the Company for its review and approval (including legal review) prior to any dissemination. Consultant shall not communicate
with any third party regarding the services, the Company, or any potential financing, transaction, or strategic matter without the Company's
prior written approval.

&nbsp;&nbsp;&nbsp;&nbsp;**3.**  **<u>Term</u>** : The term of this Agreement shall commence as of the Effective Date, until cancelled
or terminated in accordance with this Agreement, and shall continue until the expiration or earlier termination of the applicable Exhibit
A-1, unless earlier terminated in accordance with this Agreement. Any continuation of services beyond the term of an Exhibit A-1 shall
require a written amendment executed by both Parties.

&nbsp;&nbsp;&nbsp;&nbsp;**4.**  **<u>Consulting Fees and Payments</u>** : Company will pay Consultant as provided for in  ***<u>Exhibit A-1</u>*** , subject to the terms and conditions set forth in this Agreement and  **<u>Exhibit A-1</u>** .

&nbsp;&nbsp;&nbsp;&nbsp;**5.**  **<u>Intellectual Property</u>** : Consultant will promptly disclose to Company, any invention, trademark,
copyrightable material, or commercial idea or plan, arising from Consultant's work under this Agreement ("  ***Work Product*** ").
Company will be or will be made the exclusive owner of any such Work Product. Consultant thereby irrevocably assigns all Work Products
right, title, and interest in and to the Work Products. Consultant will execute such documents and take such other action if requested
by the Company, at Company's expense, as may be necessary or appropriate to establish, register, record or otherwise document Company's
ownership therein in the United States and/or globally. Consultant hereby irrevocably appoints Company as Consultant's attorney-in-fact
for the purpose of executing such documents, if so desired by the Company. Consultant shall ensure that any subcontractors or freelance

Consultant shall assign such rights to Company to the extent such work product constitutes Work Product hereunder. Consultant agrees to
obtain Company's prior written approval for any presentation or publication relating to the services provided to Company hereunder
or to information disclosed to Consultant by Company in connection with this Agreement, both as to content and time of publication or
presentation. Company, in its sole discretion, reserves the right to withhold or deny such approval of any presentation or publication
relating to the services provided to Company pursuant to this Agreement or to Confidential Information disclosed to Consultant by Company
in connection with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;**6.**  **<u>Independent Contractor</u>** : It is understood that in carrying out any of the services under
this Agreement, Consultant is at all times acting and performing as an independent contractor of the Company , and nothing herein shall
be deemed to create any partnership, joint venture, fiduciary, employment, or agency relationship between the Parties. Consultant will
pay all obligations imposed by any federal, state or local law, regulation or order now or hereafter in force, including, but not limited
to, taxes, unemployment compensation or insurance, social security and workmen's compensation and including the filing of all returns
and reports required of employers and the payment of all assessments, taxes, contributions and other sums required of them. Consultant
may, with the prior knowledge and approval of the Company, introduce potential investors or other third parties to the Company; provided,
however, that Consultant shall not solicit investments, negotiate investment terms, recommend or advise any investor regarding an investment
in the Company, engage in any sales or promotional activity, receive any transaction-based or success-based compensation, or act as a
broker, dealer, finder, placement agent, or similar intermediary with respect to any securities or financing transaction. Any and all
contracts, agreements, communications, or representations made by Consultant in the performance hereof shall be made by Consultant as
principal and not as agent of Company, and Company has no liability to any party to any such contracts made by Consultant. Consultant
shall have no authority to bind to the Company, make commitments on behalf of the Company, or hold itself out as having any such authority,
and the Company shall have no liability to any third party arising from any such contract, communication, or representation.

&nbsp;&nbsp;&nbsp;&nbsp;**7.**  **<u>Warranties and Representations</u>** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** Consultant warrants and represents during the term of this Agreement that: (a) Consultant will perform all services in a professional manner in accordance with all applicable laws, regulations and other legal requirements and in compliance with all of Company's policies provided to Consultant; (b) Consultant is a U.S. citizen or registered entity in the United States or is authorized to work in the U.S., is not acting and will not act during the term of this Agreement in violation of the Immigration Reform and Control act of 1986, its amendments, and regulations thereunder; (c) Consultant has the full power and authority to enter into this Agreement and to perform the obligations set forth herein; and (d) entering into and performing this Agreement will not violate any laws, contracts, or obligations that Consultant is bound by and no third-party approvals are required for Consultant to enter into this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** Company warrants and represents during the term of this Agreement that: (a) Company has the full power and authority to enter into this Agreement and to perform the obligations set forth herein; (b) Company is duly organized, validly existing, and in good standing under the laws of its jurisdiction of organization; (c) entering into and performing this Agreement will not violate any laws, contracts, or obligations that the Company is bound by and no third-party approvals are required for the Company to enter into this Agreement; (d) Company is financially solvent and has the financial resources to pay the compensation to Consultant that is set forth in ***<u>Exhibit A-1</u>*** hereto; and (e) Company will comply with all applicable laws in regulations related to the services being performed by Consultant.

&nbsp;&nbsp;&nbsp;&nbsp;**8.**  **<u>Indemnification</u>** : Each Party hereby indemnifies and holds the other Party and its subsidiaries,
affiliates, parents, partners and licensees harmless from and against any loss, cost, liability, damage or expense (including reasonable
attorney's fees and expenses) any of them may incur or be liable for arising out of any breach or alleged breach of obligations
hereunder, including but not limited to negligence, willful misconduct as well as breach of any of the representations and warranties
made by the Parties hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;**9.**  **<u>Cancellation</u>** : Either Party may cancel this Agreement by written notice to the other Party
with notice of thirty (30) days, and Company agrees to pay Consultant for any fees due and accrued by Consultant through the effective
termination date. Upon termination of this Agreement, each Party will promptly return all of the other Party's property and Confidential
Information. In addition, each Party may terminate this Agreement with no advanced notice for Cause. "Cause" shall include
(i) a material breach of this Agreement that is not cured within ten (10) days after written notice, (ii) breach of confidentiality or
intellectual property obligations, (iii) fraud, gross negligence, willful misconduct, or unlawful acts, or (iv) material misrepresentation
by Consultant. Upon termination of this Agreement, each Party shall promptly return or destroy the other Party's property and Confidential
Information. Sections relating to confidentiality, intellectual property ownership, payment obligations, and any provisions which by their
nature should survive termination shall survive termination.

&nbsp;&nbsp;&nbsp;&nbsp;**10.**  **<u>Confidentiality/Nondisclosure/Non solicitation</u>** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** Each Party may disclose certain of its Confidential Information to the other Party in connection with the services under this agreement, including information related to the disclosing Party's business, services, product, partners, investors, operators, business plans, financial information, trade secrets, know-how, and other proprietary or sensitive information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** Each Party agrees that it will not divulge, disclose, communicate or release or in any way make available or furnish, either directly or indirectly, to any person, firm, corporation, association or organization, at any time, any Confidential Information of the other Party, summary of Confidential Information or any reports based on Confidential Information without the express written consent of the other Party. Each Party shall restrict disclosure of the Confidential Information to only those of his/her employees, agents, or consultants with a need to know such information in order to consider perform under this Agreement and advise those employees, agents or consultants of their obligation under this Agreement to protect the Confidential Information. Each Party shall take all necessary measures to ensure that the absolute confidentiality of the Confidential Information is maintained, including but not limited to any measures that a Party takes to safeguard his/her own valuable Confidential Information, but in no event less than a reasonable standard of care.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** Notwithstanding the foregoing, each Party's obligations to keep information confidential shall not apply to information which (i) was lawfully known to the receiving without an obligation to keep confidential, (ii) becomes publicly available through no breach of this agreement; (iii) was received from a third party as long as such third party was under no obligation to keep such information confidential; (iv) was independently developed by the receiving Party independently without use of disclosing Party's Confidential Information; and (v) is approved for disclosure by the prior written authorization of disclosing Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** If any Confidential Information is subpoenaed from or a demand for production is made by any other form of legal process on a receiving Party or any of partners, directors, officers, subsidiaries, affiliates or agents by any court, administrative or legislative body or any other person or entity purporting to have authority to subpoena or demand the production of Confidential Information, receiving Party, shall not (nor shall receiving Party permit partners, directors, officers, employees or agents to) produce the Confidential Information without first, to the extent legally permissible, giving written notice of the subpoena or demand (including the delivery of a copy thereof) to counsel for disclosing Party within sufficient time prior to the time when production of the Confidential Information is requested by subpoena or demand to give disclosing Party a reasonable time within which to object to such production.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** Upon termination of this Agreement, the receiving Party agrees to promptly return to disclosing Party, all reports, summaries, copies, notes documents, papers, or other matters that contain Confidential Information, whether in physical or electronic form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(f)** Each Party acknowledges that a breach of this Section 10 may not be adequately compensated by monetary damages, and each Party agrees that the disclosing Party may be entitled to, in addition to any other right or remedy available to it at law or inequity, seek injunctive relief restraining such breach or threatened breach, and to specific performance of Section 10 of this Agreement, and, in either case, no bond or other security will be required in connection therewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(g)** Consultant agrees that for a period of one (1) year, the Consultant will not, directly or indirectly, solicit, hire, or induce any employee, contractor, consultant, operator, partner, vendor, or other consultants of the Company without prior written authorization of the Company. In addition, Consultant will not utilize any list of existing investors of the Company without prior written authorization of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(h)** The confidentiality obligations under this Section shall survive termination of this Agreement for a period of three (3) years, provided that obligations relating to trade secrets shall survive for so long as such information remains a trade secret under applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;**11.**  **<u>Assignment</u>** : Consultant acknowledges that this Agreement is for his/her personal services
and may not be assigned, transferred, or subcontracted, in whole or in part by Consultant without the express written consent of Company,
which will not be unreasonably withheld, conditioned, or delayed. Company may assign this Agreement, without Consultant's consent,
to any affiliate or in connection with a merger, reorganization, sale of assets, financing, or similar transaction upon written notice
to Consultant.

&nbsp;&nbsp;&nbsp;&nbsp;**12.**  **<u>Notices</u>** : Service of all notices under this Agreement shall be sufficient if given personally
or mailed or emailed to any officer of Company or to Consultant at their respective addresses as herein set forth. Any notice mailed shall
be deemed to have been given on the day it is mailed.

&nbsp;&nbsp;&nbsp;&nbsp;**13.**  **<u>Failure to Exercise Rights</u>** : The failure of any of the Parties hereto to exercise the rights
granted them herein upon the occurrence of any of the contingencies set forth herein shall not in any event constitute a waiver of any
such rights upon the recurrence of any such contingency.

&nbsp;&nbsp;&nbsp;&nbsp;**14.**  **<u>Entire Agreement, Amendments</u>** : There are no other Agreements or understandings, written or
oral between the Parties, regarding the conditions specified herein. This Agreement shall not be modified or amended except by a written
document executed by both parties to this Agreement, and such written modification shall be attached hereto.

&nbsp;&nbsp;&nbsp;&nbsp;**15.**  **<u>Governing Law</u>** : This Agreement shall be construed pursuant to the laws of the State of California
without giving effect to its conflicts of law rules.

&nbsp;&nbsp;&nbsp;&nbsp;**16.**  **<u>Attorneys' Fees</u>** : In any action to enforce this Agreement, the prevailing Party shall be
entitled to recover all court costs and expenses and reasonable attorneys' fees, in addition to any other relief to which it may be entitled.

&nbsp;&nbsp;&nbsp;&nbsp;**17.**  **<u>Non-Exclusivity</u>** : The Parties acknowledge that this Agreement is non-exclusive and either
Party will be free, during and after the term of this Agreement, to engage or contract with third parties for the provision of services
similar those contained in this Agreement, notwithstanding the Consultant agreements that it shall not, during the term of this Agreement,
provide services to any third party that would create a material conflict with the Company, nor use the Company's confidential information
in connection with any such services. Consultant shall promptly disclose to the company any engagement that could reasonably be expected
to present a conflict of interest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. <u>Advice of Counsel</u>: Each Party acknowledges that, in executing this Agreement, such Party has had the opportunity to seek the advice of independent legal counsel, and has read and understood all of the terms and provisions of this Agreement. This Agreement shall not be construed against any Party by reason of the drafting or preparation hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. <u>Counterparts</u>: This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Moreover, this Agreement,
including any counterparts, if affixed with an electronic signature platform, or signed and submitted by facsimile, or by e-mail as a
scanned document, will be deemed an original signed Agreement binding on the Parties.

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this instrument as of the Effective Date. By signing below, each Party attests to understanding and agreeing to conditions listed above.

---

| | | |
|:---|:---|:---|
| **Company:**<br>**Tranquil Healthcare, Inc.** | **Company:**<br>**Tranquil Healthcare, Inc.** | **Company:**<br>**Tranquil Healthcare, Inc.** |
| <br> By: |  |  |
|  | Name: | Tyler Ehler |
|  | Title: | CEO |
| Email: |  |  |

---

 

---

| | | |
|:---|:---|:---|
| **Consultant:**<br>**OCIFG, Inc.** | **Consultant:**<br>**OCIFG, Inc.** | **Consultant:**<br>**OCIFG, Inc.** |
| <br> By: |  |  |
|  | Name: | Kevin Wiltz |
|  | Title: | Chairman |
| Email: |  |  |

---

 

**EXHIBIT A-1**

**Service Assignment #1 Under Consulting Agreement**

**Dated:** December 1, 2025

**Description of Services:**

Consultant will render the following services to Company (the "**Services**"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. **Strategic and Corporate Advisory** 

Advise the Company with regard to strategic alternatives, corporate finance considerations, and business positioning.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. **Business Development Support** 

Analyze business development initiatives and assist the Company, on an as needed basis, with evaluating and prioritizing such initiatives. This includes providing feedback on new potential clinic partners within fourteen (14) days from receipt of a request to do so by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. **Strategic Opportunities and Partnerships** 

Assist the Company in identifying and analyzing potential strategic opportunities, partnerships, or transactions, and where appropriate, developing high-level frameworks for implementation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. **Professional Services & Network Infrastructure** 

On an as requested basis, introduce the Company to professional services providers, with the two key providers being legal and accounting, as appropriate to support the Company's strategic initiatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. **Investor & Corporate Communications** 

Review, updated, and provide feedback on investor presentations, corporate decks, and related materials, including preparing updated presentation materials on a monthly basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F. **Industry & Company Analysis** 

Analyze the Company's business and industry and provide the Company with a written report, including financial models, summarizing its findings (the "Corporate Profile"), for internal or external use, at the Company's discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G. **Visibility and Thought Leadership** 

Assist the Company with identifying and attending networking events to increase the Company's visibility in its industry, with a minimum of one (1) conference or networking event per quarter.

**Deliverables** 

Subject to the Company's cooperation, availability of information, and strategic priorities, Consultant shall use commercially reasonable efforts to support the following deliverables related to the Services:

&nbsp;&nbsp;&nbsp;&nbsp;1. **Presentation Materials:** <br>
Review and update the Company's primary investor or corporate presentation materials **no less than once per calendar month**,
or more frequently as reasonably requested by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;2. **Thought Leadership & Speaking Opportunities:** <br>
Identify and propose **at least one (1) speaking, panel, or conference opportunity per calendar quarter**, which may include industry
events, webinars, or moderated discussions.

&nbsp;&nbsp;&nbsp;&nbsp;3. **Strategic Briefings:** <br>
Provide periodic strategic updates, written summaries, or briefing materials, as requested by the Company, to support management and Board-level
discussions.

&nbsp;&nbsp;&nbsp;&nbsp;4. **Networking & Introductions:** <br>
Facilitate relevant introductions and meetings on an ongoing basis, as appropriate, to advance the Company's strategic and visibility
objectives.

Consultant shall devote such time and effort, as it deems commercially reasonable and adequate under the circumstances to the affairs of Company to render the Services contemplated by this <u>Exhibit A-1.</u> Consultant is not responsible for the Company's decisions or agreements, and will not be responsible for any Services not rendered or deliverables not provided as a result of the Company's failure to provide the necessary information reasonably requested by Consultant. Services will not constitute the rendering of any legal opinions or performance of work that is in the ordinary purview of the Certified Public Accountant. The acceptance of any advice shall be at the sole discretion of the Company. It is understood that a portion of the compensation paid hereunder is being paid by Company to have Consultant remain available to advise on an as-needed basis.

**Term:**

The term of this <u>Exhibit A-1</u> will begin on December 8, 2025 and continue until October 3, 2026, or such earlier date the Agreement is terminated.

**Fees And Reimbursement:**

Consultant shall be paid pursuant to the following Schedule:

(i) $25,000 on the Effective Date ("First Payment"),

(ii) $25,000 on or before the 60<sup>th</sup> day after the Effective Date,

(iii) $50,000 on or before the 120<sup>th</sup> day after the Effective Date,

(iv) $50,000 on or before the 180<sup>th</sup> day after the Effective Date,

(v) $50,000 on or before the 240<sup>th</sup> day after the Effective Date, and

(vi) $50,000 on or before the 300<sup>th</sup> day after the Effective Date.

Except for the First Payment, the Company may defer subsequent payments if the Board of Directors of the Company determines, at its sole discretion, that there is not sufficient cash available to make such applicable payment. Once the Board of Directors determines sufficient cash is available, the applicable deferred payments will be paid within five (5) days thereafter.

Any costs associated with marketing and other third party services will be approved in writing by the Company's CEO prior to being incurred and paid directly by the Company to such applicable third party and shall not be considered a part of the fees charged by Consultant.

Consultant will be reimbursed for all out of pocket expenses pre-approved by the CEO of the Company, in writing.

Upon any termination of the Agreement, the Company will be responsible for payments up through the date of termination ratably based on the days elapsed from the for the applicable payment period.

The parties have executed this ***<u>Exhibit A-1</u>*** as of the date set forth herein.

---

| | | |
|:---|:---|:---|
| **Company:**<br>**Tranquil Healthcare, Inc.** | **Company:**<br>**Tranquil Healthcare, Inc.** | **Company:**<br>**Tranquil Healthcare, Inc.** |
| <br> By: |  |  |
|  | Name: | Tyler Ehler |
|  | Title: | CEO |
| Email: |  |  |

---

 

---

| | | |
|:---|:---|:---|
| **Consultant:**<br>**OCIFG, Inc.** | **Consultant:**<br>**OCIFG, Inc.** | **Consultant:**<br>**OCIFG, Inc.** |
| <br> By: |  |  |
|  | Name: | Kevin Wiltz |
|  | Title: | Chairman |
| Email: |  |  |

---

## Ex1A-12

**Exhibit 12.1**

March 16, 2026

Tranquil Healthcare Fund I, LLC

18200 Von Karman Ave., Suite 850

Irvine, CA 92612

**Re: Tranquil Healthcare Fund I, LLC Offering Statement on Form 1-A**

Ladies and Gentlemen,

We have acted as special counsel to Tranquil Healthcare Fund I, LLC (the "**Company**"), a limited liability company organized under the laws of the State of Delaware, in connection with the filing of an offering statement on Form 1-A (the "**Offering Statement**") under Regulation A of the Securities Act of 1933, as amended (the "**Securities Act**"), with the Securities and Exchange Commission (the "**Commission**") relating to the proposed offering by the Company (the "**Offering**") of up to (i) 5,000,000 Class A Preferred Shares, which represents a Class A Preferred limited liability interest (the "**Preferred Shares**"), and (ii) 500,000 Preferred Shares ("**Incentive Shares**") issuable to certain purchasers as a bonus for purchasers purchasing at least 10,000 Preferred Shares in a closing. Collectively, the Preferred Shares and Incentive Shares are referred to herein collectively, as the "**Securities**".

For purposes of rendering this opinion, we have examined originals or copies (certified or otherwise identified to our satisfaction) of :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. the Company's Certificate of Formation, as filed with the Secretary of State of the State of Delaware on March 3, 2026;

2. the Company's Operating Agreement, in the form filed as Exhibit 2.2 to the Offering Statement, filed with the Commission on March 16, 2026;

3. the form of Subscription Agreement for the Preferred Shares, in the form filed as Exhibit 4.1 to the Offering Statement, filed with the Commission on March 16, 2026; and

4. Resolutions of the Manager of the Company approving the transactions contemplated by the Offering Statement dated March 16, 2026.

We have also examined such other certificates of public officials, such certificates of executive officers of the Company and such other records, agreements, documents and instruments as we have deemed relevant and necessary as a basis for the opinion hereafter set forth.

In such examination, we have assumed: (i) the genuineness of all signatures, (ii) the legal capacity of all natural persons, (iii) the authenticity of all documents submitted to us as originals, (iv) the conformity to original documents of all documents submitted to us as certified, conformed or other copies and the authenticity of the originals of such documents and (v) that all records and other information made available to us by the Company on which we have relied are complete in all material respects. As to all questions of fact material to this opinion, we have relied solely upon the above-referenced certificates or comparable documents and other documents delivered pursuant thereto, have not performed or had performed any independent research of public records and have assumed that certificates of or other comparable documents from public officials dated prior to the date hereof remain accurate as of the date hereof.

Based on the foregoing and on such legal considerations as we deem relevant, assuming that the Offering Statement has been qualified by the Commission, and that the Securities are issued and sold in accordance with the terms and conditions described therein, we are of the opinion that:

(i) the Preferred Shares, when issued and delivered against payment therefor as described in the Offering Statement, will be validly issued, fully paid and non-assessable and

(ii) the Incentive Shares, when issued and delivered as described in the Offering Statement, will be validly issued, fully paid and non-assessable.

The foregoing opinion is limited to the laws of the State of Delaware and we do not express any opinion herein concerning any other law.

The opinion expressed herein is rendered as of the date hereof and is based on existing law, which is subject to change. Where our opinion expressed herein refers to events to occur at a future date, we have assumed that there will have been no changes in the relevant law or facts between the date hereof and such future date. We do not undertake to advise you of any changes in the opinion expressed herein from matters that may hereafter arise or be brought to our attention or to revise or supplement such opinion should the present laws of any jurisdiction be changed by legislative action, judicial decision or otherwise.

Our opinion expressed herein is limited to the matters expressly stated herein, and no opinion is implied or may be inferred beyond the matters expressly stated.

We hereby consent to the use of this letter as an exhibit to the Offering Statement and to any and all references to our firm in the offering circular that is a part of the Offering Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations of the Commission.

Very truly yours,

SILVESTRE LAW GROUP, P.C.

---

| | |
|:---|:---|
| By: | /s/ Raul Silvestre |
|  | Raul Silvestre, Managing Partner |

---

## Ex1A-13

**Exhibit 13.1**

![](image_007.jpg)

Regulation A Offering This presentation and the accompanying oral commentary are provided for informational purposes only and do not constitute an offer to sell or the solicitation of an offer to buy any securities. Tranquil Healthcare Fund I, LLC (the "Company," "Tranquil," "we," "our," or "us") has filed an offering statement on Form 1 - A under Regulation A of the Securities Act of 1933, as amended (the "Offering Statement") with the U.S. Securities and Exchange Commission (the "SEC") relating to the securities discussed in this presentation. The Offering Statement has not yet been qualified by the SEC. No offer to buy securities can be accepted and no part of the purchase price can be received until the Offering Statement has been qualified by the SEC.

![](image_008.jpg)

Forward - Looking Statements This presentation contains forward - looking statements relating to future events and the future financial or operating performance, business strategy, and potential market opportunity of Tranquil. Words such as "anticipate," "objective," "may," "will," "might," "should," "could," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," and similar expressions are intended to identify forward - looking statements. Forward - looking statements are based on estimates and assumptions that, while considered reasonable by the Company, are inherently uncertain and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. There can be no assurance that these expectations will prove to be correct. Forward - looking statements involve numerous assumptions and known and unknown risks and uncertainties that may cause the Company's actual results or performance to differ materially from those expressed or implied in such statements. Except as required by law, the Company undertakes no obligation to update or revise any forward - looking statements. This presentation also contains industry and market data obtained from third - party sources and prepared by the Company based on such sources. Although the Company believes these sources are reliable, the Company has not independently verified the accuracy or completeness of such information. Such data is subject to assumptions and uncertainties. All third - party trademarks, service marks, logos, and brand names referenced in this presentation are the prope rty of their respective owners. References to such marks are for identification purposes only and constitute nominative fair use. Rule 255 Legend No money or other consideration is being solicited at this time and, if sent in response, will not be accepted. No offer to buy securities can be accepted and no part of the purchase price can be received until the Offering Statement has been qualified by the SEC. Any indication of interest involves no obligation or commitment of any kind. Any indication of interest may be withdrawn or revoked at any time, without obligation or commitment of any kind, before notice of acceptance is given after the qualification of the Offering Statement. You should read the Offering Statement and any other documents the Company has filed (or will file) with the SEC for more complete information about the Company and the offering. Copies of the most recent Offering Statement may be obtained free of charge from the SEC's website at www.sec.gov , or from: Tranquil Healthcare Fund I, LLC 18200 Von Karman Ave. #850 Irvine, CA 92612 646 - 902 - 4953 invest@tranquil.healthcare

![](image_009.jpg)

FINANCING THE BUILDOUT OF MENTAL HEALTH CLINICS For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_010.jpg)

Physicians in Private Practice – Creating a Capital Gap $1.6B → $2.5B 1 21M+ U.S. Adults 2 Specialty Financing for a Growing Sector For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. ¹ Mordor Intelligence, Transcranial Magnetic Stimulator Market Report , 2025. https:// www.mordorintelligence.com/industry - reports/transcranial - magnetic - stimulator - market ² National Institute of Mental Health (NIMH), Major Depression Statistics , 2022. nimh.nih.gov/health/statistics/major - depression ³ U.S. Food and Drug Administration, TMS Device Clearance Records; Neuronetics, Inc. and BrainsWay Ltd. FDA clearance announcements, 2008 – 2024. fda.gov ⁴ American Medical Association, Physician Practice Characteristics in 2024: Private Practices Account for Less Than Half of Physicians in Most Specialties , May 2025. ama - assn.org 5+ FDA Cleared I n di c a t i o n s 3 18 - pt Drop Since 2012 4 With More Expected Approvals Diagnosed with TMS - Eligible Conditions TMS Market Size Growing to 2031

![](image_011.jpg)

Business Model For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. \*This model is based on anticipated agreements Interest on Loans 10% Consulting Fees 10% of EBITDA per Clinic Clinic Sale Participation Repayment of Loans + 10% of Net Proceeds

![](image_012.jpg)

✓ Limited Equity Dilution For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Tranquil has entered into a non - binding term - sheet with DGR Health Services, LLC. ✓ Turnkey Financing ✓ Consulting Support ✓ Aligned Incentives ✓ Scalable Model Why Operators Choose Tranquil

![](image_013.jpg)

Ran 30+ Clinics in Multiple States Our First Partner 600+ TMS Patients Treated Per Day Licensed Across 20+ States Clinical, Operational, and Marketing Expertise For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Tranquil has entered into a non - binding term - sheet with DGR Health Services, LLC.

![](image_014.jpg)

YOUR INVESTMENT FUNDS CAPITAL LOANS TO ESTABLISHED TMS CLINIC OPERATORS For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_015.jpg)

EVERY INVESTMENT STARTS HERE DISTRIBUTION P AR T I CI P A T IO N of all Distributions after 8% Preference 1 % 8 7 0 % Annual Cumulative Preference 1 INVESTING WITH TRANQUIL HEALTHCARE 8% CUMULATIVE ANNUAL PREFERENCE ON DISTRIBUTIONS 1 Class A Preferred Shares / Membership Interests $10.00 per Share \| $50M Raise \| $2,500 Min Investment Regulation A Offering Terms and Conditions Apply 10% Bonus in Class A Preferred Shares for $100,000 Investment For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1 Distributions are not guaranteed and are made at the discretion of our manager after 8% cumulative preference is satisfied

![](image_016.jpg)

Tyler Ehler CEO of Tranquil Healthcare For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_017.jpg)

Tyler Ehler 10+ Years as a Healthcare Executive Specializing in Biotech and Investor Relations For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_018.jpg)

OUR MANAGER'S TEAM Tyler Ehler CEO Jeff Campbell Board Member Biotech CEO Board Member For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_019.jpg)

For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. Logos represent prior employers and academic institutions of Tranquil's management team and board. These organizations have no affiliation with Tranquil Healthcare Fund I, LLC and do not endorse this offering. OUR MANAGER TEAM'S PROFESSIONAL BACKGROUND

![](image_020.jpg)

OUR OPERATING PARTNER DGR HEALTH SERVICES 1 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Tranquil has entered into a non - binding term - sheet with DGR Health Services, LLC. and is our first anticipated operating partner. Dr. Kevin Moore, MD, DFAPA Primary Physician & Medical Lead Randy Syrop Co - founder of DGR Health Services, LLC (OpCo) Dr. George Chu, Ph.D Co - founder of DGR Health Services, LLC (OpCo)

![](image_021.jpg)

For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. National Institute of Mental Health (NIMH). Mental Illness Statistics; National Alliance on Mental Illness (NAMI). Mental Health By the Numbers . 2022 MENTAL I L L NE S S Impacts 1 in 5 Americans 1

![](image_022.jpg)

48 MILLION AMERICANS SUFFER FROM DE P R E S S I O N 1 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Gallup, "U.S. Depression Rate Remains Historically High," Sept. 9, 2025, https://news.gallup.com/poll/694199/u.s. - depression - rate - remains - historically - high.aspx

![](image_023.jpg)

OVER 5 MILLION AMERICANS HAVE AUTISM 1 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Centers for Disease Control and Prevention, "Prevalence of Autism Spectrum Disorder Among Adults in the United States, 2014 – 2021," MMWR Supplements , 2020, https://www.cdc.gov/mmwr/volumes/69/su/su6904a2.htm

![](image_024.jpg)

13 MILLION A M ERI C ANS SUFFER FROM PTSD 1 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. U.S. Department of Veterans Affairs, National Center for PTSD, "How Common Is PTSD in Adults?", updated March 2025, https://www.ptsd.va.gov/understand/common/common_adults.asp

![](image_025.jpg)

For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Cleveland Clinic, "Treatment - Resistant Depression," last reviewed May 16, 2023, https://my.clevelandclinic.org/health/diseases/24991 - treatment - resistant - depression STANDARD OF CARE IS FAILING P A T I EN T S ❖ First - line treatment for depression, PTSD, and OCD is antidepressant medication ❖ ~30% of patients with major depression do not respond adequately to medication 1 ❖ TMS is FDA - cleared as a non - drug alternative for patients who have failed medication

![](image_026.jpg)

COMMON SIDE EFFECTS Loss of appetite or increased appetite Blurred vision Gastrointestinal discomfort / abdominal pain Muscle or joint pain Increased blood pressure or heart rate Cognitive effects (brain fog, difficulty concentrating, memory issues) Rash or skin irritation Increased risk of infection Vomiting Tremor or shakiness Dizziness Diarrhea C o n s t i pa t i o n Insomnia or sleep disturbances Anxiety or nervousness Sedation or drowsiness Increased sweating OF ANTIDEPRESSANT MEDICATIONS 1 Nausea Headache Brain Fog Dry Mouth Fatigue Weight Gain Sexual Dysfunction For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Frontiers in Pharmacology, "Neurological adverse events associated with antidepressants: a comprehensive 22 - year analysis of the FDA adverse event reporting system," July 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1644241/ful l

![](image_027.jpg)

T R A N S C R AN I A L M AGNETIC S TIMULATION For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_028.jpg)

No Drugs. No Sedation. No Known Systemic Side Effects 1 . 60% Remission Rate 2 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all 1. Systemic side effects refer to whole - body effects associated with medications. 2. Tendler A, et al., "Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis," Psychiatry Research , June 2023, https://pubmed.ncbi.nlm.nih.gov/37030054/ .

![](image_029.jpg)

S U C C E SS CASE BEFORE TMS AFTER TMS Complete Mind Care For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_030.jpg)

24 A u t i s m Depression Obsessive Compulsive Disorder (OCD) Smoking Addiction Chronic Pain Multiple Sclerosis (MS) Parkinson's Disease Post Stroke Rehabilitation P T SD 3 Negative Symptoms of Schizophrenia Alzheimer's Disease Bipolar Disorder For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1 U.S. Food and Drug Administration 510(k) clearances: Depression (2013), OCD (2018), Smoking Cessation (2020). Source: BrainsWay Ltd., https://www.brainsway.com/our - treatments/ 2 EU CE mark approvals per BrainsWay Ltd., www.brainsway.com/our - treatments 3 Post Traumatic Stress Disorder APPROVED Treatments 1 E U - O n l y 2

![](image_031.jpg)

Insurance Reimbursement TMS therapy is widely covered by major insurers and Medicare. For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. Insurance carrier logos shown for illustrative purposes only. Coverage varies by plan, location, and indication. Not all carriers shown cover TMS at all locations.

![](image_032.jpg)

NOT ENOUGH AWARENESS, NOT ENOUGH CLINICS For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_033.jpg)

THE TREATMENT EXISTS, THE I N F R AS T R U C T U R E DOES NOT For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_034.jpg)

Operating Partner DGR 1 Ran 30+ Clinics in Multiple States DTC Patient Acquisition Financing Expertise Proven Track Record For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Tranquil has entered into a non - binding term - sheet with DGR Health Services, LLC.

![](image_035.jpg)

"I've had the privilege of watching you execute before, and that history matters. What you're building now feels like a natural next chapter: focused, ambitious, and well - timed. I'm very much looking forward to watching you and your team open many clinics alongside the BrainsWay team and to seeing this partnership translate into real clinical and business success." Hadar Levy, CEO of BrainsWay Inc. NASDAQ: BWAY For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. O p e r a t i ng Partner's Proven Track Record

![](image_036.jpg)

Direct To Consumer Radio O ff lin e Online Ads Jeff Campbell (Manager) 25 Years of DTC Expertise $4 billion Media Spend Randy Syrop (DGR 1) 35+ clinics Successful Acquisition of Clients CRM C l i n i c s ʛ For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Tranquil has entered into a non - binding term - sheet with DGR Health Services, LLC.

![](image_037.jpg)

POLL QUESTION What brought you to today's webinar? For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_038.jpg)

OUR SOLUTION Identify Regions for TMS Clinics and Finance Operators in High - Value Markets For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_039.jpg)

Fund TMS Clinic Partners to Achieve Full Patient Capacity OUR GOAL For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_040.jpg)

Identified Operating Partner DGR Health Services, LLC 1 Setup of Operations & Bridge Loan 2025 Company Founded Deploy Capital to TMS Clinic Partners Across Target Markets 2026 Raise Up To $50 Million in the Reg A Support Operators in Clinic Buildout Expand DTC Marketing 2027+ Expand Clinic Partner Network Optimize Portfolio Performance Across Clinic Partners OUR PLAN For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Tranquil has entered into a non - binding term - sheet with DGR Health Services, LLC.

![](image_041.jpg)

Clinic Infrastructure Marketing First Year Interest Reserved Working Capital Bridge Loan Repayment Clinic Infrastructure Marketing Capital Reserve Working Capital Accrued Liabilities Bridge Repayment 40, 0 0 0, 0 00 2,500,000 4,000,000 3,038,500 91, 5 0 0 370, 0 00 T o t a l $50,000,000 USE OF P R O C EE D S 1 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. This is an anticipated use of proceeds based on raising an aggregate of $50,000,000 with no assurance we raise that much capital.

![](image_042.jpg)

Exit Plan Initial Raise (Target of $50 Million USD) Deploy Capital to TMS Clinic Partners Generate Returns through Loan Repayments and Profit Participation Potential Future Exit 1 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1. Potential future exit pathways may include portfolio sale, fund refinancing, or wind - down with return of capital to investors. No exit is guaranteed and there can be no assurance that any exit will be achieved.

![](image_043.jpg)

PRESERVING TAX - FREE STATUS You can earn tax - free passive income by using self - directed IRA funds to fund your investment. Traditional, SEP, and ROTH IRAs, 401k from Prior Employer, Retired TSP Plans, and 403b plans are eligible. •Tax - Deferred Yield •Option to Compound •Custodian Fees Covered Purchase through your IRA Custodian Have your custodian make the purchase or contact us for more information. Ask for a Call from Tranquil Our team can help you if needed Purchase Directly from your IRA Our team can help you if needed INVEST T HRO U GH YOUR IRA For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_044.jpg)

How familiar were you with TMS treatment prior to today's presentation? POLL QUESTION 2 For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_045.jpg)

EVERY INVESTMENT STARTS HERE DISTRIBUTION P AR T I CI P A T IO N of all Distributions after 8% Preference 1 % 8 7 0 % Annual Cumulative Preference 1 INVESTING WITH TRANQUIL HEALTHCARE 8% CUMULATIVE ANNUAL PREFERENCE ON DISTRIBUTIONS 1 Class A Preferred Shares / Membership Interests $10.00 per Share \| $50M Raise \| $2,500 Min Investment Regulation A Offering Terms and Conditions Apply 10% Bonus in Class A Preferred Shares for $100,000 Investment For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all. 1 Distributions are not guaranteed and are made at the discretion of our manager after 8% cumulative preference is satisfied

![](image_046.jpg)

5 4 3 2 1 Personalized Login Tracked on Blockchain Non - Tradeable, Non - Transferable Transparent Ledger Transparent Recordkeeping To k e n i z ed Shareholder Logs For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

![](image_047.jpg)

INVEST IN THE FUTURE OF MENTAL HEALTH INFRASTRUCTURE (646) 902 - 4953 I n v e s t @ T r a nqu i l . H e a l t hc a r e Tranquil.Healthcare Tyler Ehler CEO & DIRECTOR For important disclaimers, visit https:// www.tranquil.healthcare/disclaimers — Planned distributions on Class A Preferred Shares are not guaranteed and may fluctuate or not be paid at all.

## Add

**Exhibit 99.1**

**TRANQUIL HEALTHCARE HOLDINGS, INC.**

**Code of Ethics and Business Conduct**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Introduction</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 The Board of Directors ("**Board**") of Tranquil Healthcare Holdings, Inc. (together with its subsidiaries, the "**Company**") has adopted this Code of Ethics and Business Conduct (the "**Code**") in order to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) promote full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the United States Securities and Exchange Commission (the "**SEC**") and in other public communications made by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) promote compliance with applicable governmental laws, rules and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) promote the protection of Company assets, including corporate opportunities and confidential information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) promote fair dealing practices;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) deter wrongdoing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) ensure accountability for adherence to the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 All directors, officers and employees are required to be familiar with the Code, comply with its provisions and report any suspected violations as described below in Section 10, Reporting and Enforcement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Honest and Ethical Conduct</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 The Company's policy is to promote high standards of integrity by conducting its affairs honestly and ethically.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 Each director, officer and employee must act with integrity and observe the highest ethical standards of business conduct in his or her dealings with the Company's customers, suppliers, partners, service providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Conflicts of Interest</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 A conflict of interest occurs when an individual's private interest (or the interest of a member of his or her family) interferes, or even appears to interfere, with the interests of the Company as a whole. A conflict of interest can arise when an employee, officer or director (or a member of his or her family) takes actions or has interests that may make it difficult to perform his or her work for the Company objectively and effectively. Conflicts of interest also arise when an employee, officer or director (or a member of his or her family) receives improper personal benefits as a result of his or her position in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 Loans by the Company to, or guarantees by the Company of obligations of, employees or their family members are of special concern and could constitute improper personal benefits to the recipients of such loans or guarantees, depending on the facts and circumstances. Loans by the Company to, or guarantees by the Company of obligations of, any director or executive officer or their family members are expressly prohibited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 Whether or not a conflict of interest exists or will exist can be unclear. Conflicts of interest should be avoided unless specifically authorized as described in Section 3.4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 Persons other than directors and executive officers who have questions about a potential conflict of interest or who become aware of an actual or potential conflict should discuss the matter with, and seek a determination and prior authorization or approval from, the Chief Financial Officer. A supervisor may not authorize or approve any matters related to a conflict of interest or make determinations as to whether a conflict of interest exists without first providing the Chief Financial Officer with a written description of the activity and seeking the Chief Financial Officer's written approval. If the Chief Financial Officer is himself involved in the potential or actual conflict, the matter should instead be discussed directly with the Chairman of the Board.

Directors and executive officers must seek determinations and prior written authorizations or approvals of potential conflicts of interest exclusively from the Audit Committee, if one exists, or alternatively from the independent members of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Compliance</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 Employees, officers and directors should comply, both in letter and spirit, with all applicable laws, rules and regulations in the cities, states and countries in which the Company operates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 Although not all employees, officers and directors are expected to know the details of all applicable laws, rules and regulations, it is important to know enough to determine when to seek advice from appropriate personnel. Questions about compliance should be addressed to the Company's outside legal counsel as identified by the Chief Financial Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 No director, officer or employee may purchase or sell any Company securities while in possession of material nonpublic information regarding the Company, nor may any director, officer or employee purchase or sell another company's securities while in possession of material nonpublic information regarding that company. It is against the Company's policies and illegal for any director, officer or employee to use material nonpublic information regarding the Company or any other company to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) obtain profit for himself or herself;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) avoid a loss for himself or herself; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) directly or indirectly "tip" others who might make an investment decision on the basis of that information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Disclosure</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 The Company's periodic reports and other documents filed with the SEC, including all financial statements and other financial information, must comply with applicable federal securities laws and SEC rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 Each director, officer and employee who contributes in any way to the preparation or verification of the Company's financial statements and other financial information must ensure that the Company's books, records and accounts are accurately maintained. Each director, officer and employee must cooperate fully with the Company's accounting and internal audit departments, as well as the Company's independent public accountants and counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 Each director, officer and employee who is involved in the Company's disclosure process must:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) be familiar with and comply with the Company's disclosure controls and procedures and its internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business condition of the Company provide full, fair, accurate, timely and understandable disclosure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Protection and Proper Use of Company Assets</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 All directors, officers and employees should protect the Company's assets and ensure their efficient use. Theft, carelessness and waste have a direct impact on the Company's financial results and are prohibited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 All Company assets should be used only for legitimate business purposes. Any suspected incident of fraud or theft should be reported for investigation immediately.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 The obligation to protect Company assets includes the Company's proprietary information. Proprietary information includes but is not limited to intellectual property such as trade secrets, patents, trademarks, and copyrights, as well as business and marketing plans, product and service development ideas, designs, databases, records and any nonpublic financial data or reports. Unauthorized use or distribution of this information is prohibited and could also be illegal and result in civil or criminal penalties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Corporate Opportunities</u>. All directors, officers and employees owe a duty to the Company to advance its interests when the opportunity arises. Directors, officers and employees are prohibited from taking for themselves personally (or for the benefit of friends or family members) opportunities that are discovered through the use of Company assets, property, information or position. Directors, officers and employees may not use Company assets, property, information or position for personal gain (including gain of friends or family members). In addition, no director, officer or employee may compete with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Confidentiality</u>. Directors, officers and employees should maintain the confidentiality of information entrusted to them by the Company or by its customers, suppliers or partners, except when disclosure is expressly authorized or is required or permitted by law. Confidential information includes all nonpublic information (regardless of its source) that might be of use to the Company's competitors or harmful to the Company or its customers, suppliers or partners if disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Fair Dealing</u>. Each director, officer and employee must deal fairly with the Company's customers, suppliers, partners, service providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job. No director, officer or employee may take unfair advantage of anyone through manipulation, concealment, abuse or privileged information, misrepresentation of facts or any other unfair dealing practice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Reporting and Enforcement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 Reporting and Investigation of Violations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Actions prohibited by the Code involving directors or executive officers must be reported to the Audit Committee or the Company's outside legal counsel as identified by the Chief Financial Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Actions prohibited by the Code involving anyone other than a director or executive officer must be reported to the Chief Financial Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) After receiving a report of an alleged prohibited action, the Audit Committee or independent members of the Board (with respect to the activities of a director or executive officer), or the Chief Financial Officer (with respect to employees), must promptly take all appropriate actions necessary to investigate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) All directors, officers and employees are expected to cooperate in any internal investigation of misconduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 Enforcement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company must ensure prompt and consistent action against violations of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If, after investigating a report of an alleged prohibited action by a director or executive officer, the Audit Committee or independent members of the Board determine that a violation of the Code has occurred, the Audit Committee or independent members of the Board will report such determination to the entire Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If, after investigating a report of an alleged prohibited action by any other person, the Chief Financial Officer determines that a violation of the Code has occurred, the Chief Financial Officer will report such determination to the Company's outside legal counsel and the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Upon receipt of a determination that there has been a violation of this Code, the Board will take such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal and, in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 Waivers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Only the independent members of the Board may, in their discretion, waive any violation of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any waiver for a director or an executive officer shall be disclosed as required by SEC and any applicable trading exchange rules that govern the Company at the time of violation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 Prohibition on Retaliation.

The Company does not tolerate acts of retaliation against any director, officer or employee who makes a good faith report of known or suspected acts of misconduct or other violations of this Code.

**Acknowledgment of Receipt and Review**

**Acknowledgment of Receipt and Review**

To be signed and returned to Tyler Ehler, CFO.

I, _______________________, acknowledge that I have received and read a copy of the Tranquil Healthcare, Inc. Code of Ethics and Business Conduct. I understand the contents of the Code and I agree to comply with the policies and procedures set out in the Code.

I understand that I should approach the CFO or representatives of the Company's outside legal counsel if I have any questions about the Code generally or any questions about reporting a suspected conflict of interest or other violation of the Code.

________________________ Signature ________________________ Name: ________________________ Date:

## Add

**Exhibit 99.2**

**NON-EMPLOYEE DIRECTOR COMPENSATION POLICY**

Each member of the Board of Directors (the "***Board***") who is not an employee or consultant to Tranquil Healthcare Holdings, Inc. (the "***Company***") or any of its subsidiaries (each such member, an "***Eligible Director***") will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service. An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date the cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of March 3, 2026 (the "***Effective Date***") and may be amended at any time in the sole discretion of the Board. This policy supersedes any prior agreement that provides for compensation terms as of the Effective Date.

**Cash Compensation** 

The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each calendar quarter in which the service occurred. If an Eligible Director joins the Board at a time other than effective as of the first day of a calendar quarter, the payment for such quarter, as set forth below, will be pro-rated based on days served in the applicable calendar quarter, with the pro-rated amount paid for the first calendar quarter in which the Eligible Director provides the service and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. Notwithstanding the foregoing, Eligible Directors will not receive, be entitled to, or accrue for, any cash payments until such time that Tranquil Healthcare Fund I, LLC ("***Tranquil Fund***"), the Company's subsidiary, completes sales of equity securities of the Company resulting in net cash proceeds of at least $300,000 in a single transaction.

The cash compensation for each Eligible Director will be $15,000 per calendar quarter.

**Equity Compensation** 

&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Initial grants for a new Eligible Director</u>. Upon joining the Board, each new Eligible Director
will receive the right to purchase 100,000 shares of the Corporation's common stock (the "  ***Eligible Director Purchase Right*** "), with each share having a purchase price equal to the fair market value of one (1) share of common stock as determined
in good faith by the Board, and which will vest as follows: (a) 25,000 shares on the grant date, (b) 25,000 shares on the one year anniversary
of the grant date, (c) 25,000 shares on the two year anniversary of the grant date and (d) 25,000 shares on the three year anniversary
of the grant date, subject to the Eligible Director continuing to serve on the Board at each vesting period. Upon any Eligible Director
ceasing to serve on the Board, the Company will have the right to purchase any shares that have not vested from the Eligible Director
Purchase Right at the same price per share that the shares were sold to the Eligible Director. Notwithstanding the foregoing, any Eligible
Director that previously served as a director of Tranquil Fund will not be entitled to the Eligible Director Purchase Right.

&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Ad Hoc Grants</u>. The Board may issue additional ad hoc grants to Eligible Directors from time to
time if and when determined by the Board.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** Tranquil Healthcare Fund I, LLC

**Jurisdiction of Incorporation/Organization:** DE

**Year of Incorporation:** 2025

**CIK:** 0002096363

**I.R.S. Employer Identification Number:** 39-5126583

**Primary Standard Industrial Classification Code:** 6159

**Total number of full-time employees:** 0

**Total number of part-time employees:** 0

**Address of Principal Executive Offices:** 18200 Von Karman Ave., Suite 850, Irvine, CA 92612

**Company Phone:** 646-902-4953

**Person to contact:** Silvestre Law Group, P.C.

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount     |
|:---|:---|
| Cash and Cash Equivalents                | $600.00    |
| Investment Securities                    | $0.00      |
| Accounts and Notes Receivable            | $0.00      |
| Property, Plant and Equipment (PP&E)     | $0.00      |
| Total Assets                             | $600.00    |
| Accounts Payable and Accrued Liabilities | $76350.00  |
| Long-Term Debt                           | $0.00      |
| Total Liabilities                        | $76350.00  |
| Total Stockholders' Equity               | $-75750.00 |
| Total Liabilities and Equity             | $600.00    |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount     |
|:---|:---|
| Total Revenues                            | $0.00      |
| Costs and Expenses Applicable to Revenues | $0.00      |
| Depreciation and Amortization             | $0.00      |
| Net Income                                | $-76350.00 |
| Earnings Per Share - Basic                | -0.12      |
| Earnings Per Share - Diluted              | -0.12      |

**Auditor Information**

| Metric          | Amount                              |
|:---|:---|
| Name of Auditor | Wahl Street Accountancy Corporation |

### Outstanding Securities

| Class                        |   Outstanding |     CUSIP | Publicly Traded   |
|:---|---:|---:|:---|
| Common Shares                |        847000 | 000000000 | None              |
| Series A Preferred Shares    |             0 | 000000000 | None              |
| Convertible Promissory Notes |        325000 | 000000000 | None              |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier2

**Financial Statement Status:** Audited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** No

**Was or is the offering to commence within two days after qualification?** No

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** No

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount       |
|:---|:---|
| Number of securities offered                                    | 5500000      |
| Number of securities outstanding                                | 0            |
| Price per security                                              | $10.00       |
| Issuer's aggregate offering price                               | $50000000.00 |
| Aggregate offering price of securities held by security holders | $0.00        |
| Aggregate price of securities offered concurrently              | $0.00        |
| Total aggregate offering price                                  | $50000000.00 |

**Anticipated Fees**

| Service Provider   | Name                                | Fees      |
|:---|:---|:---|
| Auditor            | Wahl Street Accountancy Corporation | $11000.00 |
| Legal              | Silvestre Law Group, P.C.           | $50000.00 |
| Promoters          |  |  |

**Estimated Net Proceeds to the Issuer:** $49939000.00

### Item 5. Jurisdictions in Which Securities are to be Offered

AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY, DC, PR, A0, A1, A2, A3, A4, A5, A6, A7, A8, A9, B0, Z4

### Item 6. Unregistered Securities Issued or Sold Within One Year

**Name of Such Issuer:** Tranquil Healthcare Fund I, LLC

**Title of Securities Issued:** Common Shares (represents limited liability company membership

**Total Amount of Securities Issued:** 841000

**Amount of such securities sold by principal security holders:** 1000000

**Aggregate consideration:** We were incorporated under the name Tranquil Healthcare, Inc. on October 21, 2025 ("Predecessor Company"). In connection with the Predecessor Company's formation, we issued a total of 825,000 shares of common stock in connection with its formation. The shares were issued to the Predecessor Company's officers, directors and consultants for total consideration of $825.00. (b) In addition, the Predecessor Company issued an aggregate of $325,000 worth of convertible notes. In connection with the notes, we issued 22,000 shares of the Predecessor Company's common stock. We did not receive any additional consideration for the shares. (ii) On March 3, 2026, in connection with the reorganization of the issuer from a corporation to a limited liability company, we changed our name to Tranquil Healthcare Fund I, LLC and issued a total of 847,000 shares of Common Stock in exchange for 847,000 shares of Tranquil Healthcare, Inc. the Predecessor Company common stock. Following the transaction, the Predecessor Company's shareholders collectively owned 100% of our issued and outstanding Common SharesStock. (iii) On March 3, 2026, all of the holders of our Common Shares entered into a purchase agreement with Tranquil Healthcare Holdings, Inc., the Issuer's manager ("Manager") whereby all of our members sold their Common Shares for shares of capital stock of the Manager. As a result of the transaction, the Issuer became the wholly owned subsidiary of the Manager who owns 100% of Issuer's issued and outstanding Common Shares.

**Basis for aggregate consideration:** 0

**Securities Act Exemption:** Exempt from registration under Section 4(2) of the Securities Act and Rules promulgated thereunder.